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Foreword
The publication of the report of the International Narcotics Control Board (INCB) for 2018 marks 
the fiftieth anniversary of the establishment of the Board, pursuant to the Single Convention on 
Narcotic Drugs of 1961.1 Since the adoption by the Board of its first annual report half a century 
ago, global drug control challenges have evolved. To meet those challenges, States adopted two 
further conventions, the Convention on Psychotropic Substances of 19712 and the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988,3 expand-
ing the responsibilities of the Board. In 2016, at the special session of the General Assembly on the 
world drug problem, Member States unanimously reaffirmed their commitment to the goals and 
objectives of the three international drug control conventions. 
Without the cooperation of Member States, the Board would not be able to fulfil its mandate of 
ensuring that the three international drug control conventions are implemented in accordance with 
the objectives and requirements that were established by States parties when they drafted and signed 
the conventions. To mark its fiftieth anniversary, the Board decided to deepen that cooperation by 
holding a meeting with representatives of Member States during its 123rd session, held in Vienna 
in November 2018, to consider the challenges currently faced in drug control and initiatives to 
address those challenges. 
A major challenge is the disparate access to and availability of internationally controlled medica-
tions. People in many countries experience untreated pain and surgery without anaesthesia, includ-
ing in emergency situations; in other regions, the non-rational prescription of opioid-based pain 
medications has contributed to a public health crisis and an increasing number of overdose deaths. 
Despite evidence of effectiveness, the use of internationally controlled methadone and buprenor-
phine for the treatment of opioid dependence is limited in some countries, including countries 
where there are significant levels of opioid dependence. In addition, the apparent oversupply of 
benzodiazepines in some countries represents a heightened risk of diversion to illicit channels. To 
support Governments in addressing the situation, the Board’s report for 2018 is accompanied by a 
supplement entitled Progress in ensuring adequate access to internationally controlled substances for 
medical and scientific purposes.4 That special report contains a review of the progress made in the 
implementation of the recommendations on availability of and access to internationally controlled 
substances as set out in the outcome document of the special session of the General Assembly and 
in the supplement to the INCB annual report for 2015.5 It offers guidance to Governments on mak-
ing progress towards alleviating suffering and realizing Sustainable Development Goal 3, on ensur-
ing healthy lives and promoting well-being for all at all ages. 
The legalization of the use of cannabis for non-medical purposes in some countries represents a 
challenge to the universal implementation of the treaties, a challenge to public health and well-
being, particularly among young people, and a challenge to the States parties to the treaties. INCB 
reiterates that the conventions limit the use of controlled substances, including cannabis, exclusively 
to medical and scientific purposes, and remains engaged in continuous dialogue with the 
Governments of countries in which the use of cannabis for non-medical purposes has been 
legalized. 
1  United Nations, Treaty Series, vol. 520, No. 7515. 
2  Ibid., vol. 1019, No. 14956. 
3  Ibid., vol. 1582, No. 27627.
4  E/INCB/2018/1/Supp.1. 
5  Availability of Internationally Controlled Drugs: Ensuring Adequate Access for Medical and Scientific Purposes— 
Indispensable, Adequately Available and Not Unduly Restricted (E/INCB/2015/Supp.1).
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The thematic chapter of the annual report for 2018 is on the risks and benefits of medical, 
scientific and “recreational” use of cannabis and cannabinoids. In several countries, poorly 
regulated medical cannabis programmes and the associated lower perception of risk of cannabis 
use may have contributed to the legalization of non-medical cannabis use. In addition, medical 
cannabis programmes that are not regulated in accordance with the conventions can result in 
diversion to non-medical use. In the thematic chapter, the control requirements for cannabis and 
cannabinoids are set out, an overview of the medical uses of cannabinoids and associated pharma-
ceutical registration systems is provided, and the adverse effects of both short-term and long-term 
cannabis use are highlighted.
In 2017, the illicit opiate economy of Afghanistan exceeded the value of the total national licit 
exports of goods and services. The Board remains very concerned about the impact of illicit opium 
production on the health and welfare of people in Afghanistan and beyond. We therefore call upon 
the relevant United Nations bodies and agencies to provide further technical and financial 
assistance to address the drug control challenges in Afghanistan. 
We are also concerned about the increase in illicit coca bush cultivation and cocaine manufacture 
in Colombia. 
The fundamental goal of the three international drug control conventions, namely, to safeguard the 
health and welfare of humanity, includes ensuring the full enjoyment of human rights. The present 
report includes recommendations concerning criminal justice responses to drug-related crime that 
take the principle of proportionality into account. We call upon States to develop effective strate-
gies for the prevention of drug use and the provision of treatment, rehabilitation, aftercare and 
social reintegration services. 
2018 also represents 30 years of precursor control, being the thirtieth anniversary of the adoption 
of the 1988 Convention. Significant results have been achieved in those 30 years, namely that there 
is virtually no diversion of scheduled precursor chemicals from licit international trade to illicit 
channels. However, non-scheduled chemicals, such as substitute chemicals and pre-precursors, pose 
a challenge to international drug control. There is a need for a policy discussion at the inter national 
level to identify a way forward to address that challenge, building upon the successful precursor 
control measures that are already in place. Governments should also build on such measures to 
address the emergence of new psychoactive substances, and to prevent those potentially harmful 
substances from reaching people. In 2018, the Board assessed three amphetamine-type stimulant 
precursors and recommended their inclusion in Table I of the 1988 Convention. Those recommen-
dations will be voted upon by the Commission on Narcotic Drugs in March 2019. The report of 
the Board for 2018 on the implementation of article 12 of the 1988 Convention6 addresses those 
issues in depth. Details of the Board’s work concerning the control of licit trade in narcotic drugs 
and psychotropic substances are found in the technical publications for 2018 on those subjects.7
To support Member States in safeguarding the well-being of their citizens through effective imple-
mentation of the international drug control conventions, INCB has developed a suite of tools that 
are available free of charge to national authorities. Those tools include the International Import and 
Export Authorization System (I2ES), the Pre-Export Notification Online system (PEN Online), the 
Precursors Incident Communication System (PICS), the Project Ion Incident Communication 
System (IONICS), INCB Learning and the global Operational Partnerships to Interdict Opioids’ 
6 Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances: Report 
of the International Narcotics Control Board for 2018 on the Implementation of Article 12 of the United Nations Convention against 
Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 (E/INCB/2018/4).
7 Narcotic Drugs: Estimated World Requirements for 2019 — Statistics for 2017 (E/INCB/2018/2) and Psychotropic 
Substances: Statistics for 2017 — Assessments of Annual Medical and Scientific Requirements for Substances in Schedules II, III 
and IV of the Convention on Psychotropic Substances of 1971 (E/INCB/2018/3).
vIllicit Distribution and Sales (OPIOIDS) Project, which are, in turn, dependent on the ongoing 
participation and support of Governments.
As we work together to address the challenges faced and to promote public health and well-being 
through effective drug control, I wish to highlight that the three international drug control treaties 
enjoy near universal adherence and that there is virtually no diversion of narcotic drugs, psycho-
tropic substances and precursors from licit international trade to illicit channels.
The drug control challenges faced may seem daunting, and their impact on public health and 
well-being wide reaching. Yet, over the past century and since the first intergovernmental meeting 
on drug control, in 1909, such challenges have been effectively surmounted through cooperative 
efforts and political will. The same spirit and commitment are needed today. I urge you to study 
and implement the recommendations contained in the present annual report, the supplement to 
the report and the report for 2018 on the implementation of article 12 of the 1988 Convention. 
INCB stands ready to support Member States with its independent expertise and experience, accu-
mulated over half a century. 
Viroj Sumyai
President
International Narcotics Control Board
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Explanatory notes
Data reported later than 1 November 2018 could not be taken into consideration in the prepara-
tion of this report.
The designations employed and the presentation of the material in this publication do not imply 
the expression of any opinion whatsoever on the part of the Secretariat of the United Nations con-
cerning the legal status of any country, territory, city or area or of its authorities, or concerning the 
delimitation of its frontiers or boundaries.
Countries and areas are referred to by the names that were in official use at the time the relevant 
data were collected.
References to dollars ($) are to United States dollars, unless otherwise stated.
The following abbreviations have been used in this report:
APAAN alpha-phenylacetoacetonitrile
ASEAN Association of Southeast Asian Nations
CARICC Central Asian Regional Information and Coordination Centre
CARICOM Caribbean Community
CBD cannabidiol
CELAC Community of Latin American and Caribbean States
CICAD Inter-American Drug Abuse Control Commission of the Organization of American 
States
ECOWAS Economic Community of West African States
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
Europol European Police Office
FELCN Special Force to Combat Drug Trafficking
GBL gamma-butyrolactone
GHB gamma-hydroxybutyric acid
I2ES International Import and Export Authorization System
INCB International Narcotics Control Board 
INTERPOL International Criminal Police Organization
IONICS Project Ion Incident Communication System
ISIL Islamic State in Iraq and the Levant
LSD lysergic acid diethylamide
MDMA 3,4-methylenedioxymethamphetamine
NATO North Atlantic Treaty Organization
PEN Online Pre-Export Notification Online system
PICS Precursors Incident Communication System
α-PVP α-pyrrolidinovalerophenone
SCO Shanghai Cooperation Organization
SMART global Synthetics Monitoring: Analysis, Reporting and Trends programme
THC tetrahydrocannabinol
UNAIDS Joint United Nations Programme on HIV/AIDS
UNAMA United Nations Assistance Mission in Afghanistan
UNODC United Nations Office on Drugs and Crime
WCO World Customs Organization
WHO World Health Organization

1Chapter I. 
Cannabis and cannabinoids for medical, 
scientific and “recreational” use:  
risks and benefits 
1. The Governments of several States have passed 
legislation allowing patients suffering from certain health 
conditions (such as terminal cancer, epilepsy and neuro-
logical illnesses) to use cannabinoids and cannabis to treat 
the symptoms of their illnesses (see box 1 for definitions 
of key terms). Some medical cannabis programmes have 
had an adverse impact on public health because they have 
not been effectively regulated in line with the international 
Box 1. 
Some key terms 
1. “Cannabis and its derivatives” describes all products derived from the cannabis plant. Cannabis plant prod-
ucts include the flowering tops (marijuana), compressed cannabis resin (hashish), cannabis oils, concentrated 
cannabis extracts (waxes) and edible preparations (e.g., infusions, cookies and chocolates). 
2. Cannabinoids are substances found only in the cannabis plant. There are estimated to be 104 unique, nat-
urally occurring cannabinoids but the 2 that have been most extensively studied are THC and CBD: 
 •  THC produces the psychoactive effects, such as euphoria, relaxation and heightened sensory experi-
ences, sought by “recreational” users 
 •  CBD has few psychoactive effects. It may moderate the psychoactive effects of THC and has antioxidant, 
anti-inflammatory and neuroprotective effects 
3. Synthetic cannabinoids are substances produced in the laboratory that have similar effects to THC or other 
cannabinoids (e.g., nabilone).
4. Approved pharmaceutical cannabinoids include dronabinol, nabilone, nabiximols and CBD. Research is being 
conducted on the potential uses of other cannabinoids.
  Sources: National Academies of Sciences, Engineering, and Medicine, The Health Effects of Cannabis and Cannabinoids: The Current State of 
Evidence and Recommendations for Research (Washington, D.C., National Academies Press, 2017); WHO, The Health and Social Effects of Nonmedical 
Cannabis Use (Geneva, 2016); and Leslie L. Iversen, The Science of Marijuana, 2nd ed. (Oxford, Oxford University Press, 2008).
drug control treaties, resulting in the diversion of 
cannabis to non-medical use. In several countries, poorly 
regulated medical cannabis programmes and the associated 
lower perception of risk may have contributed to the 
legalization of non-medical cannabis use, contrary to the 
international drug control treaties (see para. 5 and sections 
H–K below).
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2. Cannabis is included under Schedules I and IV of the 
Single Convention on Narcotic Drugs of 1961 as amended 
by the 1972 Protocol1 because it produces dependence 
and has adverse public health consequences (see section 
E below).2 Those consequences include injuries in motor 
vehicle crashes, mental illnesses such as psychoses, 
impaired cognitive and educational performance, dis-
rupted adolescent development and adverse effects on 
fetal development. Cannabis use that begins during ado-
lescence can damage the developing brain at a time of 
increased vulnerability. 
3. The main cannabinoids with psychoactive properties, 
namely, THC and its isomers and their stereochemical 
variants, are included in Schedule I of the Convention on 
Psychotropic Substances of 19713 because they have the 
capacity to produce a state of dependence and constitute 
a public and social problem. 
4. In its annual report for 2017,4 INCB re-examined the 
terminology surrounding the medical use of cannabi-
noids. Accordingly, in the present chapter, the term 
“medicinal cannabinoids” refers only to cannabinoids that 
have been extracted from the plant or synthesized, have 
had their safety and effectiveness evaluated in controlled 
clinical trials and have been licensed for use as 
medicines. 
5. Poorly controlled programmes for the medicinal use 
of cannabinoids can potentially have adverse effects on 
public health. They may increase non-medical cannabis 
use among adults and contribute to the legalization of 
non-medical cannabis use by weakening public percep-
tions of the risks of using cannabis and reducing public 
concern about legalizing non-medical (so-called “recrea-
tional”) cannabis use, which is contrary to the inter-
national drug control treaties.
6. In the present chapter, the conditions under which 
the international treaties allow the medical use of can-
nabinoids are specified. The chapter also contains a brief 
summary of the evidence on the safety and effectiveness 
1 United Nations, Treaty Series, vol. 976, No. 14152.
2 At the time of finalizing the present report, the WHO Expert Com-
mittee on Drug Dependence was due to hold its forty-first meeting (12–
16 November 2018), during which it was to conduct a critical review of, 
inter alia, cannabis and cannabis-related substances, namely cannabis 
and cannabis resin, extracts and tinctures of cannabis, delta-9-THC and 
isomers of THC, to advise the Director General of WHO on any recom-
mendation or assessment to be transmitted by WHO to the Commission 
on Narcotic Drugs for its consideration pursuant to articles 3, paragraphs 
3 (iii), 4, 5 and 6 of the 1961 Convention as amended, and article 2, para-
graph 4, of the Convention on Psychotropic Substances of 1971. 
3 United Nations, Treaty Series, vol. 1019, No. 14956. 
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of cannabinoids for various types of medical use. The 
strengths and limitations of different regulatory approaches 
to permitting the medical use of cannabinoids, including 
the risks of diversion of cannabis to non-medical use, are 
also described. The chapter contains a discussion on how 
weak regulation of medical cannabis programmes may 
facilitate moves to legalize the non-medical use of can-
nabis and concludes with recommendations on how 
States should implement programmes for medicinal can-
nabinoids that comply with the requirements of the inter-
national drug control treaties.
A.  Cannabis, its derivatives  
and the international drug 
control conventions
7. Article 4, paragraph (c), of the 1961 Convention as 
amended limits the use of drugs scheduled under the 
Convention, including cannabis and its derivatives, to 
medical and scientific purposes. Under the Convention, 
cannabinoids may be evaluated in controlled clinical tri-
als to assess the benefits and harms of their use in 
medicine. 
8. The treaties set out requirements on States parties as 
to how they may allow the use of cannabis and its deriv-
atives for medical purposes. For example, articles 23 and 
28 of the 1961 Convention as amended require that 
Governments establish a national cannabis agency to con-
trol the production and regulate the supply of cannabi-
noids for medical use. The national agency is required to 
license producers, purchase and take possession of stocks 
and maintain a monopoly on wholesale trading and 
stocks. The agency must provide annually to INCB esti-
mates of the quantities of the drug that will be used for 
medical purposes and must also provide estimates of the 
number of patients who will be treated with the drug.
9. In order to prevent abuse of and trafficking in can-
nabis, States parties must take measures to prevent the 
unauthorized cultivation of cannabis plants and must 
seize and destroy illicitly cultivated cannabis crops. All 
programmes for the medical use of cannabinoids must be 
developed and implemented under the full authority of 
the State concerned. 
10. The treaties require that effective legislative frame-
works are put in place to ensure the medically supervised 
use of cannabis and its derivatives and to prevent the 
diversion of cannabis and its derivatives to non-medical 
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use. Governments allowing the medical use of cannabis 
must ensure that cannabis is prescribed by competent 
medical practitioners according to sound medical prac-
tice and based on sound scientific evidence. 
11. Cannabinoids should be approved for medical use 
on the basis of scientific evidence on their quality, safety 
and efficacy for medical use from controlled clinical tri-
als. Approved medicinal cannabinoids should be pre-
scribed by a physician and dispensed by a pharmacist. 
Governments should monitor prescribers, dispensers and 
patients to ensure that those cannabinoids are not diverted 
to non-medical use or abuse. 
12. The Board has repeatedly stated that personal culti-
vation of cannabis for medical purposes is inconsistent 
with the 1961 Convention as amended because, inter alia, 
it heightens the risk of diversion.5 Personal cultivation of 
cannabis to be used for medical purposes does not allow 
Governments to exercise the supervision required by the 
1961 Convention over the production, manufacture, 
export, import and distribution of, trade in and use and 
possession of cannabis, the establishment of estimates of 
medical usage, the furnishing of related statistical returns 
or the implementation of the provisions of article 28 of 
that Convention. In addition to the risks of diversion, 
allowing private individuals to cultivate cannabis for per-
sonal medical consumption may present additional health 
risks, in that the dosages and levels of THC consumed 
may be different from those medically prescribed. The 
production of very high THC concentrates and extracts 
for “medical use” heightens the Board’s concerns about 
the risks of diversion for non-medical use. 
B.  Pharmaceutical registration and 
prescription regimes
13. Smoking cannabis is not a medically acceptable way 
to obtain standardized doses of cannabinoids for two rea-
sons: first, cannabis plants vary in their composition, 
which makes it difficult to prescribe specific doses;6 sec-
ond, there are health risks to patients from inhaling the 
carcinogens and toxins in cannabis smoke.7
5 Ibid., para. 177.
6 EMCDDA, Cannabis Legislation in Europe: An Overview (Luxem-
bourg, Publications Office of the European Union, 2018), p. 7.
7 United States of America, National Academies of Sciences, Engi-
neering, and Medicine, The Health Effects of Cannabis and Cannabinoids: 
The Current State of Evidence and Recommendations for Research (Wash-
ington, D.C., National Academies Press, 2017).
14. Attempts to market and promote the medical use of 
cannabis products as “herbal medicines” are inconsistent 
with the classification of cannabis and its derivatives 
under the 1961 and 1971 conventions. 
15. Pharmaceutical-quality cannabinoids should be 
approved for clearly defined medical uses by the coun-
try’s pharmaceutical regulatory system. The pharmaco-
logical specificity of cannabinoids to treat defined medical 
conditions should be demonstrated in order to avoid their 
being used to treat medical conditions for which there is 
limited evidence of benefit. Cannabinoids approved in 
these ways can best deliver high-quality, standardized 
doses of known substances for medical use.8 
16. Medical regulatory authorities license the medical 
use of a drug when there is evidence that the drug has 
been manufactured to a required level of quality and 
safety. Those authorities also require evidence from ran-
domized controlled clinical trials that show that the drug 
is safe and effective, i.e., that the drug is more effective 
than a placebo, or equally as effective as an active treat-
ment, when used to treat patients with a specified medi-
cal disorder.9 
17. While assessing the potential for a controlled sub-
stance to be used for medical purposes, States should 
make sure that the therapeutic advantages it provides can-
not be afforded by some other non-controlled drug with 
no or few addiction-producing properties.10
18. Once drugs have been approved for medical use, 
medical colleges and clinical societies often develop clin-
ical practice guidelines for their use. Such guidelines are 
designed to assist prescribers with regard to how best to 
incorporate the use of new drugs into clinical practice, 
for example, the disorders for which they may be used, 
whether they will be used as first-line or later-line treat-
ments, and if they will be used as adjuncts or 
monotherapies. 
8 Jennifer H. Martin, Yvonne Bonomo and Adrian D. B. Reynolds, 
“Compassion and evidence in prescribing cannabinoids: a perspective 
from the Royal Australasian College of Physicians”, Medical Journal of 
Australia, vol. 208, No. 3 (February 2018). 
9 Odilia Osakwe, “Pharmaceutical regulation: the role of Government 
in the business of drug discovery”, in Social Aspects of Drug Discovery, 
Development and Commercialization, Odilia Osakwe and Syed A. A. Rizvi, 
eds. (London, Elsevier, 2016); and Lembit Rägo and Budiono Santoso, 
“Drug regulation: history, present and future”, in Drug Benefits and Risks: 
An International Textbook of Clinical Pharmacology, revised 2nd ed., 
Chris J. van Boxtel, Budiono Santoso and I. Ralph Edwards, eds. (Uppsala, 
Sweden, Uppsala Monitoring Centre, 2008). 
10 Martin, Bonomo and Reynolds, “Compassion and evidence in 
prescribing cannabinoids”.
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19. After a drug is licensed for medical use, the health 
authorities may monitor adverse effects among patients 
who use it. Post-market surveillance is needed to detect 
rare but serious adverse effects that may not be detected 
in the clinical trials used to obtain a licence for the drug’s 
medical use. Clinical trials are usually short term and 
conducted in highly selected patient populations. Rarer 
adverse effects of medical use may only come to light 
when a drug has been used to treat a large number of 
unselected patients.
20. A company that markets a drug can promote its use 
to medical practitioners for the approved medical uses. 
Physicians may use approved drugs off-label, that is, to 
treat medical conditions other than those for which the 
drugs have been approved. The regulatory system, 
however, does not allow companies to promote the use 
of a drug beyond its approved indications, for example, 
by expanding the indications for its use, encouraging 
doctors to prescribe it off-label, or overstating its bene-
fits or understating any adverse effects. 
21. Many national pharmaceutical regulatory systems 
have established special-access schemes that enable 
patients with serious illnesses (such as cancer) to access 
unapproved medicines. This requires evidence that the 
patient has failed to respond to conventional treatment 
and patients must give informed consent for the use of 
an unapproved medicine. Medicines obtained in this way 
may have been approved for medical use in other coun-
tries but are not available in the country where a patient 
lives, or the medicine may still be undergoing clinical 
trial.11 They usually require a prescription from a licensed 
medical practitioner and approval by the pharmaceutical 
regulator to import and use the drug. 
C. Medical uses of cannabinoids
22. A large variety of preparations containing cannabi-
noids are used in various regions of the world to provide 
different dosage forms and concentrations of active and 
psychoactive ingredients by different routes of adminis-
tration. They are used in the belief that they will allevi-
ate a wide range of symptoms, often in the absence of 
high-quality evidence that they are safe and effective. In 
many cases, it is unclear what cannabinoids these 
11 J. Martinalbo and others, “Early market access of cancer drugs in 
the EU”, Annals of Oncology, vol. 27, No. 1 (January 2016), pp. 96–105. 
products contain (active principles and dosage), what the 
best route of administration is or what their adverse side 
effects may be. When used in these ways, patients may 
confuse the acute euphoric effects of cannabinoids for 
longer-term medicinal effectiveness.12 
23. The results of some controlled clinical trials suggest 
that some cannabinoids may relieve the symptoms of 
some illnesses, but not modify the underlying diseases.13 
Such cannabinoids are primarily used in combination 
with other drugs and typically only after a patient has 
failed to respond to other approved treatments for his or 
her condition. Cannabinoids are not first-line treatments 
for any of these conditions. The following summary of 
the evidence on the effectiveness of cannabinoids for 
medical uses is drawn from systematic reviews of the 
literature.14 
(a)  Neuropathic pain and spasticity in 
multiple sclerosis 
24. Randomized clinical trials have compared the effi-
cacy of nabiximols (which contain equal amounts of 
THC and CBD) with a placebo in treating muscle spasm 
and neuropathic pain in patients with multiple sclero-
sis. Patients given nabiximols reported less muscle spas-
ticity than patients given a placebo, but the differences 
in muscle spasticity identified by physicians were 
marginal.15 
25. Systematic reviews of trials have found that 
nabiximols reduce neuropathic pain more than a placebo 
in patients with multiple sclerosis. However, the cannab-
inoids were only marginally more effective than a 
placebo: a 50 per cent reduction in pain was reported by 
21 per cent of patients who received the cannabinoid and 
12 Martin, Bonomo and Reynolds, “Compassion and evidence in 
prescribing cannabinoids”.
13 Vincenzo Di Marzo and Luciano De Petrocellis, “Plant, synthetic, 
and endogenous cannabinoids in medicine”, Annual Review of Medicine, 
vol. 57 (2006), pp. 553–574; Institute of Medicine, Marijuana and Medi-
cine: Assessing the Science Base (Washington, D.C., National Academies 
Press, 1999); The Health Effects of Cannabis and Cannabinoids.
14 Including The Health Effects of Cannabis and Cannabinoids; and 
Penny F. Whiting and others, “Cannabinoids for medical use: a system-
atic review and meta-analysis”, Journal of the American Medical Associa-
tion, vol. 313, No. 24 (June 2015), pp. 2456–2473. 
15 The Health Effects of Cannabis and Cannabinoids; Whiting and 
others, “Cannabinoids for medical use”; and John Zajicek and others, 
“Cannabinoids for treatment of spasticity and other symptoms related to 
multiple sclerosis (CAMS study): multicentre randomised placebo-con-
trolled trial”, Lancet, vol. 362, No. 9395 (November 2003), pp. 1517–1526. 
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by 17 per cent of those who received a placebo.16 There 
have not been any trials comparing the analgesic effects 
of cannabinoids with other analgesics such as non- 
steroidal anti-inflammatory drugs. 
(b) Intractable childhood epilepsy 
26. Randomized controlled trials have compared the 
frequency of epileptic seizures in children with Dravet 
and Lennox-Gastaut syndromes (rare genetic forms of 
epilepsy) who were given CBD or a placebo in addition 
to other anti-epileptic drugs. CBD produced a larger 
reduction in the frequency of seizures than the placebo, 
but more clinical trials are needed to identify the doses 
of CBD that reduce seizures with a minimum of adverse 
effects.17 Clinical trials are also needed to assess the 
efficacy of CBD in treating other types of epilepsy in 
children and adults. 
(c) Cannabinoids as anti-emetics 
27. Randomized clinical trials have been held to assess 
whether THC (taken orally) is more effective in reducing 
nausea and vomiting than a placebo or another anti-
emetic drug in cancer patients whose nausea and vomit-
ing are caused by chemotherapy. Systematic reviews have 
drawn different conclusions on their efficacy, ranging from 
a Cochrane review that concluded that the evidence was 
of low quality18 to a study in which “conclusive evidence” 
was found that THC (or a cannabinoid with similar 
effects) was more effective in reducing nausea and 
vomiting than a placebo or the anti-emetic drug with 
which it was compared.19 
28. A major limitation of these trials is that THC was 
compared with a drug that is no longer used and that is 
much less effective in controlling nausea and vomiting 
than newer drugs.20 There have been very few clinical 
16 Martin Mücke and others, “Cannabis-based medicines for chronic 
neuropathic pain in adults”, Cochrane Database of Systematic Reviews, 
No. 3 (2018). 
17 Emily Stockings and others, “Evidence for cannabis and cannabi-
noids for epilepsy: a systematic review of controlled and observational 
evidence”, Journal of Neurology, Neurosurgery and Psychiatry, vol. 89, 
No. 7 (July 2018). 
18 Whiting and others, “Cannabinoids for medical use”.
19 The Health Effects of Cannabis and Cannabinoids.
20 Marijuana and Medicine; and Rudolph M. Navari, “Pharmacologi-
cal management of chemotherapy-induced nausea and vomiting: focus 
on recent developments”, Drugs, vol. 69, No. 5 (March 2009), pp. 515–533.
trials in which the effects of THC were compared with 
drugs such as ondansetron.21 
(d) Appetite stimulation 
29. In 1992, THC was approved in the United States of 
America for use as an appetite stimulant in the treatment 
of AIDS-related wasting. Systematic reviews have con-
cluded that the clinical trials provide weak evidence for 
the use of THC as an appetite stimulant because of a sub-
stantial risk of bias in those trials.22 There is also little 
clinical need to stimulate the appetite of AIDS patients 
because few persons infected with HIV develop AIDS-
related wasting if treated with highly active antiretroviral 
drugs. There are other medical disorders in which appe-
tite may need to be stimulated (e.g., cancer and anorexia 
nervosa), but the evidence for the medical use of cannab-
inoids in those disorders is weak.23
D.  Adverse effects of short-term 
medicinal cannabinoid use
30. Evaluations of the adverse effects of medicinal 
cannabinoids have only been short term. Randomized, 
controlled clinical trials of cannabinoids to treat nausea 
and vomiting have assessed adverse effects over 1–6 days 
and trials for appetite, pain and spasticity in multiple 
sclerosis have lasted for 8–15 weeks.
31. An analysis of adverse events in 79 randomized 
clinical trials of cannabinoids in treating the conditions 
indicated above found that patients receiving a cannabi-
noid were approximately three times more likely than 
patients receiving a placebo to have an adverse event, 
nearly three times more likely to cease treatment because 
of adverse events and 40 per cent more likely to report a 
serious adverse event. The adverse events most often 
reported by patients receiving medicinal cannabinoids 
were dizziness, dry mouth, disorientation, euphoria, 
confusion and drowsiness.24 
21 The Health Effects of Cannabis and Cannabinoids; and Navari, 
“Pharmacological management of chemotherapy-induced nausea and 
vomiting”. 
22 The Health Effects of Cannabis and Cannabinoids; and Whiting and 
others, “Cannabinoids for medical use”.
23 The Health Effects of Cannabis and Cannabinoids.
24 Whiting and others, “Cannabinoids for medical use”.
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E.  Adverse effects of long-term use 
of cannabis and its derivatives 
32. The adverse health effects of short- and long-term 
use of cannabis for non-medical reasons are summarized 
in box  2 below. By contrast, there is very limited infor-
mation on the adverse effects of using cannabinoids reg-
ularly (e.g., daily) for medical purposes over periods of 
months and years.25 Cannabis dependence is a probable 
consequence of long-term medical cannabinoid use.26 It 
is reasonable to assume, in the light of experience with 
other drugs, that the risk of dependence would be higher 
for patients with chronic pain using cannabinoids daily 
for months than the risk for patients using THC to treat 
chemotherapy-induced nausea for a week or less. There 
are no data on those risks, however. 
33. Long-term cannabis smoking is associated with an 
increased risk of chronic bronchitis, but the evidence is 
mixed as to whether daily cannabis smoking increases the 
risk of chronic obstructive pulmonary disease.27 The res-
piratory risks of non-medical cannabis use28 arise because 
it is smoked, in many cases with tobacco and by tobacco 
smokers.29 A patient taking medicinal cannabinoids orally 
would avoid those respiratory harms. 
34. Long-term, daily, non-medical use of cannabis has 
been associated with poorer memory, attention, decision-
making and planning in adolescents and young adults. 
Those effects may be of concern in patients with neuro-
logical disorders for whom regular use of cannabinoids 
could worsen any cognitive impairments caused by their 
disorders.30
25 Tongtong Wang and others, “Adverse effects of medical cannabi-
noids: a systematic review”, Canadian Medical Association Journal, 
vol. 178, No. 13 (June 2008), pp. 1669–1678. 
26 Wayne Hall, Louisa Degenhardt and Michael Lynskey, The Health 
and Psychological Effects of Cannabis Use, Monograph Series, No. 44, 
2nd ed. (Canberra, Commonwealth Department of Health and Ageing, 
2001). 
27 WHO, The Health and Social Effects of Nonmedical Cannabis Use 
(Geneva, 2016); and The Health Effects of Cannabis and Cannabinoids.
28 Jeanette M. Tetrault and others, “Effects of marijuana smoking 
on pulmonary function and respiratory complications: a systematic 
review”, Archives of Internal Medicine, vol. 167, No. 3 (February 2007), 
pp. 221–228. 
29 Wan C. Tan and others, “Marijuana and chronic obstructive lung 
disease: a population-based study”, Canadian Medical Association 
Journal, vol. 180, No. 8 (April 2009), pp. 814–820. 
30 Rebecca D. Crean, Natania A. Crane and Barbara J. Mason, “An 
evidence-based review of acute and long-term effects of cannabis use on 
executive cognitive functions”, Journal of Addiction Medicine, vol. 5, No. 1 
(March 2011), pp. 1–8; and Nadia Solowij and others, “Cognitive func-
tioning of long-term heavy cannabis users seeking treatment”, Journal of 
the American Medical Association, vol. 287, No. 9 (2002), pp. 1123–1131. 
35. Daily use of cannabis may precipitate psychotic 
symptoms and disorders in young persons, especially in 
those with a personal or family history of such disorders. 
There are no data on the risk of psychosis in older patients 
using cannabinoids. Persons with a personal or family 
history of psychosis would be wise to avoid using 
cannabinoids.31, 32 The non-psychoactive cannabinoid, 
CBD, may have anti-psychotic effects that require further 
investigation.
36. The cardiovascular risks of long-term cannabis and 
cannabinoid use may be a concern in older patients who 
have a higher risk of cardiovascular disease.33 
Epidemiological investigations into cardiovascular out-
comes in patients using cannabinoids for medical purposes 
are needed. 
F.  Medical use of approved 
cannabinoids 
37. A number of countries, mostly in Europe and North 
America, permit the medical use of cannabinoids (see 
table 1). The United States Food and Drug Administration, 
for example, has approved several cannabinoids for medi-
cal use. In 1985, it approved a synthetic THC, dronabi-
nol (Marinol), for use as an anti-emetic drug in cancer 
patients undergoing chemotherapy. Nabilone (Cesamet), 
a synthetic cannabinoid (with similar effects to THC), 
was approved in 1992 in capsule form as an appetite 
stimulant in patients with AIDS-related wasting.34 In June 
2018, the Food and Drug Administration approved the 
use of a CBD product (Epidiolex) to treat patients aged 
2 years and older with Lennox-Gastaut and Dravet 
syndromes.
31 Louisa Degenhardt and Wayne Hall, “Is cannabis use a contribu-
tory cause of psychosis?”, Canadian Journal of Psychiatry, vol. 51, No. 9 
(August 2006), pp. 555–565; The Health and Social Effects of Nonmedical 
Cannabis Use; and The Health Effects of Cannabis and Cannabinoids.
32 Philip McGuire and others, “Cannabidiol (CBD) as an adjunctive 
therapy in schizophrenia: a multicenter randomized controlled trial”, 
American Journal of Psychiatry, vol. 175, No. 3 (2018), pp. 225–231.
33 Wayne Hall and Rosalie Liccardo Pacula, Cannabis Use and 
Dependence: Public Health and Public Policy, reissued ed. (Cambridge, 
Cambridge University Press, 2010). 
34 Marijuana and Medicine; and Douglas C. Throckmorton, Deputy 
Director for Regulatory Programs, Center for Drug Evaluation and 
Research, Food and Drug Administration, Department of Health and 
Human Services, “Researching the potential medical benefits and risks of 
marijuana”, statement to the Subcommittee on Crime and Terrorism, 
Committee on the Judiciary, United States Senate, 13 July 2016. 
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Box 2.
Adverse effects of cannabis use on health
The short-term adverse effects of cannabis use include:
•  Intoxication, with disturbed consciousness, cognition, perception, affect or behaviour, and psychophysio-
logical functions 
• Panic attacks, hallucinations and vomiting (in a minority of first-time users)
• Impairment of driving and an increased risk of road traffic injuries (1.3–2.0-fold) 
• Possible triggering of coronary events in younger cannabis smokers
• Adverse effects on the fetus if a mother smokes cannabis during pregnancy
The long-term psychosocial effects of regular cannabis use include: 
•  Dependence (the risk is 1 in 10 among those who have ever used it, 1 in 6 for adolescent users and 1 in 3 
for daily users)
• More severe and persistent negative outcomes among adolescents than among adults 
•  A dose-response relationship between cannabis use in adolescence and the risk of developing psychotic 
symptoms or schizophrenia in young adulthood 
•  Increased risk of early school leaving, cognitive impairment, illicit use of other drugs, depressive symp-
toms and suicidal ideation and behaviour (when cannabis is used daily in adolescence and young adult-
hood) 
The other longer-term physiological risks of regular cannabis use may include: 
• Chronic and acute bronchitis and injury to bronchial lining cells 
• Myocardial infarctions and strokes in young cannabis users
• An increased risk of cancer and other respiratory diseases if used with tobacco
• Testicular cancer (the link requires further investigation) 
Source: WHO, The Health and Social Effects of Nonmedical  Cannabis Use (Geneva, 2016).
Table 1.
Pharmaceutical cannabinoids that have been approved for medicinal use 
Cannabinoid Composition Trade name Route Indication
Dronabinol Synthetic delta-9-THC Marinol Oral capsule Nausea and vomitinga 
Nabilone Synthetic cannabinoid that mimics the effects of THC Cesamet Oral capsule
Nausea and vomiting;  
appetite stimulationb
Nabiximols Cannabis extract with equal doses of THC and CBD Sativex Oral mucosal spray 
Muscle spasticity and pain in  
multiple sclerosisc 
CBD CBD extracted from  cannabis plants Epidiolex Oil for oral use 
Epilepsy in Lennox-Gastaut and 
Dravetd syndromes for patients  
aged 2 years and older 
a National Academies of Sciences, Engineering, and Medicine, The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recom-
mendations for Research (Washington, D.C., National Academies Press, 2017).
b Ibid.
c United Kingdom, electronic Medicines Compendium (eMC), “Sativex Oromucosal Spray”. Available at www.medicines.org/uk.
d United States Food and Drug Administration.
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38. Dronabinol and nabilone have not been widely 
used in the United States because patients find it diffi-
cult to achieve therapeutic effects without adverse side 
effects.35 When THC is taken orally, its effects have a 
delayed onset; often, patients either do not receive 
enough THC to achieve a therapeutic effect or they receive 
too much and experience adverse side effects.36
39. In several countries, including the United Kingdom 
of Great Britain and Northern Ireland, nabiximols 
(Sativex) have been approved to treat muscle spasms in 
multiple sclerosis patients,37 but have not been widely 
used, in part because of the absence of public subsidies, 
which increases the cost borne by patients. 
G.  Special-access schemes for 
medicinal cannabinoids
40. Several countries around the world have established 
special-access schemes for cannabinoids. The paragraphs 
below contain examples of schemes that have been 
described in the literature. It is not a complete account, 
because schemes in many countries have been in opera-
tion for shorter periods of time and information on how 
they operate is not yet readily available. 
41. Since 2001, Israel has allowed the medical use of 
cannabis, with the approval and oversight of the Medical 
Cannabis Unit in the Ministry of Health. The Unit issues 
permits for patients to use herbal cannabis and nabixi-
mols for medical purposes on the recommendation of 
physicians. It also authorizes growers to produce canna-
bis and supply it to patients. 
42. Israel supplies herbal cannabis as an oil or as dried 
flower for smoking or vaporization. The physician speci-
fies the THC and CBD content. Nabiximols are licensed 
to treat moderate to severe spasticity in multiple sclero-
sis patients and to treat cancer pain.38
35 Franjo Grotenhermen, “Cannabinoids for therapeutic use: design-
ing systems to increase efficacy and reliability”, American Journal of Drug 
Delivery, vol. 2, No. 4 (2004), pp. 229–240; and Marijuana and Medicine.
36 Grotenhermen, “Cannabinoids for therapeutic use”; and Leslie L. 
Iversen, The Science of Marijuana, 2nd ed. (Oxford, Oxford University 
Press, 2007).
37 Iversen, The Science of Marijuana; and Ethan Russo and Geoffrey 
W. Guy, “A tale of two cannabinoids: the therapeutic rationale for 
combining tetrahydrocannabinol and cannabidiol”, Medical Hypotheses, 
vol. 66, No. 2 (2006), pp. 234–246.
38 Jacob Ablin and others, “Medical use of cannabis products: 
lessons to be learned from Israel and Canada”, Der Schmerz, vol. 30, No. 1 
(January 2016). 
43. Since July 2014, the medical use of cannabinoids in 
Israel has only been permitted if the physician has utilized 
and the patient has failed to respond to recognized 
treatments. Approved uses include cancer treatment; 
inflammatory bowel disease; neuropathic pain after more 
than a year of treatment in a pain clinic; AIDS-related 
wasting; neurological diseases such as multiple sclerosis, 
Parkinson’s disease and Tourette’s syndrome; post- 
traumatic stress disorder; and terminal illnesses.39 
44. In 2003, legislation was passed in the Netherlands 
to allow physicians to prescribe cannabis for a range of 
medical indications. Cannabis is produced under govern-
ment licence by a private company and dispensed by 
pharmacists to patients in a standardized form for oral 
consumption, on a doctor’s prescription. 
45. In 2011, legislation was passed in Switzerland to 
allow the medical use of cannabis to treat chronic pain 
and spasticity, under exceptional circumstances with the 
approval of the Swiss Federal Office of Public Health. 
Doctors can request a licence for each patient to use a 
commercially available synthetic THC (dronabinol) or a 
tincture of cannabis sativa containing 5 per cent THC, 
prepared by a pharmacist. 
H.  Poorly regulated medical 
cannabis programmes in  
North America 
46. Under medical cannabis programmes in Canada 
and some states in the United States, patients have been 
allowed to purchase cannabis from commercial outlets for 
use for a variety of medical conditions, under minimal 
medical supervision. Weak regulation of medical usage 
has allowed the diversion of cannabis to non-medical 
use and, according to some, has facilitated the legaliza-
tion of non-medical cannabis use in some states in the 
United States.40 The key features of these programmes are 
summarized in box 3 and elaborated upon in the follow-
ing paragraphs.
47. In some states in the United States, the medical use 
of cannabis was legalized through citizen-initiated refer-
endums. For example, in 1996 in California, voters voted 
39 Ibid.
40 Beau Kilmer and Robert J. MacCoun, “How medical marijuana 
smoothed the transition to marijuana legalization in the United States”, 
Annual Review of Law and Social Science, vol. 13 (2017), pp. 181–202. 
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in favour of proposition 215, on allowing cannabis to be 
used to treat nausea, weight loss, pain and muscle spasm, 
and any other illness for which it may provide relief. 
48. In the United States, the medical use of cannabis is 
now allowed in more than 30 states and the Federal 
District of Columbia. Those states differ in how they regu-
late their medical cannabis programmes. In some states, 
“medical use” is defined very broadly and cannabis may 
be sold by commercial dispensaries to persons with a 
medical recommendation. In other states, the use of can-
nabis is restricted to limited medical conditions and the 
sale of cannabis by commercial dispensaries is not 
permitted.41
49. The profiles of patients in medical cannabis 
programmes in California suggest that “medical use” is 
very loosely defined in that state. During the period 
2001–2007, of 4,117 patients in the San Francisco Bay 
Area, 77 per cent were males. Most (88 per cent) started 
using cannabis before the age of 19 and 90 per cent were 
daily smokers.42 In a representative survey of Californian 
adults, 7 per cent reported “medical cannabis use”. The 
highest rate was among those aged 18–24 (10 per cent) 
and the lowest rate (1.5 per cent) was among persons aged 
over 65.43 Those characteristics do not correspond to the 
41 Rosalie Liccardo Pacula and Rosanna Smart, “Medical marijuana 
and marijuana legalization”, Annual Review of Clinical Psychology, vol. 13 
(2017), pp. 397–419. 
42 Thomas J. O’Connell and Ché B. Bou-Matar, “Long term mari-
juana users seeking medical cannabis in California (2001–2007): demo-
graphics, social characteristics, patterns of cannabis and other drug use 
of 4117 applicants”, Harm Reduction Journal, vol. 4, No. 16 (2007). 
43 Suzanne Ryan-Ibarra, Marta Induni and Danielle Ewing, “Preva-
lence of medical marijuana use in California, 2012”, Drug and Alcohol 
Review, vol. 34, No. 2 (March 2015), pp. 141–146. 
cases highlighted in advocacy for medical uses of canna-
bis, namely, older adults with terminal illnesses, persons 
with neurological diseases and children with epilepsy.
50. Most medical cannabis programmes in the United 
States do not comply with the requirements of the inter-
national drug control treaties or United States national law. 
The cannabis sold in dispensaries may be illicitly produced 
and sold. There may be substantial diversion of cannabis 
products intended for medical use to non-medical use. 
There is often little or no scientific evidence to support the 
effectiveness of many of the purported medical uses of 
cannabis and there is very little medical supervision of 
these “medical” uses of cannabis. 
51. In April 2001, the Government of Canada passed 
legislation allowing patients to access cannabis for medi-
cal purposes.44 They could do so if they had a terminal 
illness and a life expectancy of less than 12 months; mul-
tiple sclerosis, a spinal cord injury or disease, cancer pain, 
AIDS, arthritis or epilepsy; or another serious medical 
condition that had not been relieved by conventional 
treatments.45 
44 Tony Bogdanoski, “Accommodating the medical use of marijuana: 
surveying the differing legal approaches in Australia, the United States 
and Canada”, Journal of Law and Medicine, vol. 17, No. 4 (February 2010), 
pp. 508–531; and Philippe G. Lucas, “Regulating compassion: an over-
view of Canada’s federal medical cannabis policy and practice”, Harm 
Reduction Journal, vol. 5, No. 5 (2008). 
45 Philippe G. Lucas, “It can’t hurt to ask; a patient-centered quality 
of service assessment of Health Canada’s medical cannabis policy and 
program”, Harm Reduction Journal, vol. 9, No. 2 (2012); and Anthony C. 
Moffat, “The legalisation of cannabis for medical use”, Science and Justice, 
vol. 42, No. 1 (January 2002), pp. 55–57. 
Box 3.
Features of poorly regulated medical cannabis programmes 
Poorly regulated medical cannabis programmes:a 
(a) Allow the smoking of cannabis for “medical” purposes;
(b) Allow “medical cannabis use” for a wide variety of medical conditions in the absence of evidence of 
safety and effectiveness from controlled clinical trials for such use; 
(c) Allow the provision of non-standardized cannabis products under minimal medical supervision, often 
authorized for a fee by physicians with no specialist expertise or history of treating the patient; 
(d) Allow patients to either grow their own cannabis or purchase cannabis products from commercial outlets 
that produce cannabis illicitly. 
a Beau Kilmer and Robert J. MacCoun, “How medical marijuana smoothed the transition to marijuana legalization in the United States”, Annual 
Review of Law and Social Science, vol. 13 (2017), pp. 181–202.
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52. In response to a succession of decisions made by 
courts in Canada, the Government was obliged to extend 
access to cannabis and its derivatives for therapeutic pur-
poses. This broadened the definition of “medical use” and 
established a cannabis cultivation industry in which 
licensed producers can provide cannabis directly to 
patients with medical documents authorizing the medi-
cal use of cannabis. The expanded list of indications 
allowed any doctor to prescribe cannabis to a patient 
whom the doctor thought might benefit.46 Persons author-
ized to use cannabis for medical purposes can also culti-
vate their own supply or designate another person to do 
so on their behalf, a practice that is inconsistent with the 
provisions of the Conventions (see para. 12 above). The 
application of successive court decisions based on consti-
tutional arguments therefore led to an outcome where the 
medical cannabis programme does not comply with the 
international drug control treaties in important aspects. 
I.  Adverse public health effects of 
medical cannabis programmes 
53. Researchers and policymakers have raised concerns 
that poorly regulated medical cannabis programmes in 
states of the United States may have increased the non-
medical use of cannabis among young people. Researchers 
have evaluated those concerns by comparing survey data 
on cannabis use in adolescents in states in the United 
States that have and have not legalized the medical use 
of cannabis. 
54. The largest study using national survey data47 found 
that there was no change in adolescent cannabis use 
before and after the passage of laws permitting the medical 
use of cannabis. Analyses of cannabis use in young peo-
ple aged 12 to 20 in the United States National Household 
Survey of Drug Use also failed to find increases in such 
use.48
46 Benedikt Fischer, Sharan Kuganesan and Robin Room, “Medical 
marijuana programs: implications for cannabis control policy – observa-
tions from Canada”, International Journal of Drug Policy, vol. 26, No. 1 
(January 2015), pp. 15–19. 
47 Deborah S. Hasin and others, “Medical marijuana laws and 
adolescent marijuana use in the USA from 1991 to 2014: results from 
annual, repeated cross-sectional surveys”, Lancet Psychiatry, vol. 2, No. 7 
(July 2015), pp. 601–608. 
48 Hefei Wen, Jason M. Hockenberry and Janet R. Cummings, 
“The effect of medical marijuana laws on adolescent and adult use of 
marijuana, alcohol, and other substances”, Journal of Health Economics, 
vol. 42 (July 2015), pp. 64–80. 
55. However, cannabis use has increased among adults 
over the age of 21 in states that have adopted legislation 
permitting the medical use of cannabis.49 Adults in states 
with legislation permitting medical use of cannabis have 
higher rates of daily cannabis use and cannabis abuse and 
dependence than adults who live in states that have not 
passed such legislation. The number of adult males seek-
ing treatment for cannabis use disorders has also increased 
more in states with medical cannabis laws;50 that increase 
has occurred among persons who were not referred by 
the criminal justice system. 
56. The evidence is mixed on the effects of medical 
cannabis legislation on motor vehicle fatalities. Some 
studies51 have found an increase in the number of driv-
ers involved in fatal crashes with cannabis in their 
bloodstream in states that have passed medical canna-
bis legislation while others52 have found a decrease in 
that number. A study comparing trends in fatal motor 
vehicle crashes in Colorado and 34 states without medi-
cal cannabis legislation between 1994 and 2011 found a 
larger increase in cannabis-related fatalities in Colorado 
after 2009. There was no change in the number of 
alcohol-related fatalities in Colorado or the 34 states 
without medical cannabis laws.53 
J.  Legalization of non-medical 
cannabis use 
57. “Medical cannabis” programmes in some states in 
the United States have been used by advocates of canna-
bis legalization to promote the legalization of non- medical 
cannabis use in those states. States that were the first to 
legalize non-medical cannabis use (Colorado, Oregon and 
Washington) had poorly regulated “medical cannabis” 
programmes, with dispensaries being used to create a de 
facto legal cannabis market for non-medical users. In 
49 Ibid.
50 Yu-Wei Luke Chu, “The effects of medical marijuana laws on illegal 
marijuana use”, Journal of Health Economics, vol. 38 (December 2014), 
pp. 43–61. 
51 Scott V. Masten and Gloriam Vanine Guenzburger, “Changes in 
driver cannabinoid prevalence in 12 U.S. States after implementing medi-
cal marijuana laws”, Journal of Safety Research, vol. 50 (September 2014), 
pp. 35–52. 
52 D. Mark Anderson, Benjamin Hansen and Daniel I. Rees, “Medical 
marijuana laws, traffic fatalities, and alcohol consumption”, Journal of Law 
and Economics, vol. 56, No. 2 (May 2013), pp. 333–369. 
53 Stacy Salomonsen-Sautel and others, “Trends in fatal motor vehi-
cle crashes before and after marijuana commercialization in Colorado”, 
Drug and Alcohol Dependence, vol. 140 (July 2014), pp. 137–144. 
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those states, cannabis was provided through dispensaries 
to any person who satisfied the broad criteria used to 
define “medical use”.54 
58. The legal tolerance of cannabis dispensaries allowed 
a quasi-legal commercial cannabis industry to develop in 
those states. In Colorado, the medical cannabis retail 
industry helped to design the regulatory system for non-
medical cannabis use, and its members were given early 
entry to the market.55 
59. The expansion of poorly regulated “medical canna-
bis” programmes has been accompanied by increased 
public support for the legalization of non-medical canna-
bis use in the United States.56 
60. The decrease in the perceived risks of cannabis use 
and active social marketing of cannabis by the cannabis 
industry presents major challenges in preventing canna-
bis use among young people. Unsubstantiated claims 
about the medical benefits of cannabis have been accom-
panied by reductions in the perceived risks of using can-
nabis among young people in the United States.57 Cannabis 
use by adults in the states of the United States in which 
non-medical cannabis has been legalized may encourage 
adolescents to use the drug at a time when their brains 
are especially vulnerable to its adverse effects.
K.  Implications for international 
drug control 
61. The legalization of non-medical use of cannabis con-
travenes the international drug control treaties. Universal 
and full implementation of the treaties is put at serious 
risk because States parties, such as Canada and Uruguay 
(as well as states in the United States), have legalized can-
nabis for non-medical use. The actions of those countries 
and state jurisdictions undermine the treaties. They may 
also encourage other States parties to follow their exam-
ple and use it as a justification for doing so. 
54 Kilmer and MacCoun, “How medical marijuana smoothed the 
transition to marijuana legalization in the United States”.
55 Wayne Hall and Michael Lynskey, “Evaluating the public health 
impacts of legalizing recreational cannabis use in the United States”, Ad-
diction, vol. 111, No. 10 (October 2016), pp. 1764–1773.
56 Kilmer and MacCoun, “How medical marijuana smoothed the 
transition to marijuana legalization in the United States”.
57 Hannah Carliner and others, “Cannabis use, attitudes, and legal 
status in the U.S.: a review”, Preventive Medicine, vol. 104 (November 
2017), pp. 13–23.
62. In 2013, Uruguay legalized the non-medical use of 
cannabis, permitted the sale of cannabis through phar-
macies and allowed the establishment of cannabis grow-
ers’ clubs and home production by users. In 2018, Canada 
legalized commercial cannabis production and sale for 
non-medical use by adults; the policy was implemented 
in October 2018. 
63. Experience with alcohol and tobacco suggests that 
legalization will reduce the perceived risks of using can-
nabis and social disapproval of adult cannabis use, and 
increase the diversion of cannabis to persons who are 
under the minimum legal age to purchase and use it.58 
The legalization of non-medical cannabis use is also likely 
to increase cannabis use among adult users by making 
cannabis more widely available, including at a lower price 
and in more potent forms, such as concentrates. Over the 
next few decades, such legalization is also likely to 
increase the number of new users among adolescents and 
young adults. 
64. One argument used by advocates of legalizing can-
nabis for non-medical use is that it will restrict minors’ 
access to cannabis. Experience in the State of Washington 
raises serious doubts about this claim. Authorities have 
reported substantial numbers of licensed cannabis busi-
nesses selling cannabis to minors, an offence punishable 
only by small fines. 
65. Any increases in non-medical cannabis use will 
increase the adverse effects of cannabis on public health. 
The most likely effects are increased rates of motor vehi-
cle injuries, cannabis dependence and abuse, psychoses 
and other mental disorders, and poor psychosocial out-
comes in adolescents. 
66. The legalization of non-medical cannabis use in 
some States will make it more difficult to enforce inter-
national drug control treaty provisions in neighbouring 
States that do comply with those provisions. It will be 
more difficult, for example, to prevent cross-border traf-
ficking in cannabis products from States that have legal-
ized non-medical cannabis use to neighbouring countries 
that have not done so. 
58 Rosalie Liccardo Pacula and others, “Developing public health 
regulations for marijuana: lessons from alcohol and tobacco”, American 
Journal of Public Health, vol. 104, No. 6 (June 2014), pp. 1021–1028. 
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L.  Conclusions and 
recommendations 
67. The medical use of cannabinoids is allowed under the 
international drug control treaties only if States comply 
with the treaty requirements that are designed to prevent 
diversion to non-medical use. The treaties require that 
States license and control cannabis production for medical 
use, provide estimates of the national requirements for can-
nabis for medical purposes and ensure that medicinal can-
nabinoids are used in accordance with evidence on their 
safety and effectiveness and under medical supervision. 
Taking those measures should also contribute to maintain-
ing the integrity of the pharmaceutical regulatory system. 
68. Recent reviews of the evidence from clinical trials 
indicate that: (a) there is weak evidence that dronabinol 
may be useful in treating nausea and vomiting in cancer 
patients; (b) there is moderate evidence that nabiximols 
may be useful in treating neuropathic pain and muscle 
spasticity in patients with multiple sclerosis; and (c) there 
is moderate evidence that CBD may reduce seizure 
frequency in some genetic intractable childhood epilepsy 
syndromes. Cannabinoids are not a first-line treatment 
for any of those conditions.
69. The evidence that cannabinoids can relieve symptoms 
of some medical illnesses does not justify the “medical use” 
of cannabis by smoking. Smoking a crude plant product is 
not a safe or reliable way to obtain standardized doses of 
cannabinoids. 
70. Poorly controlled programmes for the medicinal use 
of cannabinoids can potentially have adverse effects on 
public health. They may increase non-medical cannabis 
use among adults and contribute to the legalization of 
non-medical cannabis use by weakening public percep-
tions of the risks of using cannabis and reducing public 
concern about legalizing non-medical (so-called “recrea-
tional”) cannabis use, which is contrary to the inter-
national drug control treaties.
71. Governments that have created special-access 
schemes to allow the medical use of cannabis should 
ensure that those programmes are not used to de facto 
legalize cannabis for non-medical use. Governments 
should limit the indications for medical use to those for 
which there is evidence of efficacy, restrict use to medic-
inal cannabinoids, and monitor the prescription and use 
of cannabinoids to minimize their diversion and abuse. 
72. Under medical cannabis programmes implemented 
in Canada and possibly in some other States, and in some 
states in the United States, the medical use of cannabi-
noids is poorly regulated. Those programmes are incon-
sistent with the international drug control treaties in 
failing to control cannabis production and supply. They 
fail to ensure that good-quality medicines are provided 
under medical supervision and they enable cannabis and 
its derivatives to be diverted to non-medical use. 
73. “Medical cannabis” programmes may also have been 
used by advocates of the legalization of cannabis use to 
facilitate the legalization of non-medical cannabis use, 
which is contrary to the international drug control 
treaties. Such programmes have used very broad defini-
tions of “medical use” and allowed commercial businesses 
to supply illicitly produced cannabis. In the United States, 
those programmes also appear to have reduced public 
perceptions of the risks of using cannabis and have 
weakened public concern about cannabis legalization. 
74. Governments that allow the medicinal use of 
cannabinoids should monitor and evaluate the effects of 
the programmes. Such monitoring should include collect-
ing data on the number of patients who use cannabinoids, 
the medical conditions for which they use them, patient 
and clinician assessments of their benefits, and rates of 
adverse events. Governments should also monitor the 
extent of diversion of cannabinoids to non-medical use, 
and in particular their diversion for use by minors. 
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Chapter II.
Functioning of the international  
drug control system
A.  Promoting the consistent 
application of the international 
drug control treaties
75. Collectively, the Single Convention on Narcotic 
Drugs of 1961 as amended by the 1972 Protocol, the 
Convention on Psychotropic Substances of 1971 and the 
United Nations Convention against Illicit Traffic in 
Narcotic Drugs and Psychotropic Substances of 1988 form 
the basis of the international drug control framework.
76. The international drug control conventions were 
developed on the basis of the international community’s 
recognition that the challenges posed by drug control in 
all its facets required a joint and coordinated response by 
States. Today, that broad consensus is reflected in the fact 
that the three international drug control conventions 
are among the most widely ratified international instru-
ments in existence, as well as in the fact that their 
central importance was unanimously reaffirmed by the 
General Assembly at its special session on the world drug 
problem held in 2016. 
77. The fundamental goal of the international drug con-
trol conventions is to safeguard the health and welfare of 
humankind. To achieve this objective, the conventions 
establish a number of general obligations to which States 
parties have explicitly agreed to be bound, including the 
following:
 (a) To limit exclusively to medical and scientific 
purposes the production, manufacture, export, import, 
distribution of, trade in, use and possession of drugs;
 (b) To adopt administrative measures for the control 
of licit trade in narcotic drugs and psychotropic sub-
stances, as well as the precursor chemicals used in their 
illicit manufacture;
 (c) To facilitate the availability of controlled sub-
stances for legitimate medical purposes while preventing 
their diversion into illicit channels;
 (d) To develop strategies for the prevention of drug use 
and mechanisms to address dependence through treat-
ment, rehabilitation, aftercare and social reintegration; 
 (e) To provide national responses to suspected drug-
related criminality that are humane and proportionate, as 
well as grounded in respect for human dignity, the 
presumption of innocence and the rule of law, and to give 
due consideration to alternatives to conviction or punish-
ment, in particular for offences committed by drug users 
in appropriate cases of a minor nature. 
Status of adherence to the international drug 
control treaties
78. In December 2017, the State of Palestine became the 
latest State party to the three international drug control 
conventions. 
79. The accession of the State of Palestine to the 1961 
Single Convention as amended brought the number of 
States parties to that Convention to 186. Among the States 
having yet to accede to the 1961 Convention as amended, 
two are located in Africa (Equatorial Guinea and South 
Sudan), one is in Asia (Timor-Leste) and seven are in 
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Oceania (Cook Islands, Kiribati, Nauru, Niue, Samoa, 
Tuvalu and Vanuatu). Chad remains the sole State to have 
ratified the 1961 Convention in its unamended form.
80. With the addition of the State of Palestine, the num-
ber of States parties to the 1971 Convention rose to 184; 
13 States are not currently parties to that Convention. 
Of those, three are in Africa (Equatorial Guinea, Liberia 
and South Sudan), one is in the Caribbean (Haiti), one 
is in Asia (Timor-Leste) and eight are in Oceania (Cook 
Islands, Kiribati, Nauru, Niue, Samoa, Solomon Islands, 
Tuvalu and Vanuatu).
81. Finally, with the accession of the State of Palestine, 
which brought the total number of parties to 190 (189 
States and the European Union), the 1988 Convention 
remains the most widely ratified of the three international 
drug control conventions. Many of the non-parties to the 
1988 Convention are concentrated in Oceania (Kiribati, 
Palau, Papua New Guinea, Solomon Islands and Tuvalu), 
and three non-parties are located in Africa (Equatorial 
Guinea, Somalia and South Sudan).
82. During the period under review, the Board 
continued to actively engage States that had not yet 
become parties to one or more of the three international 
drug control conventions, including through bilateral 
meetings, and cooperated with other United Nations 
bodies as part of its efforts to facilitate the accession of 
those States to the conventions.
83. The Board continues to encourage States that have 
not yet become parties to one or more of the interna-
tional drug control conventions to do so at the earliest 
opportunity, and to take all legislative and policy action 
necessary to ensure their comprehensive implementation 
at the national level.
B.  Ensuring the implementation  
of the provisions of  
the international drug  
control treaties
84. The fundamental goal of the international drug con-
trol system is assuring the health and welfare of human-
kind. That goal is to be achieved through two, twin 
actions: ensuring the availability of internationally con-
trolled substances for medical and scientific purposes 
and, in the case of precursor chemicals, also ensuring 
their legitimate industrial use; and preventing the diver-
sion of controlled substances into illicit channels.
85. To monitor compliance with the international drug 
control treaties, the Board examines action taken by 
Governments to implement the treaty provisions aimed 
at achieving the overall goals of the conventions. Over 
the years, the treaty provisions have been supplemented 
with additional control measures adopted by the Economic 
and Social Council and the Commission on Narcotic 
Drugs to enhance their effectiveness. In the present 
section, the Board highlights action that needs to be taken 
to implement the international drug control system, 
describes problems encountered in that regard and 
provides specific recommendations on how to deal with 
those problems.
1.  Preventing the diversion of 
controlled substances
(a) Legislative and administrative basis
86. Governments have to ensure that national legislation 
complies with the provisions of the international drug 
control treaties. They also have the obligation to amend 
the lists of substances controlled at the national level when 
a substance is included in a schedule of an international 
drug control treaty or transferred from one schedule to 
another. Inadequate legislation or implementation mech-
anisms at the national level or delays in bringing lists of 
substances controlled at the national level into line with 
the schedules of the international drug control treaties will 
result in inadequate national controls being applied to 
substances under international control and may lead to 
the diversion of substances into illicit channels. The Board 
is therefore pleased to note that, as in previous years, 
Governments have continued to furnish information to 
the Board on legislative or administrative measures taken 
to ensure compliance with the provisions of the inter-
national drug control treaties. At the same time, the Board 
is concerned that some Governments have introduced or 
are planning to introduce legislative measures in contra-
vention of the requirements of the international drug con-
trol treaties. The Board would like to remind Governments 
that, in General Assembly resolution S-30/1, entitled 
“Our joint commitment to effectively addressing and 
countering the world drug problem”, adopted by the 
Assembly on 19 April 2016, Member States reaffirmed 
their commitment to the goals and objectives of the three 
international drug control conventions. 
87. On 14 March 2018, at its sixty-first session, the 
Commission on Narcotic Drugs decided to include six 
new substances in the Schedules of the 1961 Convention 
as amended. By its decision 61/1, the Commission 
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decided to include carfentanil in Schedules I and IV of 
the 1961 Convention as amended. By its decisions 61/2, 
61/3, 61/4, 61/5 and 61/6, the Commission decided to 
include ocfentanil, furanylfentanyl, acryloylfentanyl 
(acrylfentanyl), 4-fluoroisobutyrfentanyl (4-FIBF, pFIBF) 
and tetrahydrofuranylfentanyl (THF-F) in Schedule I of 
the 1961 Convention as amended. In accordance with 
article 3, paragraph 7, of the 1961 Convention as amended, 
that decision was communicated by the Secretary-General 
to all Governments, WHO and the Board on 15 May 
2018, and became effective with respect to each party 
upon receipt of that notification. The Board acknowl-
edges the efforts made by Governments that have already 
put those substances under control and urges all other 
Governments to amend the lists of substances con-
trolled at the national level accordingly and to apply to 
those substances all control measures required under 
the 1961 Convention as amended.
88. The Board also wishes to draw the attention of 
Governments to the fact that six substances were placed 
under international control under the 1971 Convention by 
the Commission on Narcotic Drugs on 14 March 2018. 
Pursuant to Commission decisions 61/7, 61/8, 61/9, 61/10, 
61/11 and 61/12, AB-CHMINACA, 5F-MDMB-PINACA 
(5F-ADB), AB-PINACA, UR-144, 5F-PB-22 and 4-fluoro-
amphetamine (4-FA) were added to Schedule II of the 1971 
Convention. In accordance with article 2, paragraph 7, 
of the 1971 Convention, those decisions of the Commission 
were communicated by the Secretary-General to all 
Governments, WHO and the Board on 15 May 2018, and 
became fully effective with respect to each party on 
11 November 2018. The Board acknowledges the efforts 
made by some Governments that have already put those 
substances under control and urges all other Governments 
to amend their lists of substances controlled at the 
national level accordingly, to apply to those substances 
the control measures required under the 1971 Convention, 
as well as in the relevant resolutions of the Commission 
and the Council, and to inform the Board accordingly. 
89. In accordance with Economic and Social Council 
resolutions 1985/15, 1987/30 and 1993/38, Governments 
are required to introduce an import authorization require-
ment for zolpidem, a substance that was included in 
Schedule IV of the 1971 Convention in 2001. In response 
to the Board’s request made in its annual reports for 2012 
and 2013 and a circular letter sent in 2016, a number of 
Governments have provided the requisite information. As 
at 1 November 2018, relevant information was available 
for 133 countries and territories. Of those, 124 countries 
and territories have introduced an import authorization 
requirement, and 1 country (the United States) requires 
a pre-import declaration. Six countries and territories 
(Cabo Verde, Gibraltar, Ireland, New Zealand, Singapore 
and Vanuatu) do not require an import authorization for 
zolpidem. Imports of zolpidem into Azerbaijan are pro-
hibited, and Ethiopia does not import the substance. At 
the same time, information on the control of zolpidem 
remains unknown for 81 countries and territories. 
The Board therefore again urges the Governments of 
countries and territories that have not yet done so to 
supply it with information on the control status of zolpi-
dem as soon as possible. 
(b)  Prevention of diversion from 
international trade
Estimates and assessments of  
annual requirements for internationally 
controlled substances
90. The system of estimates and assessments of annual 
licit requirements for narcotic drugs and psychotropic 
substances is the cornerstone of the international drug 
control system. It enables both exporting and importing 
countries to ensure that trade in those substances stays 
within the limits determined by the Governments of 
importing countries and that diversion of controlled 
substances from international trade is effectively pre-
vented. For narcotic drugs, such a system is mandatory 
under the 1961 Convention, and the estimates furnished 
by Governments need to be confirmed by the Board 
before becoming the basis for calculating the limits on 
manufacture and import. 
91. The system of assessments of annual requirements 
for psychotropic substances was adopted by the Economic 
and Social Council in its resolutions 1981/7, 1991/44, 
1993/38 and 1996/30, and the system of annual legitimate 
requirements for selected precursors was adopted by the 
Commission on Narcotic Drugs in its resolution 49/3, to 
help Governments to prevent attempts by traffickers to 
divert internationally controlled substances into illicit 
channels. The assessments of annual legitimate require-
ments for psychotropic substances and annual legitimate 
requirements for selected precursors help Governments 
to identify unusual transactions. The diversion of drugs 
and precursors has been prevented in many cases when 
the exporting country declined to authorize the export of 
the substance because the quantities of the substance to 
be exported would have exceeded the quantities required 
in the importing country.
92. The Board regularly investigates cases involving pos-
sible non-compliance by Governments with the system of 
estimates or assessments, given that non-compliance 
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could facilitate the diversion of controlled substances 
from licit international trade into illicit channels. In that 
connection, the Board provides information, support and 
guidance to Governments on the working of the system 
for estimates or assessments, as necessary.
93. Governments are obliged to comply with the limits 
on imports and exports of narcotic drugs provided for 
under articles 21 and 31 of the 1961 Convention. 
Article 21 stipulates, inter alia, that the total of the quan-
tities of each drug manufactured and imported by any 
country or territory in a given year is not to exceed the 
sum of the following: the quantity consumed for medical 
and scientific purposes; the quantity used, within the lim-
its of the relevant estimates, for the manufacture of other 
drugs, preparations or substances; the quantity exported; 
the quantity added to the stock for the purpose of bring-
ing that stock up to the level specified in the relevant esti-
mate; and the quantity acquired within the limit of the 
relevant estimate for special purposes. Article 31 requires 
all exporting countries to limit the export of narcotic 
drugs to any country or territory to quantities that fall 
within the limits of the total of the estimates of the 
importing country or territory, with the addition of the 
amounts intended for re-export.
94. As in previous years, the Board finds that, in 
general, the system of imports and exports continues to 
be respected and works well. In 2018, a total of 11 coun-
tries were contacted regarding possible excess imports or 
excess exports identified with regard to international 
trade in narcotic drugs that had been effected during the 
year. As at 1 November 2018, three of those countries had 
responded. One country confirmed that excess exports 
had occurred, and it was reminded of the need to ensure 
full compliance with the relevant treaty provisions. In the 
two other cases, the drug had been exported to a coun-
try and subsequently re-exported by that country. The 
Board continues to pursue the matter with those coun-
tries that have failed to respond.
95. Pursuant to Economic and Social Council resolutions 
1981/7 and 1991/44, Governments are requested to pro-
vide to the Board assessments of annual domestic medical 
and scientific requirements for psychotropic substances 
listed in Schedules II, III and IV of the 1971 Convention. 
The assessments received are communicated to all States 
and territories to assist the competent authorities of export-
ing countries when approving exports of psychotropic 
substances. As at 1 November 2018, the Governments of 
all countries and territories, except for South Sudan, for 
which assessments were established by the Board in 2011, 
had submitted at least one assessment of their annual 
medical requirements for psychotropic substances.
96. The Board recommends that Governments review 
and update the assessments of their annual medical and 
scientific requirements for psychotropic substances at 
least every three years. However, 45 Governments have 
not submitted a revision of their legitimate requirements 
for psychotropic substances for three years or more. The 
assessments valid for those countries and territories may 
therefore no longer reflect their actual medical and 
scientific requirements for psychotropic substances. 
97. When assessments are lower than the actual legiti-
mate requirements, the importation of psychotropic 
substances needed for medical or scientific purposes may 
be delayed. When assessments are significantly higher 
than legitimate needs, the risk of psychotropic substances 
being diverted into illicit channels may be increased. The 
Board has repeatedly reminded Governments of the 
importance of estimating and assessing correctly and real-
istically the initial needs of their country. 
98. As in previous years, the system of assessments of 
annual requirements for psychotropic substances contin-
ues to function well and is respected by most countries 
and territories. In 2017, the authorities of 29 countries 
issued import authorizations for substances for which 
they had not established any such assessments or for 
quantities that significantly exceeded their assessments. 
Only two countries were identified as having exported 
psychotropic substances in quantities exceeding the rele-
vant assessment. 
99. The Commission on Narcotics Drugs, in its 
resolution 49/3, entitled “Strengthening systems for the 
control of precursor chemicals used in the illicit 
manufacture of synthetic drugs”, requested Member States 
to provide the Board, on a voluntary basis, with annual 
legitimate requirements for imports of four precursors of 
amphetamine-type stimulants and, to the extent possible, 
preparations containing those substances. As at 
1  November 2018, 166 Governments had provided an 
estimate for at least one of those substances, thus provid-
ing the competent authorities of exporting countries with 
an indication of the legitimate requirements of importing 
countries and thereby preventing diversion attempts.
Requirement for import and export 
authorizations
100. The universal application of the requirement for 
import and export authorizations laid down in the 1961 
and 1971 Conventions is key to preventing the diversion 
of drugs into the illicit market. Such authorizations are 
required for transactions involving any of the substances 
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controlled under the 1961 Convention or listed in Schedules 
I and II of the 1971 Convention. Competent national 
authorities are required by those Conventions to issue 
import authorizations for transactions involving the impor-
tation of such substances into their country. The compe-
tent national authorities of exporting countries must verify 
the authenticity of such import authorizations before issu-
ing the export authorizations required to allow shipments 
containing the substances to leave their country.
101. The 1971 Convention does not require import and 
export authorizations for trade in the psychotropic sub-
stances listed in its Schedules III and IV. However, in view 
of the widespread diversion of those substances from licit 
international trade during the 1970s and 1980s, the 
Economic and Social Council, in its resolutions 1985/15, 
1987/30 and 1993/38, requested Governments to extend 
the system of import and export authorizations to cover 
those psychotropic substances as well.
102. Most countries and territories have already intro-
duced an import and export authorization requirement 
for psychotropic substances listed in Schedules III and IV 
of the 1971 Convention, in accordance with the above-
mentioned Economic and Social Council resolutions. As 
at 1 November 2018, specific information had been made 
available to the Board by 206 countries and territories, 
showing that all major importing and exporting countries 
now require import and export authorizations for all psy-
chotropic substances in Schedules III and IV of the 1971 
Convention. Twice a year, the Board disseminates to all 
Governments a table showing the import authorization 
requirements for substances in Schedules III and IV pur-
suant to the relevant Economic and Social Council reso-
lutions. That table is also published in the secure area of 
the Board’s website, which is accessible only to specifi-
cally authorized government officials, so that the compe-
tent national authorities of exporting countries may be 
informed as soon as possible of changes in import author-
ization requirements in importing countries. The Board 
urges the Governments of the few remaining States in 
which national legislation and/or regulations do not yet 
require import and export authorizations for all psycho-
tropic substances, regardless of whether they are States 
parties to the 1971 Convention, to extend such controls 
to all substances in Schedules III and IV of the 1971 
Convention as soon as possible, and to inform the Board 
in that regard. 
103. The 1988 Convention does not impose any require-
ments for import and export authorizations for trade in 
substances listed in Tables I and II of that Convention. 
However, under the Convention, countries are requested 
to provide advance notification of planned shipments to 
the authorities of the importing Government with a view 
to preventing the diversion of those substances (see paras. 
106 and 107 below regarding pre-export notifications for 
precursor chemicals).
International electronic import and export 
authorization system for narcotic drugs and 
psychotropic substances
104. As part of its endeavours to harness technological 
progress for the effective and efficient implementation of 
the import and export authorization regime for licit inter-
national trade in narcotic drugs and psychotropic sub-
stances, the Board has spearheaded efforts to develop an 
electronic tool to facilitate and expedite the work of com-
petent national authorities and to reduce the risks of 
diversion of narcotic drugs and psychotropic substances. 
I2ES is an innovative, web-based application that was 
developed by the Board in cooperation with UNODC and 
with the support of Member States. I2ES allows 
Governments to generate electronically import and export 
authorizations for licit imports and exports of narcotic 
drugs and psychotropic substances, to exchange those 
authorizations in real time and to verify instantly the 
legitimacy of individual transactions while ensuring full 
compliance with the requirements of the international 
drug control conventions. I2ES significantly reduces the 
risk of drug consignments being diverted into illicit chan-
nels (see section F below for more details). 
105. I2ES was officially launched in 2015 and compe-
tent national authorities from 53 countries have since reg-
istered with the system. In March 2018, a user-group 
meeting was held on the margins of the sixty-first session 
of the Commission on Narcotic Drugs to gather feedback 
on the system. More than 30 experts from over 30 coun-
tries participated in that meeting. The meeting afforded 
government officials of participating countries a valuable 
opportunity to exchange ideas on bringing about the 
fuller implementation of I2ES and to provide feedback to 
INCB and the information technology service of UNODC 
to guide future action and the further development of the 
system. The user group emphasized the importance of 
sharing the experiences of competent national authorities 
from different parts of the world with other users and 
potential users as a way of promoting greater usage of the 
system. 
Pre-export notifications for precursor chemicals
106. To assist importing and exporting Governments in 
communicating with each other as regards international 
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trade in precursors and to provide alerts about any sus-
picious transactions, in 2006, the Board established a 
secure web-based tool, PEN Online. As at 1 November 
2018, a total of 162 Governments had registered to use 
it. INCB calls upon Governments to use PEN Online 
actively and systematically and urges those Governments 
that have not yet registered to use the system to do so 
as soon as possible. The Board stands ready to assist 
Governments in that regard.
107. To prevent the diversion of precursors, article 12, 
paragraph 10 (a), of the 1988 Convention allows the 
Governments of importing countries to make it manda-
tory for exporting countries to inform them of any 
planned export of precursors to their territory. As at 
1 November 2018, 113 States and territories had invoked 
the provision and had formally requested pre-export 
notifications, thus allowing them to carry out the prior 
verification of the legitimacy of a planned transaction. 
The Board encourages those Governments that have not 
formally requested pre-export notifications to invoke 
article 12, paragraph 10 (a), of the 1988 Convention.
(c)  Effectiveness of the control measures 
aimed at preventing the diversion of 
controlled substances from 
international trade 
108. The system of control measures laid down in the 
1961 Convention provides effective protection to inter-
national trade in narcotic drugs against attempts to divert 
such drugs into illicit channels. Similarly, as a result of 
the almost universal implementation of the control meas-
ures stipulated in the 1971 Convention and the relevant 
Economic and Social Council resolutions, there have been 
no identified cases involving the diversion of psychotropic 
substances from international trade into illicit channels 
in recent years. In addition, the 1988 Convention requires 
parties to prevent the diversion of precursor chemicals 
from international trade to the illicit manufacture of nar-
cotic drugs and psychotropic substances. The Board has 
also developed various systems to monitor compliance 
with that aspect of the 1988 Convention and to facilitate 
cooperation between Governments to that end. 
109. Discrepancies in government reports on inter-
national trade in narcotic drugs and psychotropic 
substances are regularly investigated with the competent 
authorities of the relevant countries to ensure that no 
diversion of narcotic drugs and psychotropic substances 
from licit international trade takes place. Those investi-
gations may reveal shortcomings in the implementation 
of control measures for narcotic drugs and psychotropic 
substances, including the failure of companies to comply 
with national drug control provisions.
110. Since May 2018, investigations regarding discrep-
ancies for 2017 related to the trade in narcotic drugs have 
been initiated with 50 countries. As at 1 November 2018, 
replies had been received from 36 countries. The responses 
indicated that the discrepancies had been caused by 
clerical and technical errors in preparing the reports, 
reporting on exports or imports of preparations in 
Schedule III of the 1961 Convention without indicating 
it on the form, or inadvertent reporting of transit 
countries as trading partners. In some cases, countries 
confirmed the quantities reported by them, resulting in 
the initiation of follow-up investigations with their 
trading partners. Reminder letters will be sent to the 
countries that did not reply.
111. Similarly, with regard to international trade in psy-
chotropic substances, investigations into 293 discrepan-
cies related to 2016 data were initiated with 63 countries. 
As at 1 November 2018, 24 countries had provided replies 
relating to those discrepancies, leading to the resolution 
of 29 of those discrepancies. In all cases in which the data 
provided were confirmed by the responding countries, 
follow-up actions with the counterpart countries were ini-
tiated as required. All the responses received indicated 
that the discrepancies had been caused by clerical or tech-
nical errors: in most cases, either the failure to convert 
amounts into anhydrous base or “overlapping”, i.e., an 
export in a given year being received by the importing 
country only at the beginning of the following year. None 
of the cases investigated indicated a possible diversion of 
psychotropic substances from international trade.
112. With regard to precursors, the 1988 Convention 
requires parties to prevent the diversion of precursors 
from international trade to the illicit manufacture of nar-
cotic drugs and psychotropic substances. In line with the 
provisions of article 12 of the 1988 Convention, which 
have been complemented by a number of General 
Assembly, Economic and Social Council, and Commission 
on Narcotic Drugs resolutions, Governments have imple-
mented a number of measures that have contributed to 
the effective monitoring of the movement of substances 
listed in Tables I and II of that Convention and to limit-
ing cases of diversion from licit international trade. As a 
result, Governments are facing new challenges, including 
the emergence of non-scheduled chemicals and diversion 
of substances listed in Tables I and II from domestic dis-
tribution channels. This is where voluntary public-private 
partnerships, which complement existing legislative 
frameworks, have an increasingly important role to play.
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113. Another important element of effective control 
measures is the real-time exchange of information 
between Governments. INCB, in its efforts to support 
Governments in the prevention and investigation of cases 
of diversion of precursors, has developed several online 
platforms, tools and projects. Over the years, those tools 
have developed notably in terms of usage and in terms 
of the volume of information and level of detail provided 
by some Governments. The two initiatives of the Board 
focusing on precursors used in the illicit manufacture of 
synthetic drugs and on chemicals related to illicit cocaine 
and heroin manufacture, namely Project Prism and 
Project Cohesion, respectively, have also contributed to 
preventing the diversion of controlled substances from 
international trade and from domestic distribution chan-
nels and to closing knowledge gaps during time-bound 
operations.
114. Detailed analysis of the latest trends and develop-
ments in legitimate international trade and in trafficking 
in precursor chemicals under international control, as 
well as their non-scheduled substitutes and alternatives, 
can be found in the report of the Board for 2018 on the 
implementation of article 12 of the 1988 Convention.59 
(d)  Prevention of diversion of precursors 
from domestic distribution channels
115. Diversion of precursors from domestic distribution 
channels remains a major source of substances listed in 
Tables I and II of the 1988 Convention that are used for 
illicit drug manufacture, as the control measures applied 
by Governments to the domestic trade in and distribution 
of chemical substances vary from one country to another 
and often lag behind those used in international trade.
2.  Ensuring the availability of 
internationally controlled 
substances for medical and 
scientific purposes
116. In line with its mandate to ensure the availability 
of internationally controlled substances for medical and 
scientific purposes, the Board carries out various activi-
ties related to narcotic drugs and psychotropic substances. 
The Board monitors action taken by Governments, inter-
national organizations and other bodies to support the 
availability and rational use of controlled substances for 
medical and scientific purposes and provides, through its 
59 E/INCB/2018/4.
secretariat, technical support and guidance to Governments 
in their implementation of the provisions of the inter-
national drug control treaties.
117. To supplement and increase the effectiveness of the 
action mentioned above, in 2016, the Board launched a 
project called INCB Learning. The project provides assis-
tance to Member States in their efforts to achieve full 
compliance with the provisions of the international drug 
control treaties. One of the objectives of the project is to 
ensure the appropriate availability of internationally con-
trolled substances, while preventing their abuse and 
diversion into illicit channels. Several regional training 
seminars were conducted in 2017 and 2018 (see section 
F below for details). The Board will also issue an update 
of its 2015 special report entitled Availability of 
Internationally Controlled Drugs: Ensuring Adequate 
Access for Medical and Scientific Purposes — Indispensable, 
Adequately Available and Not Unduly Restricted.60 
Supply of and demand for opiate raw materials 
118. The Board, in fulfilment of the functions assigned 
to it under the 1961 Convention as amended by the 1972 
Protocol and the relevant resolutions of the Economic 
and Social Council and the Commission on Narcotic 
Drugs, regularly examines issues affecting the supply of 
and the demand for opiates for licit requirements and 
endeavours to ensure a standing balance between that 
supply and demand. The present section contains an anal-
ysis of the current situation based on the data provided 
by Governments. 
119. In order to establish the status of the supply of and 
the demand for opiate raw materials, the Board analyses 
the data provided by Governments on opiate raw 
materials and on opiates manufactured from those raw 
materials. In addition, the Board analyses information on 
the utilization of those raw materials, estimated consump-
tion for licit use and stocks at the global level. A detailed 
analysis of the current situation as it pertains to the 
supply of and the demand for opiate raw materials is 
contained in the technical report of the Board for 2018 
on narcotic drugs.61 
120. The total area of cultivation of opium poppy rich 
in both morphine and thebaine declined in 2017, which 
can be attributed to the fall in demand for opiate raw 
60 E/INCB/2015/1/Supp.1.
61 E/INCB/2018/2.
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material owing to a combination of factors such as the 
opioid crisis in the United States and the change in regu-
lations in Australia and France, where codeine was sched-
uled as a prescription drug, which contributed to a fall in 
demand on the local market in those two countries. 
Morphine
121. The total actual harvested area of opium poppy 
rich in morphine was 46,025 ha in 2017, down from 
53,765 ha in 2016. In 2017, the actual harvested area of 
opium poppy rich in morphine decreased from the 
amount of the previous year in all major producing coun-
tries except India. In Australia, the actual harvested area 
decreased by 53 per cent compared with 2016; in Hungary, 
by 43 per cent; in Spain, by 43 per cent; and in France, 
by 28 per cent. 
122. The total production of morphine-rich opiate raw 
materials in the main producing countries decreased to 
282 tons in morphine equivalent in 2017, from 463 tons 
in 2016. Australia continued to be the largest producer in 
2017, with 67 tons, followed, in descending order, by 
France, Turkey, Spain, Hungary and India. Australia’s 
production in 2017 declined by more than 63 per cent 
compared with 2016 mainly due to the decrease in demand 
for those raw materials. Australia, France, Turkey and India 
accounted for 83 per cent of global production in 2017.
123. Stocks of opiate raw materials rich in morphine 
(poppy straw, concentrate of poppy straw and opium) 
held at the end of 2017 amounted to about 725 tons in 
morphine equivalent, a slight decrease from the level at 
the end of 2016. Those stocks were considered sufficient 
to cover 19 months of expected global demand by manu-
facturers at the 2018 level of demand. In 2017, Turkey 
was the country with the largest stocks of opiate raw 
materials (161 tons in morphine equivalent, mainly in 
the form of poppy straw and concentrate of poppy straw), 
followed by France (128 tons), Australia (106 tons), Spain 
(99 tons), India (66 tons, all in the form of opium), the 
United Kingdom (66 tons), the United States (39 tons), 
Slovakia (27 tons), Belgium (17 tons) and Japan 
(11 tons). Those 10 countries together accounted for 99 
per cent of global stocks of opiate raw materials rich in 
morphine. The remaining stocks were held in other 
producing countries and in countries importing opiate 
raw materials. 
124. Global stocks of opiates based on morphine-rich 
raw materials, mainly in the form of codeine and 
morphine, held at the end of 2017 amounted to 517 tons 
in morphine equivalent, which was considered sufficient 
to cover global demand for those opiates for about 
14 months. On the basis of data reported by Governments, 
total stocks of both opiates and opiate raw materials are 
fully sufficient to cover demand for medical and scien-
tific purposes for morphine-based opiates.
125. From 2009 until 2016, global production of opiate 
raw materials rich in morphine exceeded global demand. 
As a result, stocks had been increasing, with some 
fluctuation. However, in 2017, for the first time in many 
years, production was less than demand, which led to a 
decrease in stocks, to 725 tons in morphine equivalent, 
at the end of the year. Stocks at the end of 2017 were 
sufficient to cover expected global demand for about 
19 months.
Thebaine
126. The total actual harvested area of opium poppy 
rich in thebaine in 2017 decreased by 16 per cent 
compared with 2016. The harvested area of opium poppy 
rich in thebaine decreased by 36 per cent in Spain and 
by 31 per cent in Australia, while it increased by 74 per 
cent in France.
127. In 2017, the global production of opiate raw mate-
rials rich in thebaine was 229 tons in thebaine equiva-
lent, of which Australia accounted for about 82 per cent 
and Spain and France for about 8 per cent each. India 
accounted for the remaining 2 per cent. The production 
in 2017 increased by 22 per cent relative to 2016. 
128. Stocks of opiate raw materials rich in thebaine 
(poppy straw, concentrate of poppy straw and opium) 
increased to 244 tons in thebaine equivalent at the end 
of 2017, up from 224 tons at the end of 2016. Those stocks 
are sufficient to cover the expected global demand by 
manufacturers for about 13 months. 
129. Global stocks of opiates based on thebaine-rich 
raw material (oxycodone, thebaine and a small quantity 
of oxymorphone) increased to 269 tons in thebaine equiv-
alent at the end of 2017, up from 242 tons in 2016. Stocks 
were sufficient to cover global demand for thebaine-based 
opiates for medical and scientific purposes for about 
21 months.
130. Because global production of opiate raw materials 
rich in thebaine increased to 229 tons in 2017 (up from 
187 tons in 2016) at the same time as demand declined 
to 190 tons (down from 210 tons in 2016), stocks 
increased, reaching 244 tons at the end of 2017, which 
was the equivalent of global demand for 13 months.
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C.  Governments’ cooperation with 
the Board
1.  Provision of information by 
Governments to the Board
131. In accordance with its mandate, the Board pub-
lishes its annual report and the report of the Board on 
the implementation of article 12 of the 1988 Convention. 
It also publishes technical reports that provide 
Governments with an analysis of statistical information 
on the manufacture, consumption, utilization and stocks 
of and trade in internationally controlled substances, 
together with an analysis of estimates and assessments of 
requirements for those substances.
132. The Board’s reports and technical publications are 
produced on the basis of information that parties to the 
international drug control treaties are obligated to sub-
mit. In addition, pursuant to resolutions of the Economic 
and Social Council and the Commission on Narcotic 
Drugs, Governments voluntarily provide information in 
order to facilitate an accurate and comprehensive evalu-
ation of the functioning of the international drug and 
precursor control system.
133. The data and other information received from 
Governments enable the Board to monitor licit activities 
involving narcotic drugs, psychotropic substances and 
precursor chemicals and to evaluate treaty compliance 
and the overall functioning of the international drug con-
trol system. On the basis of its analysis, the Board makes 
recommendations to improve the workings of the system 
with a view to ensuring the availability of narcotic drugs 
and psychotropic substances for medical and scientific 
needs, while at the same time preventing their diversion 
from licit into illicit channels and preventing the diver-
sion of precursors to illicit drug manufacture.
2.  Submission of statistical 
information
134. Governments have an obligation to furnish to the 
Board the annual and quarterly statistical reports required 
by the international drug control conventions.
(a) Narcotic drugs
135. As at 1 November 2018, the Board had received 
annual statistics reports from 169 States (both parties 
and non-parties) and territories on the production, 
manufacture, consumption, stocks and seizures of 
narcotic drugs covering the calendar year 2017 (form C), 
or about 79 per cent of those requested. That number was 
higher than in 2017 (when 164 reports pertaining to 2016 
were received) and significantly higher than in 2016 
(when 157 reports pertaining to 2015 were received). 
136. A total of 114 Governments (53 per cent) submit-
ted their data on time, that is, by the deadline of 30 June, 
which was more than in the two preceding years 
(89 countries in 2017 and 84 in 2016). As at 1 November 
2018, 44 Governments (20 per cent), or 39 countries 
(18 per cent) and 5 territories (2 per cent) had not sub-
mitted their annual statistics for 2017. It is expected that 
several (10–15) additional countries and territories will 
be submitting the data over the coming months. Most 
countries and territories that have not submitted their 
reports are in Africa, Central America and the Caribbean, 
Asia and Oceania, which could be indicative of a lack of 
capacity in the drug control administrations of some 
countries in those regions.
137. Almost all countries that produced, manufactured, 
imported, exported or consumed large amounts of 
narcotic drugs submitted annual statistics in 2017. In its 
annual report for 2016, INCB highlighted the importance 
of accurate and timely reporting for the effectiveness and 
efficiency of the operation of the international drug 
control system and the significant impact that the avail-
ability of reliable data had on the ability of the Board to 
accurately monitor the world situation. The Board, how-
ever, remains very concerned about the quality of some 
of the data provided, especially those from some of the 
major producing and manufacturing countries, as they 
indicate deficiencies in national mechanisms for regulat-
ing and monitoring internationally controlled substances. 
The Board urges Governments to enhance their national 
mechanisms to monitor the cultivation, production and 
manufacture of and trade in controlled substances. This 
may be achieved, in part, by improving and developing 
national data-collection systems, training staff of the 
competent national authorities and ensuring close 
cooperation with companies licensed to deal with inter-
nationally controlled substances.
138. As at 1 November 2018, the complete set of four 
quarterly statistics of imports and exports of narcotic 
drugs for 2017 (form A) had been received from 
152  Governments (136 countries and 16 territories), or 
about 71 per cent of the 213 Governments requested. In 
addition, 21 Governments (about 10 per cent) had 
submitted at least one quarterly report. A total of 
37 countries and 4 territories (about 19 per cent) had 
failed to submit any quarterly statistics for 2017.
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(b) Psychotropic substances
139. As at 1 November 2018, annual statistical reports 
for 2017 on psychotropic substances (form P) had been 
submitted to the Board in conformity with article 16 of 
the 1971 Convention by 147 States and territories, 
amounting to 69 per cent of those required to do so. In 
addition, 115 Governments had voluntarily submitted all 
four quarterly statistical reports on imports and exports 
of substances listed in Schedule II of the 1971 Convention 
for 2017, in conformity with Economic and Social Council 
resolution 1981/7, and a further 39 Governments had 
submitted several quarterly reports. 
140. While the majority of Governments regularly sub-
mit their mandatory and voluntary statistical reports, the 
cooperation of some has not been satisfactory. In 2018, 
about 60 per cent of the countries that submitted form P 
for 2017 did so by the deadline of 30 June 2018. Among 
those that failed to submit form P by the deadline were 
major manufacturing, importing and exporting countries 
such as Belgium, Brazil, China and France.
141. The Board notes with concern that the number of 
countries and territories that have not furnished form P 
continues to be highest in Africa (30, or 53 per cent of 
countries and territories in that region),62 followed by 
Oceania (11, or 50 per cent)63 and Central America and 
the Caribbean (13, or 46 per cent).64 Form P for 2017 was 
furnished by all countries and territories in Europe and 
by all countries in North America. In South America, two 
countries (15 per cent) failed to furnish form P for 2017.65 
In Asia, 9 countries,66 or 19 per cent of countries and ter-
ritories in the region, did not furnish form P for 2017.
142. The Economic and Social Council, in its resolu-
tions 1985/15 and 1987/30, requested Governments to 
provide the Board with details on trade (data broken 
down by countries of origin and destination) in sub-
stances listed in Schedules III and IV of the 1971 
Convention in their annual statistical reports on 
62 Ascension, Burkina Faso, Burundi, Cameroon, Central African 
Republic, Chad, Comoros, Congo, Côte d’Ivoire, Djibouti, Equatorial 
Guinea, Eritrea, Ethiopia, Gabon, Gambia, Guinea, Guinea-Bissau, Kenya, 
Lesotho, Libya, Mali, Mauritania, Mauritius, Niger, Sao Tome and 
Principe, Senegal, Somalia, South Sudan, Togo and Tristan da Cunha. 
63 Cook Islands, French Polynesia, Kiribati, Marshall Islands, Nauru, 
Niue, Papua New Guinea, Samoa, Solomon Islands, Tuvalu, and Wallis 
and Futuna Islands. 
64 Anguilla, Antigua and Barbuda, Aruba, Bermuda, British Virgin 
Islands, Cayman Islands, Cuba, Curaçao, Dominican Republic, Grenada, 
Honduras, Saint Kitts and Nevis, and Trinidad and Tobago. 
65 Paraguay and Suriname.
66 Bangladesh, Cambodia, Iraq, Kyrgyzstan, Mongolia, Singapore, 
Turkmenistan, Viet Nam and Yemen. 
psychotropic substances. As at 1 November 2018, com-
plete details on such trade had been submitted by 98 
Governments (70 per cent of all submissions of form P 
for 2017), which is slightly lower than for 2016. The 
remaining 42 Governments submitted blank forms or 
forms containing incomplete trade data for 2017. 
143. The Board notes with appreciation that a number 
of countries have already submitted consumption data 
for psychotropic substances on a voluntary basis in 
accordance with Commission on Narcotic Drugs resolu-
tion 54/6. Thus, for 2017, a total of 73 countries and 
territories submitted data on the consumption of some 
or all psychotropic substances, which is more than for 
2016. The Board appreciates the cooperation of the 
Governments concerned and calls upon all Governments 
to report on the consumption of psychotropic sub-
stances on an annual basis pursuant to Commission 
resolution 54/6, as such data are essential for an 
improved evaluation of the availability of psychotropic 
substances for medical and scientific purposes. 
144. The Board notes with appreciation that reports on 
seizures of psychotropic substances were furnished by the 
Governments of India and Romania, and that notifica-
tions of seizures of internationally controlled substances 
smuggled through the mail, including those ordered over 
the Internet, were furnished by the Governments of 
Lithuania, Norway and Romania pursuant to Commission 
on Narcotic Drugs resolution 50/11. The Board acknowl-
edges the interdiction efforts of the Governments con-
cerned and calls upon all Governments to furnish 
regularly to the Board information on seizures of inter-
nationally controlled substances ordered over the Internet 
and delivered through the mail, pursuant to Commission 
on Narcotic Drugs resolution 50/11. 
(c) Precursors
145. In accordance with article 12 of the 1988 Convention, 
parties are obliged to furnish information on substances 
frequently used in the illicit manufacture of narcotic drugs 
and psychotropic substances. That information, provided 
on form D, assists the Board in monitoring and identify-
ing trends in trafficking in precursors and the illicit manu-
facture of drugs. It also enables the Board to provide 
Governments with recommendations concerning reme-
dial action and policies, as necessary.
146. As at 1 November 2018, a total of 120 States 
parties, corresponding to nearly 64 per cent of the States 
parties to the 1988 Convention, had submitted form D 
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for 2017. However, there continued to be a number of 
States parties submitting blank forms or forms contain-
ing incomplete information. 
147. Of the States parties that provided data on form D 
for 2017, 79 reported the mandatory information on 
seizures of substances in Tables I and II of the 1988 
Convention, and 51 reported seizures of non-scheduled 
substances. As in previous years, most Governments did 
not provide details on the methods of diversion and illicit 
manufacture.
148. Pursuant to Economic and Social Council resolu-
tion 1995/20, Governments are also requested to provide 
information regarding their licit trade in substances listed 
in Tables I and II of the 1988 Convention on a voluntary 
and confidential basis. As at 1 November 2018, 115 States 
parties had provided such information for 2017 to the 
Board, and 109 had furnished data on licit uses of and/
or requirements for one or more of the substances in 
Tables I and II of the 1988 Convention.
149. Complementing PEN Online, as well as the 
aggregated seizure data received annually from 
Governments through form D, PICS has, since early 2012, 
provided a secure online platform for sharing informa-
tion in real time on chemical-related incidents such as 
seizures, shipments stopped in transit, diversion attempts 
and the dismantling of illicit laboratories. PICS has 
provided leads for national authorities to initiate back-
tracking investigations and, on several occasions, the 
timely communication of details of precursor incidents 
has led to further seizures or has prevented diversion 
attempts. The usefulness of PICS, however, depends 
largely on the timeliness of the information provided so 
that it can facilitate immediate follow-up and cooperation 
to identify those responsible for the diversion of and 
trafficking in precursors. 
150. As at 1 November 2018, PICS had registered users 
from more than 240 agencies in 109 countries, who had 
shared information about more than 2,300 incidents. 
During the reporting period, more than 230 new inci-
dents were communicated through PICS.
3.  Submission of estimates and 
assessments
(a) Narcotic drugs
151. Under the 1961 Convention, parties and non- 
parties are requested to provide the Board each year with 
estimates of their requirements for narcotic drugs for the 
following year. As at 1 November 2018, a total of 
175  States and territories, 82 per cent of those required, 
had submitted estimates of their requirements for nar-
cotic drugs for 2019 for confirmation by the Board. 
Confirmed estimates are valid until 31 December of each 
year and need to be revised annually by Governments. 
152. As in previous years, the Board established 
estimates for those countries and territories that had not 
submitted their estimates on time in accordance with arti-
cle 12 of the 1961 Convention to ensure that these nar-
cotic drugs, many of which are essential in medical 
practice, can be imported. About 90 Governments adjust 
their estimates throughout the year through the submis-
sion of supplementary estimates to the Board. Special 
provisions of the Convention may be used to ensure 
access to narcotic drugs during acute emergencies. 
(b) Psychotropic substances
153. As at 1 November 2018, the Governments of all 
countries except South Sudan and all territories had sub-
mitted to the Board at least one assessment of their 
annual medical and scientific requirements for psycho-
tropic substances. In accordance with Economic and 
Social Council resolution 1996/30, the Board established 
the assessments of requirements for South Sudan in 2011 
to enable that country to import psychotropic substances 
for medical purposes without undue delay.
154. In line with Economic and Social Council resolu-
tions 1981/7 and 1991/44, Governments are requested to 
provide to the Board assessments of their annual medi-
cal and scientific requirements for psychotropic sub-
stances listed in Schedules II, III and IV of the 1971 
Convention. Assessments for psychotropic substances 
remain in force until Governments modify them to reflect 
changes in national requirements. To facilitate the sub-
mission of such modifications by competent national 
authorities, the Board created a form, entitled “Supplement 
to form B/P”, which has been made available to all 
Governments in the six official languages of the United 
Nations since October 2014 and can be accessed on the 
website of INCB. As at 1 November 2018, almost all coun-
tries were using it. The Board recommends that 
Governments review and update the assessments of 
their annual medical and scientific requirements for 
psychotropic substances at least once every three years. 
155. Between 1 November 2017 and 1 November 2018, 
a total of 96 countries and 8 territories submitted fully 
revised assessments of their requirements for 
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psychotropic substances, and a further 85 Governments 
submitted modifications to their assessments for one or 
more substances. As at 1 November 2018, Governments 
of 41  countries and 4 territories had not submitted any 
revision of their legitimate requirements for psychotropic 
substances for over three years.
(c) Precursors
156. In its resolution 49/3, entitled “Strengthening 
systems for the control of precursor chemicals used 
in the illicit manufacture of synthetic drugs”, the 
Commission on Narcotics Drugs requested Member 
States to provide the Board with annual legitimate 
requirements for imports of four precursors of 
amphetamine-type stimulants — ephedrine, pseu-
doephedrine, 3,4-methylenedioxyphenyl-2-propanone 
(3,4-MDP-2-P), and 1-phenyl-2-propanone (P-2-P) — 
and, to the extent possible, preparations containing those 
substances that could be easily used or recovered by read-
ily applicable means. The estimates help Governments to 
assess the legitimacy of shipments and to identify any 
excesses in pre-export notifications for those substances.
157. Although those estimates are provided to the 
Board on a voluntary basis, as at 1 November 2018, 
166  Governments had provided an estimate of their 
annual legitimate requirements for at least one of the 
above-mentioned substances. During the reporting 
period, more than 80 Governments reconfirmed or 
updated their annual legitimate requirements for at least 
one substance. 
158. Governments provide estimates of annual legiti-
mate requirements for precursors on form D and can 
update them at any time throughout the year. The latest 
annual legitimate requirements, as submitted by countries 
and territories, are regularly updated and published on 
the Board’s website. They are also accessible to registered 
users through PEN Online. 
4.  Improving the quality of information 
provided to the Board
159. The regular submission of comprehensive and 
reliable statistical data from Governments to the Board is 
vital for the proper overall functioning of the inter-
national drug control system and the analysis of global 
trends. Good-quality data also provide information that 
is necessary to uncover diversions of controlled sub-
stances for illicit purposes. 
160. Incomplete submissions, data gaps and other 
problems encountered by Governments in furnishing 
adequate statistics and/or estimates and assessments to 
the Board are often an indication of deficiencies in their 
national control mechanisms and/or health-care systems. 
Such deficiencies may reflect problems in the implemen-
tation of treaty provisions, for instance gaps in national 
legislation, shortcomings in administrative regulations or 
a lack of training for staff of competent national 
authorities.
161. The Board strongly recommends that 
Governments strengthen national mechanisms to mon-
itor the cultivation, production and manufacture of and 
trade in controlled substances. This may be achieved, in 
part, by improving and developing national data-
collection systems, training staff of competent national 
authorities and ensuring that companies licensed to deal 
with internationally controlled substances fulfil the legal 
requirements associated with their licences.
162. The Board invites all Governments concerned to 
identify the causes of deficiencies in reporting statistics 
and/or estimates and assessments to the Board and to 
inform the Board accordingly with a view to resolving 
problems and ensuring adequate and timely reporting. 
To assist Governments, the Board has developed tools 
and kits, as well as several sets of guidelines, for use by 
competent national authorities. They are available on its 
website free of charge and include training materials and 
the Guide on Estimating Requirements for Substances 
under International Control. Governments are invited to 
make full use of those tools in their efforts to comply 
with the international drug control treaties.
D.  Evaluation of overall treaty 
compliance
1.  New developments with regard to 
overall treaty compliance in 
selected countries 
163. The scope of the areas covered by the international 
drug control conventions is vast. The conventions 
encompass regulatory aspects for the monitoring of licit 
production, manufacture and trade in narcotic drugs, 
psychotropic substances and precursor chemicals; estab-
lish the permitted uses for controlled substances; and 
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require States to adopt legislative and policy measures to 
combat drug trafficking and diversion, and to take all 
practicable measures for the prevention of drug abuse and 
for the early identification, treatment, education, aftercare 
and social reintegration of persons affected by drug abuse.
164. As with other international treaty instruments, 
States parties to the international drug control conven-
tions are afforded significant discretion in the adoption 
of the policy, legislative and administrative measures they 
opt for in their efforts to implement their treaty 
obligations.
165. It remains that, as States parties to the international 
drug control conventions, States must adhere to the fun-
damental legal tenets set forth in those treaties, which 
include the limitation of use of narcotic drugs and psy-
chotropic substances exclusively to medical and scientific 
purposes, the respect for human rights and human dig-
nity, the adequate provision of controlled substances to 
meet legitimate medical needs, and the adherence to the 
principle of proportionality in the formulation of drug-
related criminal justice policy.
166. In carrying out its mandate as the treaty monitor-
ing body responsible for reviewing the implementation of 
the three international drug control conventions, the 
Board reviews developments in States parties with the 
aim of identifying any shortcomings in the implementa-
tion of those conventions by States with a view to recom-
mending remedial action, which may include the 
application of good practices that may have been adopted 
in other jurisdictions. 
167. The Board’s evaluation of the status of implemen-
tation by States of their legal obligations pursuant to the 
international drug control conventions is informed by its 
ongoing dialogue and exchange of information with 
Governments, including through extensive correspond-
ence, meetings with Government representatives, country 
missions, participation in INCB initiatives, and through 
the submission of statistical reports to the Board. In the 
period under review, the Board reviewed the drug 
control situation in Canada, Denmark, Myanmar, Poland 
and South Africa.
(a) Canada
168. Since the Government of Canada announced its 
intention to pursue the legalization and regulation of 
cannabis for non-medical purposes, the Board has main-
tained an ongoing dialogue with the country’s authorities 
on the matter, including through a high-level mission to 
the country led by the President of the Board in 2016, a 
written submission to the Standing Senate Committee on 
Foreign Affairs and International Trade, several meetings 
with senior representatives of the Government and an 
extensive exchange of correspondence.
169. Throughout this extensive consultation process, the 
Board has stressed that the legalization and regulation of 
cannabis for non-medical and non-scientific purposes 
would be a violation of the provisions of the international 
drug control conventions, notably the 1961 Convention as 
amended, which includes, in its article 4 (c), the general 
obligation for States parties to “limit exclusively to medi-
cal and scientific purposes the production, manufacture, 
export, import, distribution of, trade in, use and posses-
sion of drugs.” 
170. In June 2018, Bill C-45 (the Cannabis Act), on 
legalizing and regulating the consumption of cannabis for 
non-medical and non-scientific purposes, received royal 
assent. 
171. With the passage of the legislation, which entered 
into force on 17 October 2018, individuals aged 18 years 
of age or older are legally permitted to purchase cannabis 
products (dried herb, oil, plants and seeds) from retailers 
regulated by the provincial and territorial governments. 
They may also possess up to 30 g of cannabis, share up 
to 30 g of dried cannabis or equivalent with other adults, 
cultivate up to 4 cannabis plants per household and pre-
pare edible cannabis products for personal use.
172. Through the passage of Bill C-45, the Government 
of Canada has chosen to put itself in a situation of default 
of its international obligations, not only under the 1961 
Convention as amended but also the 1988 Convention, 
which obliges States parties to establish as criminal 
offences under their domestic law the production, 
manufacture, extraction, preparation, offering, offering 
for sale, distribution, sale and delivery on any terms 
whatsoever any narcotic drug or any psychotropic 
substance contrary to the provisions of the 1961 
Convention, the 1961 Convention as amended or the 
1971 Convention.
173. The incompatibility of Bill C-45 with its inter-
national legal obligations under the three international 
drug control conventions has also been repeatedly 
acknowledged publicly by senior members of the 
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Government of Canada. The Board is concerned that the 
legalization of the use of cannabis for non-medical 
purposes undermines the international legal drug control 
framework and constitutes a dangerous precedent for the 
respect of the rules-based international order.
174. In addition, the Board is concerned that the 
measures envisaged in Bill C-45 would lead to reduced 
perceptions of harm and to higher rates of cannabis use, 
particularly among young people, through greater avail-
ability of the drug and weaknesses in control measures, 
including with regard to the authorization of personal 
cultivation in households. The Board notes that the rates 
of cannabis abuse among young people in Canada are 
already among the highest in the world.
175. In the exercise of its mandate, the Board will 
remain seized of the matter and will continue to engage 
with Canada and other members of the international 
community in addressing it.
(b) Denmark
176. During the reporting period, the Board continued 
to monitor drug-related developments in Denmark and 
engaged in dialogue with the Government on various 
issues, including the recent introduction of a medical 
cannabis pilot programme in the country. 
177. According to the information provided by the 
Government, Denmark adopted legislation on a medical 
cannabis pilot project in December 2017 that is intended 
to serve as the legal basis for a four-year medical cannabis 
pilot project. The law allows licensed medical doctors to 
prescribe cannabis for medical purposes to eligible patients. 
Once the prescription has been obtained, the patient can 
purchase, from a licensed pharmacy, cannabis that has 
been produced under good manufacturing practice rules 
of the Danish Medicines Agency and approved by the 
Agency. The number of patients, patterns of prescription 
and side effects are monitored through the register of all 
prescriptions and other reports collected from the licensed 
doctors, which are accessible to the Danish Medicines 
Agency and other relevant government agencies.
178. Patients with the following medical conditions may 
be eligible for treatment under the programme: multiple 
sclerosis, chronic pain, spinal cord injuries and 
chemotherapy-induced nausea and vomiting. In addition, 
under the new law, companies in Denmark can also 
receive approval for cultivation or repackaging of canna-
bis for medical purposes, which can then be used either 
for export or for domestic consumption. However, at the 
initial stage, the cannabis for the pilot project would have 
to be imported until the approved companies start 
cultivating cannabis in Denmark. The Government of 
Denmark has expressed its commitment to importing, 
cultivating and exporting cannabis for medical use, as 
well as reporting of estimates and statistical returns, in 
line with the relevant provisions of the 1961 Convention 
as amended.
179. On its website (https://laegemiddelstyrelsen.dk/en), 
the Danish Medicines Agency has published some details 
of the pilot project that are addressed to medical doctors 
and patients. The Agency states that the cannabis products 
included in the pilot programme are not authorized medi-
cines in either Denmark or other countries, and that the 
products have rarely been tested in clinical trials. The web-
site provides some guidelines for doctors based on experi-
ences in other countries in this area and contains a warning 
that doctors should take full responsibility for the product 
they prescribe, keeping in mind that they might not have 
the same knowledge of effects and side effects compared 
with authorized medicines. The Danish Medical Association 
has advised doctors that prescribing cannabis could com-
promise the health of their patients because no clinical tri-
als have provided clear evidence on the efficacy or adverse 
effects of consuming cannabis for medical purposes. 
180. The Board will continue to monitor the develop-
ments regarding the pilot medical cannabis programme 
in Denmark and urges the Government of Denmark to 
continue to meet its stated commitment to developing 
its medical cannabis scheme in accordance with the 
provisions of the 1961 Convention as amended and with 
the Board’s recommendations published in chapter II of 
its annual report for 2017, in particular paragraphs 177 
and 178.
(c) Myanmar
181. In February 2018, the Central Committee for Drug 
Abuse Control of Myanmar released its national drug 
control policy. The policy was developed in conjunction 
with the Myanmar Police Force and the Ministry of Home 
Affairs, with the support of UNODC. 
182. The national drug control policy was developed fol-
lowing wide-ranging consultations with over 150 national 
experts and is aimed at incorporating international best 
practices, aligning approaches with the outcome document 
of the special session of the General Assembly on the world 
drug problem held in 2016, complying with the inter-
national drug control conventions and supporting the 
achievement of the Sustainable Development Goals. 
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183. According to the Central Committee for Drug 
Abuse Control, the policy is the result of an acknowledg-
ment by the Government that the country’s previous drug 
control approaches, based primarily on Government-led 
supply-reduction initiatives such as opium poppy eradi-
cation, needed to be reviewed. 
184. The new strategy also represents an important 
departure from previous policy through its involvement of 
non-governmental organizations and civil society stake-
holders, its emphasis on health and social policy responses 
in addition to criminal justice mechanisms, its promotion 
of sustainable alternative development for opium poppy 
farmers and its emphasis on international cooperation.
185. The national drug control policy sets out general 
objectives grouped into five main thematic areas: (a) sup-
ply reduction and alternative development; (b) demand 
reduction and harm reduction; (c) international cooper-
ation; (d) research and analysis; and (e) compliance with 
human rights.
186. In order to meet the objectives established by 
Myanmar in its national drug control policy, a series of 
measures are foreseen, including: strengthening the legal 
framework to combat drug-related offences and money-
laundering and corruption related to drug offences; 
reviewing legislation related to drug control every five 
years and training prosecutors, judges and law enforce-
ment personnel in drug case management; developing 
and implementing alternative development programmes, 
including through the creation of opportunities for sus-
tainable livelihoods, and the development of infrastruc-
ture and human resources; bolstering prevention initiatives 
aimed at the general population as well as those targeted 
at children, young people, women and vulnerable popu-
lations; improving the quality of treatment, rehabilitation 
and social-reintegration services; more effectively regulat-
ing the availability of controlled substances for medical 
purposes; increasing international cooperation in the field 
of drug control; and investing in research and analysis in 
order to inform the development of an evidence-based 
and targeted drug policy. The national drug control pol-
icy is scheduled to be implemented over the next five 
years, with regular evaluations to be carried out.
187. In addition to the adoption of the national drug 
control policy, the Government of Myanmar has made a 
series of legislative amendments to the main drug con-
trol law, the 1993 Narcotic Drugs and Psychotropic 
Substances Law. The amendments include the insertion 
of references to the international drug control conven-
tions and to the use of international cooperation mecha-
nisms; the inclusion of alternative livelihood measures; 
and the institutionalization of harm-reduction approaches 
to drug treatment and prevention. 
188. The Board will continue to monitor the continued 
implementation by the Government of Myanmar of its 
national drug control policy, as well as other develop-
ments related to the implementation of the international 
drug control conventions.
(d) Poland
189. In November 2017, amendments to the Act on 
Counteracting Drug Addiction, which serve as a legal 
basis for introducing access to cannabis upon prescrip-
tion, entered into force in Poland. Under the amended 
legislation, cannabis from imported plants can be 
processed into medicines at registered pharmacies in 
Poland. To manufacture medicines from cannabis plants, 
pharmacies must obtain authorization from the country’s 
Office for the Registration of Medicinal Products, Medical 
Devices and Biocidal Products.
190. According to the Polish Pharmaceutical Chamber, 
pharmacists will be given specific training if required. 
The Chamber also estimated that there are up to 300,000 
patients who could qualify for medical cannabis treatment 
in Poland. The legislation does not permit the 
cultivation of cannabis by patients or by any other persons; 
Poland currently imports cannabis from the Netherlands. 
191. The new legislation stipulates that, to use cannabis 
for medical purposes, patients must receive permission 
from a regional pharmaceutical inspector in addition to 
a prescription from a physician. The qualifying conditions 
for cannabis use for medical purposes include, but are 
not limited to, chronic pain, chemotherapy-induced 
nausea, multiple sclerosis, spasticity and treatment- 
resistant epilepsy. 
192. The Board will continue to monitor the drug-
related developments in Poland, including its newly 
implemented medical cannabis programme. The Board is 
currently engaged in a dialogue with the authorities of 
Poland in order to secure additional information on the 
new programme and the compliance thereof with the 
international drug control treaties.
(e) South Africa
193. The Board notes that, in September 2018, the 
Constitutional Court of South Africa ruled that the 
prohibition of private possession and consumption of 
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cannabis and the cultivation of cannabis for personal use 
was unconstitutional, as it violated section 14 of the 
Constitution of South Africa, which guarantees the right 
of citizens to privacy. 
194. The Court’s ruling is a result of an appeal by the 
Government against the High Court ruling that legalized 
cannabis use for personal purposes in 2017. The Board 
acknowledges the fact that the Government argued in 
those proceedings that legalizing cannabis for personal 
use was not in line with the constitutional values of South 
Africa, because it would harm citizens. Nevertheless, in 
its latest judgment, the Constitutional Court declared that 
the provisions of the national legislation prohibiting the 
use of and the possession and cultivation for personal 
consumption of cannabis by an adult in a private place 
were unconstitutional and, therefore, invalid. It also held 
that the right to privacy extends “beyond the boundaries 
of a home”. 
195. The Board notes that it was underlined in the judg-
ment that the use or possession of cannabis by a child any-
where, or by an adult in public, was not decriminalized. 
The Constitutional Court suspended the order of invalid-
ity for a period of 24 months to give Parliament the oppor-
tunity to “correct the constitutional defects” in the national 
legislation. The Court also stated that, during the period 
of suspension of invalidity, it would not be a criminal 
offence for an adult person to use or to possess or culti-
vate cannabis for personal consumption in private.
196. The Board will continue monitoring the develop-
ments in South Africa regarding the Constitutional 
Court’s decision and its effects on national legislation and 
practice, including the adoption by the Government of 
South Africa of any guidance for police to deal with cases 
of personal use of cannabis until the Parliament adopts 
the legislative changes. The Board will continue to engage 
in dialogue with the authorities of South Africa to facil-
itate the full compliance of the country with the provi-
sions of the international drug control treaties, including 
those related to limiting the use of controlled substances 
to medical and scientific purposes.
2. Country missions
197. As part of its treaty-monitoring functions, INCB 
undertakes a series of country missions each year. The 
conduct of country missions is an essential tool for the 
Board in informing its analysis of the implementation by 
States parties of their obligations under the various 
facets of the international drug control conventions.
198. By enabling the Board to meet with relevant 
national stakeholders including legislators, policymakers, 
representatives of regulatory authorities, customs and law 
enforcement officials, medical practitioners, persons 
involved in prevention and treatment efforts and repre-
sentatives of civil society groups, country missions con-
tribute to the Board gaining a comprehensive overview 
of the drug control frameworks in place and identifying 
both areas for improvement and best practices. Discussions 
with national stakeholders are held on a confidential 
basis, so as to encourage frank and open dialogue.
199. On the basis of its analysis of the information gath-
ered during a country mission, the Board adopts a series 
of recommendations for improving compliance with the 
international drug control conventions. Those recom-
mendations are then transmitted confidentially to the 
Government of the country that hosted the mission for 
its consideration and implementation. 
200. During the period under review, the Board under-
took missions to Armenia, Australia, Botswana, Estonia, 
France, Germany, Guyana, Luxembourg, Mauritius, 
Mongolia, Nepal, the Netherlands, Qatar, the Russian 
Federation, Switzerland, Tunisia, the United Arab 
Emirates and the United Kingdom.
201. At the time of finalizing the present report, 
missions to Jamaica and Paraguay were due to take place 
in late November and early December 2018. Additional 
missions have been accepted in principle by the 
Governments of Chile, Colombia, Côte d’Ivoire, Dominica, 
Maldives, Mauritania, New Zealand and the Philippines, 
but the plans for those missions have not yet been final-
ized. In addition, the Board has contacted the Governments 
of Belize, the Democratic People’s Republic of Korea, the 
Gambia, Grenada, Guinea, Kazakhstan, Kuwait, 
Kyrgyzstan, the Lao People’s Democratic Republic, 
Liberia, Madagascar, Montenegro, the Niger, Rwanda, 
South Sudan, Suriname, Tajikistan, the former Yugoslav 
Republic of Macedonia, Trinidad and Tobago, Ukraine, 
the United States and Uzbekistan, as well as of Kosovo,67 
but has not yet received confirmation of acceptance of a 
mission. In the case of the Philippines, the Board has 
invited representatives of the Government to attend one 
of its sessions for consultations. 
67 All references to Kosovo in this report should be understood to be 
in the context of Security Council resolution 1244 (1999).
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(a) Armenia
202. In June 2018, the Board undertook a mission to 
Armenia with the objective of discussing developments 
related to the country’s implementation of the three inter-
national drug control conventions since the Board’s 
previous mission to the country, in 2010. 
203. Armenia has, in recent years, reported increases in 
seizures of narcotic drugs including cocaine, opium and 
cannabis resin, which may indicate that the country is 
increasingly being targeted as a transit country. While 
illicit drug use in the country is thought to be moderate, 
its exact extent is difficult to gauge in the light of the 
limited epidemiological data available. 
204. The Board notes that various legislative and regula-
tory reforms are currently under way in Armenia in the 
field of drug control and welcomes those aimed at facili-
tating greater access to narcotic drugs and psychotropic 
substances for rational medical use, as well as those aimed 
at ensuring proportional responses to drug-related offences, 
in particular offences committed by people who use drugs.
(b) Australia
205. In November 2017, the Board undertook a mission 
to Australia in order to discuss the country’s implemen-
tation of the three international drug control conventions 
since the previous mission to the country, in 2009.
206. Owing to its large size, long coastline and lucrative 
illicit drug market, Australia is a target for international 
drug trafficking syndicates. While the country’s remoteness 
presents some obstacles to trafficking, the higher price paid 
for drugs smuggled into the country acts as an incentive 
for traffickers. Australian law enforcement and customs 
authorities continue to report record drug seizures for 
many drugs such as cocaine, MDMA and methampheta-
mine. According to official statistics, Australia has one of 
the highest rates of methamphetamine use in the world, 
with the number of users growing. 
207. The Board notes the significant efforts and 
resources being deployed by the Government of Australia 
in the implementation of its drug control policy, includ-
ing the adoption of the National Drug Control Strategy 
2017–2026, as well as the continued implementation of 
the “National Aboriginal and Torres Strait Islander 
Peoples’ drug strategy 2014–2019” and the National Ice 
Action Strategy. The Board also notes the country’s strong 
commitment to multilateralism and its support for 
regional and international drug control efforts.
(c) Botswana
208. A mission of the Board was carried out to Botswana 
in June 2018. Botswana is a party to the 1961 Convention 
as amended, the 1971 Convention and the 1988 
Convention. 
209. The objective of the mission was to obtain updated 
information on the Government’s policy, national legisla-
tion and practical experiences in the area of drug control 
and to re-engage in dialogue about the country’s compli-
ance with the conventions. The country’s treaty obliga-
tions and the availability of narcotic drugs and psychotropic 
substances were among the main issues discussed.
(d) Estonia
210. In April 2018, the Board carried out a mission to 
Estonia. The objective of the mission was to review the 
implementation of the international drug control treaties 
by Estonia and to examine drug control developments 
since the Board’s previous mission to the country, in 2006.
211. Estonia is a party to all three international drug 
conventions. It acceded to both the 1961 Convention and 
the 1971 Convention in 1996 and to the 1988 Convention 
in 2000.
212. The Board notes that the Government of Estonia 
is committed to the objectives of the international drug 
control treaties, that the national legislation provides ade-
quate basis for their implementation and that the man-
datory reports by Estonia to the Board are up to date and 
of high quality. The high number of fentanyl-related opi-
oid overdose deaths and new cases of HIV infection 
among people who inject drugs were also among the sub-
jects discussed during the mission. 
(e) France
213. In June 2018, the Board conducted a mission to 
France, the first since 1999, to discuss the implementa-
tion of the international drug control legal framework 
with national stakeholders. France is a party to the three 
international drug control conventions.
214. Following legislative changes overhauling its health 
system in 2016, France launched a six-year trial pro-
gramme aimed at reducing the harms associated with 
drug use through the establishment of so-called “reduced-
risk drug consumption rooms” in the cities of Paris and 
Strasbourg. The country is also engaged in a process of 
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legislative reform aimed at developing a proportionate 
and practicable system to address drug-related crimes of 
a minor nature.
215. The Board recognizes the strong commitment of 
the Government of France to the objectives of the inter-
national drug control conventions and the significant 
resources that the country has invested in the pursuit of 
a balanced and evidence-based drug policy.
(f ) Germany
216. The Board undertook a mission to Germany in 
September 2018. The objective of the mission was to 
review the drug control situation in Germany and the 
Government’s compliance with the three international 
drug control conventions. The Board notes that the 
Government of Germany continues addressing all aspects 
of the drug problem through an integrated and balanced 
approach. The previous mission of the Board had taken 
place in 2003. 
217. The Board notes that, under legislation adopted in 
March 2017, use of cannabis for medical purposes is per-
mitted only as the last available treatment option and 
when there is the prospect of a noticeable improvement 
in the health of the patient and subject to strict prescrip-
tion criteria by certified medical practitioners. 
218. The mission visited a “drug consumption room” 
and a number of facilities for the treatment and rehabil-
itation of drug-dependent individuals. The Board notes 
the efforts of the authorities to ensure that “drug con-
sumption rooms” are well integrated into and part of a 
wide spectrum of health service facilities provided to 
drug-dependent persons. 
(g) Guyana
219. The Board undertook a mission to Guyana in 
December 2017. The primary objective of the mission was 
to discuss with relevant government counterparts the pro-
gress made by Guyana in the implementation of the inter-
national drug control conventions. The previous mission 
of the Board to Guyana was in 2002, when Guyana had 
just acceded to the 1961 Convention. 
220. Guyana is a transit country, mainly for cocaine 
originating in Colombia and trafficked through Brazil, 
Suriname and Venezuela (Bolivarian Republic of), des-
tined mainly for North America and Europe. Cocaine is 
often concealed in legitimate commodities and trafficked 
using commercial maritime vessels, aeroplanes, human 
couriers, “go-fast” boats or various postal services. 
Trafficking takes place using the poorly monitored 
ports, remote airstrips and porous land borders that are 
difficult to control without proper equipment. 
221. The mission was coordinated by the newly estab-
lished National Anti-Narcotics Agency. Discussions 
focused on compliance with the international drug con-
trol treaties and national and international drug control 
policy, including the National Drug Strategy Masterplan 
(2016–2020), which contains a review and revision of the 
2014–2018 Masterplan.
(h) Luxembourg
222. In October 2018, the Board undertook a mission 
to Luxembourg. The objective of the mission was to 
review the implementation of the international drug con-
trol treaties by Luxembourg and discuss drug control 
developments since the Board’s last visit to the country, 
in 2006.
223. Luxembourg is party to the three international 
treaties. It acceded to the 1961 Convention as amended 
in 1972 and to the 1971 Convention in 1991. It also 
became a party to the 1988 Convention in 1992. 
224. A landlocked country, Luxembourg shares borders 
with Belgium, France and Germany. That, together with 
the facts that 46 per cent of its population of 560,000, are 
foreigners and that it has a very important cross-border 
flow of workers, makes the country vulnerable to drug 
transit and trafficking. 
225. During the mission, the Government demon-
strated its commitment to addressing drug addiction in 
Luxembourg. The Board notes that Luxembourg had 
implemented effective treatment and rehabilitation ser-
vices and also notes efforts in drug prevention. 
226. A thorough description of and information on the 
medical cannabis project was provided to the delegation 
of the Board, including the legislative framework and 
planned prescription practices. 
(i) Mauritius
227. In July 2018, the Board undertook a mission to 
Mauritius. The objective was to review the drug control 
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situation and the Government’s compliance with the three 
international drug control conventions since the previous 
mission of the Board, in 2008.
228. Although located in a strategically important part 
of the Indian Ocean basin, Mauritius is not a significant 
transit country for trafficking in drugs, with most illicit 
drugs entering the country intended for domestic con-
sumption. The Board notes the Government’s efforts to 
tackle drug trafficking, in particular the interdiction 
efforts undertaken by law enforcement and customs 
authorities. Mauritius has also made efforts to deepen 
cooperation with other countries in the Indian Ocean in 
order to combat drug trafficking. During the mission, 
information regarding the country’s drug treatment and 
rehabilitation programmes was provided, along with 
information on demand-reduction initiatives.
229. The Board notes the convening of the independ-
ent Commission of Inquiry on Drug Trafficking and the 
development of a new national drug control master plan, 
expected to be launched in 2019, as examples of the 
country’s commitment to the implementation of the 
international drug control conventions.
(j) Mongolia
230. The Board undertook a mission to Mongolia in 
July 2018, with the primary objective of reviewing the 
implementation of the international drug control conven-
tions and discussing with the Government drug policy 
developments since the previous mission of the Board, 
in 1999. 
231. The Board notes the commitment and strong polit-
ical will of the Government to strengthen its efforts with 
regard to national drug control policy. The Board’s dele-
gation was informed about developments in demand and 
supply reduction and noted results achieved through the 
recently adopted national programme on combating traf-
ficking in narcotic drugs and psychotropic substances. 
(k) Nepal
232. In September 2018, the Board undertook a mis-
sion to Nepal. The objective was to review the drug con-
trol situation and the Government’s compliance with the 
three international drug control conventions since the 
previous mission of the Board, in 2007.
233. Located between China and India, with both of 
whom Nepal shares a long open border, and with air links 
to major cities in Asia and the Middle East, Nepal is a 
trans-shipment point for trafficking in drugs. The Board 
notes the Government’s efforts to tackle drug trafficking, 
in particular the trafficking in medicines containing 
internationally controlled substances, as well as its efforts 
to update its national legislation to address new trends 
and ensure that the control of drugs is applied in the 
country’s new federal system. During the mission, infor-
mation was provided regarding the country’s drug treat-
ment and rehabilitation initiatives and on its demand 
reduction initiatives.
234. The Board takes particular note of efforts by the 
Government of Nepal to develop a new multi-tiered drug 
prevention programme for deployment in primary and 
secondary schools to raise awareness of the dangers of 
drug use and provide life skills training to students to 
build greater resilience against drug use.
(l) Netherlands
235. In June 2018, the Board undertook a mission to 
the Netherlands to discuss issues related to the implemen-
tation by the Government of the three international drug 
control conventions, to which the Netherlands is a party. 
The previous mission to the country had taken place 
in 1998.
236. Cannabis and synthetic drugs are illicitly produced 
in and exported from the Netherlands. The country is 
also a transit country for cocaine produced in South 
America and heroin trafficked to the country from 
Afghanistan along the Balkan route. Drug policy in the 
Netherlands has the stated objective of preventing and 
reducing the use of drugs and associated harms through 
outreach work and the delivery of services in so-called 
“low-threshold facilities” and “centres for social addiction 
care”. It is also characterized by a policy of “toleration” of 
the non-medical use of “soft drugs”, a category which 
includes cannabis.
237. The Board acknowledges the commitment of the 
Government of the Netherlands to dialogue on drug 
policy issues. The Board also recognizes the extensive 
efforts and significant investments made by the country 
in its attempts to limit the harms associated with drug 
use.
(m) Qatar
238. The Board undertook a mission to Qatar in 
October 2018. It was the first-ever mission of INCB to 
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Qatar. Qatar has been a party to the 1961 Convention as 
amended since 1986, to the 1971 Convention since 1986 
and to the 1988 Convention since 1990. The primary 
objective of the mission was to review the drug control 
situation in Qatar and to discuss with the Government 
its experience in the implementation of the international 
drug control treaties. The Board notes the commitment 
of Qatar to the implementation of the international drug 
control conventions.
239. The delegation was informed about the Qatar Drug 
Control Strategy for 2018–2022, the main strategic goal 
of which is to protect Qatari society from drugs, focus-
ing on the continuous monitoring and control of the 
ports in coordination with the relevant authorities to 
reduce the supply and demand of drugs. Discussions were 
held on the importance of regional cooperation in that 
area and the delegation of the Board underlined the need 
for all States parties in the region to strengthen their 
cooperation. 
240. The delegation was also informed about the Qatar 
National Health Strategy for 2018–2022, two key aspects 
of which are mental health and cancer control. The Board 
notes the efforts made by Qatar in ensuring the availabil-
ity of controlled substances for medical and scientific 
purposes through its health services. The Board also notes 
the efforts made to provide the population with evidence-
based treatment and rehabilitation services. 
(n) Russian Federation
241. The Board undertook a mission to the Russian 
Federation in November 2017. The primary objective of 
the mission was to review the implementation of the 
international drug control treaties by the Government 
and to examine drug control developments since the pre-
vious mission of the Board, in 2005. The Government is 
committed to the implementation of the letter and the 
spirit of the international drug control treaties. Aware of 
its low rate of consumption of opioid analgesics for medi-
cal purposes, the Government has implemented several 
initiatives aimed at removing regulatory and other barri-
ers to access to those drugs and it is expected that those 
measures will, in the long term, lead to their increased 
availability.
242. The Russian Federation remains an important des-
tination and transit country for heroin produced in 
Afghanistan. There has also been an increase in the illicit 
manufacture of and trafficking in new psychoactive sub-
stances and other synthetic drugs.
(o) Switzerland
243. In November 2017, the Board undertook a mission 
to Switzerland. The objective was to review the drug con-
trol situation and the Government’s compliance with the 
three international drug control conventions. 
244. The Board notes that, since its previous mission, 
in 2000, the Government has made considerable progress 
in the formulation and implementation of an integrated 
drug policy and its action plan. The country has also 
made significant improvement in fulfilling its reporting 
obligations and containing the “open drug scenes” 
through various measures. 
245. In its discussions with representatives of the 
Government, the delegation of the Board was informed 
about the licit manufacture of medicines containing 
controlled substances, the market situation of products 
containing CBD and the challenges brought forth by new 
psychoactive substances and designer precursors. The 
dele gation also visited the “drug consumption rooms” in 
Bern and one of the manufacturing facilities of a 
company manufacturing controlled substances. 
246. The Board commends Switzerland for the close 
coordination among various stakeholders in the area of 
drug control within the country, and its participation in 
regional and international cooperation. 
(p) Tunisia
247. The Board undertook a mission to Tunisia in 
October 2018 with the objective of discussing the devel-
opments related to the country’s implementation of the 
three international drug control treaties since the last 
mission of the Board, in 2002. 
248. Tunisia is party to the three international treaties. 
It acceded to the 1961 Convention as amended in 1976 
and the 1971 Convention in 1979. It became a party to 
the 1988 Convention in 1990. 
249. During the mission, the Government demon-
strated its commitment and will to continuing to 
strengthen its efforts regarding drug abuse prevention and 
the treatment and rehabilitation of individuals with prob-
lems associated with drug use, including in prisons. 
During its interaction with technical staff at all levels, the 
INCB delegation was impressed by the calibre and pro-
fessionalism of the country’s civil servants. The Board 
notes the country’s efforts and the positive steps taken 
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towards legislative and regulatory reforms and the 
strengthening of the National Bureau of Narcotics.
(q) United Arab Emirates
250. In September 2018, the Board undertook a 
mission to the United Arab Emirates with the objective 
of discussing developments related to the country’s imple-
mentation of the three international drug control conven-
tions since the Board’s last mission to the country, 
in 2008. 
251. The Board notes that the country is committed to 
the objectives of the international drug control treaties 
and is making significant efforts to achieve the goals and 
objectives of the country’s drug control strategy, in both 
drug supply and drug demand reduction. In recent years, 
the country has been increasingly targeted by traffickers 
of precursor chemicals, in particular acetic anhydride. 
The Board also notes changes in drug abuse patterns, 
including the emerging abuse of methamphetamine, 
synthetic cannabinoids and certain prescription drugs. 
The delegation was informed of recent legislative changes 
concerning penalties for drug-related offences, including 
alternatives to punishment for drug use.
(r) United Kingdom of Great Britain and 
Northern Ireland
252. A delegation of the Board visited the United 
Kingdom in October 2018. The objective of the mission 
was to review the drug control situation in the country 
and the implementation of the international drug treaties 
by the Government and to discuss significant develop-
ments since the last mission of the Board to the country, 
in 2007. 
253. The Board notes the commitment of the 
Government to the full implementation of the inter-
national treaties. The 2017 Drug Strategy was adopted by 
the Government to address the national drug problem 
and the Serious Violence Strategy was adopted in 2018 
to respond to recent increases in knife crime, gun crime 
and homicide, crimes that are often associated with drug 
trafficking. At the international level, the Government is 
committed to cooperation with other countries in Europe 
and around the world to promote a balanced approach, 
sharing best practices and the latest evidence across a 
global network. 
254. Overall drug use has remained largely stable over 
the past five years among 16 to 59 year olds in England 
and Wales; however, the country has been experiencing 
an increase in the number of deaths related to drug use, 
mostly relating to heroin and morphine. The United 
Kingdom has played a leading role in the management of 
new psychoactive substances and the delegation of the 
Board visited the Club Drug Clinic, one of the few treat-
ment centres in Europe that assists users who have devel-
oped problematic use patterns of synthetic drugs and new 
psychoactive substances. The Board notes the active role 
played by the Government in addressing the problem of 
drug trafficking and the interdiction efforts undertaken 
by the national drug law enforcement agencies. 
3.  Evaluation of the implementation by 
Governments of recommendations 
made by the Board following its 
country missions
255. Every year, the Board follows up on developments 
in countries that hosted INCB missions three to four 
years previously and requests the Governments in ques-
tion to apprise it of any developments in the country since 
the mission, including any legislative or policy actions 
taken in implementation of the Board’s post-mission rec-
ommendations. This important exercise is a means of 
building on the momentum created by the missions to 
the countries in question and the synergies forged with 
national stakeholders. 
256. In 2018, the Board invited the Governments of 
Bahrain, to which a mission had been undertaken in late 
2014, and China, Ghana, Honduras, Iran (Islamic 
Republic of), Italy, the Republic of Moldova and Timor-
Leste, to which missions had been undertaken in 2015, 
to report on drug-related developments in those coun-
tries, including those that might have been taken in 
furtherance of the Board’s recommendations.
257. The Board wishes to express its appreciation to the 
Governments of Bahrain, China, Ghana, Iran (Islamic 
Republic of), Italy and the Republic of Moldova for hav-
ing submitted information to the Board and renews its 
call to the Governments of Honduras and Timor-Leste to 
provide the information requested.
(a) Bahrain
258. The Board notes that the Government of Bahrain 
has made some progress in implementing the recommen-
dations of the Board following its mission to the country 
in December 2014.
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259. The Board welcomes the efforts made by the 
Government to allocate additional resources to the treat-
ment and rehabilitation of drug users. In addition to the 
treatment services provided by the Psychiatric Hospital 
of Bahrain, the Bahraini Council of Ministers decided in 
2015 to allocate 22,000 square metres of land, in line with 
the recommendation of the National Anti-Drug 
Committee, for the construction of three buildings, for 
the drug treatment of men, women and juveniles. The 
Government has also announced that a competent com-
mittee would be formed to further study the treatment 
requirements in the country. The Board takes note of the 
measures being put in place and encourages the 
Government to further expand and improve its provision 
of services for inpatient and outpatient treatment of 
persons affected by drug use disorders, including by 
improving access to treatment to all groups including 
women, young people and resident non-nationals and by 
providing specialized services for co-morbidities that 
affect patients diagnosed with drug use disorders.
260. The Government of Bahrain has taken further 
steps to effectively control new psychoactive substances, 
including the establishment of a committee under Law 
No. 15 of 2007, on narcotics and psychoactive substances, 
which will be mandated to amend the schedules of nar-
cotic drugs and psychoactive substances. In August 2016, 
the Prime Minister of Bahrain issued Decree No. 39/2016, 
amending the lists of controlled substances contained in 
Law No. 15 of 2007, to schedule synthetic cannabinoids, 
synthetic cathinone, tramadol, ketamine and APAAN, 
and tasking the ministers, according to their mandates, 
to implement the Decree.
261. During the mission, the Board observed the need 
for training of laboratory technicians in the detection and 
analysis of drugs. In addition, the Board encouraged the 
Government to strengthen its forensic detection and anal-
ysis of substances through the provision of training and 
the increased availability of reference standards. In 
response to those recommendations, the Government 
reported that devices to detect and test for drugs and 
psychoactive substances were in the process of being 
procured following the completion of a bidding process. 
On the issue of training, the authorities acknowledged 
that the crime laboratory must increase the capacity of 
its technical staff through the provision of additional 
training. In that regard, the Government of Bahrain has 
maintained contact with UNODC to discuss relevant 
training courses that may be provided to its officials. 
262. To further strengthen the provision of services for 
the prevention of HIV/AIDS among drug users, the 
Government adopted Law No. 1 of 2017, on the 
protection of society from AIDS and protection of the 
rights of persons living with AIDS. However, the 
Government has not yet provided further details on the 
new legislation that would allow the Board to have a more 
comprehensive understanding of the developments in 
HIV/AIDS-related issues in the country. 
263. In response to the recommendation of the Board 
to conduct a nationwide survey on drug abuse in the 
country, the Government informed the Board that the 
Royal Academy of Police had been assigned with the 
coordination of the preparation of a national survey on 
drug use. While efforts are under way to complete the 
survey, the Government stated that there are multiple 
agencies in Bahrain dealing with the problem of drug 
abuse including, but not limited to, the Ministry of 
Health, the Ministry of the Interior and the Ministry of 
Education; the absence of a unified coordination mecha-
nism had made it difficult for Bahrain to effectively assess 
the drug problem and determine the number of drug 
users. Therefore, the Board calls upon the Government 
to establish an effective coordination mechanism in the 
area of drug abuse prevention and treatment, including 
through institutional and legislative steps as well as the 
allocation of sufficient human and financial resources, 
with a view of enabling coordinated responses to the drug 
abuse situation in the country.
264. The Board is aware that the destruction of seized 
drugs in the country takes place once every five or six 
years. The Board encourages the Government to establish 
procedures for the pretrial destruction of seized drugs 
and for samples to be taken and to be admissible as 
evidence in accordance with article 14, paragraph 5, of 
the 1988 Convention. Such a measure would reduce the 
likelihood of seized substances being diverted into illicit 
markets. Moreover, the Board calls upon the Government 
to submit regularly to the Board data on the quantities 
of drugs seized and disposed of. 
265. The Board acknowledges the effective cooperation 
of the Government of Bahrain with the Board in fulfill-
ing the country’s obligations under the international drug 
control treaties, and notes that it will continue working 
closely with the Government of Bahrain to facilitate the 
implementation of the recommendations of the Board 
following its mission to the country in 2014.
(b) China 
266. The Board notes that, since its mission to China in 
October 2015, the Government of China has taken 
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several measures to implement the Board’s recommenda-
tions on ways to strengthen the country’s implementation 
of the three international drug control conventions. 
267. In 2015, China introduced regulation for the rapid 
scheduling of non-medical narcotic drugs and psycho-
tropic substances, including new psychotropic substances. 
More than 138 new psychotropic substances have been 
brought under national control. China has scheduled all 
internationally controlled fentanyl substances, adding 
23 classes of fentanyl substances to the national 
schedules. In 2017, the Government brought the main 
precursors of fentanyl, namely N-phenethyl-4-piperidone 
(NPP) and 4-ANPP, under national control. 
268. The Board notes that China has also taken meas-
ures to more effectively monitor international trade in 
precursors and to verify the legitimacy of transactions 
involving precursor chemicals, in particular through the 
scheduling of new precursors, including “hydroxylamine”, 
o-chlorophenyl cyclopentyl ketone, APAAN, 1-bromo-
1-phenyl-1-propanone, bromine, chloropseudoephedrine, 
1-phenyl-1-propanone, NPP and ANPP. In recent years, 
more than 14,900 companies have been inspected for 
transactions involving non-scheduled substances and 
equipment that could be used for the illicit manufacture 
of drugs. Strengthened control in this area has led to 
seizures of about 1,500 tons of chemicals in the border 
region with Myanmar in 2017, of which 400 tons were of 
scheduled precursor chemicals. 
269. The Board welcomes the steps taken by the 
Government to increase its cooperation with the chemi-
cal industry and to promote voluntary cooperation 
between the Government and the chemical industry, 
including through the establishment of a credit rating and 
certification system for companies involved with precur-
sor chemicals. 
270. With respect to the availability of narcotic drugs 
and psychotropic substances for medical treatment, the 
Board notes that some progress has been made, as 
evidenced by the increased consumption of morphine in 
the country. The Board encourages the Government to 
continue to take steps to foster the greater availability of 
narcotic drugs and psychotropic substances, which 
remains low.
271. In addition, while inroads related to demand 
reduction and treatment measures have been made since 
the Board’s 2015 mission, the Board also believes that 
additional investments in this field may be warranted.
272. Finally, in keeping with its call to all States to 
abolish capital punishment for drug-related offences, in 
accordance with the principle of proportionality, the 
Board encourages the Government of China to consider 
abolishing the death penalty for this category of offence.
(c) Ghana
273. The Board undertook a mission to Ghana in 2015. 
The Board notes the high level of commitment of the 
Government of Ghana to drug control and also notes that 
significant progress has been achieved in addressing the 
problems of drug trafficking and abuse since the previ-
ous mission of the Board, in 2005. In particular, the Board 
notes that new drug control legislation, the Narcotics 
Control Commission Bill 2017, has been drafted. Its 
adoption is considered a priority for the Government and 
the Bill will replace the current legislation, the Narcotic 
Drugs Law of 1990. The Board notes that the new Bill 
also includes proposals for alternatives to imprisonment 
for drug-related offences. The Board also notes efforts 
made by the Government to strengthen the independence 
of the Narcotics Control Board, the main drug control 
coordinating body in the country.
274. The Board remains concerned that much work 
remains to be done in Ghana in strengthening control at 
the retail level of pharmaceutical preparations containing 
controlled substances such as diazepam. Although most 
legislation and regulations in that area are adequate, the 
Government of Ghana has been unable to ensure 
adequate compliance, and it is often possible to obtain 
those preparations without a prescription. While a 
number of control measures have been enforced by the 
competent national authorities to monitor the utilization 
of diazepam at the wholesale level, the Board requests the 
Government of Ghana to further examine the matter and 
identify the reasons behind the high level of imports of 
diazepam by, among other measures, strengthening 
monitoring of the distribution of finished pharmaceuti-
cal products containing diazepam at the retail level.
275. The Board notes that little progress has been 
made in reviewing the availability of human resources 
across different medical fields with a view to ensuring 
equal access to medical services across the country. The 
availability of opiates for the treatment of pain in medi-
cal institutions continues to be inadequate. The Board 
requests the Government to examine the current 
situation and take the steps necessary to ensure that 
narcotic drugs, particularly opiates, are made available for 
medical purposes. 
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(d) Iran (Islamic Republic of)
276. The Government of the Islamic Republic of Iran 
has taken several steps to implement the recommenda-
tions made by the Board following its mission to the 
country in May 2015.
277. The Board notes that the Government of the 
Islamic Republic of Iran, through its competent authori-
ties, continues to closely monitor the import, export, 
transit, manufacture and use of precursors. The Ministry 
of Health, as the regulatory body, and the Drug Control 
Headquarters, as the law enforcement agency, cooperate 
with each other to prevent the diversion of chemical 
precursors into illicit channels. The Government reported 
that it was in the process of invoking article 12, paragraph 
10 (a), of the 1988 Convention in order to request 
pre-export notifications for precursor chemicals listed in 
Table I of the 1988 Convention.
278. In addition, the Government has also named focal 
points for Project Cohesion (international operations 
focusing on cocaine and heroin precursors) and its related 
communication platform, namely PICS. Those focal 
points have recently reported, through PICS, some cases 
related to precursor trafficking. 
279. During its mission, the Board noted the need to 
raise awareness about the threat to public health posed 
by new psychoactive substances, including GHB and 
synthetic cannabinoids, and recommended that the 
Islamic Republic of Iran take targeted law enforcement 
action to prevent the proliferation of illicit markets for 
such substances. The Government reported that it had 
taken new preventive measures, including the sharing of 
best practices with other countries and the provision of 
training on those substances for staff of organizations 
working on reducing the harm associated with drug use, 
as well as by establishing treatment clinics.
280. Since the INCB mission was conducted, the 
Government of the Islamic Republic of Iran has also 
stepped up its efforts to provide specialized drug abuse 
prevention and treatment services to women. The 
country carried out a series of measures aimed at women 
who are high-risk injecting drug users through the set-
ting up of 247 drop-in centres. There are 371 outreach 
teams providing services to approximately 16,000 women. 
Approximately 10,000 female drug users have received 
treatment services in more than 45 medium-term 
residential centres throughout the country. Supportive 
services and shelters were provided for approximately 
30,000 homeless women who were drug users in more 
than 20 night shelters. Pregnant women are provided with 
specialized care at Government-run hospitals. Pregnant 
women, who are referred to primary health-care centres, 
receive screening services on drug use disorders. Women 
who are recovering from addiction and the children of 
women recovering from addiction receive treatment 
services at two “mother and child” centres. 
281. The Government has also developed its fourth stra-
tegic country programme on HIV/AIDS control (2015–
2019), in close collaboration with all relevant agencies. 
Preventive measures have been expanded among girls and 
women and pregnant women with HIV/AIDS. 
Furthermore, measures have been taken aimed at detect-
ing HIV cases, expanding access to antiretroviral treat-
ment and improving the medicine supply, distribution 
chain and the prevention and treatment of cases that are 
resistant to treatment. Other activities have been 
carried out, such as improving the detection of tubercu-
losis among individuals with HIV/AIDS; detecting HIV/
AIDS among persons suffering from tuberculosis, with 
special importance attached to prisons; promoting non-
stigmatizing attitudes aimed at reducing potential dis-
crimination and facilitating access to services; promoting 
applied research for monitoring treatment and drug 
resistance; and strengthening HIV/AIDS technical sub-
committees for further coordination and preventing over-
lapped activities.
282. As discussed in more detail in chapter III of the 
current report, the Islamic Republic of Iran adopted 
amendments to its counter-narcotics legislation in 2017 
to replace the punishment for some drug-related offences 
that had previously carried the death penalty with a 
prison term of 25–30 years and fines. The same amend-
ments also replaced life imprisonment for drug offences 
with a term of imprisonment of 15–20 years and fines.
283. The Board acknowledges actions undertaken by the 
Government of the Islamic Republic of Iran to strengthen 
national responses to drug abuse and criminality, and notes 
that it will continue working closely with the Government 
to further facilitate implementation of the recommenda-
tions made following its mission to the country.
(e) Italy
284. The Board notes that the Government of Italy has 
taken several steps to implement the recommendations 
made following its mission to Italy in June 2015.
285. Italy continued to support multilateral cooperation 
in international drug control through undertaking 
numerous multilateral, bilateral, training and legislative 
ChaPTER II. fuNCTIONINg Of ThE INTERNaTIONal dRug CONTROl sysTEm   37
initiatives, as well as initiatives concerning technical 
support, promoted by the Central Directorate for Anti-
Drug Services of the Ministry of the Interior through its 
network of law enforcement attachés posted abroad.
286. During the course of its mission, members of the 
Board discussed matters relating to the draft legislation 
on the liberalization of the non-medical use of drugs that, 
at the time, was then being reviewed by the Parliament 
and drew the attention of the Government of Italy to the 
obligations under international drug control treaties in 
that regard. Based on the information provided by the 
Government, the Board notes that the draft law entitled 
“Provisions on legalization, cultivation, processing and 
sale of cannabis and its derivatives” was revised to deal 
only with the use of cannabis-based medicines for thera-
peutic use. However, the revised draft law was not adopted 
as a result of the early dissolution of the Parliament by 
the President of Italy in December 2017.
287. The Board notes that the country has established 
and continued the implementation of a psychological 
counselling programme targeted at substance users within 
the prison settings of Rebibbia penitentiary in Rome. The 
Board observed that the programme, implemented by the 
addictions service of the local health authority, resulted in 
the reduction of self-harm among the prisoners in that 
penitentiary. 
288. The Board notes the effective action undertaken by 
law enforcement agencies in Italy against drug traffick-
ing, including several significant seizures of drugs. A total 
of 72 tons of narcotic drugs and psychotropic substances 
were seized in 2016, including 477 kg of heroin, 4.7 tons 
of cocaine, 65 tons of cannabis, 23 kg of amphetamine 
and 6,139 doses of LSD. 
289. Italy has strengthened the monitoring of new psy-
choactive substances through the placement of the early 
warning system under the National Institute of Health, 
which is the leading technical and scientific public body 
of the Italian National Health Service. In order to further 
consolidate the national early warning system, the role of 
the Central Directorate for Anti-Drug Services (DCSA) 
has also been reinforced.
290. The Italian Ministry of the Interior, through DCSA, 
participates in INCB international operational initiatives 
supporting national authorities’ efforts to prevent new 
psychoactive substances from reaching users (Project Ion 
and IONICS). The Board notes that the Ministry of the 
Interior is considering the possibility of increasing the 
number of its focal points participating in those initiatives, 
as well as organizing training sessions in that area. 
291. The Board also notes that, in December 2016, Italy 
initiated the production of cannabis for medical purposes 
under a pilot project for the national production of active 
substances of plant origin derived from cannabis. The first 
product that was available under that pilot project is 
named Cannabis FM2, cultivated according to the 
European Medicines Agency’s good agricultural and col-
lection practice and good manufacturing practice stand-
ards. Italy plans to produce other varieties of cannabis for 
medical purposes in the coming years and will continue 
to import such cannabis from the Netherlands until then 
to satisfy the needs of patients under treatment in Italy. 
The Military Chemical-Pharmaceutical Plant (SCFM), 
one of the plants of the Defence Industries Agency, was 
identified by the legislative decree issued in November 
2015 as the national cannabis agency for the cultivation 
and production of cannabis for medical purposes. 
292. The Board will continue to engage in a close 
dialogue with the Government of Italy regarding the 
legislative developments on the use of cannabis-based 
medicines for therapeutic use, implementation of the 
pilot project on cultivation of cannabis plants for 
medical purposes, and the participation of government 
officials in the INCB international operational initiatives 
supporting national authorities’ efforts to prevent new 
psychoactive substances from reaching users.
(f ) Republic of Moldova 
293. The Board undertook a mission to the Republic of 
Moldova in 2015. The Board acknowledges the commit-
ment of the Government of Moldova to drug control and 
notes that some progress in the field of drug control has 
been achieved since its 2015 mission. The Board notes 
that the Standing Committee on Drug Control has inten-
sified its activities to monitor and control the movement 
of narcotic drugs, psychotropic substances and precursors 
in the territory of the country, in accordance with Law 
No. 382-XIV. 
294. The Board notes that legislative action has been 
taken by the Government in order to strengthen its drug 
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control framework and its legal response to drug-related 
crime. In particular, the Board notes the adoption of Law 
No. 193, which amends Law No. 382-XIV to introduce 
new concepts into national legislation, such as analogue 
scheduling, and which also amends the Penal Code to 
place a series of new definitions and substances under 
control (including analogues). In addition, Law No. 164 
has established controls over 40 new substances (24 nar-
cotic drugs and 16 psychotropic substances). 
295. The Standing Committee on Drug Control is 
responsible for issuing authorizations for the import and 
export of narcotic drugs, psychotropic substances and 
precursor chemicals on the basis of requests received 
from commercial operators. The Board is pleased to note 
that mandatory reporting by the Republic of Moldova has 
improved since 2015.
296. Treatment facilities supported by the Government 
through the Republican Narcological Dispensary, includ-
ing methadone and buprenorphine substitution therapy, 
appear to be limited. Since 2015, only 35 persons have 
benefited from substitution therapy with methadone or 
buprenorphine and post-treatment social and profes-
sional reintegration services. According to the Ministry 
of Health, a total of 11,661 drug users had received medi-
cal treatment in public health-care institutions by the end 
of 2017. 
297. The Board notes that other significant challenges 
remain. Although the Government continues to make 
efforts, corruption remains a serious obstacle to drug 
control activities. 
298. Another difficulty still facing the country is the 
availability of narcotic drugs and psychotropic substances 
for medical purposes, which remains low. The Board 
encourages the Government to continue its efforts to 
ensure the greater availability of narcotic drugs and psy-
chotropic substances and encourages authorities to eval-
uate procedures and possible obstacles in that area. The 
Board recommends that further progress be made with 
regard to the availability of facilities for the treatment of 
drug abuse throughout the country and the establishment 
of reliable data on the drug abuse situation in the coun-
try. The Board encourages the Government to conduct 
drug prevalence surveys to establish reliable data on drug 
abuse that can be used to understand and address the 
problem of drug abuse in a more effective manner. 
E.  Action taken by the Board to 
ensure the implementation of 
the international drug control 
treaties
1.  Action taken by the Board pursuant 
to article 14 of the Single 
Convention on Narcotic Drugs of 
1961 as amended by the 1972 
Protocol and article 19 of the 
Convention on Psychotropic 
Substances of 1971 
299. The international drug control treaties set out 
measures that the Board may invoke to ensure the trea-
ties’ implementation in cases where the Board has objec-
tive reason to believe that the aims of the treaties are 
being seriously endangered by the failure of a party, coun-
try or territory to comply with the obligations contained 
therein. These measures, which consist of a series of steps, 
are set out in article 14 of the 1961 Convention as 
amended, article 19 of the 1971 Convention and article 
22 of the 1988 Convention. 
300. In the past, INCB has invoked article 14 of the 
1961 Convention and/or article 19 of the 1971 Convention 
with respect to several States. In accordance with those 
provisions, in those cases, the Board engaged in dialogue 
with the States in question with a view to bringing about 
compliance with the treaties, where other means had been 
exhausted. As a result, most of the States took remedial 
measures to address issues of compliance with the trea-
ties, and the Board decided to terminate the action taken 
under those articles with regard to those States. 
301. In such cases, the names of the States concerned 
are not publicly disclosed and related consultations with 
the Board are confidential, unless the Board decides to 
bring the situation to the attention of the parties, the 
Economic and Social Council or the Commission on 
Narcotic Drugs. 
302. Afghanistan currently remains the only State for 
which action is being taken pursuant to article 14 of the 
1961 Convention. In 2000, taking into account the seri-
ousness of the extent of illicit cultivation of opium poppy 
and trafficking in opium and heroin from Afghanistan, 
the Board concluded that the situation in the country, if 
left unaddressed, would seriously endanger the aims of 
the 1961 Convention as amended, and decided to invoke 
article 14, subparagraph 1 (a), of that Convention with 
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respect to Afghanistan. A year later, in 2001, the Board 
determined that a serious situation existed that called for 
cooperative action at the international level and with the 
authorities of any future governing body in Afghanistan, 
whether transitional or permanent, and decided to call 
the attention, through its annual report, of the parties, 
the Economic and Social Council and the Commission 
on Narcotic Drugs to the situation in Afghanistan, under 
the provisions of article 14, paragraph 1 (d), of the 1961 
Convention.
2.  Consultation with the Government 
of Afghanistan pursuant to article 
14 of the 1961 Single Convention on 
Narcotic Drugs as amended by the 
1972 Protocol
303. During the reporting period, the Board continued 
its consultations with the Government of Afghanistan. 
304. In February 2018, the President of the Board met 
with the newly appointed Permanent Representative of 
Afghanistan to the United Nations in Vienna. During the 
meeting, a number of issues were discussed, including 
drug control challenges, the importance of alternative 
livelihood programmes and the deteriorating security 
situation in Afghanistan, as well as the need to effectively 
implement the Board’s recommendations following its 
high-level mission to Afghanistan in May 2016. In 
particular, the President reiterated the importance of the 
Board’s decision to invoke article 14 bis of the 1961 
Convention as amended with respect to Afghanistan, 
recalling that such action had been recommended 
following the aforementioned mission to Afghanistan, 
and sought the express agreement of the Government of 
Afghanistan to such invocation, in line with the provi-
sions of article 14 bis.
305. In March 2018, the President of the Board met 
with the delegation of Afghanistan to the sixty-first ses-
sion of the Commission on Narcotic Drugs, led by Javid 
Ahmad Qaem, Deputy Minister of the Ministry of 
Counter-Narcotics of Afghanistan. The meeting focused 
on the recent drug control and policy developments in 
the country, new drug legislation and follow-up actions 
that Afghanistan needed to take to implement the Board’s 
recommendations, and the possibility of invoking article 
14 bis of the 1961 Convention as amended. 
306. On 28 March 2018, the Board received a letter 
from the Government of Afghanistan expressing its agree-
ment to the invocation of article 14 bis of the 1961 
Convention as amended, in addition to the measures 
already invoked by the Board under article 14. At its 
122nd session, in May 2018, the Board decided to invoke 
article 14 bis with regard to Afghanistan.
307. Article 14 bis of the 1961 Convention as amended 
is concerned with the technical and financial assistance 
to be provided to a country for which the article has been 
invoked. It states that, in cases which it considers appro-
priate and either in addition or as an alternative to meas-
ures set forth in article 14, paragraphs 1 and 2, the Board, 
with the agreement of the Government concerned, may 
recommend to the competent United Nations organs and 
to the specialized agencies that technical or financial 
assistance, or both, be provided to the Government in 
support of its efforts to carry out its obligations under 
the Convention. The article thus explicitly authorizes the 
Board to address its recommendations regarding the need 
to provide such assistance, in this case to Afghanistan in 
the area of drug control, to the competent United Nations 
organs and to the specialized agencies. 
United Nations action
308. On 8 March 2018, the Security Council adopted 
resolution 2405 (2018), extending the mandate of 
UNAMA until 17 March 2019. In the same resolution, 
the Security Council expressed its deep concern about the 
significant increase in the illicit cultivation and produc-
tion of and trade and trafficking in drugs in Afghanistan, 
which significantly contributed to the financial resources 
of the Taliban and its associates and could also benefit 
Al-Qaida and ISIL and its affiliates, and encouraged the 
Government of Afghanistan, supported by the inter-
national community and regional partners, to intensify 
its efforts to address drug production and trafficking with 
a balanced and integrated approach, in accordance with 
the principle of common and shared responsibility. 
Situation in Afghanistan 
309. The security situation in Afghanistan continued to 
worsen and remains extremely volatile. The year 2017 saw 
the highest number of security-related incidents ever 
recorded by UNAMA, although the number was only 
slightly higher than that in 2016. In total, 23,744 inci-
dents were registered in 2017, of which 63 per cent 
involved armed clashes. Targeted killings and abductions 
increased by 6 per cent and suicide attacks increased by 
50 per cent. The eastern regions of Afghanistan suffered 
the highest number of incidents, followed by the south-
ern regions.
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310. There were many high-profile and large-scale 
bombing attacks in Afghanistan during the reporting 
period. All of the attacks were condemned by the Security 
Council in statements stressing the need to maintain the 
collective resolve to make progress on ending the 
conflict.
311. Some progress was made in the preparations for 
parliamentary and district council elections. In December 
2017, the Independent Election Commission finalized 
and presented a voter registration system and an associ-
ated budget of $28 million, of which donors pledged to 
fund up to 90 per cent. In April 2018, the Commission 
set 20 October 2018 as the date on which the elections 
would be held. In the meantime, electoral preparations 
were affected by a series of violent attacks targeting 
election-related facilities, which resulted in a lower 
number of voter registrations than had been hoped for.
312. In November 2018, UNODC and the Afghan 
Ministry of Counter-Narcotics released the Afghanistan 
Opium Survey 2018. According to the survey, there was 
a 20 per cent decrease in the total area under opium 
poppy cultivation in Afghanistan in 2018 compared with 
2017, which was mainly attributed to a drought, in par-
ticular in the northern and western regions of the coun-
try, as well as declining farm-gate prices of dry opium. 
The total area under opium poppy cultivation in 
Afghanistan in 2018 was estimated at 263,000 ha, com-
pared with 328,000 ha in 2017. Potential opium produc-
tion also saw a decrease, of 29 per cent, and was estimated 
at around 6,400 tons in 2018, compared with 9,000 tons 
in 2017. The Board notes that, despite the reported 
decreases in opium poppy cultivation and potential opium 
production, the levels of cultivation and production 
remained very high in 2018. The Board observes with 
concern that eradication of opium poppy declined in 
2018 and amounted to only 406 ha in four provinces of 
the country, compared with the, still very low, 750 ha in 
14 provinces in 2017.
313. As mentioned in the Afghanistan Opium Survey 
2018, the main drivers of illicit cultivation continue to 
include political instability, lack of government control 
and security in the country, and the dependence of many 
Afghans on illicit cultivation of opium poppy, work on 
poppy fields or participation in the illicit drug trade for 
their livelihoods.
314. With the support of partners from the inter national 
community, Afghanistan continued to undertake efforts 
to tackle drug trafficking in the country on the basis of 
its National Drug Action Plan (2015–2019). Furthermore, 
law enforcement authorities in the country continued to 
seize substantial amounts of heroin, morphine, opium, 
methamphetamine, various synthetic drugs, cannabis 
resin and precursors during the reporting period. Opium 
prices dropped significantly, decreasing by 41 per cent 
from December 2016 to December 2017, while heroin 
prices saw a smaller decline, of 7 per cent. 
315. As reported in chapter III, section C, of the pre-
sent report, the Government of Afghanistan took some 
notable legislative measures to strengthen national 
responses to drug-related challenges in the country. It 
adopted a new counter-narcotics law in February 2018 
that was aimed at further strengthening coordination of 
drug control activities in the country and harmonizing 
the provisions on drug offences with the newly adopted 
penal code. In the same month, the new penal code 
entered into force; it is aimed at improving the country’s 
compliance with international human rights and crimi-
nal justice standards, as well as with the provisions of the 
United Nations Convention against Corruption68 and the 
United Nations Convention against Transnational 
Organized Crime and the Protocols thereto.69 
Cooperation with the international 
community 
316. Afghanistan continued to intensify its multilateral 
and bilateral cooperation with the international commu-
nity, including its neighbouring countries. Afghanistan 
and Pakistan finalized an agreement on the Afghanistan-
Pakistan Action Plan for Peace and Solidarity, which 
included several commitments by both parties to build-
ing peaceful and mutually beneficial bilateral relations. 
The visit of the President of Afghanistan to Uzbekistan 
in December 2017 resulted in the conclusion of 20 bilat-
eral agreements in the areas of security, intelligence- 
sharing, transit and trade. Trade relations with the Islamic 
Republic of Iran have improved markedly since early 2017 
as a result of the intensification of trade at the ports of 
Bandar Abbas and Chabahar. In February 2018, work on 
the construction of the Afghan segment of the 
Turkmenistan-Afghanistan-Pakistan-India natural gas 
pipeline was officially launched. 
317. In February 2018, the Government of Afghanistan 
hosted the second meeting of the Kabul Process for Peace 
and Security Cooperation. With the participation of 26 
countries, the European Union, the North Atlantic Treaty 
Organization and United Nations entities, the event con-
cluded with the adoption of a joint declaration calling for 
68 United Nations, Treaty Series, vol. 2349, No. 42146.
69 Ibid., vols. 2225, 2237, 2241 and 2326, No. 39574.
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greater regional and international cooperation on peace 
and reconciliation and counter-terrorism matters. The call 
for peace and reconciliation was further reiterated at a 
conference held in Tashkent in March 2018, at which 23 
countries, the European Union and United Nations enti-
ties were represented. In their final declaration, the con-
ference participants expressed their support for an 
Afghan-led and Afghan-owned peace process that would 
lead to a peace agreement between the Government and 
the Taliban. 
318. A ministerial conference on Afghanistan, hosted 
jointly by Afghanistan and United Nations entities, was 
held in Geneva on 27 and 28 November 2018 to discuss 
the development and reform agendas for Afghanistan and 
provide an opportunity for the Government of Afghanistan 
to renew its commitments to reform, democratic pro-
cesses and development. The conference provided an 
opportunity for the international community to pledge its 
support to such efforts and to measure achievements on 
the basis of the $15.3 billion committed by the donor 
community in support of Afghanistan in 2016. 
Conclusions 
319. During the reporting period, Afghanistan contin-
ued to face critical challenges to its security and peace-
building efforts. Insurgencies and terrorist attacks 
continued on a regular basis, affecting both the local civil-
ian populations and international cooperation partners. 
At the same time, the Government of Afghanistan, on 
several occasions, announced its renewed commitment to 
peace and reconciliation, including its engagement in 
peace talks with the Taliban.
320. Afghanistan continued to strengthen regional 
cooperation with neighbouring countries. There was a 
tangible improvement in relations between Afghanistan 
and Pakistan, which resulted in agreement on the 
Afghanistan-Pakistan Action Plan for Peace and 
Solidarity. 
321. Afghanistan, with the support and cooperation of 
international partners, continued to carry out drug inter-
diction efforts resulting in substantial seizures of illicit 
substances, in particular opiates. Despite the reported 
decrease in opium poppy cultivation and potential opium 
production, the levels of cultivation and production 
remained very high in 2018. Owing to the increased avail-
ability of opium in the illicit market caused by the record 
harvests reported in 2017, opium prices dropped signifi-
cantly. Several legislative initiatives in the area of drug 
control, including legislation on drugs and crime, were 
undertaken with a view to improving national responses 
to drug-related threats.
322. Tangible progress was made in the Board’s consul-
tations with the Government of Afghanistan regarding 
the implementation of recommendations emanating 
from its high-level mission to Afghanistan in May 2016, 
in particular the recommendation relating to article 14 
bis of the 1961 Convention as amended. After sustained 
contacts with the Government of Afghanistan, the 
express agreement of the Government to the invocation 
of article 14 bis was communicated to the Board in 
March 2018. 
323. The Board recognizes the extraordinary work car-
ried out in Afghanistan over the last two decades and 
more by United Nations organs and specialized agencies 
as well as the donor community and non-governmental 
organizations in support of the counter-narcotics efforts 
of Afghanistan. Individuals working for those entities, 
non-governmental organizations and donors, frequently 
at great personal risk, have helped their Afghan counter-
parts through a broad range of counter-narcotics pro-
grammes related to education, prevention, demand 
reduction, interdiction and alternative livelihoods, and 
have provided technical and material assistance related to 
law enforcement.
324. To further encourage such efforts, with due recog-
nition of the significant ongoing work as outlined above 
and on the basis of the provisions of article 14 bis of the 
1961 Convention as amended, the Board again wishes to 
call the attention of the competent United Nations 
organs and specialized agencies to the drug control sit-
uation in Afghanistan and to encourage them to pro-
vide, individually and collectively, further technical and 
financial assistance, within their respective mandates, to 
address the drug control challenges in the country, in 
line with the provisions of the 1961 Convention as 
amended. Such assistance may involve a multitude of 
measures, including, but not limited to, legislative and 
institutional capacity-building, provision of support for 
alternative livelihoods, direct financial assistance and 
the promotion of regional and international coopera-
tion. The Board wishes to once again draw the attention 
of the international community to the challenges faced 
by Afghanistan and to stress that efforts to stabilize the 
country will not be sustainable if the country’s illicit 
drug economy is not effectively controlled. Unless local, 
national, regional and international efforts to address 
those challenges are effectively pursued, poverty, insur-
gency, terrorism and obstacles to development are likely 
to remain unaddressed.
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F. Special topics 
1.  Extrajudicial responses to 
suspected drug-related offences
325. Under the international drug control conventions, 
States parties are required to act in a manner consistent 
with the rule of law in their responses to drug-related 
offences and in their treatment of suspected offenders. In 
the outcome document of the special session of the 
General Assembly on the world drug problem held in 
2016, the international community reiterated its commit-
ment to respecting, protecting and promoting human 
rights, fundamental freedoms and the inherent dignity of 
all individuals, and the rule of law in the development 
and implementation of drug policies. 
326. The international drug control conventions require 
that criminal justice responses to suspected drug-related 
criminality include internationally recognized due pro-
cess standards, which reject extrajudicial sanctions. With 
respect to drug abuse, the conventions commit to a 
humane and balanced approach, requiring the parties to 
give special attention to and take all practicable measures 
for the prevention of drug abuse and the early identifica-
tion, treatment, education, aftercare, rehabilitation and 
social reintegration of the persons affected.
327. The international drug control conventions require 
that drug-related crime be addressed through formal 
criminal justice responses, an approach consistent with 
the Universal Declaration of Human Rights and the 
International Covenant on Civil and Political Rights, 
which require adherence to internationally recognized 
due process standards.
328. The Board notes with serious concern that in 
several countries, in particular in South and South-East 
Asia, extrajudicial acts of violence endorsed by senior 
officials of those countries continue against persons 
suspected of drug-related activities, frequently at the 
direct behest of senior political figures or with their active 
encouragement or tacit approval.
329. The Board has communicated with the 
Governments of the States in which extrajudicial acts of 
violence have been reported to seek clarification and to 
remind them of their obligations under the international 
drug control conventions, including the requirement to 
respect the rule of law and due process when carrying 
out their obligations under those conventions. 
330. In the pursuit of its mandate, the Board will con-
tinue to monitor these developments and to draw the 
attention of the international community to them. 
2.  Ensuring the availability of narcotic 
drugs and psychotropic substances 
in emergency situations
331. During the period covered by the present report, 
the international community has been faced with a num-
ber of disasters, both natural and human-made. Those 
disasters, which have included earthquakes, floods, hur-
ricanes, epidemics, conflicts and displacements of popu-
lations, have given rise to emergency situations. For 
example, emergency situations arose following the major 
earthquakes and aftershocks in Lombok, Indonesia, and 
the surrounding region in August 2018, and the devas-
tating earthquake and tsunami in central Sulawesi, 
Indonesia, on 28 September 2018. The State of Kerala in 
India was also severely affected in August 2018 by the 
worst floods in nearly a century. In September 2017, the 
Secretary-General appealed to the international commu-
nity to provide humanitarian assistance to persons dis-
placed or affected by another major emergency in the 
Myanmar-Bangladesh border region, where refugee 
camps have been established for people in need of human-
itarian assistance. According to United Nations estimates, 
1.2 million people are in those camps. The need to pro-
vide medical treatment to the many victims in situations 
such as those has frequently resulted in acute shortages 
of essential medicines, leading to unnecessary human 
suffering.
332. In such acute situations, Governments, inter-
national organizations and non-governmental organiza-
tions are actively involved in the provision of humanitarian 
assistance, including the provision of vital medical sup-
plies such as narcotic drugs and psychotropic substances, 
many of which are controlled under the international 
drug control treaties. However, they often face serious 
difficulties providing controlled medicines because of the 
regulatory requirements for their import and export. 
333. The international drug control conventions estab-
lished a control regime with the aim of preventing 
trafficking in and abuse of narcotic drugs and psycho-
tropic substances. Under normal circumstances, the 
import and transport of medicines containing such drugs 
and substances are subject to strict regulatory require-
ments. However, in catastrophic situations, those regula-
tions may delay the urgent delivery of medicines for 
emergency humanitarian relief.
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334. In the light of the need for expediency in the 
delivery of relief efforts, including in the provision of 
medicines containing controlled narcotic drugs and psy-
chotropic substances, the Board reminds all Governments 
that, in emergencies, it is possible to apply simplified 
control procedures for the export, transportation and 
provision of controlled medicines. Urgent deliveries of 
essential medicines need not be included in the estimates 
of the receiving countries. Under such circumstances, 
competent authorities may, therefore, allow the export of 
medicines containing controlled narcotic drugs and/or 
psychotropic substances to affected countries, even in the 
absence of the corresponding import authorizations and/
or estimates. Further information on this subject is 
available in the Model Guidelines for the International 
Provision of Controlled Medicines for Emergency 
Medical Care, developed by WHO in cooperation with 
INCB. The Guidelines are available on the INCB website 
(www.incb.org). 
3.  Challenges and opportunities in 
promoting paperless trade for 
internationally controlled 
substances: the International 
Import and Export Authorization 
System (I2ES)
335. Pursuant to the 1961 Convention as amended, the 
1971 Convention and relevant resolutions of the Economic 
and Social Council, import and export authorizations are 
required for the international trade in narcotic drugs and 
psychotropic substances. In the light of the growing 
volume of licit trade in internationally controlled 
substances and the increasing workload of competent 
national authorities, modernizing the import and export 
authorization system is essential to reduce the risk of 
diversion while continuing to ensure the adequate avail-
ability of and access to those substances. 
336. The International Import and Export Authorization 
System (I2ES), a web-based electronic system developed 
by the Board together with UNODC, with financial and 
technical support from Member States, was designed to 
promote paperless trade in internationally controlled sub-
stances by facilitating the online exchange of import and 
export authorizations.
337. Available to all Governments free of charge, I2ES 
serves as a secure platform for generating and exchang-
ing import and export authorizations between trading 
countries while ensuring full compliance with all provi-
sions of the 1961 Convention and the 1971 Convention. 
The System’s user-friendly interface helps competent 
national authorities to reduce errors in data entry and to 
save time and communication costs, as they can issue 
their import and export authorizations through the 
System. 
338. Unlike paper-based systems, in which authoriza-
tions can be further processed only after their physical 
delivery and receipt, the online exchange of import and 
export authorizations using I2ES enables the instantane-
ous transfer of data between trading countries, thus facil-
itating a much faster approval process. Authorities of the 
trading countries can also use the System to securely 
communicate and exchange information directly with 
each other, should a transaction request require further 
clarification. 
339. More than three years after its launch, 
53  Governments have registered with I2ES, and 40 
Governments have activated their administrator 
accounts.70 Among them, 10  countries (Australia, 
Bangladesh, Belgium, Brazil, Finland, Spain, Switzerland, 
Thailand, Turkey and the United States) have uploaded 
data to the System. 
340. The Commission on Narcotic Drugs, in its 
resolution 61/5 of March 2018, welcomed the political 
and technical support provided by all Member States to 
further improve the implementation of I2ES and invited 
the secretariat of INCB to identify the obstacles that had 
prevented wider participation in the System and to make 
concrete proposals to increase the number of participat-
ing Member States.
341. Three user-group meetings on I2ES have been 
organized by the secretariat of INCB since the launch of 
the System, each of which was attended by representa-
tives of about 30 to 40 Governments. The sharing of expe-
riences and the discussions during those meetings allowed 
some of the challenges faced in the further implementa-
tion of I2ES to be highlighted. Information provided by 
Governments in two surveys also provided insight into 
some of the difficulties of participation in the System.71 
70 Those 40 countries are Australia, Austria, Bangladesh, Belgium, 
Brazil, Canada, Chile, China, Colombia, Comoros, Estonia, Finland, 
France, Germany, Hungary, India, Italy, Jordan, Kenya, Lithuania, 
Luxembourg, Malaysia, Mexico, Norway, Paraguay, Peru, Poland, 
Portugal, Qatar, Romania, Saint Lucia, Saudi Arabia, Singapore, Spain, 
Sweden, Switzerland, Thailand, Turkey, the United States and Uruguay.
71 An online survey was sent to 75 competent national authorities in 
early 2017 in preparation for the user-group meeting held in March 2017. 
Questions concerning competent national authorities’ awareness of the 
System were included in the latest version of the questionnaire, sent by 
INCB to Member States in April 2018.
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342. According to the information available to INCB as 
of April 2018, 63 countries have no national electronic 
systems to process their import and export authoriza-
tions. While a number of Governments indicated their 
willingness to do so using I2ES, 10 countries were not 
aware of the functionalities of I2ES and how the System 
could help expedite their work. Even though I2ES is 
available to all Governments free of charge, five 
Governments considered it too expensive to use. 
343. The limited usage of I2ES is partly explained by 
the propensity of Governments to maintain the status 
quo. Competent national authorities issuing only a small 
number of import and export authorizations each year 
perceived that using the System provided only limited 
benefits. Other authorities considered their existing 
paper-based system to be adequate and saw little incen-
tive for change. 
344. Some Governments reported that implementation 
of I2ES would not be feasible until certain legislative and 
institutional barriers were mitigated or removed. Measures 
to address those barriers included the repealing of legis-
lation mandating the use of paper-based documents, the 
adoption of domestic legislation supporting electronic 
transactions and the upgrading of information technol-
ogy and telecommunications infrastructure. The identifi-
cation and removal of those barriers could add to the 
delay in implementing I2ES.
345. Technical challenges were another factor impeding 
wider participation in I2ES. For competent national 
authorities already processing significant volumes of 
authorizations using their national electronic systems, the 
prospect of transferring their data to I2ES while contin-
uing to perform daily operations on their own system was 
a major drawback to implementation of I2ES, as it would 
be inefficient to duplicate work by using two systems. 
While the XML prototype for such data transfer is made 
available on I2ES, some investment is required by author-
ities to generate data compatible with I2ES and upload 
those data to I2ES. Unless more technical support and 
help can be provided to those authorities, such technical 
difficulties will continue to be a significant obstacle. 
346. Another common obstacle is the lack of financial 
or human resources. For countries that have a national 
electronic system, the redesign and upgrade of or mak-
ing of changes to existing national-level information tech-
nology structures in order to implement I2ES might 
require upfront investment and the prioritization of I2ES 
implementation. A number of Governments might face 
budgetary restraints affecting the availability of additional 
resources to implement the required structural changes 
to their information technology systems, even though 
only a relatively small amount of resources would be 
required. More significantly, some competent national 
authorities may be prevented from moving forward with 
the implementation of the System owing to a lack of staff 
with the necessary information technology know-how or 
because the authorities have difficulty accessing such 
know-how.
347. The I2ES user interface is currently available only 
in English, and the absence of a multilingual interface 
poses an operational challenge for some Governments 
and is thus another reason for non-implementation. 
Despite their expressed interest in using the System, 
countries with only a limited number of staff with suffi-
cient knowledge of English would experience difficulties 
in using the platform.
348. The experiences of early adopters of I2ES, however, 
suggest that most of these challenges can be overcome 
relatively easily. The following three paragraphs provide 
information on the successful experiences of some early 
adopters and shed light on how they have capitalized on 
the opportunities made possible by I2ES and how other 
competent national authorities could do likewise. 
349. The most critical factor for successful I2ES imple-
mentation is government commitment. Without strong 
political support from their management, competent 
national authorities would not be able to change the sta-
tus quo, ensure the prioritization of I2ES implementation 
or secure the necessary financial and/or human resources 
to overcome the challenges. 
350. Effective communication and coordination, both 
within the country and with relevant stakeholders, is 
another important element for enhancing I2ES imple-
mentation. While the processing and approval of author-
izations might be carried out by different personnel 
within the same authority, only one I2ES administrator 
account can be granted to each requesting Government. 
Effective internal coordination to decide on the owner-
ship of that account and the communication of that deci-
sion to INCB are imperative to attaining an active I2ES 
account; they are crucial first steps that are overlooked 
by some authorities.
351. Since the online exchange of authorizations cannot 
be completed without the approval of both the import-
ing and exporting countries, coordination with trading 
partners to undertake simultaneous implementation of 
I2ES would enable authorities to maximize the benefits 
of their participation and realize the full potential of the 
System. Such simultaneous implementation of I2ES, 
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which offers the advantages of a greater network, not only 
enhances the benefits for existing users but also makes 
I2ES implementation more attractive for other 
countries. 
352. In the light of the above-mentioned considerations, 
the Board would like to encourage all existing users of 
I2ES to invite their trading partners to register with 
I2ES and to start utilizing the System as soon as 
possible. Early adopters of I2ES can be powerful advo-
cates by demonstrating the benefits of using the System 
and sharing their experiences in overcoming challenges. 
Their further implementation of I2ES and active use of 
the System also serve as a strong incentive for their trad-
ing partners to join, as data regarding their counterparts’ 
import or export authorizations have already been 
uploaded to the System.
353. The Board would also like to encourage all 
Governments to provide additional support, including 
extrabudgetary resources, to advance further implemen-
tation of I2ES, as well as its maintenance and updating. 
While it has been possible to complete its development 
entirely from extrabudgetary resources, further funding 
is required to increase the number of participating 
Member States by promoting greater awareness of the 
System, facilitating the sharing of experiences among all, 
developing a multilingual interface and providing relevant 
technical support and training.
4. INCB Learning 
354. Launched in 2016, INCB Learning is one of the 
Board’s initiatives for promoting the implementation of 
the international drug control conventions and assisting 
Member States in following up on the commitment 
expressed during the special session of the General 
Assembly on the world drug problem held in 2016 to 
improving access to controlled substances for medical 
and scientific purposes. INCB Learning addresses barri-
ers to the adequate availability of indispensable sub-
stances, in particular by raising awareness and building 
capacity.
355. INCB Learning provides training to enable 
Governments to accurately estimate their requirements 
for controlled substances and to monitor and control 
their licit trade in those substances. Timely reporting of 
estimated requirements and statistical data to the Board 
is essential to ensure that controlled substances are avail-
able for medical and scientific purposes. The estimates of 
annual legitimate requirements for precursors, provided 
on a voluntary basis, are essential for assessing the 
legitimacy of a proposed import and thus preventing the 
diversion of those substances.
356. As part of INCB Learning, regional training sem-
inars are organized for officials of competent national 
authorities. Since April 2016, six regional seminars have 
been held, attended by over 180 officials from 79 coun-
tries and territories that are home to almost half of the 
world’s population. Regional training seminars were held 
in Nairobi from 25 to 29 April 2016, for officials from 
countries in East Africa; in Bangkok from 12 to 15 July 
2016, for officials from countries in South and East Asia 
and the Pacific; in Vienna from 4 to 6 July 2017, for offi-
cials from countries in Europe; in Sydney, Australia, from 
28 to 30 November 2017, for officials from countries in 
Oceania; in Guatemala City from 11 to 13 December 
2017, for officials from countries in Central America; and 
in Dakar from 10 to 12 September 2018, for officials from 
French-speaking countries in Africa. 
357. National awareness-raising workshops were also 
conducted in Kenya and Thailand as part of INCB 
Learning. The workshops were aimed at promoting dia-
logue between Governments, international organizations 
and civil society to find common ground and allow for 
the proposal of suggestions for improving access to opi-
oids for pain relief and psychotropic substances for the 
treatment of mental health and neurological conditions.
358. To complement the delivery of training seminars 
and awareness-raising workshops, three e-learning mod-
ules were launched as part of INCB Learning for use by 
competent national authorities. Developed in cooperation 
with UNODC, the modules provide interactive training 
on the estimates system for narcotic drugs, the assess-
ment system for psychotropic substances and estimates 
of annual legitimate requirements for imports of precur-
sors of amphetamine-type stimulants. Available on 
demand to staff of competent national authorities, the 
new e-learning tools assist authorities in building capac-
ity and maintaining an institutional knowledge base, even 
at times of staff turnover or when faced with resource 
constraints. 
359. The most recent training seminar implemented 
under INCB Learning was held in Dakar in September 
2018. It brought together 29 drug control officials from 
Cameroon, the Central African Republic, the Congo, the 
Democratic Republic of the Congo, Gabon, Guinea, Mali, 
Mauritania, the Niger, Senegal and Togo. Specialized 
training was provided on treaty requirements relating to 
the regulatory control and monitoring of licit trade in 
narcotic drugs, psychotropic substances and precursors. 
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Participants were also introduced to the INCB online 
tools I2ES, PEN Online, PICS and IONICS. The seminar 
was organized together with the UNODC Regional Office 
for West and Central Africa. Experts from WHO and the 
African Palliative Care Association provided input to the 
segment of the seminar on the availability of controlled 
substances for medical and scientific purposes.
360. Preparations are under way for a follow-up semi-
nar for Central America to be held in Vienna in January 
2019. The first seminar for the region took place in 
Guatemala City in December 2017 and was attended by 
officials from Guatemala and Honduras. The follow-up 
seminar was to include a study visit to the INCB secre-
tariat and UNODC headquarters in Vienna to further 
deepen the knowledge of participants. The seminar is part 
of an extended initiative in support of Central America, 
a region that, together with the Caribbean, continues to 
be used by transnational criminal organizations for the 
shipment of drugs from South America to drug markets 
in the United States and in Europe. The levels of 
consumption of opioid analgesics and psychotropic 
substances for medical and scientific purposes reported 
by some countries in Central America are also among the 
lowest in the world.
361. In the outcome document of the special session of 
the General Assembly on the world drug problem held 
in 2016, entitled “Our joint commitment to effectively 
addressing and countering the world drug problem”, the 
international community recognized the importance of 
training and awareness-raising to improve the availabil-
ity of controlled substances for medical and scientific 
purposes. Training provided through INCB Learning has 
effectively raised awareness of the importance of 
adequately estimating legitimate requirements and has 
strengthened participants’ technical knowledge of moni-
toring and reporting, leading to improved submissions of 
data to the Board. Capacity-building, however, can only 
have a lasting impact when ongoing follow-up is provided 
and adequate resources are available. The Board is 
grateful for the contributions to INCB Learning made 
by the Governments of Australia, Belgium, France and 
the United States. The Board calls upon Governments 
to provide further support to sustain and expand 
activities under INCB Learning.
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Chapter III.
Analysis of the world situation
Highlights
• africa is increasingly being used as a transit region for trafficking in cocaine.
• abuse of and trafficking in tramadol are of growing concern in North, Central and West africa.
• The quantities of cannabis and cocaine seized in Central america increased in 2017.
• In 2017, a clandestine fentanyl laboratory was dismantled in the dominican Republic.
• Central america and the Caribbean continue to be used for the trans-shipment of drugs from south america to 
the united states and Europe.
• In Canada, the Cannabis act, on providing legal access to cannabis for non-medical purposes and controlling and 
regulating its production, distribution, sale and possession, came into force in October 2018.
• In the united states, the states of California and Vermont legalized the use of cannabis for non-medical purposes. 
• The opioid overdose epidemic continued to worsen in the united states, with more than 70,000 reported drug 
overdose deaths in 2017, representing a 10 per cent increase over 2016. The united states continued to adopt 
various measures to tackle the situation.
• Coca bush cultivation and cocaine manufacture in Colombia reached an all-time high.
• Rising cocaine manufacture in south america appears to be having an impact on the European and North american 
markets.
• Illicit opium production in East and south-East asia has scaled down; the area under illicit opium poppy cultiva-
tion in myanmar dropped from 55,500 ha in 2015 to 41,000 ha in 2017.
• Trafficking in and abuse of methamphetamine have continued to increase and have reached alarming levels in 
many countries in East and south-East asia.
• several jurisdictions in south asia are considering making greater use of the death penalty for drug-related 
offences. In addition, there have been reports of high-level public officials condoning extrajudicial killings in the 
name of a “war on drugs”.
• Increased amounts of narcotic drugs and psychotropic substances seized in countries in south asia, in particu-
lar methamphetamine pills (“yaba”) in Bangladesh, indicate a rise in drug trafficking in the region.
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• as a result of significant increases in potential opium production in afghanistan in 2017, which almost doubled 
compared with the previous year, reaching 9,000 tons, the illicit opiate economy in 2017 substantially surpassed 
the level of the country’s total licit exports of goods and services.
• Instability and armed conflicts across the middle East continued to facilitate the trafficking in narcotic drugs and 
psychotropic substances in the subregion.
• south-West asia had the highest prevalence of hIV among people who inject drugs, at 2.4 times the global 
average.
• In the European union, the drug problem is evolving, with signs of high availability of drugs, which is facilitated 
in part by the use of online markets as platforms for the marketing and distribution of illicit drugs.
• more than a quarter of the population aged 15 to 64 in the European union have consumed illicit drugs at least 
once in their lifetime.
• The European union became a major source of acetic anhydride seized in both Europe and West asia.
• The growing market for and increase in consumption of crystalline methamphetamine have become major 
concerns in Oceania.
• several countries in Oceania are not yet parties to the international drug control conventions.
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A. Africa
1. Major developments
362. In September 2018, the Constitutional Court of 
South Africa upheld a lower court ruling striking down 
certain provisions of the country’s Drug and Drug 
Trafficking Act and the Medicines and Related Substances 
Act that criminalized the use, possession or cultivation 
of cannabis in a private place by an adult for his or her 
own personal consumption, on the grounds that those 
provisions violated an individual’s constitutional right to 
privacy. The Court suspended its judgment for 24 months, 
during which time the Parliament of South Africa was 
ordered to revise the two acts to allow for the personal 
consumption and cultivation of cannabis in a private 
space by adults.
363. Africa is increasingly being used as a transit region 
for trafficking in cocaine. While West and Central Africa 
used to be the main transit areas in Africa for cocaine 
trafficking, the North African subregion accounted for 
69 per cent of all cocaine seized in Africa in 2016, and 
the quantities of cocaine seized in Africa in 2016 dou-
bled from the previous year. 
364. Abuse of and trafficking in tramadol, a synthetic 
opioid not under international control, are of growing 
concern in parts of Africa. According to the UNODC 
World Drug Report 2018, North, Central and West Africa 
accounted for 87 per cent of pharmaceutical opioids 
seized worldwide, and that development was due almost 
entirely to trafficking in tramadol.
365. Lesotho has begun issuing licences to authorize the 
cultivation of cannabis for medical purposes. National 
authorities state that cultivation is intended solely for 
export to markets permitting the use of cannabis for 
medical purposes and that use of cannabis for medical or 
other purposes in Lesotho would not be permitted. 
Lesotho is the first country in the region to permit the 
cultivation of cannabis for medical purposes. 
2. Regional cooperation
366. UNODC launched a project in December 2017 to 
assist the Gambia, Guinea-Bissau and Senegal in enhanc-
ing their national capacities to detect and investigate 
cross-border crime affecting those countries. The project 
began with a two-week training course on detection and 
interdiction on cross-border crime for law enforcement 
officials of the Gambia. Additional training courses were 
given for law enforcement officials of Guinea-Bissau and 
Senegal in the course of 2018. 
367. In December 2017, the East African Community 
adopted its Second Regional Pharmaceutical Manufacturing 
Plan of Action for the period 2017–2027. The principal 
aim of the Plan of Action is to bolster regional produc-
tion of pharmaceuticals in order to reduce dependence on 
imported pharmaceuticals, which currently account for 
70 per cent of supply, and expand the regional product 
portfolio to cater to more than 90 per cent of health 
conditions.
368. The States members and secretariat of ECOWAS, 
with the support of UNODC and the European Union, 
undertook several drug control activities throughout 2018 
as part of the ECOWAS Regional Action Plan on illicit 
drug trafficking, organized crime related to it and drug 
abuse in West Africa. Such activities included the estab-
lishment of the West African Network of Civil Society on 
Substance Abuse, to better coordinate drug prevention 
and treatment efforts, the carrying out of school surveys 
on health and substance use in Cabo Verde, Côte d’Ivoire 
and Liberia and the establishment of the West African 
Epidemiology Network on Drug Use, which will collect 
data for an upcoming regional drug use report. 
369. In February 2018, the United States military Africa 
Command (AFRICOM) donated seven patrol boats – two 
to the Navy of Senegal and five to the Navy of Cabo Verde 
– in order to strengthen their capacity to counter drug 
trafficking in national and international waters. That was 
in addition to the five boats that AFRICOM had donated 
to Cabo Verde in December 2017. Along with the patrol 
craft, the United States also provided training and other 
equipment for the operation and maintenance of the 
vessels.
370. Twenty countries72 in Africa, with the support of 
several countries in Europe, the United States and Canada, 
participated in the Obangame Express maritime exercise 
of 2018, organized by AFRICOM. The objective of the 
eight-day exercise held in late March 2018 was to develop 
the capacity and capability of countries of the Gulf of 
Guinea and West Africa to counter illicit sea-based 
activity, including drug trafficking.
371. At the Ministerial Conference on Maritime Security 
in the Western Indian Ocean held in April 2018, the 
72 Angola, Benin, Cabo Verde, Cameroon, Côte d’Ivoire, Congo, 
Democratic Republic of the Congo, Gabon, Gambia, Ghana, Guinea, 
Guinea-Bissau, Liberia, Morocco, Namibia, Nigeria, Sao Tome and 
Principe, Senegal, Sierra Leone and Togo.
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Comoros, Djibouti, Madagascar, Mauritius and Seychelles 
signed agreements on strengthening their cooperation on 
maritime security in the western Indian Ocean to 
combat drug trafficking, illegal fishing and other illicit 
activities. The agreements will improve the sharing of 
information between law enforcement and security 
services and enhance coordination in joint operations of 
those countries.
372. Ministers of Health of African Union countries 
adopted a treaty in May 2018 to establish the African 
Medicines Agency, whose purpose is to provide a 
common regulatory framework for medical products 
among African Union countries and regional organiza-
tions, including systems to assure the quality of medicines 
and other pharmaceuticals in order to combat the 
presence of counterfeit drugs across the region. The treaty 
establishing the Agency still requires formal endorse-
ment, expected in early 2019, from the Heads of State 
and Government of the African Union before operations 
can begin.
373. In September 2018, INCB organized a training 
seminar, held in Senegal, for competent national author-
ities of francophone countries in Africa responsible for 
monitoring the licit international trade in controlled sub-
stances. The seminar was part of the global INCB 
Learning project to enable Member States to fulfil the 
commitments they had made at the special session of the 
General Assembly on the world drug problem held in 
2016. At the seminar, participants enhanced their knowl-
edge of the international drug control framework, the 
technical reporting required under the three international 
drug control conventions and the availability and use of 
the electronic tools developed by INCB, including I2ES, 
PEN Online, PICS and IONICS. Participants from 
Cameroon, the Central African Republic, the Congo, the 
Democratic Republic of the Congo, Gabon, Guinea, Mali, 
Mauritania, the Niger, Senegal and Togo attended the 
seminar. Input was also provided by UNODC, WHO and 
the African Palliative Care Association.
374. The Twenty-eighth Meeting of Heads of National 
Drug Law Enforcement Agencies, Africa, was held in 
Dar es Salaam, United Republic of Tanzania, from 17 to 
21 September 2018. In working groups, participants 
considered the following topics: (a) recent trends in drug 
trafficking in Africa and links to organized crime; (b) best 
practices in prison reform and alternatives to conviction 
or punishment; (c) practical measures to operationalize 
regional cooperation in drug law enforcement; and 
(d) awareness-raising on drug-related issues in educa-
tional settings.
3.  National legislation, policy and 
action
375. In June 2018, the Parliament of Botswana passed 
the Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances Act, 2018. The Act imposes penalties for 
various drug-related offences and provides a legal basis 
for the establishment of drug rehabilitation centres and 
the Drug Enforcement Agency. The Drug Enforcement 
Agency has the following functions: (a) collecting, collat-
ing and disseminating information on the illegal use of 
narcotic drugs and psychotropic substances; (b) receiving 
and investigating any complaint of alleged or suspected 
breach of the Act and, subject to the directives of the 
Director of Public Prosecutions, prosecuting offences 
under the Act; (c) addressing and advising government 
ministries and departments, public bodies, companies, 
institutions, statutory bodies and corporations on ways 
and means of preventing prohibited activities relating to 
narcotic drugs and psychotropic substances, and suggest-
ing measures, procedures or methods of work compati-
ble with the proper performances of their duties that, in 
the opinion of the Agency, would reduce prohibited 
activities relating to narcotic drugs and psychotropic 
substances; (d) disseminating information intended to 
educate the public on the dangers and effects of drug 
abuse or psychotropic substance abuse; and (e) enlisting 
and fostering public support for countering drug abuse 
and psychotropic substance abuse.
376. In January and February 2018, Cameroon con-
ducted a large-scale national media campaign to raise 
awareness of the dangers posed by the cultivation and 
consumption of cannabis and other narcotic drugs. The 
campaign sought to harmonize the overall national-level 
effort to combat drugs and overcome taboos that impede 
progress on drug issues. The campaign was organized by 
the government ministries for education, youth, health 
and social affairs, along with regional governors.
377. Cameroon has undertaken alternative development 
initiatives as a way of curbing the illicit cultivation of 
cannabis by young people. The initiatives focus on 
expanding existing national programmes supporting 
agricultural production to include young people by 
providing seeds, supplies, training and other services to 
promote self-employment in the agricultural sector.
378. The Commission of Inquiry on Drug Trafficking 
of Mauritius released its report on the drug situation in 
the country in July 2018. During its work, the Commission 
heard from many government, private sector and civil 
society stakeholders on issues related to drug use and 
trafficking in the country. The report summarizes the 
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drug situation in Mauritius and is intended to give the 
country’s policymakers a better understanding of 
institutional and programmatic shortcomings. The 
Commission identified several issues, including the need 
to establish a central coordinating body for drug policy 
within the Government, the uneven administration of 
the country’s opioid substitution therapy programme 
using methadone, the ability of drug traffickers to con-
tinue to conduct their operations from prison and the 
fragmentation and lack of coordination of anti-narcotic 
units within the national police and the customs 
authority.
379. In November 2017, the National Council on Health 
of Nigeria, at its sixtieth meeting, approved four policy 
documents, namely the national policy for controlled 
medicines and its implementation strategies, national 
guidelines for the quantification of narcotic medicines, 
national guidelines for the estimation of psychotropic 
substances and precursors, and national minimum stand-
ards of drug dependence treatment. The objective of those 
documents is to establish a legal framework to ensure the 
availability of and access to affordable controlled medi-
cines for medical and scientific purposes, while 
preventing diversion, to provide guidance for evaluating 
drug dependence treatment facilities and to outline the 
process for obtaining accurate estimates of national 
requirements of controlled substances.
380. Nigeria banned the production, import and sale of 
cough syrups containing codeine in May 2018. The 
Ministry of Health reported that the ban was necessary 
because of the level of abuse of codeine in the country 
and advised that dextromethorphan should be used in 
its place.
381. Senegal conducted its thirty-first national 
Drug Awareness and Mobilization Week at the end of 
June 2018. The week-long event sought to raise aware-
ness in the country of the danger of drug use and the 
steps that people could take to support the Government’s 
drug control initiatives. Activities during the week 
included an opening ceremony led by the Minister of the 
Interior, football matches, a poetry contest, public round-
table discussions that included national drug control 
authorities and activities organized by civil society 
groups. 
382. Zambia has launched the Seventh National 
Development Plan (for the period 2017–2021) in order 
to attain the Sustainable Development Goals. The Plan 
includes a broad-based drug, alcohol and substance 
policy to strengthen the prevention and treatment of 
substance abuse, including illicit drug consumption.
4.  Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
383. Africa continues to be a major transit region for 
drug trafficking as well as a growing destination market 
for narcotic drugs. Trafficking in cocaine, heroin and can-
nabis is prevalent, although patterns vary for the differ-
ent drugs. Cannabis continues to be illicitly cultivated in 
all subregions and is often intended for local markets as 
little is trafficked internationally, although some countries 
report that some of the cannabis cultivated is intended 
for export to Europe. On the other hand, the production 
of cannabis resin within Africa is limited to Morocco, 
with the trafficking flow of cannabis resin going through 
North Africa and Spain into the rest of Europe.
384. Cannabis is the narcotic drug most widely seized 
by law enforcement authorities in Africa, as reported by 
countries in the region. In 2017, Morocco reported seiz-
ing the largest amounts of cannabis (over 117 tons of can-
nabis resin and 283 tons of cannabis herb); seizures of 
large amounts of cannabis were also reported by Nigeria 
(approximately 191 tons of cannabis herb), Algeria (over 
52 tons, nearly all of which was cannabis resin), Zambia 
(over 17 tons of cannabis herb), Madagascar (over 10 tons 
of cannabis herb), Kenya (8.6 tons of cannabis herb), 
Cameroon (6 tons of cannabis herb), Ghana (over 4.6 
tons of cannabis herb) and Côte d’Ivoire (over 3 tons of 
cannabis herb). Ghana also reported that drug trafficking 
organizations brought individuals with cultivation exper-
tise into the country in order to improve the quantity and 
quality of the cannabis being illicitly cultivated. Authorities 
in Algeria reported that trafficking patterns for cannabis 
in North Africa shifted in 2017, with new routes going 
through Mali and Mauritania in order to reach destina-
tion markets.
385. With regard to cocaine, there is minimal consump-
tion in the region overall, as the drug is mostly trafficked 
to Europe. According to UNODC and reports from some 
countries, there is a change in the patterns of trafficking 
in cocaine from South America, continuing to shift from 
West Africa to North Africa, before proceeding to desti-
nation markets.
386. In February 2018, Moroccan authorities reported 
an exceptionally large seizure of 541 kg of cocaine, found 
in a container at the Port of Casablanca. In May 2018, 
the coastguard of Algeria effected an exceptionally large 
seizure, of 701 kg of cocaine hidden among frozen beef 
in a container ship in the Port of Oran. That amount is 
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in contrast to the total of 6.27 kg of cocaine seized by the 
country’s authorities in all of 2017. With regard to other 
cocaine seizures in 2017, Morocco reported the largest 
total seizures in the region, at 2.8 tons, Angola reported 
31 cases for a total of 153 kg of cocaine seized, Kenya 
seized 11.78 kg, Cameroon seized 5.2 kg, Ghana seized 8 kg 
and Madagascar seized less than 1 kg. Among countries 
of the Gulf of Guinea, Nigeria reported the largest total 
seizures, with 92 kg seized, and Zambia reported seizing 
13 kg.
387. Heroin from Afghanistan continues to be trafficked 
through the region to destination markets worldwide 
although consumption has become a greater concern in 
some countries of the region. Although data are limited, 
trafficking in heroin in the region is not as prevalent as 
trafficking in some other drugs. In 2017, only a few coun-
tries in Africa reported seizures of heroin, namely Kenya 
(112.6 kg), Nigeria (85.4 kg), Morocco (11.47 kg), Algeria 
(2.1 kg), Côte d’Ivoire (approximately 1.7 kg) and 
Madagascar (1 kg). In almost all reported cases, 
Governments indicated that Afghanistan was the source 
of the heroin seized.
388. There is little other information or data regarding 
the seizure of other internationally controlled narcotic 
drugs. However, the authorities of Nigeria seized approx-
imately 10 tons of cough syrups containing codeine as 
well as a total of 221 kg of pethidine and methadone 
during 2017.
(b) Psychotropic substances
389. While trafficking in psychotropic substances is not 
as great a concern for countries in Africa as trafficking 
in narcotic drugs, psychotropic substances are a growing 
concern in some countries. In particular, there is a grow-
ing prevalence of the use of amphetamine-type stimulants 
and other psychotropic substances in some countries in 
the Gulf of Guinea, including Cameroon and Nigeria. 
Some countries have reported that trafficking in MDMA 
is carried out by means of networks that source the drug 
from Europe.
390. Nigeria reported that just over 782 kg of amphetamine-
type stimulants had been seized in 2017 and that one 
clandestine laboratory manufacturing such stimulants 
had been detected. In addition, Nigeria reported seizing 
nearly 1.8 tons of internationally controlled 
sedatives and tranquillizers, including methaqualone 
and GHB. Authorities in Cameroon seized 75 kg of 
methamphetamine in January 2017 alone. Authorities in 
Algeria reported seizures of over 1.2 million tablets of 
amphetamine-type stimulants, including 246,000 tablets 
of MDMA. In addition, authorities in Morocco reported 
seizures of nearly 550,000 tablets of MDMA trafficked 
from Europe.
391. Côte d’Ivoire reported diversions of some benzo-
diazepines from legitimate channels during 2017 and sei-
zures by authorities of less than 30 g of clonazepam and 
9.65 kg of diazepam.
(c) Precursors
392. During the reporting period, only a few countries 
in Africa, namely, Algeria, Benin, Egypt, Morocco and 
the Sudan, provided the mandatory information related 
to seizures of substances in Tables I and II of the 1988 
Convention. This has a significant impact on the identi-
fication of emerging trends on the African continent. 
393. However, the information that is available to the 
Board suggests that the African continent remains affected 
by trafficking in precursors. During the reporting period, 
the following countries in Africa were involved in 
precursor-related incidents, as countries of transit or 
destination: Benin, Mozambique, Nigeria, South Africa 
and Zambia. The substances seized were mostly ephed-
rine in its raw form and in the form of preparations. In 
2018, for the second consecutive year, the Government 
of Benin reported seizures of ephedrine preparations in 
quantities far in excess of the country’s reported annual 
legitimate requirements (1 kg). Those seizures amounted 
to nearly 300 kg in 2016 and to more than 150 kg in 2017.
394. Nigeria continued to report seizures of ephedrine 
destined for other countries in Africa. Similarly to previ-
ous years, the destinations included, in particular, 
Mozambique and South Africa. Those seizures also con-
firm that South Africa continues to be a key destination 
for trafficking in ephedrine. A number of other precur-
sors were also reported by Nigeria in connection with 
illicit methamphetamine laboratories dismantled in the 
country in 2018. Reportedly, the substances had been 
diverted domestically. 
395. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in Africa can be found in 
the report of the Board for 2018 on the implementation 
of article 12 of the 1988 Convention.
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(d)  Substances not under international 
control
396. Tramadol, a synthetic opioid not under inter-
national control, is a substance of growing concern, par-
ticularly in North, Central and West Africa. UNODC, in 
its World Drug Report 2018, noted that those subregions 
of Africa now account for 87 per cent of pharmaceutical 
opioids seized worldwide and that the recent rise is due 
almost entirely to trafficking in tramadol.
397. According to the National Drug Law Enforcement 
Agency of Nigeria, the trafficking of tramadol into the 
country has risen sharply in the past two years. Authorities 
reported that over 100 tons of the drug were seized 
between January 2017 and March 2018. In 2017, the 
country seized 96 tons, in comparison with 3 tons in 
2016. Seizures of tramadol in Nigeria now exceed those 
of cocaine, heroin and methamphetamine combined. In 
fact, the quantity of tramadol seized in Nigeria in 2017 
exceeded the overall quantities of tramadol seized in all 
of Africa in 2016 (over 64 tons). Authorities also noted 
the wide proliferation of tramadol tablets with unap-
proved dosages, ranging from 120 mg to 250 mg. 
398. Côte d’Ivoire reported diversions of tramadol from 
legitimate channels in 2017, during which over 26 kg of 
the substance were seized by law enforcement authorities. 
In neighbouring Ghana, the Food and Drugs Authority 
reported that an investigation into pharmacies in the 
Region of Ashanti had determined that tramadol was 
being improperly sold over the counter contrary to 
national regulations requiring a prescription. Additionally, 
Ghana has seen a proliferation of high-dose tramadol 
tablets, with doses ranging from 120 mg to 250 mg, con-
tributing to growing abuse of the drug across the country.
399. Large quantities of tramadol continue to be 
reported to be seized by the Government of Egypt, where 
the substance has been under national control since 2013. 
It is reported that most of the substance is intercepted, 
in the form of tablets, at the country’s seaports. The 
national seizure totals increased from 217 million tablets 
in 2016 to more than 231 million tablets in 2017. An 
analysis of some of the tablets seized confirmed the pres-
ence of a range of impurities, indicating the illicit manu-
facture of those tablets. According to the reports of the 
Forensic Medicine Authority of the Ministry of Justice of 
Egypt, in 2017, there were 43 deaths related to tramadol 
abuse.
400. Morocco continues to see the proliferation of tram-
adol in the country, with authorities reporting the seizure 
of nearly 40 million tablets in 2017.
401. Zambia is the only country in Africa that officially 
reported seizures of khat, reporting seizures of over 
200 kg in 2017.
402. Kenya reported seizing approximately 729 litres of 
various ketamine preparations in 2017.
403. Authorities in Mauritius reported a significant rise 
in the prevalence of new psychoactive substances in the 
country. The country’s authorities reported total seizures 
of approximately 0.3 kg of new psychoactive substances 
in 2015 and 0.1 kg in 2016. In 2017, seizures of such sub-
stances rose to over 2.1 kg. As a result of that growing 
prevalence, new psychoactive substances have become 
the main drug-related reason for inpatient treatment in 
public health institutions in Mauritius.
5. Abuse and treatment
404. It is difficult to determine the true extent of the 
drug use situation in Africa because of the lack of avail-
able data in the region. Broadly, to judge by the available 
data, the drug use situation in the region has not 
improved. Countries report that cannabis remains the 
most prevalent drug of use among drug users. Studies 
from some countries suggest that use of other drugs is 
also on the rise.
405. In March 2018, the authorities of Algeria released 
a report on substance abuse among students in primary 
and secondary schools across Algeria based on data gath-
ered from a survey conducted in 2016. The report found 
that students aged 18 years and older had the highest 
rates of prevalence of substance abuse, with 8 per cent 
having used cannabis in the previous 12 months, 5 per 
cent having used a controlled psychotropic substance, 
2 per cent having used MDMA and 1 per cent having 
used cocaine. Among students aged 15 to 17, prevalence 
rates among boys greatly surpassed the rates among girls 
for all drugs. For example, the prevalence rate of canna-
bis use in the previous 12 months among boys was 7.42 
per cent, in comparison with 0.23 per cent among girls. 
Likewise, the prevalence rate of MDMA use among boys 
stood at 2.23 per cent, in comparison with 0.08 per cent 
among girls. The study also noted that the most common 
reason given among students for why they used drugs 
was “escaping from reality”.
406. A drug consumption study conducted in late 2017 
of schoolchildren aged 14 to 18 in the Cameroon capital 
of Yaoundé found that 6.11 per cent of students con-
sumed tramadol for non-medical purposes. The study 
also found that awareness of some drugs among students 
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was high, with more than 95 per cent of students being 
aware of tramadol and cocaine. Rates of awareness of 
other drugs including cannabis were lower, at 37.8 per 
cent. The study also found that a large majority of stu-
dents were against drugs being sold to students, and the 
majority of students were against punishing drug users, 
depending on the nature of the sanction.
407. Following a heroin abuse crisis in late 2010, Kenya 
has been developing a programme of medically assisted 
therapy for people who inject drugs as part of a broader 
national AIDS strategic plan. The programme has pro-
vided services to 2,800 injecting drug users thus far, has 
carried out initiatives to reduce the stigmatization of peo-
ple who inject drugs and has provided vocational and 
other opportunities following treatment. Kenya seeks to 
expand the programme to treat up to 9,000 people in the 
next three years and plans to introduce the use of 
buprenorphine and naltrexone to increase the available 
treatment options.
408. According to the National Drug Observatory Report 
of Mauritius, released in March 2018, approximately 
5,000 persons inject drugs in the country. The report indi-
cates that persons who inject drugs remain the primary 
driver of the high prevalence of HIV and hepatitis C in 
Mauritius. Among people who inject drugs, over 95 per 
cent are infected with hepatitis C and 44 per cent are co-
infected with HIV and hepatitis C. The report also indi-
cates that, as of June 2017, just over 4,000 persons were 
participating in the country’s opioid substitution therapy 
programme.
409. In February 2018, the Agency for the Prevention 
of Drug Abuse and Rehabilitation of Seychelles published 
a study entitled Seychelles Biological and Behavioural 
Surveillance of Heroin Users 2017. The main objective of 
the study was to determine the size of the population of 
heroin users, including people who inject heroin and 
other drugs, and the demographic characteristics of her-
oin users in the country. The results of the study provided 
two different figures on the population of drug injecting 
users through the use of two different methodologies. The 
first method yielded an estimate of 4,000–4,800 people 
who inject drugs. The second method, based on rates of 
usage of drug treatment services, yielded an estimated 
population of 2,560 people who inject drugs. A previous 
study in 2011 utilizing the second method estimated a 
population of 1,671 people who inject drugs. The 2017 
study noted that, regardless of which of the two methods 
was used, the population of people who inject drugs in 
Seychelles is high (about 3 per cent), given that the coun-
try’s total population is 95,843.
410. In February 2018, a new methadone clinic was 
opened in Mwanza, in the Lake Zone of the United 
Republic of Tanzania. In the first six months of opera-
tion, the clinic served over 100 drug users. The metha-
done programme was first introduced in the country in 
2011, at the Muhimbili National Hospital clinic, and in 
2018 there were five such facilities in the country, and a 
total of about 6,000 clients had received methadone treat-
ment. In addition, the Drug Control and Enforcement 
Authority was in the process of opening another metha-
done clinic in the capital city, Dodoma. 
B.  Americas
Central America and the Caribbean
1. Major developments
411. Central America and the Caribbean continue to be 
used by transnational organized criminal organizations 
for the trans-shipment of drugs from South America to 
the main drug markets in the United States and Europe. 
Cocaine and cannabis are the drugs most frequently traf-
ficked in large quantities through the region, and the 
most abused as well. Similar trends have been reported 
with regard to cannabis herb and cocaine seizures in 
some countries, which may reflect the utilization of can-
nabis herb as partial payment for cocaine traffickers along 
the trafficking chain.
412. Central America accounted for 11 per cent of the 
cocaine seized worldwide in 2016, most of which was 
seized in Panama. 
413. Overall, the quantities of cocaine seized in Central 
America increased in 2017 compared with 2016 and 2015. 
This is likely to be related to the sharp increases in the 
levels of illicit coca bush cultivation and cocaine produc-
tion in Colombia, and the demand for cocaine in Europe 
and North America. 
2. Regional cooperation
414. In August 2018, the Regional Commission on 
Marijuana of CARICOM issued a report entitled Waiting 
to Exhale: Safeguarding our Future through Responsible 
Social-Legal Policy on Marijuana. The Commission was 
established in 2014 by Heads of Government in the region 
in response to their concerns about rates of incarceration 
of young people for cannabis use and growing public 
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interest in the use of cannabis for medicinal purposes. 
The report contains reference to experiences with the 
establishment of regulated regimes for the medical and 
non-medical use of cannabis in neighbouring countries 
and states of the United States. In the report, the 
Commission recommended that the end goal of 
CARICOM should be to establish a regulated framework 
for cannabis, similar to that for alcohol and tobacco. It 
also recommended that CARICOM member States should 
not consider themselves bound by the international drug 
control conventions in making decisions on the way for-
ward regarding cannabis legislation reform and that 
CARICOM member States should work together to for-
mulate a formal, regional position on the need to amend 
the existing United Nations treaties governing the use and 
production of cannabis. The Board reiterates that the 
1961 Convention limits the use of cannabis exclusively 
to medical and scientific purposes, as a fundamental 
principle that lies at the heart of the international drug 
control legal framework and that cannot be derogated 
from. States parties to the Convention have the obliga-
tion to carry out the provisions of the Convention 
within their own territory. The Board encourages States 
to adopt proportionate responses for minor drug-related 
offences committed by drug users, including, where 
appropriate, alternatives to arrest and incarceration, and 
points out that such responses are provided for in the 
international drug control conventions.
415. In December 2017, 24 officials from Guatemala 
and Honduras participated in a seminar organized by the 
Board under its INCB Learning project. The seminar took 
place in Guatemala City and was hosted by the Ministry 
of Foreign Affairs of Guatemala. Representatives of WHO 
and the UNODC-WCO Container Control Programme 
also contributed to the meeting. INCB Learning is the 
Board’s global initiative to strengthen Governments’ 
capacity in the regulatory control and monitoring of the 
licit trade in narcotic drugs, psychotropic substances and 
precursor chemicals (see section F of chapter II above for 
more details). 
416. Countries in Central America and the Caribbean 
have been collaborating in countering organized crime 
and drug trafficking and in promoting an effective drug 
demand reduction approach, with the support of UNODC, 
through a number of strategic initiatives. Such initiatives 
include the Container Control Programme, AIRCOP, the 
Network of Prosecutors against Organized Crime, the 
UNODC project on strengthening criminal investigation 
and criminal justice cooperation along the cocaine route 
in Latin America, the Caribbean and West Africa,  and 
the Office’s drug demand reduction-oriented strong fam-
ilies and parenting skills programmes.
417. In December 2017, the secretariat of the Central 
American Integration System and the European Union 
signed an agreement in support of the region’s efforts to 
combat transnational organized crime. The European 
Union has pledged 20 million euros to the project, enti-
tled “Cooperation on criminal investigation in Central 
America to fight transnational crime and drug traffick-
ing” (ICRIME). The initiative will be part of the broader 
framework of the Central American Security Strategy and 
will also receive contributions from Spain and the Central 
American Integration System secretariat. 
418. In January and February 2018, the Financial Action 
Task Force published mutual evaluation reports for 
Panama and Barbados, respectively. The reports include 
analysis and recommendations related to the countries’ 
progress in implementing measures to combat money-
laundering, terrorist financing and other related threats, 
including drug trafficking. In July 2018, Panama hosted 
the thirty-seventh meeting of the Financial Action Task 
Force of Latin America.
3.  National legislation, policy  
and action
419. In Costa Rica, an Organized Crime Section was 
established by the Judicial Investigative Police in 2017. 
Furthermore, the National Forensics Laboratory has col-
laborated with the United States to strengthen its inves-
tigatory capacity, and in 2017 received accreditation 
under the International Standards Organization standards 
17020 and 17025 for chemical analysis, toxicology and 
biochemistry.
420. Honduras created the Sanitary Regulation Agency 
through Executive Decree PMC-032-2017, published in 
the official gazette in May 2017. The Agency is techni-
cally, financially and administratively independent from 
the Secretary of Health and is hosted at the Sectorial 
Cabinet for Development and Social Inclusion. The cre-
ation of the Agency is aimed at decentralizing and 
strengthening sanitary regulation activities. It will support 
the monitoring and control of movements of scheduled 
substances in the country, and act as the new competent 
national authority in Honduras for the international drug 
control conventions.
421. In 2017, the Ministry of National Security of 
Trinidad and Tobago established the Organized Crime 
Intelligence Unit within the Trinidad and Tobago Police 
Service. The Unit absorbed the Service’s Organized Crime, 
Narcotics and Firearms Bureau and the Criminal Gang 
and Intelligence Unit. The objective of the reform is to 
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improve information-sharing and operational collabora-
tion between national institutions.
4.  Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
422. Sharing a border with Colombia and being located 
on the route used to traffic cannabis, cocaine and “crack” 
cocaine northwards from the Andean region to North 
America and Europe, Panama has been seizing the larg-
est amounts of cocaine in the region for several years. 
Panama reported to INCB that, in 2017, 66.9 tons of 
cocaine had been seized, an increase of 12.7 per cent over 
the amount reported for 2016 (59.3 tons), and 35.9 per 
cent more than that reported for 2015 (49.2 tons). That 
increase is likely to be related to the sharp increases in 
the levels of illicit coca cultivation and cocaine produc-
tion in Colombia in 2016 and 2017 that have led to 
increased amounts of cocaine being trafficked through 
most countries in Central America and the Caribbean. 
423. A similar trend was observed in Costa Rica, which 
is also located on the northwards trafficking route. In 
2017, the country reported seizing the second-highest 
amount of cocaine in the region, which was about half 
of the amount seized in neighbouring Panama. Cocaine 
originating in Colombia and destined for Mexico and the 
United States and Europe reaches Costa Rica through 
Panama. Costa Rica reported seizing 20.1 per cent more 
cocaine in 2017 (27.9 tons in total) than in 2016 (23.2 
tons), and 63.9 per cent more than in 2015 (17 tons).
424. In Guatemala, the number of opium poppy and 
cannabis plants eradicated increased in 2017. The 
Government of Guatemala eradicated 417,004,278 opium 
poppy plants, most of it in the Department of San Marcos, 
and 6,033,345 cannabis plants, mainly in the Departments 
of Totonicapan and Petén. Cocaine seizures also contin-
ued to increase in the country, reaching 13.6 tons in 2017, 
a 6.5 per cent increase over 2016 (12.8 tons) and 121 per 
cent more than in 2015 (6.2 tons). The organized crimi-
nal groups involved in drug trafficking are composed of 
families that are mostly of Guatemalan origin. Nationals 
of Colombia, Ecuador and Mexico are also involved.
425. Among countries in Central America and the 
Caribbean reporting seizure data to the Board and 
UNODC, the Dominican Republic and Guatemala reported 
seizing the highest amounts of heroin, with similar trends 
over the period 2016–2018. Guatemala reported seizing 
83.40 kg of heroin in 2015, 143.43 kg in 2016 and 47.94 
kg in 2017, while the Dominican Republic seized 51.20 kg 
in 2015, 68.49 kg in 2016 and 27.57 kg in 2017. In 2017, 
the Dominican Republic reported dismantling a clandes-
tine fentanyl laboratory in the city of Santiago.
426. In Honduras, 2017 marked the reversal of a declin-
ing trend in the amount of cocaine seized, which reached 
a low of 735 kg in 2016, but increased to 2.1 tons the fol-
lowing year, slightly above the 2015 level, but below the 
level in 2014, when 11.7 tons were seized. In a similar 
trend, cannabis herb seizures also increased sharply in 
2017, to 5 tons, much higher than the low point in 2016 
(155 kg), but lower than the total seized in 2014 (29.8 tons). 
On the other hand, seizures of “crack” cocaine have been 
on the rise since 2015.
427. Similar to most of its neighbours in Central 
America, Nicaragua reported to INCB that it had seized 
higher levels of cocaine in 2017 (5.5 tons) than in 2016 
(4.5 tons) and 2015 (4.5 tons). Seizures of cannabis herb, 
however, were the lowest in 2017 since 2013, at 1.7 tons.
428. In September 2018, the United Nations Development 
Programme published a Human Development Report for 
El Salvador entitled I’m young! Now what? (¡Soy joven! ¿Y 
ahora qué?). The report highlights the challenges faced by 
those aged between 15 and 29 years in the country in 
terms of education, the labour market, public participa-
tion and social integration. The impact of violence, which 
is considered the main challenge for the country’s society, 
on young people is also analysed, including in terms of 
their resilience and the cultural stigma they face owing to 
the association between young people and violent gangs, 
which affects their employment and education opportuni-
ties. The report presents the effects of the presence of 
drugs in young people’s communities, schools and fami-
lies. Of the main threats to young people in their com-
munities, mugging (42.6 per cent) and the sale of and 
trafficking in drugs (39.5 per cent) were mentioned the 
most often by young people surveyed for the report. The 
report identifies five priority groups that should receive 
special support through public policies: young people out-
side of the education system and at risk of dropping out; 
young people transitioning into the labour market; young 
women not in education who provide care in their fami-
lies; young people in rural areas; and young people at risk.
429. According to the Attorney General’s office of 
El Salvador, between January and September 2018, the 
country recorded 1,360 deaths related to youth gang 
violence and 2,667 people were imprisoned for drug 
trafficking.
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430. Unlike its neighbouring countries in Central 
America, Belize usually reports seizing larger amounts of 
cannabis than cocaine, a trend also observed in some 
islands of the Caribbean, including Saint Lucia. In 2018, 
Belize reported to INCB that 64.5 kg of cocaine had been 
seized in 2017, which was 347 per cent higher than the 
amount seized in 2016 (14.4 kg). The amount of canna-
bis seized in 2017 (958.2 kg) in the country was 6.2 per 
cent higher than that seized in 2016 (901.9 kg).
431. Colombia and Jamaica were the countries most fre-
quently mentioned as a source of the cannabis herb seized 
by countries in Central America and the Caribbean. 
Other sources reported by countries in the region 
included Bolivia (Plurinational State of), Costa Rica, 
El Salvador, Guatemala and Peru. 
432. In a working paper submitted to the third United 
Nations Conference to Review Progress Made in the 
Implementation of the Programme of Action to Prevent, 
Combat and Eradicate the Illicit Trade in Small Arms and 
Light Weapons in All Its Aspects, in June 2018, the impact 
of the proliferation of small arms in Jamaica was high-
lighted. Drugs are smuggled from Jamaica to Canada, the 
United Kingdom and the United States, and arms are 
smuggled into the country, mostly from Haiti and the 
United States. In the paper, it was estimated that approx-
imately 274 active gangs, many transnational in scope, are 
responsible for about 80 per cent of major crimes in 
Jamaica. According to statistics from the Jamaica 
Constabulary Force, in 2017, 81.4 per cent of murders 
were committed using a gun, and the majority of the per-
petrators and victims of violent crimes were young men.
433. Trafficking in firearms is also of increasing concern 
in the Eastern Caribbean region, namely Antigua and 
Barbuda, Barbados, Dominica, Grenada, Saint Kitts and 
Nevis, Saint Lucia, and Saint Vincent and the Grenadines. 
Guns are reportedly entering countries in the subregion 
from the United States, Trinidad and Tobago, and 
Venezuela (Bolivarian Republic of). In 2017, homicide 
rates and drug-related violent and non-violent crimes 
increased; most homicides are believed to be the outcome 
of disputes for territory between organized criminal 
organizations involved in drug trafficking. 
(b) Psychotropic substances
434. While Central America and the Caribbean is less 
affected by the manufacture of and trafficking in 
amphetamine-type stimulants than other regions, in the 
past five years, some countries have regularly reported 
seizing such substances, as well as LSD. Countries of 
origin mentioned by reporting countries include 
Colombia, the Dominican Republic, Guatemala and the 
Netherlands, as well as Curaçao. 
435. In 2017, authorities in the Dominican Republic 
dismantled a clandestine laboratory producing “ecstasy” 
and ketamine in the city of Puerto Plata.
436. Also in 2017, Costa Rica reported the seizure of a 
total of 53,991 “doses” of “ecstasy”. That was the largest 
amount of “ecstasy” reported seized by the country 
during the period 2010–2017.
(c) Precursors
437. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in the region can be found 
in the report of the Board for 2018 on the implementa-
tion of article 12 of the 1988 Convention.
(d)  Substances not under  
international control
438. In August 2017, the Sanitary Regulation Agency of 
Honduras published an updated list of substances under 
national control. The list includes, for the first time, 
11 substances not under international control, including 
tramadol.
439. Panama reported seizures of ketamine in both 
2017 and 2016.
5. Abuse and treatment
440. In June 2017, the Dominican Republic started an 
opioid substitution treatment programme in partnership 
with UNODC. As of September 2018, 45 heroin users 
were benefiting from the programme.
441. In August 2017, the Government of the Bahamas 
published the results of its national household drug prev-
alence survey. The survey contained data from individu-
als aged between 12 and 65 on their abuse of licit and 
controlled substances. The results showed a lifetime prev-
alence of cannabis herb use of 20 per cent for men and 
7 per cent for women, compared with 14 per cent and 13 
per cent, respectively, in 1991. The reported average age 
of first cannabis herb use was 17. Lifetime prevalence of 
cocaine use was 2 per cent for men and 0.4 per cent for 
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women, down from 6 per cent and 1 per cent, respec-
tively, in 1991. The average age of first use of cocaine was 
25 years. 
442. According to the 2017 annual report of the 
National Drugs Observatory of the Executive Secretariat 
of the Commission against Addiction and Illicit Drug 
Trafficking (SECCATID) of Guatemala, the main drug for 
which 24.2 per cent of people sought treatment in 2017 
was cannabis herb. Alcohol was the main substance for 
29.3 per cent of those seeking treatment, inhalants for 2.5 
per cent, cocaine and “crack” cocaine for 1.6 per cent 
each, and psychotropic substances for 0.96 per cent. 
443. According to the World Drug Report 2018,73 the 
highest annual prevalence of drug use in Central America 
and in the Caribbean in 2016 was for cannabis, with 
2.8 per cent and 2.2 per cent, respectively. After canna-
bis, the highest prevalence in Central America was 
cocaine (0.7 per cent), amphetamines and prescription 
stimulants (0.2 per cent) and “ecstasy” (0.1 per cent). In 
the Caribbean, cannabis was followed by amphetamines 
and prescription stimulants (0.9 per cent), cocaine (0.6 per 
cent) and “ecstasy” (0.1 per cent).
North America
1. Major developments
444. Legislation and policy pertaining to cannabis con-
tinued to shift throughout North America in 2018. In 
Canada, Bill C-45, on providing legal access to cannabis 
and on controlling and regulating its production, distri-
bution, sale and possession, came into effect in October 
2018. Under the law, and subject to provincial or territo-
rial restrictions, persons aged 18 or older are legally 
allowed to possess up to 30 g of cannabis, buy dried or 
fresh cannabis from a provincially or federally licensed 
retailer, grow up to four cannabis plants per residence for 
personal use and make cannabis products.
445. Also in October 2018, the Supreme Court of 
Mexico ruled that a prohibition of the use of cannabis for 
non-medical purposes was unconstitutional on the basis 
that adults had a “fundamental right to the free 
73 Global Overview of Drug Demand and Supply Latest Trends, 
Cross-Cutting Issues (United Nations publication, Sales No. E.18.XI.9 
(Booklet 2)).
development of the personality” without interference 
from the State.
446. In the United States, the States of California and 
Vermont legalized the use of cannabis for non-medical 
purposes, and legislative developments also took place in 
the States of Maine and Massachusetts in that regard. In 
November 2018, during the United States congressional 
elections, voters in the States of Missouri and Utah 
approved ballot initiatives for the establishment of medi-
cal cannabis programmes. A proposal to legalize the pos-
session and personal cultivation of cannabis by persons 
aged 21 or older and to license the commercial produc-
tion and retail sale of the drug was adopted by voters in 
Michigan. In North Dakota, a ballot proposal aimed at 
legalizing the non-medical use of cannabis was rejected 
by the state’s electorate.
447. In December 2017, the Ministry of Health of 
Mexico issued guidelines on the medical use of cannabis, 
whereby preparations containing a concentration of less 
than 1 per cent THC are considered as having broad thera-
peutic uses and as presenting a limited risk of abuse and 
dependence and of public health problems.
448. Given the need to coordinate, integrate and follow 
up on the objectives, strategies and lines of action to 
address the world drug problem, the Criminal Investigation 
Agency of Mexico proposed the creation of a national 
office on drug policies. The office would be attached to 
the Attorney General’s Office, which is in charge of coor-
dinating drug policy in the country. 
449. Meanwhile, the opioid overdose epidemic contin-
ued to worsen in the United States, with provisional data 
showing that over 70,000 drug overdose deaths had been 
reported in the country in 2017. In 2016, 63,632 people 
died from drug overdoses, a 21.4 per cent increase com-
pared with 2015. According to the Centers for Disease 
Control and Prevention, opioids accounted for 66.4 per 
cent (42,249) of those deaths, with increases across all age 
groups, racial and ethnic groups and urbanization levels 
and in many states. The largest increases occurred among 
deaths involving cocaine (52.4 per cent) and synthetic 
opioids (100 per cent), likely driven by illicitly manufac-
tured fentanyl and its analogues.
450. Overdose deaths involving opioids contributed to 
a loss of 0.21 years in life expectancy for the entire popu-
lation of the United States between 2000 and 2015. In 
addition, life expectancy declined from 78.7 in 2015 to 
78.6 in 2016, owing in part to the increased number of 
deaths among younger people and deaths from uninten-
tional injuries, including drug overdose. Similarly, during 
ChaPTER III. aNalysIs Of ThE WORld sITuaTION  59
the period 2014–2016, life expectancy at birth in British 
Columbia, Canada, declined by a total of 0.38 years: drug 
overdose contributed a loss of 0.12 years to that decline.
451. In 2017, homicide rates in Mexico increased mark-
edly. According to the National Institute of Statistics and 
Geography of Mexico, the average number of homicides 
between 2012 and 2016 was about 22,000 per year; in 
2017, however, over 31,000 deaths were attributed to 
homicide in the country. The states with the highest num-
ber of homicides were Baja California, Chihuahua, 
Guanajuato, Guerrero and the State of Mexico. The high-
est rates of violence were also reported in those states and 
are attributed partly to the presence and operations of 
criminal organizations involved in drug production or 
trafficking or other drug-related activities.
2. Regional cooperation
452. Effective cooperation in law enforcement matters 
and in combating illicit drug manufacture and trafficking 
continued to be promoted through various regional 
mechanisms. In December 2017, representatives from 
Canada, Mexico and the United States met in Mexico City 
for the second meeting of the North American Drug 
Dialogue. Delegates from the three countries reviewed the 
progress made since the previous meeting in October 
2016 on opioid policies and actions affecting the region. 
They also discussed the increase in synthetic drugs, diver-
sion of chemical precursors from licit to illicit use and 
ongoing activities to reduce the demand for drugs and 
reaffirmed their commitment to achieving effective solu-
tions to the challenges posed by the production and con-
sumption of and trafficking in drugs in North America. 
To further broaden cooperation, in 2017, Mexico and the 
United States held two cabinet-level meetings of the 
Strategic Dialogue on Disrupting Transnational Criminal 
Organizations.
453. Regional cooperation between the three countries 
of the region includes initiatives and joint operations in 
the areas of law enforcement, intelligence-sharing and 
border control, as well as land and maritime activities.
3.  National legislation, policy and 
action
454. In the United States, the 2018 Consolidated 
Appropriations Act, which came into force in March 
2018, provided nearly $4 billion for the fiscal year 2018 
to address the opioid crisis, including through funding 
for drug courts, treatment for prisoners, monitoring of 
prescription drugs and scheduled chemical products, the 
provision of resources for law enforcement agencies in 
states with high rates of primary treatment admissions 
for the use of heroin and other opioids, overdose preven-
tion programmes and various research activities.
455. Also in March 2018, the President of the United 
States launched an initiative entitled “Stop opioid abuse 
and reduce drug supply and demand”. One of the key 
pillars of the initiative is aimed at reducing drug demand 
through education, increased awareness and preventing 
over-prescription, supporting research and implementing 
a safer prescribing plan. The initiative is to focus on 
combating the flow of illegal drugs into the country and 
illicit online sales of opioids, securing borders and detect-
ing high-risk shipments, and strengthening criminal 
penalties for trafficking in opioids. Furthermore, under 
the initiative, emphasis is placed on expanding access to 
overdose-reversing drugs, such as naloxone, evidence-
based treatment and addiction recovery services.
456. The United States Department of Justice announced 
a series of measures in January 2018, including the estab-
lishment of a joint criminal opioid darknet enforcement 
team as a Federal Bureau of Investigation-led initiative 
aimed at targeting drug trafficking, in particular fentanyl 
and other opioids, on the darknet. The team is to coor-
dinate efforts across the Bureau’s offices around the world, 
bringing together Drug Enforcement Administration 
drug trafficking task forces and other assets to counter 
online drug trafficking. Also in January 2018, the Attorney 
General of the United States announced a 45-day Drug 
Enforcement Administration surge to focus on pharma-
cies and prescribers dispensing unusual or disproportion-
ate amounts of drugs and to investigate and prosecute 
drug traffickers. One month later, the Department of 
Justice Prescription Interdiction and Litigation Task Force 
was formed to tackle the prescription opioid crisis at var-
ious levels of the distribution system. At the manufac-
turer level, the Task Force is to use all criminal and civil 
remedies available under federal law to hold opioid manu-
facturers accountable for unlawful practices. The Task 
Force is also to build on and strengthen existing 
Department of Justice initiatives to ensure that opioid 
manufacturers market their products truthfully and in 
accordance with the rules of the Food and Drug 
Administration.  
457. In addition, a number of state attorneys general 
initiated legal action against manufacturers and distribu-
tors of medicinal opioids for fuelling the opioid epidemic 
and launching marketing campaigns with deceptive con-
tent regarding the effectiveness and low risk of addiction 
of their medicinal products containing opioids. Relief 
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sought in those lawsuits by the various states included 
damages, restitution, injunctive relief and civil penalties. 
In response, one company, Purdue Pharma, undertook a 
large-scale public relations campaign, involving full-page 
newspaper advertisements, expressing its concern about 
the overdose death epidemic that its products had con-
tributed to.
458. In February 2018, the Drug Enforcement 
Administration placed all fentanyl analogues into sched-
ule I of the Controlled Substance Act on a temporary 
basis (until February 2020), with the possibility of a one-
year extension.
459. In addition, the Drug Enforcement Administration 
issued a final rule, effective as of 15 August 2018, on regu-
lations to strengthen the process to prevent the diversion 
of controlled substances and making other improvements 
to the quota management regulatory system for the pro-
duction, manufacturing and procurement of controlled 
substances in schedules I and II. If the Administration 
believes that a particular opioid or a particular compa-
ny’s opioids are being diverted for misuse, it is allowed 
to reduce the amount that can be produced in a given 
year. Those revised limits are to encourage vigilance on 
the part of opioid manufacturers and help the 
Administration respond to the changing drug threat envi-
ronment, while ensuring the availability of those sub-
stances for medical, scientific, research and industrial 
needs.
460. In October 2018, the President of the United States 
signed the Substance Use-Disorder Prevention that 
Promotes Opioid Recovery and Treatment for Patients 
and Communities Act, or the SUPPORT for Patients and 
Communities Act. Pursuant to the Act, the Department 
of Health and Human Services will oversee a grant pro-
gramme to expand the use of “comprehensive recovery 
centres”, which provide job training, mental health ser-
vices and housing alongside addiction treatment. In addi-
tion, the Act is aimed at improving coordination between 
Customs and Border Protection, the United States Postal 
Service and other entities to stop illicit shipments of drugs 
from entering the country. The Act also fast-tracks 
research projects undertaken by the National Institutes of 
Health related to the use of non-addictive drugs for the 
treatment of pain. Finally, the Act expands Medicare cov-
erage for opioid treatment and increases screening for 
opioid use disorder. Under the Act, a state Medicaid pro-
gramme would be required to suspend, rather than 
terminate, a minor’s medical coverage upon incarceration.
461. According to government figures released in 
September 2018, there were nearly 4,000 apparent 
opioid-related deaths in 2017 in Canada, corresponding 
to an increase of 33 per cent compared with the number 
in 2016 (3,005). From January to March 2018, there were 
at least 1,000 apparent opioid-related deaths, 94 per cent 
of which were accidental (unintentional); 73 per cent of 
those accidental deaths involved fentanyl or fentanyl ana-
logues. British Columbia remained the province hardest 
hit by the opioid crisis, with 1,399 deaths in 2017, an 
increase from the 974 recorded in 2016.
462. In response to the opioid crisis, the Minister of 
Health of Canada announced a series of measures to 
address the pharmaceutical industry’s opioid marketing 
practices, including severely restricting most forms of 
prescription opioid marketing. Until new regulations are 
formally in place, the Minister called on opioid manufac-
turers and distributors to immediately cease marketing 
activities associated with opioids in Canada, on a volun-
tary basis. The Minister also announced the creation of a 
dedicated marketing compliance and enforcement team 
within Health Canada, supported by approximately 
$4 million in operational resources over five years. The 
team is to proactively monitor opioid marketing to enforce 
rules around improper advertising and to take action, 
including recommending criminal charges where appro-
priate. The Government has also been exploring the 
development of new enforcement tools, including admin-
istrative fines that could be levied rapidly in the case of 
less serious violations. At the same time, legal action 
against pharmaceutical companies manufacturing opioids 
has been launched by some provinces in Canada.
463. In November 2017, the National Commission 
against Addictions (CONADIC) of Mexico announced 
that it would begin research on the consumption of new 
psychoactive substances. A first workshop was held to 
identify strategies to strengthen the identification of the 
profiles and chemical composition of narcotics and new 
psychoactive substances, in order to implement an early 
warning system in the country. Furthermore, in June 
2018, CONADIC signed an agreement to collaborate with 
the National Polytechnic Institute, as part of prevention 
efforts targeted at young people.
464. Under the Cannabis Act, which came into effect in 
Canada in October 2018, and subject to provincial or ter-
ritorial restrictions, persons aged 18 or older are legally 
allowed to possess and share with other adults up to 30 g 
of cannabis, buy dried or fresh cannabis and cannabis oil 
from a provincially or federally licensed retailer, grow up 
to four cannabis plants per residence for personal use and 
make cannabis products, such as foods and drinks, at 
home. The federal Government is responsible for estab-
lishing the requirements for producers and industry-wide 
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rules and standards. The provinces and territories are 
responsible for developing, implementing, maintaining 
and enforcing systems to oversee distribution and sale. 
They are also able to add their own safety measures, such 
as increasing the minimum age, lowering the personal 
possession limit or placing restrictions on where adults 
can consume cannabis. The Cannabis Act further foresees 
several measures aimed at preventing young people from 
accessing cannabis, including restrictions on packaging 
or labelling, on promoting cannabis and on selling it 
through self-service displays or vending machines. The 
Act creates two new criminal offences for giving or sell-
ing cannabis to young people and for using a youth to 
commit a cannabis-related offence; both carry maximum 
penalties of 14 years in prison. On 21 June 2018, Bill 
C-46, which amended provisions of the Criminal Code 
dealing with offences and procedures related to drug-
impaired driving, received royal assent.
465. A number of companies have been investing in 
research on the production of cannabis-infused non-
alcoholic beverages and beer in Canada. While there 
seem to be a lack of scientific studies on the effects of 
such beverages on health, it is expected that these 
products will become available in the country once the 
relevant regulations take effect.
466. Following the adoption of the Cannabis Act, the 
Government of Canada approved the provision of approx-
imately $700,000 over three years to the Centre for 
Addiction and Mental Health to study drug-impaired 
driving. The study is to explore how increased levels of 
THC in blood and oral fluids could impact a driver, 
including his or her ability to anticipate hazards; levels of 
risk-taking behaviour; reaction times; position and speed 
on the roads; and differences that may exist between driv-
ers, depending on age, gender, THC levels and driving 
impairment. The study is to be completed by June 2020.
467. Health Canada announced an investment of 
approximately $170,000 for three organizations – the 
Centre for Addiction and Mental Health, the University 
of Western Ontario and Health Nexus – to support front-
line workers in informing the public about health and 
safety-related issues pertaining to cannabis. Those organ-
izations are to develop public education tools and 
resources for public health professionals, education sec-
tor stakeholders (such as educators, school counsellors, 
school and school board administrators) and community 
service providers. In the federal budget for 2018, approx-
imately $48 million were committed over five years to 
support community-based and indigenous organizations 
in educating their communities about the risks associated 
with cannabis use. That was in addition to a previously 
announced investment of $35 million over five years to 
support public education, awareness and monitoring 
activities.
468. Following the amendment to its General Health 
Law in June 2017, by which Mexico legalized the use of 
cannabinoids for medical purposes, the Ministry of 
Health was tasked with designing and implementing pub-
lic policies regulating the medicinal use of cannabis and 
research and national production. In December 2017, the 
Government announced guidelines permitting the import 
of pharmacological derivatives of cannabis, oils, pills and 
foods with less than 1 per cent THC, with higher poten-
cies requiring special government approval for individual 
patients.
469. In January 2018, the Attorney General of the 
United States issued a memorandum to all district-level 
United States Attorneys on the enforcement of cannabis-
related legislation. The memorandum stated that previous 
nationwide guidance on the issue had been rescinded, 
and the Attorneys were instructed to use previously estab-
lished principles that governed all federal prosecutions. 
When deciding which cases to prosecute, the seriousness 
of the crime, the deterrent effect of criminal prosecution 
and the cumulative impact of particular crimes on the 
community were to be taken into account. Also in the 
memorandum, the Attorney General recalled federal law 
and Congress’ determination that cannabis was a danger-
ous drug and that related activities were serious crimes.
470. California became the eighth state in the United 
States (after Alaska, Colorado, Maine, Massachusetts, 
Nevada, Oregon and Washington)74 to legalize and regu-
late the sale of cannabis for non-medical purposes. 
According to the regulatory scheme established in 
California, adults over the age of 21 may possess up to 
28 g of cannabis and can grow up to six plants at home. 
Cannabis may also be sold in retail outlets licensed by 
the California Bureau of Cannabis Control. As at 1 July 
2018, cannabis goods must meet a number of statutory 
and regulatory requirements, including as regards labo-
ratory testing, packaging and labelling, established by the 
Bureau. According to the California Department of Tax 
and Fee Administration report of 11 May 2018, the tax 
revenue from the cannabis industry in the first quarter 
of 2018 totalled $60.9 million, which included state cul-
tivation, excise and sales taxes. It did not include local 
tax revenue collected by cities or counties.
74 The use of cannabis for non-medical purposes has been legalized 
in the District of Columbia, but commercial sales of cannabis are not 
regulated and remain illegal.
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471. Vermont became the first state to legalize the use 
of cannabis for non-medical purposes through an act of 
the state legislature, without the issues first being approved 
by popular vote. Since July 2018, persons aged 21 and 
older are allowed to possess up to 1 ounce of cannabis 
(28.3 g) and two mature and four immature plants. 
However, the legislation does not create a framework for 
the production, distribution and sale of the drug. The 
Governor’s Marijuana Advisory Commission was directed 
to prepare a study on the implementation of a legal 
market in which cannabis is taxed and regulated, which 
is to be presented in December 2018.
472. In May 2018, the Legislature of the State of Maine 
overrode the Governor’s veto of April 2018 on the Act to 
Implement a Regulatory Structure for Adult-Use 
Marijuana. The Act facilitates the development and 
administration of a regulated market in Maine and the 
regulation of personal use and home cultivation for non-
medical purposes. While possession for personal use of 
2.5 ounces (71 g) of cannabis and growing three mature 
plants became legal in January 2017 in Maine, there was 
a moratorium in effect on the implementation of parts of 
the state law related to retail sales and taxation.
473. Following a vote in November 2016 to legalize the 
non-medical use of cannabis, the State of Massachusetts 
established the Cannabis Control Commission, mandated 
to draft related regulations. The approved Adult-Use 
Cannabis Regulations entered into force in March 2018. 
The final regulations include nine licence categories for 
cannabis establishments: cultivator, craft marijuana coop-
erative, microbusiness, product manufacturer, independ-
ent testing laboratory, storefront retailer, third-party 
transporter, existing licensee transporter, and research 
facility.
474. In February 2018, the New Hampshire House of 
Representatives voted in favour of Bill 656, on legalizing 
and regulating the use of cannabis for non-medical pur-
poses; however, the Bill was referred for interim study on 
the potential impact of the legislation in the State.
475. The Board wishes to reiterate that article 4 (c) of 
the 1961 Convention restricts the use of controlled 
narcotic drugs to medical and scientific purposes and 
that measures providing for non-medical use are in 
contravention of that Convention.
476. Statistics Canada conducted a survey of the coun-
try’s licensed cannabis producers under the Access to 
Cannabis for Medical Purposes Regulations in the fourth 
quarter of 2017 and in early 2018. Revenue from the sale 
of cannabis products was approximately $190 million in 
2016 and expenses were approximately $230 million. The 
55 producers licensed at the time of the study reported 
that 8.7 ha of cultivation area were in active use in 2016 
and about 10 times that amount (85.7 ha) were available 
for future production. Those producers were intending to 
invest approximately $600 million in new structures, land, 
equipment and inventories in 2017, roughly doubling 
their stock of capital compared with the end of 2016. As 
of July 2018, 114 producers had been licensed by Health 
Canada to produce and sell dried cannabis, fresh canna-
bis and cannabis oil to the public or starting materials to 
eligible persons. 
477. According to Statistics Canada, cannabis prices 
remained unchanged in the first two quarters of 2018. 
The average price in the second quarter was $5.18 per 
gram, down slightly from the first quarter ($5.21 per 
gram). In 2018, the average price for cannabis was $5.20 
per gram, down 25 per cent from 2012, when it was $6.98 
per gram. The highest prices for cannabis in the first six 
months of 2018 were in the three territories (Northwest 
Territories, Yukon and Nunavut) and in Ontario.
478. On 25 June 2018, the Food and Drug Administration 
of the United States approved a CBD oral solution for the 
treatment of seizures associated with two rare and severe 
forms of epilepsy, Lennox-Gastaut and Dravet syndromes, 
in patients aged 2 years and older. This is the first drug 
approved by the Administration that contains a purified 
drug substance derived from cannabis.
4.  Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
479. In the fiscal year 2017/18, the Canadian Border 
Services Agency seized a total of almost 500 kg of can-
nabis, 3 tons of cocaine, 190 kg of heroin and 15 kg of 
fentanyl. During the same period, the United States 
Customs and Border Control agency seized more than 
970 tons of narcotics, including over 680 kg of fentanyl.
480. In 2017, Mexico reported seizures of 400 tons of 
cannabis herb, 34,600 cannabis plants, 321 kg of heroin 
and almost 12 tons of cocaine. Seizures of cocaine and 
cannabis represented a decrease of 8 per cent and 56 per 
cent, respectively, compared with the quantities seized in 
2016.
481. In Mexico, 28,830 ha of opium poppy were 
eradicated in 2017, an increase of 28 per cent over 2016 
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(22,437 ha). With regard to cannabis, 4,193.34 ha were 
eradicated in 2017, which was 23 per cent less than in 
2016 (5,477 ha). The United States reported the eradica-
tion of 4,940,569 cannabis plants at 5,513 sites in 2016. 
While the United States continued to report the largest 
quantity of cannabis herb seized worldwide in 2016, fol-
lowed by Mexico, seizures were at their lowest level since 
2000 and 1995, respectively.
(b) Psychotropic substances
482. Methamphetamine is reportedly manufactured in 
Mexico in clandestine laboratories, with chemical precur-
sors trafficked mostly by sea. The Government of Mexico 
reported the discovery of 92 such laboratories and the sei-
zure of nearly 1.2 kg of amphetamine and over 10 tons of 
methamphetamine in 2017. In August 2018, the Secretariat 
of the Navy (SEMAR) dismantled a number of clandes-
tine laboratories and underground warehouses in various 
parts of Mexico, having seized methamphetamine and 
precursor chemicals weighing approximately 76 tons.
483. In 2016, over 87 tons of methamphetamine were 
seized in North America overall. According to the World 
Drug Report 2018, availability of methamphetamine in the 
region was reported to have increased between 2013 and 
2016; in 2016, the drug was reported to be the second 
greatest drug threat in the United States after heroin.75 
(c) Precursors
484. Reports of seizures of precursors from countries in 
the region came mainly from Mexico. Canada and the 
United States reported seizures of low amounts, the 
majority involving substances listed in Table II of the 
1988 Convention. An increasing number of non- scheduled 
chemicals are being reported, providing further evidence 
that access to internationally controlled precursors for the 
illicit manufacture of drugs has become more difficult, 
leading traffickers to source alternative or substitute 
chemicals to replace them. 
485. A detailed analysis of the situation with respect to 
the control of precursors and chemicals frequently used 
in the illicit manufacture of narcotic drugs and psycho-
tropic substances in the region can be found in the report 
of the Board for 2018 on the implementation of article 12 
of the 1988 Convention. 
75 World Drug Report 2018: Analysis of Drug Markets. Opiates, 
Cocaine, Cannabis, Synthetic Drugs (United Nations publication, Sales 
No. E.18.XI.9 (Booklet 3), pp. 9 and 55.
(d)  Substances not under international 
control
486. In June 2018, Health Canada issued a notice on its 
proposal to add tramadol and its salts, isomers and deriv-
atives to schedule I of the Controlled Drugs and 
Substances Act and the schedule of the Narcotic Control 
Regulations. Tramadol, an opioid analgesic used to treat 
moderate to moderately severe pain, has been marketed 
in Canada since 2005, and is available on prescription. In 
its notice, Health Canada stated that placing tramadol 
under national control would help to prevent its diver-
sion and protect the population from the health risks 
associated with unauthorized use, while maintaining its 
availability for legitimate medical and scientific use. 
Pharmacists would continue to be authorized to dispense 
tramadol to patients with a written prescription. 
487. According to the World Drug Report 2018, some 
opioid users in the United States have reported using 
kratom (Mitragyna speciosa) products for the self- 
management of withdrawal symptoms. Some 500 tons of 
kratom were seized during 2016, triple the amount of the 
previous year, suggesting an increase in use. In May 2018, 
the Food and Drug Administration of the United States 
issued warning letters to three marketers and distributors 
for illegally selling unapproved drug products containing 
kratom and making claims about their ability to help in 
the treatment of opioid addiction and withdrawal. 
5. Abuse and treatment
488. Following the adoption of the Cannabis Act in 
Canada, the Government announced a series of measures 
to monitor cannabis consumption before and after the 
legislative change to legalize and regulate cannabis use for 
non-medical purposes. To that end, Statistics Canada 
launched the National Cannabis Survey, to be undertaken 
quarterly throughout 2018. Based on data collected dur-
ing the second quarter of 2018, about 16 per cent of those 
aged 15 years and older (4.6 million people) reported 
some use of cannabis products for medical or non- 
medical use in the previous three months. The propor-
tion was similar to that reported in the first quarter. 
About 14 per cent of cannabis users with a driver’s licence 
reported driving within two hours of using cannabis.
489. During an address to the sixty-third regular ses-
sion of CICAD, a representative of CONADIC Mexico 
stressed the harmful effects that the legalization of canna-
bis for non-medical purposes could have on individuals 
and on society as a whole. Negative effects related to men-
tal and physical health, threats to public health and impact 
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on care service capacity were presented. Illicit drug use by 
persons aged 12 to 65 has significantly increased in 
Mexico, from 1.5 per cent in 2011 to 2.7 per cent in 2016. 
Illicit drug use by women aged 12 to 17 increased by 
175 per cent. According to the Ministry of Health, 
cannabis was the most used drug in that period, followed 
by cocaine. Consumption of amphetamine-type stimulants 
remained stable, as did lifetime use of heroin. 
490. In comparison, according to the results from the 
2016 National Survey on Drug Use and Health in the 
United States, approximately 28.6 million people aged 12 
and above (10.6 per cent of that population group) were 
current drug users in 2016. Overall, the percentage was 
higher in 2016 than the percentages from 2002 to 2015. 
With regard to specific substances, cannabis was the drug 
that was most commonly illicitly used, followed by mis-
used prescription opioids. Although cannabis use 
increased among persons aged 18 and above, use among 
adolescents aged 12 to 17 was lower in 2016 than in most 
years from 2009 to 2014, and similar to that in 2015. In 
contrast, the percentages of people aged 12 and above 
have shown little change since 2007 for current use of 
cocaine and since 2014 for heroin. 
491. In November 2017, the Council of Economic 
Advisers, an agency within the Executive Office of the 
President of the United States, published a report on the 
underestimated cost of the opioid crisis in the country. 
The Council estimated that, in 2015, the economic cost 
of the opioid crisis had been $504 billion, or 2.8 per cent 
of gross domestic product that year. The estimation 
included economic evaluations related to fatalities and the 
non-fatal costs of misuse, as well as underreported over-
dose fatalities, and took into account prescription opioids 
and illicitly produced opioids, including heroin. It was the 
first such report issued by the Council and it was aimed 
at providing policymakers with economic analysis to 
review and assess potential policy options. 
492. The Centres for Disease Control and Prevention 
reported that, between July 2016 and September 2017, 
visits to the emergency department in hospitals by those 
aged 11 and above as a result of opioid overdoses 
increased 29.7 per cent overall, and 34.5 per cent in 16 
states with a high prevalence of overdose mortality. 
Significant increases were found in the States of Wisconsin 
(109 per cent), Delaware (105 per cent) and North 
Carolina (31 per cent). A decrease of 15 per cent was 
noted in Kentucky. Substantial increases were seen among 
men and women and in all age groups. 
493. There are currently three approved medication-
assisted treatments for opioid use disorders in the United 
States, namely, methadone, buprenorphine and naltrex-
one. To encourage and support the development of treat-
ment options for people with opioid use disorder, the 
Food and Drugs Administration released draft guidance 
in April 2018 focusing on ways that drug companies 
could more efficiently explore innovations in buprenor-
phine products.
494. The Drug Enforcement Administration amended 
its regulations to incorporate statutory and regulatory 
changes regarding the categories of practitioners who 
may, under certain conditions and on a temporary basis, 
dispense a narcotic drug in schedule III, IV, or V of the 
Controlled Substances Act for the purpose of mainte-
nance or detoxification treatment. Those changes entered 
into force in January 2018. Nurse practitioners and phy-
sician assistants can now become qualifying practitioners, 
which gives them the authority to prescribe and dispense 
buprenorphine from their offices. Prior to the enactment 
of the Drug Abuse Treatment Act of 2000, only physi-
cians could treat people with opioid dependence and had 
to register with the Administration as both physicians and 
operators of narcotic treatment programmes. Waiving 
that second registration prompted more physicians to 
offer treatment services. 
495. Similarly, the Government of Canada amended the 
Narcotic Control Regulations and the New Classes of 
Practitioners Regulations to remove restrictions on the 
prescription of diacetylmorphine (prescription-grade 
heroin) to allow doctors to prescribe and administer and 
nurse practitioners to administer the drug for opioid-
substitution purposes outside hospital settings under the 
special access programme of Health Canada. The amend-
ment also removed the obligation for practitioners to 
obtain an exemption from Health Canada before they 
could prescribe, sell, provide or administer methadone. 
The regulatory changes came into effect in May 2018. 
496. In Quebec, naloxone is available free of charge and 
without prescription at pharmacies and in some health-care 
settings. Similarly, free naloxone kits have been available in 
pharmacies in almost 15 cities in Ontario since March 2018. 
Furthermore, to address a lack of youth-focused treatment 
programmes, the British Columbia Centre on Substance Use 
developed new guidelines aimed at improving treatment for 
young people with opioid dependence. 
497. The Canadian Centre on Substance Use and 
Addiction and the Canadian Institute for Substance Use 
Research at the University of Victoria estimated that the 
overall cost of opioid use in Canada had been approxi-
mately $2.6 billion in 2014. In its 2018 budget, the 
Government of Canada committed more than 
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$175 million over five years to address the opioid crisis. 
That funding included $110 million for a cost-shared 
Emergency Treatment Fund. On 28 June 2018, the 
Government of Canada and the government of 
Newfoundland and Labrador signed a bilateral agreement 
under the Emergency Treatment Fund to improve access 
to opioid dependence treatment in the Province. 
Newfoundland and Labrador is the first province to sign 
a bilateral agreement under the Fund. 
498. Public health officials in the Provinces of Alberta 
and Manitoba have raised concerns about the significant 
rise in amphetamine and methamphetamine use. The 
number of people reporting crystalline methampheta-
mine use nearly tripled between 2014 and 2018 in Alberta, 
and the number of confirmed deaths resulting from fen-
tanyl that had methamphetamine listed as an additional 
substance doubled in 2017 compared with 2015. Reported 
past-year usage of amphetamine increased by 48 per cent 
among young people and 104 per cent among adults 
between the periods 2014–2015 and 2016–2017. The 
number of monthly emergency room visits for which 
amphetamine and methamphetamine were reported as 
the cause of admission also increased in the province, 
from 10 visits in January 2013 to 180 visits in December 
2017, representing an increase of 1,700 per cent.
499. Following an amendment to the Canadian 
Controlled Drugs and Substances Act in May 2017, the 
number of conditions that applications for supervised 
“drug consumption rooms” must meet decreased from 26 
to 5, and the number of such rooms in the country 
expanded. In 2018 alone, 18 additional rooms were 
approved and went into operation in Alberta, British 
Columbia, Ontario and Quebec. On 2 April 2018, Royal 
Alexandra hospital in Edmonton, Alberta, opened the 
first hospital-based supervised “drug consumption room” 
in North America. 
500. Pilot study results from on-site testing conducted 
in November 2017 at two supervised “drug consumption 
rooms” in Vancouver found that only 19 per cent of sub-
stances purchased as opioids contained the expected sub-
stance and that 88 per cent contained fentanyl. The 
Minister of Health announced that Health Canada would 
authorize additional drug-checking services at such 
rooms. New programmes would use on-site technologies, 
and partnerships would be developed between front-line 
agencies and laboratories for off-site analysis. 
501. As part of its overdose prevention strategy, imple-
mented by the Mayor’s task force, in January 2018, the 
city of Philadelphia announced its intent to open one or 
more comprehensive user engagement sites, also known 
as supervised “drug consumption rooms”. The facilities 
would be funded, built and run by Philadelphia community-
based organizations. The Mayor of Philadelphia recalled 
that the city’s fatal overdose rate was the worst among 
large cities in the United States and that the comprehen-
sive user engagement sites were part of a broader strat-
egy to address the opioid crisis and a recommended 
action from the Mayor’s Task Force to Combat the Opioid 
Epidemic in Philadelphia. Other major cities in the 
United States, including Denver, New York, San Francisco 
and Seattle, are reported to also be considering opening 
such sites.
502. The Board wishes to remind Governments that, 
in order for the operation of supervised injection sites 
to be consistent with the international drug control 
conventions, certain objectives must be advanced. The 
objective of such sites should be to reduce the adverse 
consequences of drug abuse through the provision of or 
active referral to treatment and rehabilitation services 
and social reintegration measures. Supervised injection 
sites should not replace demand reduction programmes, 
particularly prevention and treatment activities. While 
recognizing that such sites may reduce the adverse 
consequences of drug abuse through treatment, rehabil-
itation and reintegration, due consideration must be 
given to preventing inadvertent encouragement of drug 
abuse and to preventing drug trafficking in and around 
the sites.
503. The Government of Mexico has been promoting a 
series of measures to expedite and ensure the availability 
of controlled substances for pain management. As part of 
the National Strategy for Pain Control and Palliative Care, 
a rapid action group was created, which facilitates the 
issuance of special prescriptions that guarantee patients 
the availability of controlled medicines. Furthermore, the 
Federal Ministry of Health of Mexico, together with the 
Federal Commission for Protection against Health Risks 
(COFEPRIS), the Mexico Foundation for Health 
(FUNSALUD) and the Secretary of Health of Mexico 
launched a project on access to controlled substances for 
medical purposes, in cooperation with UNODC. The aim 
of the project is to contribute to the design of an 
evidence-based plan to strengthen national and state-level 
efforts to improve the availability of pain medication 
through collecting information from each of the pain 
clinics, palliative care units and in-hospital and private 
pharmacies in Mexico City. 
504. The Food and Drug Administration of the United 
States established a new drug shortages task force to 
implement long-term solutions to prevent shortages of 
opioids and other required medication in hospitals in the 
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United States. According to the 2017 annual report to 
Congress on drug shortages, the drugs in question 
included injectable opioid analgesics (pain medications), 
hydromorphone, morphine and fentanyl. 
505. In January 2018, the Food and Drug Administration 
finalized and published a draft opioid analgesic risk eval-
uation and mitigation strategy education blueprint for 
health-care providers involved in the treatment and moni-
toring of patients with pain. It modified the 2012 strat-
egy and included all immediate-release opioids used in 
outpatient settings. The blueprint is aimed at educating 
health-care providers on safe opioid practices, as well as 
on current federal and state regulations, national guide-
lines and professional organization and medical society 
guidelines on treating pain and prescribing opioids.
506. In addition to the measures described above, 
public health and law enforcement authorities continued 
their efforts to dispose of prescription drugs that are no 
longer needed in order to prevent their diversion and 
illicit use. During its sixteenth National Prescription Drug 
Take Back Day, on 27 October 2018, nearly 460 tons of 
potentially dangerous expired, unused and unwanted 
prescription drugs were collected by the Drug Enforcement 
Administration at almost 6,000 sites across the United 
States that had been set up together with a record-setting 
amount of local, state and federal partners. The largest 
quantities were collected in California, Texas and 
Wisconsin. Similar initiatives are also organized in 
Canada.
South America 
1. Major developments
507. In South America, illicit cocaine manufacture 
increased, impacting the European market, where evi-
dence of increased availability and use is a cause for con-
cern. In Colombia, both illicit coca bush cultivation and 
cocaine manufacture increased in 2017, by 17 per cent 
and 31 per cent, respectively, reaching an all-time high. 
In the Plurinational State of Bolivia, the area under coca 
cultivation increased by 6 per cent in 2017, compared 
with 2016, according to the UNODC/Government of 
Bolivia coca cultivation survey for 2017. 
508. Most cocaine continued to be trafficked from the 
Andean countries, in particular from Colombia, to the 
main consumer markets in North America and Europe, 
according to seizure data. Cocaine shipments intercepted 
in South America were mainly destined for the United 
States. 
509. In order to address this development, in March 
2018, the Governments of Colombia and the United States 
agreed to formulate a five-year plan to reduce illicit crop 
cultivation by 50 per cent by 2023 in relation to the level 
of illicit coca bush cultivation in 2018. In that connection, 
on 14 June 2018, the Minister of Defence of Colombia 
presented a white paper on the eradication of illicit crops 
in Colombia, which contained a five-year plan for the 
period 2018–2023; the main objective of the plan is to 
reverse the trend of the increase in crops since 2013. In 
addition, the plan is intended to ensure the continuity of 
current efforts aimed at eradication and interdiction and 
strengthening cooperation with the United States.
510. On 4 May 2018, the Minister of Government of 
the Plurinational State of Bolivia inaugurated the Regional 
Anti-Narcotics Intelligence Centre (CERIAN), which is 
intended to coordinate actions against drug trafficking 
among its five bordering countries, Argentina, Brazil, 
Chile, Paraguay and Peru. The Centre is expected to ena-
ble countries of the region to process information on the 
modus operandi, composition and operation of criminal 
organizations in port, airport and land movements, and 
implement joint coordinated efforts.
511. In 2018, Paraguay and Peru took steps towards 
legalizing the use of cannabis and its derivatives for medi-
cal purposes.
2. Regional cooperation
512. In 2017, countries in South America strengthened 
their cooperation efforts at the bilateral, regional and 
interregional levels to better address the challenges posed 
by illicit drugs. Countries in the region continued to 
exchange information and experiences on technological 
and operational aspects and to engage in policy dialogue. 
Discussions in the region addressed trends in relation to 
new psychoactive substances, women and drug policy, 
new legislative approaches and alternative development, 
among others. With regard to capacity-building, govern-
ment officials attended specialized training events and 
workshops on the topics of precursor chemicals, new psy-
choactive substances and early warning systems, property 
confiscation and financial crimes. In addition, 
Governments worked to coordinate action along com-
mon borders, including by creating the above-mentioned 
Regional Anti-Narcotics Intelligence Centre in the 
Plurinational State of Bolivia. 
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513. Under the auspices of the second phase of the 
Cooperation Programme between Latin America, the 
Caribbean and the European Union on Drugs Policies II 
(COPOLAD II), the second Annual Meeting of National 
Drugs Observatories was held in Lisbon from 13 to 17 
November 2017, with the participation of representatives 
of national drug observatories from 32 countries in the 
Latin American and Caribbean region. COPOLAD, a 
cooperation programme implemented jointly by CELAC 
and the European Union, pursues its objectives through 
four components: (a) consolidation of national drug 
observatories through the provision of technical assis-
tance; (b) strengthening capacities in demand reduction; 
(c) strengthening capacities in supply reduction; and (d) 
supporting the policy dialogue and consolidation of the 
European Union-CELAC Coordination and Cooperation 
Mechanism on Drugs. The meeting was attended by rep-
resentatives of authorities from 18 countries in Latin 
America, 14 countries in the Caribbean and 6 European 
Union member States, with the objectives of analysing the 
role of the national drugs observatories in shaping pub-
lic policy and improving the dissemination of good prac-
tices. The meeting included training on early warning 
systems and the production of national reports on drugs.
514. Within the framework of efforts to strengthen 
international cooperation in the fight against drug traf-
ficking, the fifth meeting of the Argentina-Paraguay Joint 
Commission on the Prevention of the Illegal Use of and 
Illicit Trafficking in Narcotic Drugs and Psychotropic 
Substances was held in Buenos Aires from 31 October to 
1 November 2017. The meeting agenda was focused on 
the control of precursor chemicals, strategies for reduc-
ing the supply of narcotic drugs and combating organ-
ized crime involving drug trafficking and related crimes 
in the border areas. The promotion of joint training and 
operations and the exchange of information were among 
the issues discussed. 
515. The Peruvian National Commission for 
Development and Life without Drugs (DEVIDA) and the 
German Agency for International Cooperation (GIZ) 
organized the third Forum for Intra-regional Dialogue on 
Alternative Development, held in Lima from 27 February 
to 1 March 2018. At the Forum, national authorities from 
seven countries of Latin America and the Caribbean and 
representatives from CICAD and UNODC exchanged 
experiences and lessons learned in implementing their 
respective alternative development programmes, with a 
focus on value chains and the marketing of products.
516. In March 2018, Colombian experts in the areas of 
property confiscation, money-laundering and financial 
crimes delivered a specialized workshop in the 
Plurinational State of Bolivia. Aimed at supporting and 
enhancing the implementation of confiscation of assets 
seized in drug trafficking cases, the workshop bolstered 
effective regional cooperation. The workshop was attended 
by officials from the Ministry of the Interior, including 
its Directorate of Social Defence, Directorate of Controlled 
Substances and Directorate for the Registry, Control and 
Administration of Seized Assets, the judiciary, the Office 
of the Attorney General, the Special Force to Combat 
Drug Trafficking (FELCN) and the Financial Investigations 
Unit, as well as by officials from INTERPOL and police 
attachés from Brazil, Colombia and Peru.
517. On 11 June 2018, the National Health Surveillance 
Agency of Brazil (ANVISA) hosted the second regional 
meeting on new psychoactive substances in the western 
hemisphere, which was attended by experts in the fields 
of forensic science, public health and law enforcement 
from more than 20 countries. The participants, from 
regional and international organizations, including 
EMCDDA, INTERPOL, WHO, CICAD, WCO and the 
WCO Regional Intelligence Liaison Office for Asia and 
the Pacific, addressed, among other topics, trends in rela-
tion to new psychoactive substances, the detection and 
identification of substances, new legislative approaches 
and early warning systems. 
518. From 13 to 15 June 2018, a workshop on regional 
coordination of land borders was held in the Plurinational 
State of Bolivia. Officials from Argentina, Brazil, Chile 
and Paraguay also took part. The workshop, developed 
within the framework of cooperation with the European 
Union and in support of the Bolivian strategy to counter 
drug trafficking, was aimed at strengthening the work of 
the National Border Directorate of the Plurinational State 
of Bolivia (Dinafron), the agency responsible for respond-
ing to cross-border crimes and drug trafficking. The out-
comes of the workshop included proposals to collaborate 
on a system of regional operational cooperation, improve 
border information exchanges and facilitate joint actions 
in border control. In addition, the Government of the 
Plurinational State of Bolivia expressed its intention to 
strengthen the organizational and structural aspects of 
the work of Dinafron. Dinafron was established on 20 
June 2017 and started operating on 4 October 2017. 
519. At the third Annual Conference of COPOLAD II, 
held in Sofia, policymakers from the European Union and 
CELAC working in the area of drugs held a discussion 
on the theme of the conference, namely, “Women and 
drugs policy: progress and challenges in the implemen-
tation of the gender approach and the empowerment of 
women as a cross-cutting matter”. At the conference, 
which was held on 19 and 20 June 2018, participants 
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explored the inclusion of the gender perspective and the 
empowerment of women as indispensable elements in the 
design and implementation of public policies, an effort 
that continues to pose challenges in the field of drugs. 
The conference, organized by the International and Ibero-
American Foundation for Administration and Public 
Policy (FIIAPP), along with the Government Delegation 
for the National Plan on Drugs  of Spain, served as a 
biregional cooperation framework for discussing the need 
to include the gender perspective in drug policies and to 
agree on cooperative action. 
520. At the sixth meeting of the Bolivia (Plurinational 
State of)-Peru Joint Commission on Drug Control, held 
in Lima on 26 and 27 June 2018, the two Governments 
agreed to strengthen joint actions to combat drug traf-
ficking along their common border and intensify the 
exchange of information on criminal organizations 
involved in drug trafficking, with a focus on actions 
addressing air traffic. 
3.  National legislation, policy and 
action
521. In recent years, several countries in the region have 
taken steps towards the legalization of cannabis for medi-
cal purposes. During the period under review, the 
Governments of Paraguay and Peru adopted legislation 
permitting the medical use of cannabis; the Governments 
of Argentina, Brazil, Chile, Colombia and Uruguay had 
already permitted the medical use of cannabis through 
legislation or juridical decisions. 
522. Through its Ministerial Resolution No. 435-2018/
MINSA of 14 May 2018, the Ministry of Health of Peru 
published draft regulations aimed at implementing Law 
No. 30681, which regulates the medical and therapeutic 
use of cannabis and its derivatives. The draft regulations 
were opened for public consultation for a period of 90 
days. They contain provisions on regulating aspects of the 
research, production, import and sale of cannabis and its 
derivatives intended solely for medical and therapeutic 
purposes, in accordance with the provisions of 
Law No. 30681. They set out provisions on competent 
control authorities; types of licences, including those for 
scientific research, production, import and/or trading; 
medical prescription; and purchase, warehousing, cus-
tody, distribution, and control of derivatives and end 
products of cannabis. They also call for the creation of a 
national registry of patients who use cannabis and its 
derivatives for medical or therapeutic purposes, as well 
as national registries of natural and legal entities in rela-
tion to import and/or trade, institutions authorized to 
conduct research on cannabis and derivatives, and public 
entities and laboratories registered and certified for 
production. Furthermore, the draft regulations contain a 
series of measures to be undertaken by the authorities to 
monitor activities and aspects relating to the cultivation 
of cannabis plants and parts thereof, including seeds, for 
medical and therapeutic purposes. Those measures cover 
planting, handling, harvesting, post-harvest processes, 
extracting derivatives, manufacturing, packaging and the 
final products, among others. As of September 2018, the 
process of gathering opinions and contributions with a 
view to adopting a consolidated regulation was still 
ongoing.
523. On 9 January 2018, the President of Paraguay 
enacted a law to regulate the legal framework governing 
the production and use of cannabis and its derivatives for 
medical and scientific purposes. The law establishes the 
National Programme for Medical and Scientific Research 
on the Medical Use of the Cannabis Plant and Its 
Derivatives (PROINCUMEC) and provides for the pro-
motion of medical and scientific research on the medical 
and therapeutic use of cannabis for the treatment of 
human diseases and conditions. Under the law, the 
National Anti-Drug Secretariat of Paraguay (SENAD) is 
responsible for overseeing all cultivation and production 
of cannabis, as well as imports of cannabis plants and 
seeds, and the National Plant and Seed Quality and 
Health Service (SENAVE) is responsible for authorizing 
the trade in cannabis products and determining which 
seeds are appropriate for cultivating medical cannabis 
crops. Decree No. 9303 of 6 August 2018 establishes the 
National Agency for the Monitoring of Health (DNVS), 
under the Ministry of Health, as the authority responsi-
ble for the administration and implementation of 
PROINCUMEC, including the granting of a maximum of 
five licences for the production and industrialization of 
cannabis, in line with the law, to national private labora-
tories, the establishment of medical conditions approved 
for the purposes of implementing the law, and the estab-
lishment of the geographical zones within the Central 
Department in which licences for production and indus-
trialization may be authorized. In addition, the Decree 
establishes the requirements for the registration in the 
national register of users of products derived from can-
nabis, restricting it to patients in treatment, including 
those participating in a research protocol.
524. In Colombia, the legal framework provides for the 
issuance of four types of licences for medical cannabis 
and its derivatives, depending on the kind of activity 
involving cannabis. As at 19 July 2018, the Government 
of Colombia had issued a total of 162 licences. Of those, 
the Ministry of Justice had issued 9 licences for the use 
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of cannabis seeds for planting, 45 licences for the culti-
vation of psychoactive cannabis plants and 60 licences for 
the cultivation of non-psychoactive cannabis plants, and 
the Ministry of Health had issued 48 licences for the man-
ufacture of cannabis derivatives.
525. In Uruguay, in accordance with Law No. 19172, 
the planting, growing, harvesting and marketing of can-
nabis in the country must be authorized by the Institute 
for the Regulation and Control of Cannabis (IRCCA), 
which is also the authority responsible for issuing licences 
for the production, processing, collection, distribution 
and sale of industrial and psychoactive cannabis. 
Furthermore, under Decree No. 120/014, there are three 
mutually exclusive methods for obtaining psychoactive 
cannabis for non-medical use: purchase in pharmacies; 
home cultivation; and membership of clubs. In accord-
ance with the regulations, it is only possible to use one 
of these three methods, and the limit for personal use is 
set at a maximum of 40 g per month. Thus, adults may 
purchase up to 10 g per week at pharmacies upon con-
firmation of their identity, or they may grow up to six 
flowering female cannabis plants per household for their 
own consumption, provided that they register the plants 
with the authorities in advance and the total annual pro-
duction does not exceed 480 g. Alternatively, adults may 
join so-called “cannabis clubs”. The clubs, which must be 
registered with IRCCA, may plant up to 99 plants per 
club and have between 15 and 45 members. The clubs are 
allowed to collectivize the cultivation, production and use 
of cannabis among their members, but cannot dispense 
more than 480 g of the drug per member per year. As 
regards the varieties of cannabis products and content 
limits, Uruguayan law allows citizens and permanent res-
idents of Uruguay to purchase cannabis products with a 
THC content of up to 9 per cent and a minimum CBD 
content of 3 per cent. As at 4 October 2018, 28,470 per-
sons had registered as purchasers at pharmacies, 6,819 
persons had registered as home-growers and 107 clubs 
were operating.
526. On 26 June 2018, the Government of Paraguay pre-
sented its National Policy on Drugs for the period 2017–
2022. It contains policy and strategic guidelines and an 
action plan for the reduction of demand and supply. 
It was approved by Decree No. 7979 of 30 October 2017.
527. On 24 May 2018, the National Secretariat for the 
Administration of Seized and Commissioned Property 
(SENABICO) and the Supreme Court of Paraguay signed 
a cooperation agreement to establish the procedures for 
the reception, identification, valuation, inventory, regis-
tration, maintenance, preservation and disposal of seized 
goods. On 28 May 2018, SENABICO held a training 
course jointly with UNODC on seizure and confiscation 
at the Office of the Public Prosecutor. The course was 
aimed at improving the results obtained in efforts to seize 
goods derived from organized crime. 
528. As a key element in support of the implementation 
of the final agreement on the termination of the conflict 
and the building of a stable and durable peace in the 
country, in February 2018, the Government of Colombia 
acted to regulate its crop substitution programme through 
Decree No. 362, thus enabling the consolidation of actions 
by the National Comprehensive Programme for the 
Voluntary Substitution of Illicit Crops. The Programme 
was established through Decree No. 896 of 2017, which 
provides the legal basis for the reduction in illicit crops, 
facilitates inter-institutional coordination and provides 
for financial and technical support for small-scale farm-
ers. According to the authorities, 54,027 families had been 
enrolled in the Programme in 2017. By June 2018, the 
number of families enrolled had increased to 77,659.
529. In July 2018, the Government of Argentina adopted 
Decree No. 683/2018, which enables the armed forces to 
participate in and support strategic activities, such as 
those carried out in close proximity to international bor-
ders, including in relation to strategic objectives of 
national defence. In particular, the Decree enables the 
armed forces to provide support to drug control opera-
tions and other security interests within the national 
territory from which they were previously precluded. 
530. On 19 June 2018, the Government of Peru adopted 
Law No. 30796, amending Legislative Decree No. 1241. 
The Law is aimed at strengthening efforts to counter drug 
trafficking, and in particular enables the country’s armed 
forces, in compliance with their constitutionally estab-
lished function of guaranteeing the independence, sover-
eignty and territorial integrity of Peru, to carry out 
terrestrial, aquatic and aerial interdiction actions against 
drug traffickers in areas declared to be in a state of emer-
gency. The Law states that the army is to collaborate with 
the national police during the execution of police inter-
diction operations involving drug trafficking, at the 
request of the police and when the circumstances exceed 
the operational capacity of the police. 
531. Through its Executive Decree No. 376 of 23 April 
2018, Ecuador dissolved the Technical Secretariat for 
Comprehensive Drug Prevention (SETED), transferring 
responsibility for regulating, coordinating, articulating, 
facilitating and monitoring the implementation of cross-
sectoral processes to prevent drug trafficking and con-
sumption to the Ministry of Health and the Ministry of 
Interior.
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532. The Government of Guyana, supported by the 
Inter-American Development Bank, initiated a project to 
support its criminal justice system. The project is intended 
to reduce the number of pretrial detentions of prisoners 
accused of minor, non-violent offences by promoting the 
use of restorative justice and alternative sentencing.
4.  Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
533. The Government of Argentina reported the seizure 
of 174.95 tons of cannabis herb and 22,330 cannabis 
plants in 2017. The authorities reported the seizure of 
almost 9 kg of heroin and 15.79 tons of cocaine (salts and 
base paste) in the same year.
534. As stated in the coca survey for the Plurinational 
State of Bolivia for 2017, published by the Government 
of the Plurinational State of Bolivia and UNODC in 
August 2018, the area under coca bush cultivation in the 
country increased from 23,100 ha in 2016 to 24,500 ha 
in 2017, representing an increase of 1,400 ha, or 6 per 
cent. According to the survey, the regions of Yungas de 
La Paz, Trópico de Cochabamba and the north of the 
Department of La Paz represented 65, 34 and 1 per cent, 
respectively, of the area under cultivation in the country 
in 2017. In comparison with 2016, the first two regions 
reported an increase of 200 ha and 1,200 ha, respectively, 
while the third region reported a decrease of 20 ha.
535. In the estimates submitted to the Board by the 
Government of the Plurinational State of Bolivia, it was 
projected that, in 2018, an area of 17,160 ha would be 
cultivated with coca bush destined for use under the pro-
visions of the reservation entered in respect of the 1961 
Convention. The General Law on Coca (Law No. 906) 
established that an area of up to 22,000 ha may be devoted 
to the cultivation of coca bush destined for the purposes 
envisaged in that reservation. The Board reiterates the 
concern expressed in its annual report for 201776 about 
the decision of the Government of the Plurinational State 
of Bolivia to nearly double, in relation to the 12,000 ha 
that had been set under Law No. 1008, the area permit-
ted for cultivating coca leaf for the purposes set out in 
the reservation.
536. In January 2018, the Government of the 
Plurinational State of Bolivia reported 533 acts of 
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incineration or destruction of illegal drugs seized during 
2017 by FELCN and the Public Prosecution Service. In 
2017, a total of 36,321 kg of drugs were seized jointly by 
FELCN and the Public Prosecution Service, as follows: 
13,745 kg of cocaine base paste, 3,884 kg of cocaine 
hydrochloride and 18,692 kg of cannabis. On 23 July 
2018, the report for the first half of 2018 on the destruc-
tion or incineration of seized illegal drugs in the 
Plurinational State of Bolivia was presented by UNODC. 
According to the report, FELCN and the Public 
Prosecution Service carried out 287 acts of incineration 
or destruction of controlled substances from January to 
June 2018, representing an increase of 8 per cent com-
pared with the same period in 2017, when 266 such acts 
were carried out.
537. The Government of the Plurinational State of 
Bolivia also reported that seizures of coca leaf had 
increased by 5 per cent, from 353 tons in 2016 to 370 tons 
in 2017. The department where most coca leaf had been 
seized was La Paz, with 67 per cent of total seizures, fol-
lowed by Cochabamba, with 20 per cent. 
538. On 23 March 2018, the Government of Brazil 
reported the seizure in the Port of Santos of nearly 2 tons 
of cocaine hidden inside three containers of coffee, soy 
and sugar destined for export. According to the authori-
ties, it was the largest seizure of cocaine in the Port’s his-
tory and the sixth significant seizure in the Port in 2018. 
Santos was the second busiest port in South America in 
2017, as reported by the Economic Commission for Latin 
America and the Caribbean. 
539. According to figures reported by the Amazon 
Military Command of the Brazilian Army, the Armed 
Forces of Brazil seized 6,674 kg of illicit drugs from 
January to May 2018 in the Amazon region, in the course 
of 170 operations. The operations were conducted in part-
nership with governmental agencies of the five States bor-
dering the Amazon region, namely, Bolivia (Plurinational 
State of), Colombia, Guyana, Peru and Venezuela 
(Bolivarian Republic of).
540. The Government of Chile reported the following 
seizures in the period from 1 November 2017 to 20 July 
2018: 6,842 kg of cocaine hydrochloride, 6,339 kg of free-
base cocaine, 14,830 kg of cannabis, 132,001 cannabis 
plants, 4,872 tablets of “ecstasy”, 2,530 g of “ecstasy”, 1,792 
units of NBOMe, 628 units of LSD, 21.5 litres of hydro-
chloric acid and 7.3 litres of sulphuric acid. Authorities 
in Chile reported that quantities of cocaine base paste 
seized between 1 January and 18 July 2018 had increased 
by 102.3 per cent relative to the same period in 2017, i.e., 
from 4,047 kg to 8,187 kg.
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541. Compared with 2016, in 2017, illicit coca bush cul-
tivation and cocaine production in Colombia increased 
by 17 per cent and 31 per cent, respectively. As stated in 
the UNODC World Drug Report 2018, in 2016, almost 
69 per cent of the total area under coca cultivation world-
wide was in Colombia. The area under illicit coca bush 
cultivation has been increasing constantly since 2013, 
from 48,000 ha in 2013 to 171,000 ha in 2017. Sixty-four 
per cent of the increased area was concentrated in the 
Departments of Antioquia, Putumayo, Norte de Santander 
and Cauca. Nariño continued to be the department with 
the largest coca cultivation area. As reported by the 
Ministry of National Defence of Colombia, 52,000 ha 
were eradicated in 2017. 
542. Although efforts to eradicate coca crops in 
Colombia were increased in 2017, the concomitant 
increase in cocaine production in the country, from 1,053 
metric tons in 2016 to 1,379 metric tons in 2017, appears 
to have resulted in the increased availability and use of 
cocaine in the United States. In March 2018, the 
Governments of the two countries agreed to develop a 
plan to reduce cultivation and production by half in rela-
tion to the levels estimated for 2018 over the next five 
years. For 2018, the outgoing Colombian authorities set 
as an objective the manual eradication of 70,000 ha of 
coca bush, to be reviewed in 2019. According to the 
Ministry of National Defence of Colombia, as at June 
2018, 42,000 ha had been replaced voluntarily with licit 
crops, of which 14,000 ha had been certified by UNODC 
as having been replaced. 
543. In 2017, cocaine seizures in Colombia increased by 
20 per cent, compared with 2016. On 26 June 2018, the 
outgoing President of Colombia announced that, after a 
series of pilot tests, the Ministry of Health and Social 
Protection and the Ministry of Environment and 
Sustainable Development had authorized the use of 
drones for the spraying of glyphosate at a concentration 
level 50 per cent lower than that used previously; aerial 
spraying of glyphosate on coca crops had been suspended 
since October 2015. According to the Presidential state-
ment, drones flying at low altitude were akin to the cur-
rent practice in which ground-based eradication crews 
sprayed glyphosate herbicide from tanks mounted on 
their backs.
544. The Ministry of National Defence of Colombia 
reported the seizure of 78.6 tons of cocaine between 
January and March 2018, 31 per cent less than the 
113.5 tons seized in the same period in 2017. Cannabis 
seizures decreased by 25 per cent, from 78.9 tons in the 
period from January to March 2017 to 59.4 tons in the 
same period in 2018. Heroin seizures increased by 30 per 
cent, from 100 kg in the period from January to March 
2017 to 130 kg in the same period in 2018.
545. According to data from the Drug Observatory of 
Colombia, in 2017, 435 tons of cocaine, 52 tons of cocaine 
base paste, 240 tons of cannabis and 521 kg of heroin 
were seized. In addition, 321 cocaine crystallization 
laboratories were dismantled.
546. Information provided by the national authorities 
of Ecuador indicated that 14,713 kg of cannabis herb, 
381 kg of heroin and 81,713 kg of cocaine salts had been 
seized in Ecuador in 2017. The Government of Ecuador 
reported that 100 per cent of the drugs seized had 
originated in Colombia. The cannabis herb had been 
destined for Ecuador (85 per cent), Chile (10 per cent) 
and Peru (5 per cent). A total of 80 per cent of the seized 
heroin had been destined for the United States. Compared 
with 2016, seizures of heroin had increased by 171 per 
cent in 2017, while seizures of cannabis had increased by 
18 per cent. 
547. Paraguay remains the main source of illicitly 
produced cannabis in South America. According to 
SENAD, 80 per cent of the illicitly produced cannabis is 
smuggled into Brazil and there is a constant flow of drugs 
to Argentina, Bolivia (Plurinational State of), Chile and 
Uruguay. The Government of Uruguay reported that, in 
2017, almost 100 per cent of the cannabis herb seized in 
the country had originated in Paraguay and had been 
trafficked overland through Argentina (53 per cent) and 
Brazil (46 per cent). The Plurinational State of Bolivia also 
reported that its territory continued to be used to traffic 
cannabis originating in Paraguay. SENAD reported the 
eradication of 1,456 ha of cannabis crops in 2017, 1,298 ha 
in 2016 and 1,995 ha in 2015, and an increase in 
cannabis seizures, from 276.379 tons in 2016 to 
1,070.9 tons in 2017.
548. On 2 February 2018, the Ministry of the Interior 
of Peru announced the eradication of almost 26,000 ha 
of illicit coca bush; almost 23,000 ha had been eradicated 
in 2017 and approximately 3,000 ha in January 2018. In 
the context of the annual plan for the reduction of the 
illegal coca growing area for 2017, which ended on 31 
January 2018, the Special Project for the Control and 
Reduction of Illegal Crops in Alto Huallaga (CORAH) of 
the National Police reported having met its eradication 
target for 2017 with the destruction of 25,784 ha of coca 
bush, equivalent to an estimated production of 
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approximately 238 tons of cocaine. During the operations, 
113 cocaine base paste laboratories were destroyed. 
549. CORAH reported the eradication of a further 
14,115 ha of illicit coca bush between 1 February and 24 
June 2018. According to the information provided by the 
Ministry of the Interior of Peru, 5,298 ha were eradicated 
in Tocache, 1,056 ha in Puerto Inca, 6,745 ha in Oxapampa 
and 1,015 ha in Padre Abad. In addition, 32 clandestine 
drug laboratories were destroyed in those same provinces. 
All the eradication efforts were carried out within the 
framework of the annual plan for the reduction of the 
illegal coca growing area for 2018, under the National 
Strategy to Combat Drugs.
550. The Government of the Plurinational State of 
Bolivia reported that its territory continued to be used 
for the transit of cocaine originating in Peru and that 
remote areas with difficult access in the east of the coun-
try were used for the establishment of clandestine cocaine 
crystallization laboratories.
551. The Government of Uruguay reported the seizure 
of 1,894 kg of cannabis herb and 1,926 cannabis plants, 
as well as 144 kg of cocaine and 32 kg of cocaine base 
paste, in 2017. The Government also reported that the 
cocaine seized in the country in 2017 had originated in 
Bolivia (Plurinational State of), Colombia and Peru, had 
entered the country through Argentina and Brazil, and 
had been destined mainly for Uruguay (85.67 per cent) 
and, to a lesser extent, for Australia (3.48 per cent) and 
China (2.58 per cent). Furthermore, the trafficking in all 
illicit drugs had mostly been done by land (85 per cent) 
and by post (15 per cent). All of the heroin seized in 
Uruguay in 2017 had originated in the Netherlands.
(b) Psychotropic substances
552. In South America, synthetic drugs are typically not 
produced locally but rather are trafficked into the region 
from other parts of the world. According to the data on 
seizures, most of the synthetic drugs found in South 
America originate in Europe.
553. Governments in South America have issued pub-
lic warnings about drugs sold as LSD that may not always 
contain the expected psychoactive substance, thus repre-
senting an additional danger for users. In Colombia, there 
were three reported deaths associated with the consump-
tion of new psychoactive substances, according to reports 
from the National Institute of Legal Medicine. On 30 
December 2017, the Ministry of Justice of Colombia 
published crime laboratory findings on samples of drugs 
sold in four Colombian cities, finding that seven new psy-
choactive substances had been sold as LSD. As a result, 
the early warning system of the Drug Observatory of 
Colombia issued a warning in that regard.
554. A particular characteristic of the region is the com-
paratively high prevalence of use of hallucinogenic drugs, 
as evidenced in surveys of the general population and 
university students. A drug use survey conducted among 
university students in Bolivia (Plurinational State of), 
Colombia, Ecuador and Peru published in November 
2017 showed a rise in the annual prevalence of LSD use 
in those countries. In South America, new psychoactive 
substances with hallucinogenic effects emerged on the 
markets for LSD and 4-bromo-2,5-dimethoxyphenethyl-
amine (2C-B). 
555. All of the methamphetamines seized in Uruguay 
in 2017 originated in the Netherlands, having been traf-
ficked through France. It was reported that, in Uruguay, 
synthetic drugs were acquired through the Internet from 
producers in Europe, who dispatched the drugs through 
mail delivery services.
(c) Precursors
556. According to official data from the Government of 
the Plurinational State of Bolivia, the Departments of 
Santa Cruz and Cochabamba recorded the highest per-
centages of cocaine base paste seized nationwide in 2017, 
accounting for 43 per cent and 28 per cent of the total 
seized, respectively, followed by the Department of La Paz 
(8 per cent). The highest percentage of seizures of cocaine 
hydrochloride were made in Santa Cruz (46 per cent) and 
Beni (28 per cent).
557. In July 2018, the National Police of Colombia 
reported the seizure of 40 tons of controlled chemical 
substances destined for use in the production of 50 tons 
of cocaine hydrochloride. The seizure operation took 
place in the Departments of Putumayo and Caquetá and 
was carried out under the country’s comprehensive strat-
egy against drug trafficking.
558. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in South America can be 
found in the report of the Board for 2018 on the imple-
mentation of article 12 of the 1988 Convention. 
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(d)  Substances not under international 
control
559. In December 2017, the Government of Argentina 
requested the scheduling of hydriodic acid, alpha-phenyl-
acetoacetamide (APAA) and PMK-glycidate under the 
1988 Convention. As indicated by the Government, the 
request responds to the need to establish more effective 
controls on these substances, given, in its view, their 
extensive use in the manufacture of some synthetic drugs. 
INCB has conducted a technical review of the request 
and has relayed its recommendation to the Commission 
on Narcotic Drugs for consideration at its sixty-second 
session, in March 2019. 
560. Analyses carried out by laboratories in Colombia 
of samples obtained in drug seizures by the national 
police confirmed the discovery of two new psychoactive 
substances, namely, AMB-FUBINACA and allylescaline. 
Allylescaline is a new psychedelic substance with effects 
similar to those caused by the consumption of substances 
such as “ecstasy”, including depressant effects on the 
central nervous system. 
561. In order to address the problem of new psycho-
active substances, DEVIDA commissioned the design of 
a national early warning system on new psychoactive sub-
stances. The system is expected to generate alerts on 
emerging drugs and new psychoactive substances in Peru 
and to periodically report them to the UNODC early 
warning advisory on new psychoactive substances.
5. Abuse and treatment
562. In January 2018, the Government of Ecuador pre-
sented its national plan on drug prevention. The plan is 
focused on children and adolescents and has four objec-
tives: (a) preventing the use and consumption of drugs; 
(b) providing comprehensive and cross-sectoral care for 
people with problematic consumption of drugs; (c) 
decreasing the supply of drugs intended for domestic con-
sumption; and (d) preventing the illicit production of 
drugs. It was developed with the participation of more 
than 1,500 social actors and involved the signing of more 
than 300 agreements with educational institutions, private 
treatment centres, institutes of art and culture, media out-
lets, sports clubs and federations, and driving schools, 
among others. Involving the participation of the police 
and other agencies, the plan is aimed at strengthening 
controls to prevent drugs from reaching stockpiling cen-
tres set up by drug traffickers in towns near the seaports 
and coastal areas. To contribute to the plan, the national 
police have developed different strategies to prevent the 
entry of drugs through the country’s borders. The plan 
was developed on the basis of a preventive approach as a 
social strategy aimed at assisting vulnerable groups, one 
in which the police are expected to actively participate, in 
addition to their responsibility for tackling the criminal 
organizations that supply drugs for local consumption and 
organize shipments of drugs to international markets.
563. The Ministry of Health of Guyana launched a sub-
stance abuse prevention programme on 30 May 2018. The 
programme is aimed at reducing the abuse and misuse of 
drugs by raising awareness of the harmful effects of such 
abuse and misuse among the school-aged population and 
other young people. 
564. The Demand Reduction Expert Group of CICAD 
held its nineteenth meeting in Santiago on 24 and 25 July 
2018 to address recommendations on drug use prevention 
and treatment. At the meeting, national experts in the area 
of drug demand reduction discussed the implementation 
of specific policies, with an emphasis on trauma treatment, 
prevention among adolescents at risk and social vulnera-
bility, and treatment outcome indicators. 
565. The Government of Uruguay reported that, in 
2017, 1,786 persons had received treatment for drug use 
disorders, of which 1,446 had received treatment for 
cocaine use. Other treatments for drug abuse disorders 
involved cannabis (316 persons) and, in far fewer cases, 
painkillers and LSD. As reported, in 2017, 75 per cent of 
the people receiving treatment for drug abuse were receiv-
ing it for the first time, and only 18 per cent of them were 
female.
566. During the first half of 2018, the UNODC support 
project on reduction of demand for illegal drugs in the 
Andean Community (PREDEM) launched two conclud-
ing activities, one that was technical in nature and one 
involving decision makers, aimed at establishing activi-
ties to ensure the future sustainability of the project. As 
a result, officials of the prevention programme Strong 
Families (Familias Fuertes) and the international network 
of drug dependence treatment and rehabilitation resource 
centres (Treatnet) agreed to continue to train profession-
als in the development of activities focused on demand 
reduction in the Andean countries. Although the 
PREDEM project ended in June 2018, the Andean coun-
tries of Bolivia (Plurinational State of), Colombia, 
Ecuador, and Peru committed to continuing its activities, 
under the leadership of Ecuador as of July 2018.
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C. Asia 
East and South-East Asia
1. Major developments
567. The illicit production of opium in the Golden 
Triangle seems to have reduced over the reporting period, 
as has trafficking in the substance from the Golden 
Triangle to other parts of East and South-East Asia. In 
particular, the total area under illicit opium poppy culti-
vation in Myanmar decreased from 55,500 ha in 2015 to 
41,000 ha in 2017, the first considerable reduction since 
2012. The amount of heroin and morphine originating in 
the Golden Triangle that was seized in the region also 
went down. Such developments, together with declining 
opium prices and the diminishing popularity of heroin as 
a drug of abuse, all signify the shrinking dominance of 
opium in the region. 
568. The unprecedented amount of methamphetamine 
seized in some countries in East and South-East Asia in 
2017 and 2018 suggests the further expansion of the illicit 
manufacture of and trafficking in the drug in the region. 
Exploiting the ongoing insecurity in some countries and 
better transport links within the region, transnational 
organized criminal groups have extended their control 
over the illicit manufacture of and trafficking in metham-
phetamine. The situation is particularly alarming and 
worrisome given the already huge and growing popular-
ity of methamphetamine as a drug of abuse.
569. The shift from opium to synthetic drugs, especially 
methamphetamine, within the region poses serious chal-
lenges to the effectiveness of law enforcement policies and 
practices and raises considerable public health concerns. 
The relative ease of relocating illicit manufacturing facil-
ities, coupled with more diversified trafficking routes 
(made feasible by greater regional integration), has height-
ened the need for multilateral cooperation and effective 
border control. Similarly, greater effort is required at the 
regional level to systematically assess and monitor the 
abuse of synthetic drugs, so as to facilitate the provision 
of relevant treatment programmes. 
2. Regional cooperation
570. The Forty-first Meeting of Heads of National Drug 
Law Enforcement Agencies, Asia and the Pacific, was held 
in Bangkok from 27 to 30 November 2017. Officials from 
law enforcement and public security agencies and repre-
sentatives of relevant international organizations assessed 
the latest drug situation, discussed related strategic and 
operational responses, and considered the progress made 
in implementing the recommendations contained in the 
outcome document of the special session of the General 
Assembly on the world drug problem held in 2016.
571. As closer economic integration among ASEAN 
countries accelerates, transnational organized criminal 
groups are further expanding their illicit activities, taking 
advantage of better infrastructure and transport links 
within the region, while exploiting vulnerable borders. 
Jointly organized by the Government of Thailand and 
UNODC, a high-level conference was held in May 2018 
to discuss major cross-border challenges and identify 
practical solutions for strengthening border management 
capacities. About 200 senior government officials and rep-
resentatives from various international organizations 
attended the meeting. 
572. Together with representatives of UNODC, senior 
drug policy officials from the six countries in the Greater 
Mekong subregion (Cambodia, China, Lao People’s 
Democratic Republic, Myanmar, Thailand and Viet Nam) 
met in Myanmar in May 2018 to discuss the latest illicit 
drug situation, review the implementation of the most 
recent Mekong strategy and negotiate a new strategic 
plan. Serving as a platform for senior management to 
share their priorities and concerns, the conference was 
instrumental in the harmonization of standard operating 
procedures for law enforcement operations and in the 
translation of standards into community-based drug 
treatment among participating countries. 
573. The first meeting of the ASEAN Inter-Parliamentary 
Assembly Advisory Council on Dangerous Drugs was 
held in Singapore on 19 and 20 June 2018. Delegates from 
the 10 ASEAN Inter-Parliamentary Assembly member 
States (Brunei Darussalam, Cambodia, Indonesia, Lao 
People’s Democratic Republic, Malaysia, Myanmar, 
Philippines, Singapore, Thailand and Viet Nam) exchanged 
information on their national situations and discussed 
strategies to support the commitment of ASEAN to a 
drug-free region. 
574. The ASEAN Plus Three workshop for narcotics law 
enforcement officers on countering amphetamine-type 
stimulants and other narcotic substances was held in 
Bangkok in July 2018. About 30 narcotics law enforce-
ment officers from the ASEAN Plus Three States partici-
pated in the workshop, which was designed to develop 
their skills and allow them to exchange experiences in 
countering drug smuggling. 
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575. The tenth global SMART programme regional 
workshop for East and South-East Asia was held from 28 
to 30 August 2018 in Chiang Rai, Thailand. Experts from 
China and 10 countries in South-East Asia discussed the 
feasibility of developing drug demand indicators in order 
to foster systematic approaches to assessing and monitor-
ing drug use in the region. Participants in the workshop 
also came from Australia, Japan, the Republic of Korea, 
the Russian Federation and the United States. The work-
shop was the first attempt at the regional level to address 
the lack, in most countries of East and South-East Asia, 
of quantitative data on drug abuse among the general 
population. 
576. The tenth annual meeting and symposium of the 
Asian Forensic Sciences Network was held in Beijing 
from 4 to 8 September 2018, on the theme “New tech-
nologies, new methods, new challenges”. The event was 
attended by forensic scientists, academics and research-
ers from countries in Asia. It provided an opportunity for 
the participants to communicate and share knowledge 
and keep abreast of state-of-the-art forensic analytical 
methods.
3.  National legislation, policy  
and action
577. The period under review was characterized by 
significant legislative and policy initiatives aimed at 
addressing State responses to drug-related criminality.
578. From the outset, it must be noted that all State 
responses to drug-related criminality must be based on 
the rule of law and respect for human rights, as well as 
on the principle of proportionality. The Board is aware of 
the continuing reports of extrajudicial action taking place 
in Cambodia, Indonesia and the Philippines in relation 
to purported drug-related activities and/or crimes. 
579. In February 2018, the Prosecutor of the International 
Criminal Court issued a statement announcing her deci-
sion to open a preliminary examination into allegations 
that crimes falling within the Court’s jurisdiction had 
been committed on the territory of the Philippines in the 
context of the so-called “war on drugs” launched by the 
Government of the Philippines. According to the state-
ment, the preliminary examination is aimed at analysing 
available information to determine whether there are suf-
ficient grounds to proceed with an investigation pursuant 
to the criteria established by the Rome Statute of the 
International Criminal Court.77
77 United Nations, Treaty Series, vol. 2187, No. 38544.
580. The Board reiterates that any State response, 
whether official or sanctioned by State actors, to drug-
related criminality that is not based on the rule of law, 
respect for human rights and the principle of proportion-
ality is a clear violation of the international drug control 
conventions and internationally recognized human rights 
norms.
581. The Government of Myanmar announced a new 
national drug control policy in February 2018. The pol-
icy was developed in partnership with UNODC and 
adopts, at the national level, the framework set out in the 
outcome document of the special session of the General 
Assembly on the world drug problem held in 2016. A 
defining feature of the new policy is that it represents a 
shift from an approach based primarily on punitive 
responses to drug use to one centred on public health. 
The new policy contains five focus areas: (a) supply 
reduction and alternative development; (b) demand and 
harm reduction; (c) international cooperation; (d) research 
and analysis; and (e) compliance with human rights 
standards. 
582. Reflecting the shift to a health-based approach to 
drug abuse and dependence, in February 2018, Myanmar 
also amended its 1993 Narcotic Drugs and Psychotropic 
Substances Law in order to address the drug issue while 
supporting health-care structures and providing treat-
ment to drug users, funding for sustainable projects such 
as civic education programmes and creating job oppor-
tunities for victims. 
583. Several amendments were made to the Narcotics 
Act of Thailand that became effective in January 2017. 
The changes mainly concern reductions in penalties for 
the possession, import, export and production of drugs 
and can be regarded as moving in the direction of more 
proportionate sentencing. Importantly, the revised Act 
amends the punishment for the sale of drugs from the 
mandatory death penalty to either life imprisonment and 
a fine or the death penalty. 
584. New rules relating to drug concentration levels and 
drug testing for drivers were released and implemented 
by the Government of China in May 2018. The rules spec-
ify the threshold values for drug levels in the blood or 
saliva of drivers, and the related methods of testing. 
585. Hong Kong, China, published a three-year plan on 
drug treatment and rehabilitation services (2018–2020) in 
March 2018. The plan sets out the strategic direction for 
drug treatment and rehabilitation services in Hong Kong, 
China, and focuses on the main challenges of the drug 
situation. To deter trafficking in and abuse of new 
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psychoactive substances, in July 2018, the Government 
added five new psychoactive substances (EPH, MPA, 
MDME-CHMICA, 5F-APINCA and U-47700) to sched-
ule 1 of the Dangerous Drugs Ordinance and two sub-
stances (ANPP and NPP) to schedule 2 of the Control of 
Chemicals Ordinance. Anyone prosecuted for trafficking 
or manufacturing those substances will be subject to a 
maximum penalty of life imprisonment and a fine of 
5 million Hong Kong dollars. 
586. On 29 August 2018, China placed 32 new psycho-
active substances under national control. The newly 
scheduled new psychoactive substances comprise 20 syn-
thetic cathinones, 8 synthetic cannabinoids and other 
substances, including the recently internationally con-
trolled fentanyl analogues 4-FIBF and THF-F.
587. In March 2017, the Government of Mongolia 
approved a national programme on combating the illegal 
sale of narcotic drugs and psychotropic substances, so as 
to improve State policy and the legal environment on 
combating the illegal sale of drugs, provide coordinated 
management among government agencies, implement 
comprehensive education and health services, identify the 
causes and conditions of drug-related offences, train 
relevant officers and introduce modern technology. 
4.  Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
588. While Myanmar continued to have the world’s 
second largest area under illicit opium poppy cultivation, 
the total area under cultivation in the country went down 
from 55,500 ha in 2015 to 41,000 ha in 2017. Reductions 
in cultivation were mainly found in the East Shan and 
South Shan States. Only minor reductions, of 600 ha in 
total, were recorded in North Shan and Kachin States, 
owing to continued instability and conflict among 
powerful ethnic militias. 
589. Total opium production in Myanmar decreased by 
14 per cent over the period 2015–2017, from 647 tons in 
2015 to 550 tons in 2017, and accounted for 5 per cent 
of the global opium production estimate in that year. 
With a fairly stable cultivation area and rising yield in 
opium production, South Shan remains the biggest pro-
ducer in Myanmar and supplies close to half of the total 
estimated amount of opium produced in the country.
590. According to UNODC, opiates produced in 
Myanmar are mostly trafficked to China and Thailand; 
the country also remains a source of heroin trafficked to 
Oceania (mostly Australia). Total heroin and morphine 
seized in East and South-East Asia dropped by 6 per cent 
in 2016, to about 11 tons. 
591. The reductions in opium poppy cultivation and the 
decreasing volume of opiates seized, together with lower 
opium prices and the declining popularity of heroin as a 
drug of abuse, seem to suggest the shrinking dominance 
of opium within the region over the past two years. 
592. With an estimated total area under opium poppy 
cultivation of less than 300 ha, authorities in Thailand no 
longer consider such cultivation a major threat. The coun-
try, however, remains one of the main transit countries 
in the region for heroin trafficking. The total amount of 
heroin seized fluctuated between 200 kg and 400 kg over 
the period 2014–2016, and rose to almost 600 kg in 2017, 
mainly because of a relatively large seizure (165 kg) from 
a shipment detected in the northern region.
593. Compared with other substances, the illicit manu-
facturing of and trafficking in cocaine remain limited 
within the region, with the majority of the cocaine being 
trafficked from South America. The annual volume of 
cocaine seized in Thailand fluctuates around 50 kg and 
has never exceeded 70 kg. On the other hand, authorities 
in China have suggested that an increasing amount of 
cocaine, mostly transported in bulk from South America, 
through the south-eastern coastal areas of the continent, 
was trafficked into the country in 2017. The drug was then 
distributed to and sold in other regions, such as Oceania. 
(b) Psychotropic substances
594. The latest global seizure data suggest that East and 
South-East Asia and North America remain the two main 
regions for methamphetamine trafficking. Most of the 
methamphetamine trafficked between regions is destined 
for countries in those two regions. Considerable increases 
in crystalline methamphetamine seizures were reported 
by many countries in East and South-East Asia over the 
past two years, including Japan, Myanmar and the 
Philippines. 
595. Although complete seizure data on methampheta-
mine for 2017 were not available at the time of writing, 
a number of media reports on record-breaking metham-
phetamine seizures in Indonesia, Malaysia and Thailand 
warrant alarm. While the modi operandi vary, the most 
common seems to be the packaging of methamphetamine 
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pills and crystalline methamphetamine into packages of 
tea for trafficking to their final destinations.
596. A number of significant methamphetamine seizure 
cases were reported by Thailand in 2017. Shipments 
involving several million tablets of methamphetamine 
have become common, and two shipments, each involv-
ing 10 million tablets, were confiscated in the last quar-
ter of the year. The total amount of methamphetamine 
pills seized reached 240 million tablets in 2017, almost 
double that seized the year before. Seizures of crystalline 
methamphetamine also tripled, surging to 7.6 tons in 
2017. The majority of crystalline methamphetamine was 
trafficked into Thailand through the country’s border with 
Myanmar, using different channels. Authorities attributed 
the significant increases to a number of reasons, includ-
ing greater production within the region, new market 
strategies of organized criminal groups and higher 
demand from other regions, most notably Oceania.
597. Exploiting the vulnerabilities of the long coastline 
in Indonesia, organized criminal groups traffic the bulk 
of the methamphetamine brought into the country by sea. 
Joint operations among the police, the navy and the com-
petent national authorities prevented the smuggling of 
huge quantities of methamphetamine in two major ship-
ments (each involving more than 1 ton of methamphet-
amine) in 2017 and 2018.
598. According to UNODC, the total number of dis-
mantled clandestine synthetic drug manufacturing facili-
ties in East and South-East Asia almost doubled during 
the period 2012–2015. The fact that methamphetamine 
was being manufactured in the majority of those facili-
ties suggests the continued growth in methamphetamine 
manufacturing capacity within the region. In 2017, 
authorities in Malaysia and the Philippines reported the 
detection of nine and two clandestine methamphetamine 
manufacture laboratories, respectively.
599. In comparison with methamphetamine, the illicit 
manufacture of and trafficking in “ecstasy” seemed to 
remain stable. Only a small number of countries (mainly 
China and Malaysia) have reported the illicit manufac-
ture of “ecstasy” over the past few years. Authorities in 
Thailand indicated that a relatively high retail price of the 
substance limited its usage to wealthy individuals. About 
84,000 “ecstasy” tablets were seized in 2017, slightly less 
than the year before.
(c) Precursors
600. The total amount of ephedrine and pseudoephed-
rine reported seized in East and South-East Asia 
continues to be far lower than the amount of metham-
phetamine seized. This, together with the limited num-
ber of reports of seizures of other methamphetamine 
precursors, points to a considerable knowledge gap 
regarding the illicit manufacture of methamphetamine 
within the region. 
601. The amount of ephedrine seized in East and South-
East Asia continues to represent a large share of global 
ephedrine seizures, with China accounting for the largest 
share of the regional total. Authorities in China reported 
an expansion of the illicit manufacture of ephedrine north 
of the Yangtze River and dismantled 27 clandestine 
ephedrine laboratories and warehouses in 2016. 
Meanwhile, law enforcement agencies in the Philippines 
continued to dismantle illicit methamphetamine labora-
tories and perceived a switch from large- to small-scale 
manufacture and the splitting of manufacturing into dif-
ferent stages in different locations. Malaysia also reported 
seizing a considerable amount of ephedrine in 2017.
602. Countries in the region accounted for more than 
half of the pseudoephedrine preparations seized globally 
during the period 2012–2016, mainly because of the huge 
quantities seized in Myanmar and Thailand. Together, 
those two countries accounted for almost 90 per cent of 
the pseudoephedrine preparations seized in East and 
South-East Asia. Detailed information regarding the 
sources of the preparations and the methods of diversion, 
however, has not been submitted by most countries in 
the region. 
603. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in the region can be found 
in the report of the Board for 2018 on the implementa-
tion of article 12 of the 1988 Convention.
(d)  Substances not under international 
control
604. Countries in East and South-East Asia continue to 
report the emergence and considerable seizures of new 
psychoactive substances. In 2017, authorities in China 
identified 34 new psychoactive substances, in addition to 
the 230 new psychoactive substances seized in various 
parts of the country that year that were mainly being used 
by young people at entertainment venues. Information 
available to the Viet Nam Border Guard also pointed to 
a sevenfold increase in the amount of synthetic drugs 
seized at the border between Viet Nam and the Lao 
People’s Democratic Republic in 2017. 
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605. As a plant indigenous to Malaysia, Myanmar and 
Thailand, kratom (Mitragyna speciosa) has long been used 
by rural populations in South-East Asia as a traditional 
remedy for minor ailments, to counter fatigue and as a 
drink in social gatherings. Its popularity as a plant-based 
new psychoactive substance has grown considerably over 
the past two years, possibly as a result of some commer-
cial claims regarding its ability to treat opioid addiction 
and withdrawal. Total worldwide seizures of kratom 
surged to more than 400 tons in 2016, surpassing that of 
all other plant-based new psychoactive substances. In 
South-East Asia, a recent study78 suggested that kratom 
is being used to ease withdrawal from opioid dependence 
in rural areas and is being consumed in adulterated 
kratom cocktails to induce euphoria by young people in 
urban areas. In this regard, the Board encourages all 
Governments to take practical measures to prevent the 
abuse of new psychoactive substances and related con-
sequences for individuals and society.
606. Although widely used as an anaesthetic in medi-
cal and veterinary practice, ketamine has been placed 
under national control by many countries in East and 
South-East Asia, mainly because of its potential for abuse 
and its popularity as a party drug. Compared with other 
regions, high levels of ketamine abuse and the significant 
quantities of ketamine seized remain a major concern for 
many countries in the region. Worldwide seizures of ket-
amine rose from 10 tons in 2012 to 22 tons in 2015 as a 
result of the significant increases in the amounts seized 
in the region. A considerable decline in the amount seized 
as reported by the authorities in China, from close to 
20 tons in 2015 to about 10 tons in 2016, brought down 
the total global amount of ketamine seized to about 
13 tons in 2016.
5. Abuse and treatment
607. UNODC has estimated that about 34.2 million 
people (0.7 per cent of the population aged between 
15 and 64) used amphetamines worldwide in 2016. 
Despite the lack of systematic estimates regarding the use 
of amphetamines among the general population in East 
and South-East Asia, many countries consider metham-
phetamine use to be a major threat. Specifically, the use 
of crystalline methamphetamine, which is usually of 
higher purity than that of methamphetamine tablets, has 
become a key concern for most countries within the 
region over the past few years. 
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608. According to the information available to UNODC, 
declines in heroin use in 2016 were reported by experts 
in countries in East and South-East Asia, including 
Indonesia, the Republic of Korea and Thailand, as well as 
Hong Kong, China. 
609. There is a higher proportion of treatment for the 
use of amphetamine-type stimulants in Asia and Oceania, 
compared with other regions. Out of the seven countries 
and territories in the region that provided such informa-
tion to UNODC, five of them reported that the largest 
share of people receiving treatment for drug use were 
receiving treatment for the use of amphetamines. Some 
countries, such as Indonesia and the Philippines, as 
well as Hong Kong, China, observed an increasing 
number of people receiving treatment for methampheta-
mine abuse. In Malaysia, crystalline methamphetamine 
users accounted for 80 per cent of amphetamine-type 
stimulant users receiving treatment in 2015.
610. Authorities in China reported that there were 
about 2.5 million registered drug users in the country at 
the end of 2017, equivalent to 0.18 per cent of the total 
population. While the total number of registered drug 
users only rose by 1.9 per cent over the previous year, the 
number of new drug users fell by almost one third, 
suggesting that drug use is continuing to grow, although 
the rate of expansion has declined. Those aged between 
18 and 35 represented the majority, followed by those 
aged between 36 and 59 (43 per cent). In contrast to the 
situation some years ago, synthetic drugs are now the 
most commonly abused substance (60 per cent), ahead 
of opioids (38 per cent). The types of drugs abused 
became more diversified in 2017.
611. In Singapore, about 3,000 drug users were arrested 
in 2017, slightly fewer than the year before. The majority 
of the new drug users were under 30 years old; 64 per 
cent of those arrested for drug use in 2017 used 
methamphetamine. 
612. The authorities in Malaysia indicated that about 
26,000 drug users were arrested in 2017. People aged 
between 19 and 39 accounted for the majority (about 
70 per cent). Among those arrested for drug use, crystal-
line methamphetamine was the most commonly used 
drug (40 per cent), followed by heroin and morphine 
(39 per cent) and methamphetamine pills (20 per cent). 
A fairly significant increase in the abuse of meth-
amphetamine pills was noted, contrasting with the stable 
trends in the abuse of other substances. 
613. A study by UNODC, WHO, UNAIDS and the 
World Bank estimated that 3.2 million people injected 
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drugs in East and South-East Asia in 2016, equivalent to 
30 per cent of the worldwide population of people who 
inject drugs. The prevalence of injecting drug use in the 
region, however, is relatively low (0.2 per cent) and is below 
the global average (0.22 per cent). Although the prevalence 
of HIV among people who inject drugs in East and South-
East Asia (9.6 per cent) is below the global average 
(11.8 per cent), 24 per cent of the global total of people 
who inject drugs living with HIV reside in the region.
614. Following efforts by a number of countries in the 
region to adopt a community-based treatment approach 
to deal with the drug abuse problem, the Narcotics 
Control Bureau of Brunei Darussalam took over the man-
agement of the Rumah Al-Islah treatment and rehabilita-
tion centre from the prison department in February 2018. 
It is the only approved treatment and rehabilitation cen-
tre in the country focusing on behaviour changes through 
a therapeutic community programme. 
South Asia 
1. Major developments
615. South Asia continues to face a multitude of drug 
control challenges that are exacerbated, in part, by its geo-
graphical location between the two main illicit opiate-
producing and trafficking regions of the world, namely 
the Golden Triangle in South-East Asia (between the Lao 
People’s Democratic Republic, Myanmar and Thailand) 
and the Golden Crescent in South-West Asia (covering 
Afghanistan, Iran (Islamic Republic of) and Pakistan). 
Against that backdrop, South Asia remains a target for 
traffickers smuggling illicitly produced opiates from 
Afghanistan to Europe and North America along the 
“alternate” southern route. In contrast to the Balkan and 
southern routes, the alternate southern route bypasses the 
Gulf countries and runs through South Asia to North 
America (in particular Canada), sometimes through East 
Africa, by air. In addition, coastal States in South Asia 
are vulnerable to maritime trafficking as a result of their 
exposure to trafficking routes across the Indian Ocean. 
616. Opiates, cannabis and amphetamine-type stimu-
lants remain the main substances of concern in the region, 
with record levels of cannabis herb seized in Bangladesh 
and India during 2017. There has been a thirtyfold increase 
in seizures of methamphetamine pills (known as “yaba” 
in countries in South Asia) in Bangladesh since 2011, and 
the amounts of illicitly produced opiates seized through-
out the region have been increasing. The diversion of 
controlled substances, particularly ephedrine and pseudo-
ephedrine, from licit to illicit channels has continued, as 
has the smuggling of pharmaceutical preparations 
containing narcotic drugs and psychotropic substances, 
notably codeine-based cough syrups, which remain a con-
siderable challenge in Bangladesh, Bhutan and India, and 
of synthetic opioids such as tramadol, which has been 
encountered in significant quantities across the region and 
has been scheduled as a narcotic drug in some countries 
of the region as of 2018.
617. There is also growing evidence of an emerging 
modus operandi of drug trafficking in the region that 
involves the use of the Internet as a marketplace for drugs 
and precursors, with mail or courier services being used 
for delivery. Authorities in India and Maldives have seized 
a comparatively large number of parcels containing con-
trolled substances. However, little is known about the 
extent of regulations applicable to Internet pharmacies 
and business-to-business platforms acting as intermedi-
aries between buyers and sellers (by offering access to 
various substances that may be abused) or about the role 
that express courier service providers play in the cross-
border movement of controlled and non-scheduled 
substances.
618. In South Asia, the death penalty for drug-related 
offences is provided for in the laws of several countries, 
but death sentences are passed infrequently and have 
reportedly never been enforced for this type of offence. 
However, during the reporting period, several jurisdic-
tions announced their intention to start executing people 
who have been sentenced to death for drug-related 
offences. In addition, there have been reports of extra-
judicial killings of alleged drug offenders by law enforcement 
officials in Bangladesh. Such killings, if the reports are 
confirmed to be true, would be in contravention of inter-
national law.
2. Regional cooperation
619. Countries in the region continue to cooperate on 
drug-control issues through a number of regional initia-
tives. The Forty-first Meeting of Heads of National Drug 
Law Enforcement Agencies, Asia and the Pacific, held in 
Bangkok from 27 to 30 November 2017, was focused, 
among other issues, on the role of the Internet in drug 
trafficking and abuse, which is an issue of concern to the 
region.
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620. In March 2018, senior law enforcement and min-
istry officials from Bangladesh, Bhutan, India, Maldives, 
Nepal and Sri Lanka finalized the agreement documents 
related to the establishment of the South Asian Regional 
Intelligence and Coordination Centre, to be based in 
Colombo. The legal framework for the operation of the 
Centre has been submitted to the participating 
Governments for endorsement. Drug trafficking will be 
one of the focus areas for cross-border cooperation 
against transnational organized crime through the Centre.
621. The fifth meeting of the Sub-Group on Prevention 
of Illicit Trafficking in Narcotic Drugs, Psychotropic 
Substances and Precursor Chemicals of the Bay of Bengal 
Initiative for Multi-Sectoral Technical and Economic 
Cooperation was held in Kathmandu on 23 May 2018. 
Delegates from the seven States members of the Initiative, 
including the five States from South Asia (Bangladesh, 
Bhutan, India, Nepal and Sri Lanka) discussed, among 
other matters, the possible association of the Initiative 
with the South Asian Regional Intelligence and 
Coordination Centre.
622. The tenth Recovery Symposium was held in Hanoi 
from 8 to 12 October 2018, hosted by the Drug Advisory 
Programme of the Colombo Plan for Cooperative 
Economic and Social Development in Asia and the Pacific. 
The Symposium brought together 174 participants, includ-
ing policymakers, resource persons, persons recovering 
from drug dependence, family members, service provid-
ers and other relevant stakeholders from 26 countries to 
exchange experiences on treating drug addiction. 
3.  National legislation, policy  
and action
623. Over the reporting period, Governments in the 
region continued to take legislative and other measures 
affecting the control of substances under their national 
legal regimes. India placed tramadol, a synthetic opioid 
not controlled at the international level, under national 
control in April 2018 and granted licensed manufacturers, 
importers and exporters of tramadol a period of 120 days 
to clear their existing stocks. Another nine substances, 
namely 4-methylethcathinone, ethylone, pentedrone, 
ethylphenidate, methiopropamine, MDMB-CHMICA, 
5F-APINACA, XLR-11 and khat (Catha edulis), were 
placed under national control in February 2018.
624. Bhutan amended its 2015 Narcotic Drugs, 
Psychotropic Substances and Substance Abuse Act in 
2018. Among other changes, as a result of the amendment, 
Bhutan: (a) criminalizes the possession of cannabis 
exceeding 50 g as a trafficking offence (unless certain miti-
gating circumstances, such as the absence of a criminal 
record, are present), thereby subjecting such possession to 
stricter sanctions; (b) employs a generic definition of new 
psychoactive substances to bring substances of a similar 
nature, effect, group or properties to those already listed 
under schedules I to VI of the Act within the purview of 
the Act; (c) has scheduled 30 new substances under the 
Act, among them tramadol; and (d) has transferred the 
competence to amend those schedules from the Parliament 
to the Narcotics Control Authority, with the Parliament 
retaining the right to be informed of changes in the scope 
of national control. The amendment came into effect on 
8 January 2018.
625. Furthermore, the Bhutan Narcotics Control 
Authority published rules and regulations setting out the 
referral process and treatment interventions associated 
with compulsory treatment for persons charged with the 
offence of substance abuse. Aftercare and follow-up inter-
ventions, including drug testing, are key components for 
successfully completing treatment under the new frame-
work. The rules and regulations entered into force on 
2  July 2018. 
626. Following a judgment rendered by the Calcutta 
High Court in November 2017, Phensedyl, a codeine-
based cough syrup used to treat common cold symptoms 
and known to be abused in Bangladesh and, to a lesser 
degree, in Bhutan and Nepal, will henceforth be considered 
a narcotic drug falling within the purview of the Narcotic 
Drugs and Psychotropic Substances Act of 1985 in India. 
As a result, persons implicated in its non-medical use or 
illicit distribution could be tried for the commission of a 
drug-related offence. The judgment represents a prece-
dent for the state in which the ruling was made and may 
be considered authoritative case law by other state courts 
in future, but it has no binding force in India as a whole. 
Phensedyl and similar preparations are banned in several 
countries in the region as a result of their potential for 
abuse.
627. In India, where capital punishment for drug-
related offences is an option for repeat offenders under 
section 31A of the Narcotic Drugs and Psychotropic 
Substances Act of 1985, but has never been carried out 
in practice, the State of Punjab has reportedly submitted 
an official proposal to amend the Act to extend the death 
penalty to first-time drug offenders. Similarly, Sri Lanka 
has announced its intention to cease the commutation of 
death sentences to life imprisonment for repeat offenders 
of drug trafficking. The announcement was made by the 
President of Sri Lanka and contradicts the de facto abo-
litionist stance on capital punishment taken by the 
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Government for the last 40 years. The last judge-ordered 
execution of the death penalty in Sri Lanka took place in 
1976. The Board is also aware of reports that Bangladesh 
is planning to reinstate the enforcement of death sen-
tences for drug-related offences, which in that country 
have been provided for in law since 1990, but considered 
optional since the Supreme Court ruled their mandatory 
application unconstitutional in 2015. In October 2018, 
Bangladesh extended the application of the death penalty 
to drug-related offences involving more than 200 g of 
methamphetamine (“yaba”), which is widely abused in 
the country, and reclassified the substance as a class-A 
narcotic drug. Although the determination of sanctions 
is a prerogative of States, the Board continues to 
encourage all States that retain the death penalty for 
drug-related offences to commute sentences that have 
already been handed down and to consider abolishing 
the death sentence for drug-related offences.
628. In May 2018, Bangladesh declared a “war on 
drugs”, which has reportedly resulted in the deaths, at the 
hands of law enforcement officials, of hundreds of people 
suspected of drug trafficking. Summary trials of drug 
offenders through “mobile drug courts”, in which suspects 
are prosecuted and sentenced on the spot, have been 
operational for a number of years, with conviction rates 
of close to 100 per cent (in 2016, for example, there were 
6,591 convictions and 1 acquittal). However, targeted 
drug law enforcement operations with large numbers of 
suspects reportedly killed as a result is an unprecedented 
development in the country. The Board stresses, as it did 
in its annual report for 2017,79 that extrajudicial 
responses to drug-related criminality are in clear vio-
lation of the international drug control conventions. 
Under the conventions, drug-related crime must be 
addressed through formal criminal justice responses, 
including internationally recognized due process 
standards. 
4.  Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
629. Illicit crop cultivation remains an issue of concern 
in some countries in South Asia, in particular with regard 
to illicit opium poppy cultivation in India, where it coex-
ists with a sizeable area under licit opium poppy cultiva-
tion, and in Nepal. Illicit cannabis cultivation is an issue 
of concern in Bangladesh, India and Sri Lanka.
79 E/INCB/2017/1, para. 256.
630. In Sri Lanka, cannabis is the only plant-based nar-
cotic drug illicitly cultivated in the country, with an esti-
mated area under illicit cannabis cultivation in 2016 of 
about 500 ha. That estimate remained unchanged during 
the three-year period 2014–2016, with no information 
available about related eradication efforts undertaken by 
the Government, including for 2017. At the same time, 
cannabis is commonly used in the preparation of tradi-
tional ayurvedic medicines in Sri Lanka. The Ministry of 
Health in Sri Lanka announced its intention to begin cul-
tivating cannabis for medicinal purposes, partly destined 
for export to North America. Cultivation was to start in 
late 2018, with a limited area of about 40 ha, which should 
yield 25 tons of cannabis herb yearly.
631. During 2017, India’s law enforcement agencies 
intensified their efforts to eradicate illicitly cultivated can-
nabis in the country. In that year alone, illicitly cultivated 
cannabis plant covering an area of more than 3,400 ha 
was eradicated in India, the largest area subjected to 
eradication in the period 2013–2017. Nevertheless, illicit 
cannabis cultivation remains a challenge in the country. 
Bangladesh eradicated 69,989 illicitly cultivated cannabis 
plants in 2017, the highest number of such plants 
eradicated in the last seven years in the country, and 
almost double the number of plants eradicated in 2013. 
632. Cannabis remains the most frequently seized nar-
cotic drug in South Asia; cannabis herb was the drug 
seized in the largest quantities across the region in 2017. 
India alone carried out 6 per cent of the world’s canna-
bis herb (“ganja”) seizures in 2016 (nearly 300 tons), and 
reported seizing even higher quantities in 2017 (353 tons, 
representing a 20 per cent increase compared with 2016). 
The figures for 2017 are the highest in India during the 
period 2013–2018. 
633. In comparison, seizures of cannabis resin (“charas”) 
have remained relatively stable in India over the years, 
fluctuating between a considerable 2 to 4 tons during the 
period 2013–2017, with 3.2 tons seized in 2017. Cannabis 
resin is reportedly trafficked from Nepal to India and, 
within India, from illicit cultivation sites located in south-
ern Kashmir to other parts of the country.
634. In order of magnitude, Bangladesh recorded the 
next-largest quantity of cannabis herb seized in the 
region, with close to 70 tons seized in 2017. While sei-
zures of cannabis herb have not fallen below 10 tons since 
the beginning of the decade, the amount seized in 2017 
was by far the highest since 2010. Following a steady 
increase since 2014, the amount seized in 2017 was more 
than triple the amount seized in that year (17 tons in 
2014, 42 tons in 2015 and 47 tons in 2016). In most cases, 
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cannabis herb is trafficked into Bangladesh from neigh-
bouring India and Nepal.
635. Sri Lanka seized almost 5 tons of cannabis herb in 
2017. This represents a 20 per cent increase compared 
with 2016, when 4.1 tons of cannabis herb were seized, 
making cannabis herb the narcotic drug seized in the 
largest quantity in the country during the period 2012–
2017. However, with the exception of 2017, seizures of 
cannabis herb have been steadily declining since 2013, 
when a record 81.9 tons were seized. Cannabis herb used 
in Sri Lanka is reportedly grown locally or trafficked into 
the country from Kerala State in India. With regard to 
cannabis resin, the trend in Sri Lanka points in the oppo-
site direction, with limited but increasing amounts seized 
over the past five years (from less than 500 g seized in 
2012 to more than 40 kg seized in 2016). Conversely, in 
2017, a slight decrease in cannabis resin seizures was 
noted in Sri Lanka, with 38 kg seized by police.
636. In Nepal in 2017, cannabis herb was also the drug 
seized in the largest quantity, with 3.7 tons, followed 
closely by cannabis resin, with 1.3 tons. The figures for 
2018 (based on available data until September 2018) sug-
gest no significant change in this regard compared with 
2017. In Bhutan, although cannabis herb was the drug 
seized in the largest amount in 2017 (not counting tab-
lets and capsules of pharmaceutical preparations contain-
ing controlled substances), the total amount seized was 
relatively small, totalling 166.4 kg in 2017 and 184.84 kg 
as of the end of October 2018. In 2018 in Maldives, the 
largest single seizures made by customs authorities 
involved cannabis and heroin (amounting to less than 
5.5 kg each).
637. Except for India, where both licit and illicit opium 
poppy cultivation continue to take place, no data regard-
ing cultivation or eradication efforts in countries in South 
Asia have been reported since 2009. Notably, the area 
under illicit opium poppy cultivation eradicated in India 
in 2017 exceeded the area under licit cultivation during 
the same crop year: the authorities eradicated an area 
under illicit opium poppy cultivation covering more than 
3,000 ha, the largest for the last five years, while opium 
poppy was grown legally on 2,322.5 ha of land licensed 
for cultivation by the Central Bureau of Narcotics. In 
comparison, in 2016, more than 2,600 ha of illicitly 
cultivated opium poppy were destroyed. By the end of 
August 2018, opium poppy illicitly cultivated on an area 
covering more than 3,200 ha had been eradicated.
638. Trafficking in opiates increased significantly in at 
least half of the countries in the region from 2016 to 2017. 
For example, seizures of illicitly produced heroin 
continued to rise in India in 2017, from 1.7 tons in 2016 
to 2.1 tons in 2017; they have been rising steadily since 
2014. According to the Narcotics Control Bureau, almost 
half of all seized heroin in India originated in countries 
in South-West Asia. Seizures of opium in the country 
have continued to increase since 2015, with more than 
2.5 tons seized in 2017 alone. That figure had already been 
surpassed in mid-2018, with more than 4 tons of opium 
seized by 30 June. In 2017, India seized 449 kg of morphine, 
the origin of which was unknown, which was 15 times 
more than in 2016 (28 kg) and was the highest amount 
during the period 2013–2017. Significantly, in September 
2018, authorities in India raided a clandestine drug 
laboratory in Indore, a city in central-west India, seizing 
9 kg of fentanyl. It was the first reported instance of a 
clandestine fentanyl-synthesizing laboratory being 
dismantled in the region.
639. India is also a transit country for illicitly produced 
opiates, in particular heroin, which originate in 
Afghanistan and are trafficked through the country via 
Pakistan en route to Europe and North America (mainly 
Canada). The route used by traffickers to smuggle opiates 
through South Asia is an alternative part of the so-called 
“southern route”, which typically runs through Pakistan 
(or the Islamic Republic of Iran) and, via the Gulf coun-
tries, continues to East Africa and on to the destination 
countries. The “alternate” southern route bypasses the 
Gulf countries and uses South Asia as a stopover for opiates 
being supplied directly to the Canadian market by air, or 
through Africa to Europe.
640. Bangladesh seized 401 kg of heroin in 2017, the 
highest amount of heroin seized in the last eight years, 
following significant year-on-year increases since 2014 
(30 kg in 2014, 110 kg in 2015 and 267 kg in 2016). The 
amounts of other illicitly produced opiates seized over the 
same period were very small. Seizures of pharmaceutical 
opioids, which caused serious problems at the beginning 
of the decade (more than 4.1 tons were seized in 2010), 
have been in decline, with only a nominal amount seized 
in 2017.
641. The overall picture of opiate trafficking in Sri Lanka 
is less clear. In 2017, nearly 315 kg of heroin were seized 
(compared with 207 kg in 2016) and less than 1 kg of 
opium was seized (compared with 15 kg seized in 2016). 
Seizures carried out in the years prior do not allow for a 
conclusive assessment to be made as to a particular trend, 
given significant year-to-year fluctuations. At the same 
time, in July 2018 alone, the country’s Police Narcotics 
Bureau seized 103.9 kg of heroin in one of the department’s 
biggest drug seizures ever. Most opiates are reportedly 
trafficked into Sri Lanka from India and Pakistan. 
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642. Codeine-based cough syrups sold under different 
trade names (e.g., Phensedyl and Corex) have continued 
to be seized in considerable quantities in Bangladesh, 
Bhutan and India and are reportedly trafficked mainly 
along the border between India and Bangladesh. These 
pharmaceutical preparations are mostly produced in 
India, often transported by road in trucks and trains and 
then trafficked across the border into Bangladesh. In the 
first six months of 2018, the Narcotics Control Bureau in 
India reported seizing 91,000 bottles of cough syrup.
643. Following an apparent peak in cocaine trafficking 
in South Asia in 2016, seizures of cocaine in the region 
in 2017 were less common and involved far lower 
amounts. In Sri Lanka, for example, some 221 kg of 
cocaine were seized in 2017, significantly less than the 
nearly 1.6 tons seized in 2016, a year that appears to have 
been the exception, with seizures in preceding years well 
below the 10 kg mark (5.7 kg in 2015, 26 g in 2014, no 
seizures in 2013 and 7.5 kg in 2012). For 2016, the main 
transit country from which cocaine arrived in Sri Lanka 
was reportedly the Bolivarian Republic of Venezuela.
644. Similarly, the amount of cocaine seized in India 
fluctuated during the period 2013–2017, between 15 kg 
(in 2014) and 113 kg (in 2015), with no clearly discern-
ible trend. In 2017, 69 kg were seized in India, mostly at 
airports. In Bangladesh, seizures of cocaine have only 
been reported since 2015, with relatively low amounts, 
ranging from 0.6 kg (in 2016) to 5.7 kg (in 2015). In 2017, 
5 kg were seized. A similar amount was seized in Nepal 
in the same year.
645. In recent years, there appears to have been a notice-
able growth in drug trafficking by sea in the Indian Ocean 
region. In India, several sizeable seizures of heroin were 
carried out at sea in 2017 (6 tons in January and some 
1.5 tons in July). In 2018, several vessels carrying large 
shipments of tramadol from India were intercepted by Sri 
Lankan authorities, while, in 2016, police in Sri Lanka 
reportedly detected 900 kg of cocaine on a ship bound 
for India, representing one of the largest cocaine seizures 
recorded in South Asia to date. The Forty-first Meeting 
of Heads of National Drug Law Enforcement Agencies, 
Asia and the Pacific, highlighted the need for closer coop-
eration among the heads of the coastguard agencies and 
anti-narcotics forces of the countries in the Indian Ocean 
coastal regions.
(b) Psychotropic substances
646. Amphetamine-type stimulants remain drugs of 
considerable concern for some countries in the region, 
notably Bangladesh, where “yaba” (methamphetamine) 
tablets have been seized in increasing numbers, although 
trends in the region as a whole have proved unpredicta-
ble over the past few years. At the global level, unprece-
dented quantities have been seized; at the regional level, 
however, the predicted development of new synthetic 
drug markets in South Asia has not materialized. 
647. Following a tenfold increase in the amount of 
amphetamine-type stimulants seized in India, from 166 kg 
in 2015 to 1,687 kg in 2016 in practically the same num-
ber of cases, in 2017, only 95 kg were seized in a com-
parable number of seizures. Indications for 2018 seem to 
show that this inconclusive trend has continued: by 
August 2018, 253 kg of amphetamine-type stimulants had 
been seized. India has reportedly also been named as a 
country of origin or transit for methamphetamine seized 
in Singapore and Spain, as well as Hong Kong, China, 
over the period 2012–2016. 
648. In Bangladesh, methamphetamine was the second 
most seized drug in 2017 after cannabis herb, with 3.6 tons 
seized. This represents the highest quantity of metham-
phetamine seized in the past eight years in Bangladesh 
and a more than tenfold increase over the amount seized 
in 2016 (355 kg). In 2016, the Department of Narcotics 
Control in Bangladesh reported seizing close to 30 mil-
lion “yaba” pills, noting a significant year-on-year increase 
since 2011 (almost thirtyfold between 2011 and 2017). 
“Yaba” tablets, the methamphetamine-caffeine compound 
associated with the drug abuse crisis in Bangladesh, are 
reportedly entering the country from Myanmar. 
649. In Maldives, synthetic drugs, in particular, amphet-
amine, methamphetamine and “ecstasy”, were among the 
drugs most often seized by customs officials over the 
reporting period. However, amounts were typically small, 
ranging from a few grams to a little under 300 g. In Sri 
Lanka, the amounts of psychotropic substances seized in 
2016 and 2017 were also very small. For 2016, Sri Lanka 
reported seizing 0.5 kg of “ecstasy”-type substances and 
1.23 kg of LSD-type hallucinogens. There were no reports 
of amphetamine or methamphetamine being seized in the 
country in 2016 or 2017.
650. India seized a total of 170 kg of mephedrone in 
2017; 110 kg of the substance, along with a range of other 
substances, was found in a single clandestine drug manu-
facturing facility. Mephedrone has also been encountered 
in Maldives, where 330 g of the substance were seized in 
four cases, all of them involving parcels sent through the 
mail. Seizures of methaqualone also continued in India. 
In 2017, authorities in India seized 124 kg of methaqualone, 
a significant decrease from the exceptionally high amount 
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of 24.1 tons seized in 2016 during the dismantling of a 
clandestine laboratory.
651. There is also evidence in South Asia of trafficking 
in prescription medicines containing psychotropic sub-
stances, in particular, tranquillizers such as diazepam 
(large quantities were seized in India between 2010 and 
2015, including from a clandestine laboratory dismantled 
in 2016), alprazolam (several hundred thousand tablets 
were seized in India in 2017), clonazepam, lorazepam and 
benzodiazepine. One of the primary ways of accessing 
such substances in India is reportedly through illicit 
Internet pharmacies.
652. The vast majority of drug seizures carried out by 
customs officials in Maldives involved parcels sent 
through the mail, which appears to be a recent, yet 
increasingly well-established modus operandi for drug 
traffickers. Examples of the trend of ordering substances 
online and using courier or mail services for delivery 
could also be found in India, where the practice has been 
noted by authorities as one of the emerging means of traf-
ficking psychotropic substances, in particular methaqua-
lone, ketamine (scheduled at the national level), precursor 
chemicals and narcotic drugs such as cocaine, heroin or 
cannabis. For example, in February 2018, authorities in 
India seized 200 tablets of nitrazepam, a benzodiazepine-
class drug, concealed in a courier parcel originating in 
the United States.
653. The global trend of purchasing drugs over the 
Internet, particularly on darknet trading platforms using 
cryptocurrencies, has already spread to the region, includ-
ing India. One recent study of the global Internet-facilitated 
illicit drug trade identified some online vendors of drugs 
over the darknet who appear to be operating from South 
Asia. More specifically, the study identified more than 1,000 
drug listings from India published across 50 online crypto-
market platforms. In 2017, authorities in India dismantled 
two illicit pharmacies selling drugs over the Internet, 
seizing close to 130,000 tablets containing psychotropic 
substances and arresting 15 people in the process.
(c) Precursors
654. In India, precursor chemicals continued to be 
diverted from licit to illicit channels in 2017. They were 
trafficked most frequently to Malaysia, Myanmar and 
some countries in Southern Africa. Acetic anhydride, one 
of the main precursors of heroin, is widely used for 
legitimate purposes by the pharmaceutical and textile 
industries in India. After an unprecedented peak in sei-
zures of acetic anhydride in 2016 (2.7 tons), authorities 
in India seized about 25 kg of the substance in 2017.
655. There is reportedly a trend of trafficking in ephed-
rine and pseudoephedrine across the border from India 
to Myanmar and reverse trafficking of methamphetamine 
back into India. In 2017, authorities in India seized almost 
3 tons of ephedrine and pseudoephedrine, almost 500 kg 
of which were seized at clandestine laboratories used for 
the illicit manufacture of amphetamine-type stimulants. 
By August 2018, authorities in India reported having 
seized 127 kg of ephedrine.
656. Since 2017, the Government of Bangladesh has 
severely restricted the distribution of pseudoephedrine 
preparations in the country. Pseudoephedrine is the 
prime precursor for the illicit manufacture of “yaba” and 
is mainly imported into Bangladesh from India. 
657. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in South Asia can be found 
in the report of the Board for 2018 on the implementa-
tion of article 12 of the 1988 Convention.
(d)  Substances not under international 
control
658. As more and more new psychoactive substances 
are scheduled, both at the international and national levels, 
reported seizures of substances that continue to fall 
within the category of new psychoactive substances have 
declined in the region. However, seizures of a number of 
unspecified new psychoactive substances have continued 
to be reported by individual countries. 
659. Ketamine has been seized only intermittently over 
the last few years in South Asia, although India was fre-
quently named as the country of origin in seizures of ket-
amine in 2017 and 2018. In 2017, Indian authorities 
seized a total of 161 kg of ketamine. Significantly, in June 
2018, as part of “Operation Vitamin”, conducted at the 
national level all over India, officials dismantled four 
illicit ketamine manufacturing facilities and seized 308 kg 
of ketamine, along with 2 tons of raw material that could 
reportedly yield another 250 kg of the substance.
660. In addition to widespread abuse of tramadol in 
countries in West Africa, North Africa and the Middle 
East, the abuse of tramadol is also of considerable concern 
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in countries in South Asia. According to UNODC, most 
of the tramadol seized worldwide in the five years to 2016 
originated in India and, to a lesser extent, in China. 
661. In addition, significant quantities of tramadol were 
seized in 2016, 2017 and 2018 throughout the region. In 
India, more than 66 million packaged tablets, 2.2 tons of 
loose tablets and a further 670 kg of tramadol powder 
were seized, along with tableting equipment, in one oper-
ation in May 2018. In Sri Lanka, 23 out of 28 major cases 
of non-medical use of pharmaceutical preparations (rang-
ing from the sale or possession of 6 to 70,000 capsules 
per case) detected by the National Medicines Regulatory 
Authority in 2017 involved tramadol (the other 5 were 
related to pregabalin). In two cases, reported in April and 
September 2018, customs authorities in Sri Lanka inter-
cepted 200,000 and more than 15 million tablets of tram-
adol, respectively, that had been shipped by sea from 
India.
662. In Bhutan, 130,316 capsules containing tramadol, 
marketed under the trade name “spasmo proxyvon plus” 
(“SP+”), were seized in 2017. Seizures of the drug contin-
ued in 2018 and, as of the end of October 2018, authori-
ties in Bhutan had seized close to 70,000 capsules, reflecting 
the continued influx of the drug into the country.
5. Abuse and treatment
663. There are no comprehensive prevalence data on 
drug use across the South Asia region for 2016 or 2017. 
Stigma associated with drug abuse has frequently been 
cited by countries in the region as an obstacle to the col-
lection of reliable data and is a decisive factor in affected 
populations’ ability to access health care and treatment.
664. Based on available information, the most fre-
quently used drug in South Asia varies from country to 
country, although cannabis tends to rank at the top, in 
particular in India and Sri Lanka. In Bangladesh, how-
ever, statistics maintained by the Department of Narcotics 
Control with regard to patients of national treatment cen-
tres showed that, in 2016, for the first time in three years, 
heroin ranked first among the drugs in respect of which 
treatment had primarily been provided: a little over a 
third of patients were primarily treated for heroin abuse, 
about a third of patients for abuse of “yaba” and less than 
a fifth of patients for cannabis abuse. Figures have fluc-
tuated over the period 2012–2016 in Bangladesh, with 
only one consistently discernible trend concerning the 
use of “yaba”: in 2012, close to 6 per cent of patients were 
treated primarily for methamphetamine abuse, a propor-
tion that had increased fivefold by 2016. 
665. The non-medical use of pharmaceutical drugs con-
taining controlled substances continues to be prevalent in 
virtually all countries of South Asia. The preparations in 
question include codeine-based cough syrups sold under 
different trade names, such as Corex (in Bhutan and India) 
and Phensedyl (in Bangladesh and India); synthetic opi-
oids such as tramadol (identified in the vast majority of 
abuse cases in Sri Lanka, along with pregabalin, a medi-
cine with anti-convulsant properties used to treat epilepsy, 
neuropathic pain and anxiety, which is frequently encoun-
tered in Bhutan and India); ayurvedic tablets containing 
opium; and tranquillizers such as alprazolam, diazepam, 
clonazepam, lorazepam and benzodiazepine.
666. South Asia is the region with the lowest estimated 
percentage of people injecting drugs worldwide. In terms 
of core interventions to prevent the spreading of HIV and 
hepatitis C among people who inject drugs, South Asia 
has the highest coverage worldwide of opioid substitution 
therapy: more than 80 per cent of persons who inject 
drugs in the region are being treated with opioid substi-
tution therapy. Regular HIV testing and needle-syringe 
distribution programmes are available to a far lesser 
extent. About 10 per cent of people who inject drugs are 
reportedly living with HIV.
667. Drug abuse has become a major concern in India 
in recent years, in particular in the State of Punjab, where 
an estimated 230,000 people were considered dependent 
on opioids and around 860,000 people were estimated as 
opioid users in 2015, according to a study commissioned 
by the Punjab Ministry of Social Justice and Empowerment 
and supported by the Department of Health, Punjab. The 
data further suggested that, among men aged 18 to 35, 
about 4 per cent were dependent on opioids. The majority 
of those men (53 per cent) reportedly used heroin, about 
33 per cent used opium and some 14 per cent used a 
variety of pharmaceutical opioids. Some reports estimate 
that more than two thirds of all households in the State 
of Punjab have at least one family member who is 
dependent on drugs. 
668. In Sri Lanka, residential care, treatment and reha-
bilitation services are offered by four governmental and 
nine non-governmental service providers. The primary 
drug of abuse for which patients received treatment 
across providers operating in Sri Lanka was heroin (92 
per cent of all patients), followed by cannabis (69 per cent 
of patients), indicating a significant level of poly-drug use.
669. In Maldives, a 24-hour support hotline for drug-
dependent persons seeking access to treatment services 
was established in 2018 by the non-governmental organ-
ization “Journey”, based in Male. “Journey”, which has 
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been operational since 2005, carried out a rapid assess-
ment survey on drug use and a national drug use survey 
in Maldives in 2006 and 2011/2012, respectively, and 
cooperates closely with the National Drug Agency in 
offering counselling to drug users and their families, as 
well as training and house calls throughout the atoll.
West Asia
1. Major developments
670. Despite substantial increases in annual opium 
poppy cultivation in Afghanistan in recent years, in par-
ticular during the period 2015–2017, the heroin supply 
from Afghanistan to destination markets in Europe and 
beyond appears to have remained stable. According to 
UNODC, this may be due to an effort by traffickers to 
keep supply smooth and stable, or heroin may have been 
manufactured with opium from different harvests.
671. Despite a decrease of 20 per cent, the level of 
opium poppy cultivation in Afghanistan remained high 
in 2018. The decrease was attributed mainly to the 
drought in the country and to declining farm-gate prices 
of dry opium. Potential opium production also saw a 
decrease, of 29 per cent, and was estimated at about 
6,400 tons in 2018, compared with 9,000 tons in 2017. 
672. The so-called “Balkan route”, which passes through 
the Islamic Republic of Iran, Turkey and the Balkan coun-
tries towards destination markets in Western and Central 
Europe, remains the main path for trafficking in opiates 
originating in Afghanistan. Countries along the Balkan 
route account for about 37 per cent of global heroin sei-
zures. At the same time, in 2017, Afghan opiates contin-
ued to be trafficked via a sub-branch of the Balkan route 
passing from the Islamic Republic of Iran to the coun-
tries of the Southern Caucasus and then onward to 
Ukraine via the Black Sea into Eastern Europe.
673. The so-called “northern route” also continues to be 
used for trafficking in Afghan opiates to markets in 
Belarus, Lithuania and the Russian Federation, via Central 
Asian States.80 However, most countries in Central Asia 
witnessed either a stable or a declining trend in traffick-
ing in opiates through their territories. The so-called 
“southern route”, which accounts for about 9 per cent of 
opiates trafficked to Europe, runs from Afghanistan to 
80 The Central Asian subregion as referred to in this report comprises 
Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan.
Pakistan for eventual trafficking through Gulf countries 
and East Africa to markets in Europe. In addition, drugs 
continue to be trafficked from Afghanistan to India and 
other countries in South Asia, with the final destination 
being markets in Europe and North America. 
674. With the significant increases in opium production 
until 2017, the illicit opiate economy substantially sur-
passed the level of the entire licit exports of goods and 
services of Afghanistan. Not only did the Taliban and 
anti-government, insurgent and powerful local power-
holders continue to benefit from the illicit opium econ-
omy, but many communities in Afghanistan that engage 
in cultivation, work on poppy fields or play a role in the 
illicit drug trade became further dependent on opium 
poppy cultivation for their livelihoods. 
675. There has been an increase in the production of 
cannabis resin in Afghanistan. The country was identified 
as the source of seized cannabis resin in 19 per cent of 
countries that reported the sources of seized cannabis 
resin in the period 2012–2016, in particular countries in 
Central Asia, the Southern Caucasus and Europe. In 2017, 
Afghanistan also continued to see increases in metham-
phetamine seizures, in addition to detecting new clandes-
tine laboratories manufacturing that substance on its 
territory.
676. In 2018, Afghanistan began to develop the new 
Afghan-led counter-narcotics strategy, intended to pro-
vide a comprehensive, coordinated and results-based 
shared approach to tackling the drug problem through 
enhanced regional efforts, and adopted new counter- 
narcotics legislation. The Board reiterates that, while it 
understands the challenges faced in the country and 
acknowledges the efforts made by the Government and 
the people of Afghanistan, curtailing the country’s illicit 
drug economy should be prioritized as part of the efforts 
to achieve sustainable development in the country, and 
acknowledges that it is a global shared responsibility to 
address that challenge through local, national, regional 
and international efforts. 
677. Instability and armed conflicts across the Middle 
East continued to facilitate trafficking in narcotic drugs 
and psychotropic substances in the subregion. Counterfeit 
“captagon” has become a drug of choice in war zones in 
the Middle East and potentially serves as a source of 
income for terrorist and insurgency groups. Lebanon con-
tinues to be a source of cannabis resin seized globally, 
and its production continued to increase. There are indi-
cations that Iraq is also gaining importance for illicit drug 
cultivation and production, including heroin manufacture 
and opium poppy and cannabis plant cultivation. In 
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addition, drug trafficking and abuse in the Basra region 
of Iraq, which borders Iran (Islamic Republic of) and 
Kuwait, has seen substantial increases in recent years. 
Many countries in the Middle East also continued to 
observe trafficking and abuse of the prescription drug 
tramadol, a synthetic opioid not under international con-
trol, and there are indications that terrorist groups may 
also be involved in its trafficking in that subregion.
678. Most countries in Central Asia reported the emer-
gence of a growing number of new psychoactive sub-
stances. The countries in the subregion are taking 
legislative and institutional measures to address that 
problem, but those efforts remain piecemeal and uneven 
across the whole subregion, leaving loopholes in the con-
trol mechanisms that are exploited by traffickers. Some 
countries in the subregion are facing increased abuse of 
synthetic cannabinoids, which are gradually replacing 
heroin and opium as the main drugs of choice, especially 
among young people. 
2. Regional cooperation
679. The 10th Review Meeting of the Memorandum of 
Understanding on Subregional Drug Control Cooperation, 
a meeting of ministers and senior officials from the five 
Central Asian States (Kazakhstan, Kyrgyzstan, Tajikistan, 
Turkmenistan and Uzbekistan), as well as Azerbaijan and 
the Russian Federation and the Aga Khan Development 
Network, took place in Astana on 31 October 2017. As 
an outcome of the meeting, a declaration was adopted 
underlining the threats posed by trafficking in and the 
abuse of illicit substances, in particular for children and 
young people, and noting with concern that an increased 
level of illicit cultivation and production of drugs in 
Afghanistan represented an immediate threat to the sub-
region and required enhanced cooperation and compre-
hensive measures. The parties to the Memorandum of 
Understanding underlined the important role played by 
CARICC in strengthening regional cooperation on drug 
control, including by facilitating intelligence-sharing and 
joint operational activities to address drug trafficking.
680. The International Conference on Security and 
Sustainable Development in Central Asia was organized 
by the Government of Uzbekistan under the auspices of 
the United Nations and in cooperation with the United 
Nations Regional Centre for Preventive Diplomacy for 
Central Asia and UNODC, and held in Samarkand, 
Uzbekistan, on 10 and 11 November 2017. The Conference 
brought together high-level representatives of the United 
Nations, the European Union, the Organization for 
Security and Cooperation in Europe, SCO, the 
Commonwealth of Independent States, the Central Asian 
States, Afghanistan, China, India, Iran (Islamic Republic 
of), Japan, Pakistan, the Russian Federation, the Republic 
of Korea, Turkey and the United States, as well as scien-
tists, public figures and representatives of the mass media. 
The Conference adopted a communiqué encouraging the 
Heads of the Central Asian States to hold regular consul-
tative meetings to maintain an open dialogue and develop 
mutually acceptable approaches on contemporary regional 
issues, including drug trafficking and abuse, and called 
for increased cooperation between the Central Asian 
States, UNODC and INTERPOL to counter drug 
trafficking.
681. In December 2017, the meeting of the Council of 
CARICC adopted the CARICC Strategy for 2018–2022. 
In 2017, CARICC facilitated several joint operations, 
including counter-narcotics operations, and long-term 
multilateral subregional operations such as Operation 
Reflex, a subregional operation for countering new psy-
choactive substances, and Operation Substitute, a sub-
regional operation for countering precursors. Additionally, 
a joint multilateral container control operation was suc-
cessfully completed. As a result, the activities of two 
transnational criminal groups engaged in the distribution 
of synthetic drugs over the Internet were interdicted, a 
number of persons were arrested and various illicit 
substances such as heroin, opium, cannabis resin and 
synthetic drugs were seized.
682. The States members of the Collective Security 
Treaty Organization, namely Armenia, Belarus, 
Kazakhstan, Kyrgyzstan, the Russian Federation and 
Tajikistan, carried out two large-scale joint operations in 
2017 to counter drug trafficking and associated money-
laundering. As a result of those subregional operations, 
more than 20 tons of controlled substances were seized, 
including 16 tons of opium and 1.5 tons of cannabis resin, 
as well as a substantial number of firearms and 
ammunition.
683. In May 2018, the Secretariat of SCO held a Meeting 
of the Senior Officials of the SCO Member States’ 
Counter-Narcotics Agencies in Beijing. At the event, 
which involved all eight member States, participants dis-
cussed the drug control situation in the subregion and 
avenues for streamlining practical measures for counter-
narcotics cooperation.
684. On 8 March 2018, the Security Council adopted 
resolution 2405 (2018), extending the mandate of 
UNAMA until 17 March 2019. In the same resolution, 
the Council expressed its deep concern about the signif-
icant increase in the illicit cultivation and production of 
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and trade and trafficking in drugs in Afghanistan, which 
significantly contributed to the financial resources of the 
Taliban and its associates and could also benefit Al-Qaida 
and ISIL and its affiliates, and encouraged the Government 
of Afghanistan, supported by the international commu-
nity and regional partners, to intensify its efforts to 
address drug production and trafficking with a balanced 
and integrated approach, in accordance with the princi-
ple of common and shared responsibility. 
3.  National legislation, policy  
and action
685. In 2017, Saudi Arabia adopted executive regula-
tions on the chemical import and management system, 
which divided chemicals into seven lists, with a view to 
bringing those substances under control in line with 
international instruments.
686. With a view to further strengthening the drug con-
trol system through an integrated and balanced approach 
in line with the outcome document of the special session 
of the General Assembly on the world drug problem held 
in 2016, Turkey adopted a new national strategy docu-
ment and action plan on the fight against drugs for the 
period 2018–2023. The strategy covers areas such as the 
provision of services for the treatment of drug use disor-
ders, rehabilitation, social reintegration and drug use 
monitoring, as well as a wide range of measures related 
to justice and law enforcement.
687. In 2017, Kyrgyzstan adopted legislation decrimi-
nalizing certain minor drug-related offences, strength-
ened judicial oversight of investigations, moved the 
criminal justice system from an inquisitorial to a more 
adversarial model and promoted the social reintegration 
of offenders through the establishment of a new, socially 
oriented probation service to manage and oversee the 
application of alternatives to incarceration.
688. An interministerial working group was established 
in Afghanistan, led by the Ministry of Counter-Narcotics, 
on the development of a new counter-narcotics strategy 
with a strong component to promote regional coopera-
tion. In parallel to that initiative, UNODC, in close coor-
dination with the Government of Afghanistan, developed 
the document “Strategic actions to respond to the global 
threats of opiates”, to step up regional and interregional 
responses to counter illicit opium poppy cultivation and 
production, and address the connection between drugs, 
crime and terrorism.
689. Amendments to the Anti-Narcotics Act were 
adopted by the Parliament of the Islamic Republic of Iran 
in August 2017 and approved by the Guardian Council 
in October of the same year. They replaced the punish-
ment for some drug-related offences that had previously 
carried the death penalty or life in prison, with a prison 
term of 25 to 30 years and fines. The amendments also 
raised the threshold for the quantity of drugs that would 
lead to the imposition of the death penalty, namely pos-
session of 50 kg of opium or 2 kg of heroin, compared 
with the previous threshold of 5 kg of opium or 30 g of 
heroin. Capital punishment was retained for serious 
drug-related offences, including those involving weapons 
or organized criminal groups, or if the offenders involved 
minors or mentally ill persons in the commission of the 
offences, as well as for repeat offences. The amendments 
have retroactive applicability, and in January 2018, a judi-
cial order was issued by the country’s Chief Justice that 
would allow for the commuting of the sentences of those 
on death row, based on their application.
690. The Government of Afghanistan adopted a new 
counter-narcotics law in February 2018. The law initiated a 
long-planned restructuring of the country’s drug control 
infrastructure, the goal of which is to give higher priority to 
drug control matters by associating them even more closely 
with the Office of the President of Afghanistan in order to 
improve coordination. The law is also more streamlined, as 
the offences contained in the recently adopted Penal Code 
of Afghanistan eliminate any duplication.
691. In February 2018, the new Penal Code of 
Afghanistan, which had been adopted in March 2017, 
came into force, replacing the Penal Code of 1976. 
According to UNAMA, for the first time, Afghanistan has 
a comprehensive criminal code complying with inter-
national treaty obligations in criminal justice and incor-
porating modern best practices in criminology. UNODC 
and UNAMA were among the international agencies that 
provided assistance to Afghanistan in drafting the new 
Penal Code. The new Code is aimed at improving 
Afghanistan’s compliance with international human rights 
and criminal justice standards, as well as with provisions 
of the United Nations Convention against Corruption and 
the United Nations Convention against Transnational 
Organized Crime and its three protocols. The new Code 
also incorporates the requirements of the Rome Statute 
of the International Criminal Court covering war crimes, 
crimes against humanity and genocide, and establishes 
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command responsibility for those who fail to prevent or 
punish subordinates who commit crimes covered by the 
Rome Statute.
692. UNODC, jointly with the Ministry of Agriculture, 
Irrigation and Livestock and the Ministry of Counter-
Narcotics of Afghanistan and the Bureau of International 
Narcotics and Law Enforcement Affairs of the United 
States, non-governmental organizations and various min-
istries, launched a new alternative development pro-
gramme (Boost Alternative Development Interventions 
through Licit Livelihoods (BADILL)) in November 2017. 
The project is being implemented in 13 provinces of 
Afghanistan and aims to reach 50,000 households in four 
years, focusing on increasing sustainable production and 
the income of Afghan farmers.
693. In June 2018, six mobile inter-agency teams for 
countering trafficking in drugs were launched in 
Uzbekistan. The teams comprise officers from the Ministry 
of Internal Affairs, the State Security Service and the State 
Customs Committee. UNODC handed over 30 vehicles 
and a range of specialized equipment to national 
authorities to support the mobile teams. The initiative has 
been supported at the highest level, through the resolu-
tion of the President of Uzbekistan adopted in June 2017 
dedicated to implementation of the activities.
694. On 30 July 2018, the Constitutional Court of 
Georgia ruled that imposition of administrative 
punishment for non-medical consumption of cannabis 
was unconstitutional, as it would violate the right of the 
person to “free development”. The Court ruled that the 
consumption of cannabis would still be illegal if it 
presented “a threat to third persons”, including consump-
tion in schools, certain public spaces and public trans-
portation, or in the proximity of children and minors. 
The Inter-Agency Coordinating Council for Combating 
Drug Abuse, chaired by the Minister of Justice, is 
working on the legislative amendments to implement the 
decision of the Constitutional Court.
695. In October 2017, Azerbaijan adopted changes to 
its criminal legislation removing criminal penalties for 
minor drug offences committed by drug-dependent per-
sons who had not committed any other offences and were 
prepared to undergo treatment. In addition, in November 
2017, the country revised its administrative code to 
strengthen sanctions for trafficking in precursors.
4.  Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
696. Heroin supply from Afghanistan to destination 
markets seems to have remained stable over recent years 
through the end of 2016, despite the substantial fluctua-
tions in the annual amounts of opium poppy cultivation 
in Afghanistan. This could be observed on the basis of 
heroin seizures along the major trafficking routes as well 
as the prices of heroin and its use in destination markets 
during that period. According to UNODC, in order to 
ensure the stability of supply, heroin may have been manu-
factured using opium from different harvests, depending 
on the existence of opium inventories and market 
strategies. More recent price data (up to June 2018) 
showed significant declines in opium prices in Afghanistan 
as opium production in the country soared in 2017. 
Heroin prices in Afghanistan, in contrast, remained 
largely stable in 2017 and in the first half of 2018. This 
suggests that increased opium production has not yet 
resulted in massive increases in heroin manufacture in 
Afghanistan.
697. The main trafficking route for opiates originating 
in Afghanistan remains the Balkan route, accounting for 
37 per cent of global heroin seizures in 2016, which runs 
through the Islamic Republic of Iran, Turkey and the 
Balkan countries to destination markets in Western and 
Central Europe. Authorities in Turkey believe that signif-
icant increases in heroin seizures, coupled with an 
increase in acetic anhydride seizures on its territory, may 
indicate that increased amounts of heroin could have 
been entering European drug markets in the period 
2017–2018. Turkey seized 17.7 tons of heroin in 2017 and 
5.5 tons in 2016. Almost 9.5 tons of heroin were seized 
between January and June 2018. Turkey also seized 933 kg 
of opium in 2017 and 337 kg in 2016. In 2017 and early 
2018, Turkey reported increased use of trucks with 
Iranian number plates arriving from the Islamic Republic 
of Iran to traffic substantial amounts of heroin into 
Turkey in transit to destination markets in Europe. In 
addition, according to its analysis, Turkey concluded that 
the opium seized on its territory was destined for illicit 
markets in Australia, Canada and the United States.
698. Some of the heroin seized in Europe transited 
Pakistan, trafficked directly from that country by air or 
sea to Europe. At the same time, opiates are being traf-
ficked from Pakistan to the Islamic Republic of Iran for 
trafficking to European markets along the Balkan route. 
The vast majority of morphine and heroin seized in the 
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Islamic Republic of Iran entered the country from 
Pakistan. Pakistan seized 24.4 tons of heroin in 2017 com-
pared with 23.1 tons in 2016, and it saw a reduction in 
opium seizures, from 64.6 tons in 2016 to 40 tons in 2017. 
Seizures of opium and heroin in the Islamic Republic of 
Iran in 2017 saw a slight increase relative to 2016 levels 
(436.6 tons of opium seized in 2017 compared with 
475 tons seized in 2016; and 23.7 tons of heroin seized 
in 2017 compared with 21 tons seized in 2016).
699. In 2017, Afghan opiates continued to be trafficked 
along a sub-branch of the Balkan route, going from the 
Islamic Republic of Iran to the Southern Caucasus, then 
to Ukraine via the Black Sea towards Eastern Europe.
700. There has been an increase in the use of air routes 
to smuggle heroin out of Afghanistan. In response to that 
development, the Government of Afghanistan established 
the Airport Interdiction Unit at Hamid Karzai International 
Airport. The Unit reported that in 2017, 191 smugglers 
had been arrested at the country’s international airports, 
with seizures of heroin totalling 140 kg. The smugglers 
were bound almost exclusively for New Delhi.
701. Central Asian States located along the northern 
route continued to be used for heroin trafficking from 
Afghanistan to the markets in the Russian Federation 
and, to a more limited extent, in Belarus and Lithuania. 
There were individual incidents in China of seizures of 
heroin trafficked from Central Asian countries.
702. The main modes of transportation used in smug-
gling heroin from Central Asia into the Russian Federation 
remain road, rail and air traffic. Increased economic inte-
gration through the Eurasian Customs Union could 
potentially create a risk of increased drug trafficking 
among Belarus, Kazakhstan, Kyrgyzstan and the Russian 
Federation. The simplification of customs requirements 
and the easing of border control measures would enable 
the increased movement of goods and services but may 
also create additional risks of drug trafficking in that 
subregion.
703. At the same time, most countries in Central Asia 
report either stable or declining levels of trafficking in 
opiates through their territories, and those reports are 
supported by the overall decline in seizures of opiates and 
a reduction in heroin use in recent years. However, it is 
unclear whether this means that the flow through the 
northern route has diminished, because there are only 
limited data on average heroin purity, prices and daily 
consumption and insufficient estimates of opiate users 
and assessments of trafficking methods.
704. Opiate seizures in Central Asia are concentrated in 
Tajikistan, where, it is assumed, most of the drugs cross 
the border from Afghanistan through the northern route, 
destined for markets in the Russian Federation and else-
where in Europe. The average annual heroin seizure in 
the period 2013–2017 was highest in Kazakhstan (391 kg), 
followed by Tajikistan (338 kg) and Kyrgyzstan (229 kg), 
while Uzbekistan (99 kg) and Turkmenistan (3 kg) had 
lower averages, which could indicate that drug traffickers 
prefer the branch of the drug trafficking route that runs 
through Tajikistan, Kyrgyzstan and Kazakhstan. Annual 
heroin seizures in the subregion decreased by 34 per cent 
in 2017 compared with 2016. Opium seizures were 
stable at around 2.3 tons in Central Asia between 2013 
and 2017.
705. There is limited opium poppy cultivation and pro-
duction in Central Asia, as over 99 per cent of opiates in 
the subregion originate in Afghanistan. The law enforce-
ment agencies of the Central Asian countries reported 
that there were no production facilities in the subregion 
for converting opium into heroin and that all opiates 
transiting Central Asia were processed in Afghanistan or 
elsewhere.
706. Another route for trafficking in Afghan opiates, 
which accounts for about 9 per cent of opiates trafficked 
to Europe, is the southern route, which runs from 
Afghanistan to Pakistan for trafficking onward by air and 
sea through Gulf countries and East Africa to markets in 
Europe. At the same time, illicit drugs are being trafficked 
from Afghanistan to India and other countries in South 
Asia, destined for markets in Europe and North America.
707. In May 2018, the Ministry of Counter-Narcotics of 
Afghanistan and UNODC released the report devoted to 
sustainable development, peace and security of the 
Afghanistan Opium Survey 2017. According to that report, 
a substantial increase in potential opium production in 
2017, of almost 87 per cent, reaching a record 9,000 tons, 
resulted in the growth of the illicit opiate economy. The 
total gross value of the opiate economy in 2017 was esti-
mated at between $4.1 billion and $6.6 billion, which is 
the equivalent of 20–32 per cent of the country’s gross 
domestic product, and the farm-gate value of opium pro-
duction was $1.4 billion. The value of the opiate econ-
omy81 was much higher than the value of the country’s 
licit exports of goods and services in 2016. Political 
81 The value of the opiate economy (gross) is the sum of the value of 
the domestic market and the value of opiates believed to be exported, 
including the value of the imported precursor substance acetic anhydride 
(see UNODC and Ministry of Counter-Narcotics of Afghanistan, 
Afghanistan Opium Survey 2017: Challenges to Sustainable Development, 
Peace and Security (Kabul, 2018), p. 5).
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instability, lack of government control and poor security 
have been found to be the main drivers of illicit cultiva-
tion. It is believed that the Taliban and anti-government, 
insurgent and powerful local power-holders have contin-
ued to benefit from “opium taxes” on the farm-gate value 
of opium production, amounting to an estimated total of 
$74 million in 2017. At the same time, opium poppy has 
become a substantial component of the livelihoods not 
only of farmers but also of the people of many commu-
nities in Afghanistan who engage in cultivation, work in 
poppy fields or play a role in the illicit drug trade.
708. According to the above-mentioned report, the 
reduction of illicit crop cultivation depends on the 
achievement of broader development goals, such as well-
established and strong State institutions for effective gov-
ernance, and functioning social protection mechanisms. 
The report concludes that addressing the opiate problem 
in Afghanistan remains a shared responsibility requiring 
a global approach that targets all stages of the supply 
chain of opiates, from source to destination.
709. Saudi Arabia reported that, in 2017, it had wit-
nessed an increase in the smuggling of illicit substances 
through express mail. The country attributes this trend to 
the weakness of the procedures of inspection and verifi-
cation in the countries of origin. In addition, the coun-
try reported the continuation of the trend of people 
hiding drugs inside their bodies. The country also wit-
nessed an increase in trafficking in heroin through its ter-
ritory, with 106 kg of the substance seized in 2017 and 
60 kg seized in 2016.
710. There is small-scale illicit cannabis plant cultiva-
tion and large areas of wild cannabis growth in Central 
Asia. Cannabis is produced primarily for local consump-
tion, with a lesser portion trafficked to markets in Europe 
and the Russian Federation. Central Asian law enforce-
ment agencies seized over 36 tons of cannabis and more 
than 4 tons of cannabis resin in 2017. Since only limited 
information is available on seizures of cannabis and can-
nabis resin of Afghanistan, it is not possible to accurately 
estimate the full scale of trafficking in these substances 
along the northern route. Tajikistan was responsible for 
55 per cent of total cannabis resin seizures in the sub-
region in 2017.82 In 2017, as in the previous year, the por-
tion of cannabis and cannabis resin seizures in the total 
volume of seized drugs was highest in Kazakhstan, 
Kyrgyzstan and Tajikistan, while most of the seized drugs 
in Turkmenistan and Uzbekistan were opiates.
82 Domestic cannabis resin production is much less in Tajikistan than 
in Kyrgyzstan and Kazakhstan.
711. In the Southern Caucasus, comprising Azerbaijan, 
Armenia and Georgia, cannabis seizures continued to 
increase over the period 2013–2017, while cannabis resin 
seizures for the same period continued to decline. Both 
those trends have been driven mainly by the drug seizure 
statistics reported by Azerbaijan.
712. The production of cannabis resin in Afghanistan is 
on the rise. Afghanistan has been reported to UNODC 
as the source of seized cannabis resin by 19 per cent of 
countries that reported the source of seized cannabis resin 
in the period 2012–2016, in particular in Central Asia, 
the Southern Caucasus and Europe. For 2016, Afghanistan 
reported a doubling of cannabis resin seizures, to 352 tons, 
and, thus, for the first time ever, was the country with 
the largest total cannabis resin seizures worldwide. In 
December 2017, the NATO Special Operations Command 
issued a press release that reported the seizure of 34 tons 
of raw cannabis resin and 300 kg of processed cannabis 
resin in Afghanistan during a raid carried out jointly with 
the National Interdiction Unit of the Afghan National 
Police. According to NATO, those raids were aimed at 
addressing the sources of income of the Taliban; the con-
fiscated cannabis resin would have represented $5.6 mil-
lion in potential revenue for the Taliban.
713. Lebanon also continues to be a source of cannabis 
resin seized globally, with 7 per cent of reporting coun-
tries identifying Lebanon as the source of cannabis resin 
seized on their territory. Prolonged conflict in the Middle 
East has contributed to the continued increase in produc-
tion in Lebanon. Farmers reported that their trade has 
grown by 50 per cent since 2012, because Lebanese 
authorities have had to focus their efforts on ensuring 
border security. Lebanese authorities seized 15 tons of 
cannabis resin in June 2018, which was intended for 
smuggling from Lebanon to Libya and then to Egypt. As 
far as cannabis is concerned, official data available to the 
Board suggest a partial reduction in seizures of cannabis 
in Lebanon, from 7.6 tons in 2016 to 6.3 tons in 2017. 
714. The reporting period has seen more reports of traf-
ficking in and, more importantly, the illicit production of 
drugs in Iraq, further confirming earlier indications of a 
shift towards illicit drug production in the country. There 
have been reports of illicit opium poppy and cannabis 
plant cultivation in the country. There have also been 
indications that heroin is being produced in northern 
Iraq, indications that are supported by the increase 
observed in the amount of seized heroin being moved in 
the direction of Turkey and the considerable amounts of 
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acetic anhydride destined for Iraq seized in the western 
border region of Turkey.
715. Drug trafficking and abuse in the Basra region of 
Iraq, which borders Iran (Islamic Republic of) and 
Kuwait, have increased substantially in recent years. Since 
late 2014, arrests for drug trafficking and drug use have 
nearly doubled in Basra as compared with the period 
2011–2014. Large amounts of drugs are being seized in 
containers at Basra ports and border crossings. 
716. Kuwait witnessed substantial increases in cannabis 
trafficking into or through its territory, as evidenced by the 
seizure of 4 tons of cannabis in 2017, compared with the 
1.2 tons seized in 2016. The same trend was observed in 
Bahrain, where 324 kg of cannabis was seized in 2017, 
compared with the 134 kg seized in the country in 2016. 
Turkey saw substantial increases in trafficking in cannabis 
resin, seizing 81 tons in 2017, compared with 36 tons in 
2016. At the same time, Turkey seized less cannabis in 
2017, namely 94 tons, whereas in 2016 it had seized 110 tons. 
Turkey witnessed a significant increase in trafficking in 
“skunk”, a highly potent form of cannabis, resulting in 
6.5 tons of that substance being seized in 2017, a fourfold 
increase from the previous year. The quantities of “skunk” 
seized in Turkey originated in Europe (mostly the 
Netherlands) and had been smuggled from Central and 
South-Eastern European countries, in particular Greece.
717. According to UNODC, the quantity of cocaine 
seized in West Asia doubled in 2016. Most cocaine seized 
in the region seems to have departed from or transited 
through Brazil. There were also some major incidents of 
cocaine trafficking in the period 2017–2018. In January 
2018, customs officers at Hamad International Airport in 
Doha seized 7.25 kg of cocaine from a passenger arriv-
ing on a direct flight from Latin America. Reports relat-
ing to another incident of a seizure of cocaine at the 
international airport in Bali, Indonesia, in March 2018 
suggest that Hamad International Airport in Doha was 
used as a transit point for the smuggling of that drug 
from Colombia. The United Arab Emirates has also been 
often used as a transit point for trafficking in cocaine in 
the region; countries in Asia, including Israel, were cited 
as the main destinations. Saudi Arabia witnessed a par-
tial reduction in seizures of cocaine on its territory, from 
842 kg in 2016 to 520 kg in 2017. 
718. Turkey saw a substantial increase in seizures of 
cocaine in its territory: 1.5 tons of cocaine were seized in 
2017, compared with 845 kg in 2016. Turkey reported 
that Istanbul Atatürk Airport had frequently been used 
for trafficking in cocaine that had arrived directly from 
South American countries, such as Brazil, Colombia and 
Venezuela (Bolivarian Republic of), or that had transited 
through African countries, such as Nigeria and South 
Africa. Similarly, Pakistan saw a substantial increase in 
seizures of cocaine, equalling 415 kg in 2017 compared 
with 231 kg in 2016. 
719. The total area under opium poppy cultivation in 
Afghanistan in 2018 was estimated at 263,000 ha, repre-
senting a 20 per cent decrease from 2017, when 328,000 
ha had been used for opium poppy cultivation. According 
to the Afghanistan Opium Survey 2018, that decrease 
could be attributed to the severe drought that has affected 
Afghanistan, especially in the northern and western 
regions of the country. The survey suggests that, follow-
ing a fall in the farm-gate prices of dry opium in 2017, 
there was a substantial drop in such prices in 2018, which 
hit their lowest level since 2004. In addition, it was esti-
mated that potential opium production was about 
6,400 tons in 2018, compared with 9,000 tons in 2017, 
representing a decrease of 29 per cent. 
720. Most (69 per cent) of opium poppy cultivation 
continued to take place in the southern region of the 
country, followed by the western region (12 per cent). The 
eastern and northern regions accounted for 8 per cent 
and 7 per cent of total cultivation, respectively. Despite 
the decrease in 2018, the area under opium poppy culti-
vation remained at very high levels in 2018, and was in 
fact at the second highest level since 1994, when the 
monitoring of illicit crop cultivation began. 
(b) Psychotropic substances
721. According to the UNODC “Central Asia synthetic 
drugs situation assessment 2017”, seizures of amphetamine-
type stimulants in Central Asia have remained at relatively 
low levels compared with other drugs. “Ecstasy” appears 
to be the most prevalent amphetamine-type stimulant 
appearing in use and trafficking data, and there have been 
sporadic reports of methamphetamine trafficking and 
manufacture over the years. It appears that the countries 
of the subregion do not have local illicit manufacture of 
amphetamine-type stimulants. It also appears that the sub-
region is used mainly as a transit point for trafficking in 
such stimulants, for example, from the Islamic Republic of 
Iran and from European countries (Germany, in particular) 
to Asia. Amphetamine-type stimulants are also being 
trafficked between the Russian Federation and Central 
Asian countries, such as Kazakhstan and Uzbekistan. 
Finally, the collection of data on amphetamine-type 
stimulants in the subregion is not comprehensive and 
remains sporadic due to the limited analytical capacities 
and varying drug control priorities in the subregion.
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722. In a reverse of the trend reported the previous year, 
the Islamic Republic of Iran witnessed a 30 per cent 
increase in methamphetamine seizures in 2017, a total of 
2.3 tons, compared with 1.7 tons in 2016. Armenia con-
tinued to seize increasing amounts of methamphetamine, 
reported to have been trafficked into the country mainly 
from the Islamic Republic of Iran. 
723. Instability and conflicts in the Middle East, cou-
pled with a lack of effective interdiction capacities, con-
tinued to contribute to trafficking in counterfeit 
“captagon”83 in the subregion. According to various 
reports, including from the scientific community, it has 
become a drug of choice in war zones in the Middle East, 
given its use in combat situations. In addition, the lack 
of control and monitoring has led to an increase in the 
manufacture of “captagon” tablets in certain countries in 
the Middle East, potentially serving as a source of income 
for the terrorist and insurgency groups in the 
subregion. 
724. Although official data on trafficking in “captagon” 
remain scarce, there has been some media coverage of 
certain notable seizures. In two separate incidents, in 
January and March 2018, customs authorities of Saudi 
Arabia foiled attempts to smuggle “captagon” tablets into 
the country. A total of about 6.3 million tablets of the 
substance were recovered during those operations at the 
border with Jordan. Jordan, for the first time, dismantled 
a clandestine laboratory manufacturing “captagon”, and 
95 per cent of the substance manufactured was destined 
for markets in neighbouring countries. Saudi Arabia also 
reported that “captagon” seized in 2017 originated in 
India and had transited Egypt with Saudi Arabia as its 
destination. Saudi Arabia has also seen an increase in traf-
ficking in methamphetamine into its territory. In 2017, 
the United Arab Emirates seized 45 million tablets of 
“captagon”. Turkey reported that it continued to be used 
as a transit country for trafficking in “captagon” manu-
factured or marketed in the Middle East, particularly in 
the Syrian Arab Republic, including by terrorist and 
insurgency groups. Some 599 bags of “captagon” were 
seized by law enforcement officers in the Basra region of 
Iraq, near the Kuwaiti border, in November 2017, from 
what is believed to be one of the largest smuggling 
operations in recent years.
83 Captagon was originally the official trade name of a pharmaceuti-
cal preparation containing the substance fenetylline, a synthetic stimu-
lant. As encountered in seizures across West Asia today and referred to in 
the present report, “captagon” is a counterfeit drug compressed into pills 
or tablets that are similar in appearance but distinct in composition from 
the earlier pharmaceutical preparation Captagon. The active ingredient in 
counterfeit “captagon” is amphetamine, which is typically cut with multi-
ple adulterants such as caffeine and other substances.
725. The amounts of methamphetamine seized have 
continued to increase in Afghanistan, with 121 kg seized 
in 2017. In addition, three methamphetamine manufac-
turing laboratories were dismantled in 2017. Afghanistan 
also seized 2,322 MDMA tablets in 2017. Tajikistan 
reported that, in 2017, it had seized 7.5 kg of powdery 
methamphetamine (no seizure of such substance had 
been recorded in the country since 2012), believed to 
have been smuggled into the country from Afghanistan.
(c) Precursor chemicals
726. Central Asian country borders with China and 
Afghanistan make the subregion particularly vulnerable 
to trafficking in precursors. Because of the substantial 
amounts of precursors needed for opium processing, 
especially in the recent years of record cultivation levels 
in Afghanistan, the precursors must be shipped in large 
volumes. Since large consignments of precursors cannot 
be moved over many mountainous borders, they must 
instead be trafficked by established roads and railways, in 
order to be shipped in large volumes. However, informa-
tion available on precursor trafficking in Central Asia is 
insufficient to estimate the scale of that trafficking, since 
no movements have been detected in the past decade.
727. Central Asian countries and Azerbaijan continued 
to carry out seizures of precursors on their territories, not 
all of which were intended for the manufacture of illicit 
drugs but which were used or imported for other pur-
poses without appropriate authorization. Azerbaijan 
seized 5.5 kg of potassium permanganate in eight sepa-
rate seizures in 2017, mostly smuggled from the Islamic 
Republic of Iran. The precursors were packed in plastic 
bags or put in glass bottles. Also in 2017, Kazakhstan 
seized 5.48 litres of precursors, while Kyrgyzstan seized 
more than 1.1 tons of hydrochloric acid and 1.7 tons of 
sulfuric acid. In the same year, Tajikistan carried out 10 
seizures of sulfuric acid, totalling 876 kg, which were in 
production shops and intended for the refuelling of car 
batteries and not for the illicit manufacture of drugs. 
Uzbekistan seized 23 litres of acetone and 3.6 kg of 
potassium permanganate in 2017.
728. The Counter-Narcotics Police of Afghanistan con-
tinue to emphasize that precursors were mainly trafficked 
through Iran (Islamic Republic of) and Pakistan. 
Smugglers were also developing new methods of trans-
porting precursors into Afghanistan, such as concealing 
them among consumer goods or among other licit chem-
icals (engine oil and antifreeze). At the same time, Turkey 
reported a significant increase in seizures of acetic anhy-
dride, a key precursor used to produce heroin, totalling 
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over 23,000 litres in 2017, compared with 1,588 litres in 
2016. Between January and June 2018, over 34,000 litres 
of acetic anhydride were seized, indicating a further surge 
in trafficking in that precursor. The authorities in Turkey 
reported that acetic anhydride seized in the country 
mostly originated in Central and Western Europe (mostly 
Germany and the Netherlands) and transited Turkey on 
the way to Iran (Islamic Republic of) and Iraq.
729. Seizures of precursors in Afghanistan continued to 
increase, as the country seized 53,046 kg of solid precur-
sor chemicals and 77,272 litres of liquid precursor chem-
icals in 2017. The operations also resulted in the 
dismantling of 50 heroin laboratories. This could be 
another explanation of the steady heroin prices in 2017 
despite the record opium poppy cultivation in Afghanistan. 
A comprehensive review of the situation with respect to 
the control of precursors in the region can be found in 
the report of the Board for 2018 on the implementation 
of article 12 of the 1988 Convention.
(d)  Substances not under  
international control
730. There is still relatively limited information availa-
ble on trafficking in and abuse of new psychoactive sub-
stances in most countries of West Asia owing to the lack 
of monitoring and analysis capacities in the countries of 
the region. 
731. The “Central Asia synthetic drugs situation 
assessment 2017”, published by UNODC in December 
2017 provides some of the latest available information on 
synthetic drugs in Central Asia, including new psychoactive 
substances. Almost all countries in the subregion reported 
the emergence of a growing number of new psychoactive 
substances, indicating that the subregion is linked to 
international trafficking in these substances. 
732. Between 2013 and 2016, a total of 58 new psycho-
active substances were reported by the authorities of 
Kazakhstan, Kyrgyzstan, Tajikistan and Uzbekistan. More 
than 43 per cent of reported new psychoactive substances 
were synthetic cathinones, with synthetic cannabinoids 
accounting for 38 per cent and phenethylamines making 
up 10 per cent of the total new psychoactive substances 
reported. Ketamine and phencyclidine-type substances, 
tryptamines, piperazines, aminoindanes and other new 
psychoactive substances were reported only once by 
countries in the subregion. While only one new psycho-
active substance was reported in the subregion (by 
Tajikistan) in 2013 and another (by Kazakhstan) in 2014, 
the number of new psychoactive substances reported 
increased to 31 in 2015 and to 48 in 2016. The trend is 
mainly dictated by dynamics in Kazakhstan, which 
reported an increase from 1 new psychoactive substances 
in 2014, to 21 in 2015 and 38 in 2016. Uzbekistan also 
observed an increase, from 3 new psychoactive sub-
stances in 2015 to 8 reported in 2016. Kyrgyzstan reported 
the emergence of new psychoactive substances for the 
first time in 2015. Tajikistan has reported the emergence 
of two or fewer new psychoactive substances annually 
since 2013.
733. The Central Asian subregion borders countries 
with dynamic markets for synthetic drugs, such as China, 
Iran (Islamic Republic of) and the Russian Federation, 
which could further stimulate the growth of this market 
in the subregion. For example, between 2013 and 2014, 
Kazakhstan reported seizures of synthetic cannabinoids 
smuggled by post, which were believed to have originated 
in China. The Russian Federation reported seizing new 
psychoactive substances that had been trafficked from or 
were to be trafficked to Kazakhstan and Uzbekistan. 
Although the countries in the subregion are taking steps 
and legislative measures and are improving their forensic 
capabilities to address new psychoactive substances, these 
efforts remain uneven across the whole subregion. This 
development argues in favour of the adoption of a com-
prehensive regional approach to the issue by strengthen-
ing regional cooperation and information exchange, 
including through the possible establishment of a sub-
regional early warning mechanism.
734. In 2017, Jordan put the following substances under 
control; AB-FUBINACA, N-ethylpentylone and pregabalin 
and its preparations. Saudi Arabia put carfentanil under 
control. Armenia put pregabalin under national control in 
2017. In May 2017, Turkey put 138 central nervous system 
depressants under national control owing to a recent 
increase in the number of those new psychoactive sub-
stances, and in August of the same year a further 31 new 
substances were put under control in the country.
735. Many countries in the Middle East continued to 
observe trafficking in and abuse of tramadol, a synthetic 
opioid not under international control. In February 2018, 
law enforcement authorities in Saudi Arabia dismantled an 
operation to smuggle 35,600 tramadol tablets. In 
November 2017, authorities in Italy seized 24 million trama-
dol tablets worth about €50 million euros in the Calabrian 
port of Gioia Tauro, en route to Libya from India, which 
were suspected of being destined for sale by ISIL to its 
fighters in North Africa and the Middle East. Increased 
misuse of and trafficking in tramadol have also been 
observed in Iraq, especially in the Basra region. There are 
also reports of tramadol that has possibly been adulterated 
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to produce a stronger psychoactive effect being smuggled 
alongside other drugs to the Gaza Strip, in the State of 
Palestine, through the tunnels that had been dug along the 
Egyptian border, leading to widespread abuse of and addic-
tion to that substance among young people. Despite report-
ing a drop in 2017 in overall trafficking in drugs into or 
through its territory, possibly owing to a blockage enforced 
by some countries in the subregion, Qatar intercepted a 
boat that was coming from the United Arab Emirates car-
rying 1.8 million tramadol tablets. There have been many 
reports of smuggling and abuse of tramadol in the Syrian 
Arab Republic, and of unregulated pharmacies in some 
parts of the country that are contributing to the widespread 
abuse of the substance.
5. Abuse and treatment
736. Most countries in the region continue to face prob-
lems with the availability of resources for conducting 
comprehensive and regular drug abuse surveys, making 
it difficult to assess the extent and trends in drug abuse 
in the region. 
737. Only a few individual country reports provide 
information on the drug abuse situation, and even that 
information is limited. Increased use of crystalline meth-
amphetamine was reported in Iraq for 2017. Kazakhstan 
reported that there is a growing trend of referrals to medi-
cal treatment of persons, mainly below 30 years of age, for 
abuse of synthetic cannabinoids, especially in its largest 
cities. Uzbekistan witnessed increased cases of con-
sumption of synthetic cannabinoids and pharmaceutical 
preparations, such as tramadol, nalbuphine (an opioid 
analgesic), zopiclone (a non-benzodiazepine hypnotic 
agent), tropicamide (a medication used to dilate the pupil 
and help with the examination of the eye, but prone to 
abuse by injection as a recreational drug), baclofen (a 
medication used to treat spasticity) and pregabalin in 2017 
among men aged 25 to 39 years old. Saudi Arabia reported 
an increase in the spread and abuse of methamphetamine, 
pregabalin and cannabis in the country in 2017.
738. According to media reports, the Ministry of Health 
of Afghanistan estimated that there were between 900,000 
and 1 million female drug addicts in the country, out of 
a total female population of 14.4 million, a prevalence rate 
that is three times that in 2010. According to statements 
from female drug users themselves, they have become 
addicted to illicit substances because of the influence of 
their spouses. They return to their drug use behaviour 
when they reunite with their families after treatment in 
rehabilitation/treatment centres in Afghanistan. One of 
the reasons for the consumption of and addiction to 
opium is the use of the substance as an unprescribed med-
icine for pain or small injuries, a practice that has been 
ongoing for centuries in the country. Opium is sometimes 
also given to children as a sedative.
739. UNODC observed that the highest prevalence of 
HIV among people who inject drugs is in South-West 
Asia, which has a rate that is 2.4 times the global average. 
South-West Asia, together with Eastern and South-Eastern 
Europe, account for 49 per cent of the total number of 
people who inject drugs worldwide living with HIV.
740. In November 2017, an assessment of illicit drug 
use (non-prescription drugs) was released in the State of 
Palestine, updating the previous 11-year-old data on drug 
abuse. In addition, UNODC is supporting the Ministry 
of Health of the State of Palestine in developing a com-
prehensive drug dependence treatment and care system 
and facilitating the establishment of the National 
Rehabilitation Centre of the State of Palestine. The prob-
lem of drug use has in recent years been mainly spread-
ing among young people and women, especially among 
family members of current drug users. 
741. That assessment estimated that 1.8 per cent of the 
male population aged 15 years and older were high-risk 
drug users. Most of these high-risk drug users were liv-
ing in the northern and southern parts of the West Bank, 
as well as the Gaza Strip. In the Gaza Strip, tramadol was 
the most commonly used substance, followed by benzo-
diazepines and methamphetamine. In the study sample 
of high-risk users, 97 per cent of respondents in the Gaza 
Strip reported the non-medical use of tramadol, while in 
the West Bank, amphetamines were the most consumed 
substances, followed by cannabis, anticonvulsants (mainly 
pregabalin) and benzodiazepines. Of the 26,500 high-risk 
drug users, 1,188 inject drugs, of which 81 per cent had 
started using drugs before turning 18 years old. Among 
the high-risk drug users, 4.2 per cent were people who 
inject drugs. In Gaza, cocaine was mostly injected by the 
high-risk drug users, while in the southern and central 
parts of the West Bank, heroin was the main drug injected. 
There was also found to be a significant prevalence of 
cannabis and cannabis resin use, as well as use of anti-
depressants and painkillers in high doses (methadone, 
morphine, phencyclidine, barbiturates, benzodiazepines, 
etc.) in the West Bank and East Jerusalem.
742. According to UNODC, Central Asian countries, as 
well as Armenia, Azerbaijan and Georgia, have high prev-
alence rates of past-year use of opiates (heroin and opium) 
(0.9 per cent of the population aged 15 to 64 years) 
among opioid users, while misuse of pharmaceutical opi-
oids such as tramadol is more prevalent in the Middle 
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East, as reflected in the number of people in treatment 
for abuse of tramadol and the number of tramadol over-
dose deaths. There is also concern about the increasing 
number of countries reporting methamphetamine use, 
especially among opioid users in West Asia. Several coun-
tries in the region reported increases in heroin use in 
2016, in particular Iran (Islamic Republic of), Iraq, Qatar 
and the United Arab Emirates, which could be due to an 
increase in trafficking in heroin from Afghanistan to 
those countries. In some other countries, including Israel, 
Jordan and Saudi Arabia, heroin use stabilized, and 
 stimulants abuse has been more prevalent. At the same 
time, based on available data for 2016, most countries in 
Central Asia have not yet been affected by the increase 
in Afghan heroin manufacture.
743. In general, synthetic drug use is not widespread in 
Central Asia, primarily due to economic factors, but is 
becoming more common because of the heroin deficit 
(i.e., more demand than supply) and the improvement of 
economic conditions in the subregion. Although a 
thorough assessment of this matter is required, the 
improvement of economic conditions, a developed licit 
chemical industry in the subregion and the availability of 
the Ephedra plant, containing ephedrine, which is a 
precursor to methamphetamine that grows in the wild 
across the Central Asian region, might all potentially 
stimulate the illicit manufacture of methamphetamine in 
the subregion. 
D. Europe
1. Major developments
744. The European drug problem is increasingly influ-
enced by developments in the drug control situation in 
countries bordering the region and worldwide. In the 
global context, Europe is a producing region for canna-
bis (mostly for local consumption) and synthetic drugs 
(for both local consumption and onward trafficking to 
other parts of the world). The region continues to be a 
major market for drugs originating in and trafficked from 
other parts of the world, including South America, West 
Asia and North Africa.
745. A wide range of new psychoactive substances that 
emerged on the European market more than a decade 
ago continues to be supplied mainly from China. There 
have, however, also been reports of the manufacture and 
tableting of such substances within the region. In 2017, 
more than 670 new psychoactive substances were being 
monitored under the European Union Early Warning 
System. With a view to responding to the public health 
and social threats posed by new psychoactive substances, 
in 2017, the European Parliament and the Council of the 
European Union passed new legislation that brought such 
substances into the official definition of a “drug” at the 
European Union level and streamlined the procedures for 
responding to them.
746. Seizures of illicit drugs are an important indicator 
of the size of drug markets. According to EMCDDA, the 
number of drug seizures in the European Union exceeded 
1 million in 2016. Seizures of cannabis, by number, 
accounted for 71 per cent of all seizures, followed by 
cocaine (9 per cent), amphetamines (5 per cent), heroin 
(4 per cent), “ecstasy” (3 per cent) and other drugs (8 per 
cent). Most reported seizures involved small quantities of 
drugs seized from drug users.
747. The importance of online markets as platforms for 
the marketing and distribution of illicit drugs continued 
to grow in recent years. It is estimated that about two 
thirds of all purchases on over 100 global darknet mar-
kets identified by EMCDDA and Europol were drug-
related. The suppliers of illicit drugs operating in European 
Union member States, in particular Germany, the 
Netherlands and the United Kingdom, accounted for 
almost one half of all drugs sold worldwide on 16 selected 
darknet markets that were monitored from 2011 to 2015. 
748. In the period 2016–2018, countries in the European 
Union became a major source of acetic anhydride seized 
within the region and in West Asia. The wider availability 
of acetic anhydride on the European black market could 
be one of the drivers of an emergence of illicit  heroin 
 laboratories, where morphine is converted into heroin, 
detected in several European Union member States.
749. Continued developments in drug use patterns and 
the need to provide treatment to drug-dependent persons 
increased the burden on national health systems in 
Europe. It is estimated that, in the European Union alone, 
over 1 million people receive treatment for drug-related 
problems every year. According to EMCDDA, in the last 
10 years, more than half of countries in the European 
Union reported comprehensive estimates for drug-related 
public expenditure, including costs of drug treatment. 
Total drug-related public expenditure was estimated to 
range from 0.01 to 0.5 per cent of gross domestic prod-
uct, with health expenditure accounting for 15–53 per 
cent of total drug-related expenditure. 
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2. Regional cooperation
750. The European Union supported countries in 
Central Asia in the fight against drugs through a trans-
regional programme entitled “EU Action against Drugs 
and Organised Crime (EU-ACT)” and the Central Asia 
Drug Action Programme. In 2017 and 2018, EMCDDA 
continued its support of that programme, the overall 
objective of which is the gradual adoption by the five 
countries in Central Asia (Kazakhstan, Kyrgyzstan, 
Tajikistan, Turkmenistan and Uzbekistan) of European 
Union and international good practice on drug policy, in 
order to contribute to the reduction of drug problems. 
The beneficiaries of the programme include policy makers, 
drug control experts, corrections and hospital staff and 
the general public.
751. In November 2017, a memorandum of under-
standing was signed between the Government of Belarus 
and the Government of Georgia on the establishment of 
a mechanism for the sharing of information to prevent 
trafficking in and the illicit movement of narcotic drugs 
and psychotropic substances.
752. A workshop on joint investigation teams and con-
trolled deliveries was held in Tbilisi from 26 February to 
2 March 2018. Representatives of law enforcement and 
customs authorities and prosecutor’s offices of Afghanistan, 
Armenia, Azerbaijan, Bulgaria, Georgia, Kazakhstan, 
Kyrgyzstan, the Republic of Moldova, Romania, Pakistan 
and Ukraine shared their experiences in combating drug 
trafficking and discussed measures to enhance future 
cooperation in drug control matters.
753. In June 2018, Bulgaria hosted the twentieth high-
level meeting of the Coordination and Cooperation 
Mechanism on Drugs of the European Union and CELAC. 
During the discussions, a particular focus was placed on 
joint measures to counteract drug trafficking over the 
darknet. Discussions were also held on measures to 
develop and implement programmes aiming at reducing 
demand for illicit drugs.
3.  National legislation, policy  
and action
754. During the reporting period, EMCDDA published 
a number of publications, technical reports, surveys and 
overviews that covered a wide range of drug control-
related topics, including a European guide on responding 
to drug problems, a report on European environmental 
prevention measures to limit unhealthy and risky sub-
stance use behaviours, an analysis of drug-related 
homicide in Europe, a policy briefing on cannabis and 
driving and a report on the growing threat of drugs and 
the darknet to health and security. 
755. In October 2017, EMCDDA released a report on 
new developments in national drug strategies in Europe. 
The report, prepared in consultation with experts and 
based on an analysis of national drug policies and scien-
tific literature, gives an overview of recent developments 
in key tools used to manage national drug policies, such 
as strategies, coordination mechanisms and evaluations. 
Among other things, the report points to a gradual change 
in national drug strategies towards a broader scope that 
goes beyond controlled substances and covers other sub-
stances and, to a lesser extent, other addictions.
756. On 15 November 2017, the relevant European 
Union institutions passed legislation that, while retaining 
the current three-step approach to responding to new 
psychoactive substances (namely, early warning, risk 
assessment and control measures), allowed for the signif-
icant strengthening of existing processes through the 
streamlining and accelerating of data-collection and 
assessment procedures. Pursuant to the new legislation, 
national authorities will have six months to place a sub-
stance under control on their territory once the decision 
of the Council of the European Union and the European 
Parliament on the substance enters into force. The legis-
lation will be applicable as of 23 November 2018.
757. In 2017, Estonia added the following 11 new psy-
choactive substances to schedule I of its national list of 
narcotic drugs and psychotropic substances: meclonaze-
pam; nifoxipam; ephenidine; 1-naphthalenyl(1-pentyl-
1H-indazol-3-yl)-methanone; 4-fluoroethylphenidate; 
metizolam; 1-propionyl-lysergic acid diethylamide; 
dimethylamylamine; CUMYL-4CN-BINACA; 6-ethyl-
6-nor-lysergic acid diethylamide (ETH-LAD); and 4-fluo-
romethylphenidate (4F-MPH). 
758. In December 2017, a new national strategy on seri-
ous and organized crime threat assessment was adopted 
in Montenegro. In the policy, the following six priority 
areas for the period 2018–2019 were identified: terrorism 
and religious extremism; drug trafficking; illegal migra-
tion; serious criminal offences arising from conflicts 
between organized crime organizations; unregulated and 
high-interest moneylending; and high-level corruption.
759. In April 2018, the Government of the Russian 
Federation adopted a resolution enforcing tighter controls 
over the movement of narcotic drugs, psychotropic sub-
stances and their precursors, to bring the regulatory acts 
into line with relevant international legislation. The 
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resolution was adopted for the purpose, among others, of 
exercising stricter controls over the circulation of the pre-
cursor 1-phenyl-2-nitropropene and of rescheduling the 
precursor diphenylacetonitrile from table III of catalogue 
IV to table II of catalogue IV of the list of precursors 
under control in the Russian Federation. 
760. In May 2018, the Council of the European Union 
decided to place two new synthetic cannabinoids, ADB-
CHMINACA and CUMYL-4CN-BINACA, under control 
in the 28 European Union member States. The substances 
had been available on the European drug market since at 
least 2014 and 2015, respectively. 
761. In March 2018, the Justice and Home Affairs 
Council adopted the European Council conclusions on 
alternatives to coercive sanctions for drug-using offend-
ers, with a view to preventing crime, reducing recidivism, 
enhancing the efficiency of the criminal justice system 
and minimizing social risks. Those alternative measures 
include education, suspension of investigation or prose-
cution, suspension of sentence with treatment, rehabilita-
tion and recovery and aftercare and social reintegration. 
762. In 2017, the Cannabis as Medicine Act, which 
regu lates the import, domestic production and  prescription 
of cannabis-based pharmaceutical products, including 
herbal cannabis, came into force in Germany. In the 
Netherlands, where new psychoactive substances are 
regu lated through amendments to schedules of the Opium 
Act, 4-fluoroamphetamine (4-FA), was listed in 2017, as 
a list I drug, because of reports of deaths related to use 
of the substance. The substance was placed in Schedule 
II of the 1971 Convention by the Commission on Narcotic 
Drugs in its decision 61/12 of 14 March 2018. In October 
2017, the Government of Luxembourg amended its drug 
control regulations by adding several psychoactive sub-
stances to the lists of narcotic drugs and psychotropic 
substances. Furthermore, in 2018, the Government of 
Luxembourg passed a bill allowing for the medical use of 
cannabis. In 2017, new legislation allowing control of syn-
thetic cannabinoids came into force in France. In Czechia, 
60 new psychoactive substances were added to the list of 
controlled substances. In 2018, 43 new psychoactive sub-
stances were added to the lists of controlled substances 
in Sweden.
763. The royal decree on controlled substances that 
entered into force in Belgium on 26 September 2017 ena-
bled the classification of controlled substances according 
to generic group definitions. The decree, among other 
things, introduced an exemption to the export authoriza-
tion requirement for psychotropic substances in case of 
humanitarian urgency by requiring only an a posteriori 
notification to the Federal Agency for Medicines and 
Health Products. 
764. A number of countries in Europe evaluate their 
drug policy and strategy through ongoing indicator moni-
toring and specific research projects. In 2017, Croatia 
evaluated its National Strategy on Combating Narcotic 
Drugs Abuse for the period 2012–2017. The results of the 
evaluation assisted the Government in developing a new 
drug strategy for the period beyond 2017.
765. In 2017, Ireland launched its national drug strat-
egy, entitled “Reducing harm, supporting recovery: a 
health-led response to drug and alcohol use in Ireland 
2017–2025”. The goals of the strategy include promotion 
and protection of health and well-being, minimization of 
the harms caused by substance abuse and promotion of 
rehabilitation and recovery, restriction of access to illicit 
drugs and development of comprehensive evidence-based 
policies and actions. 
766. The 2017 drug strategy of the United Kingdom, 
launched in July 2017, is aimed at reducing illicit and 
other harmful drug use and increasing the rates of peo-
ple recovering from dependency. In 2018, the Government 
of the United Kingdom announced a review of the sched-
uling of cannabis. The review will cover the medicinal 
and therapeutic benefits of cannabis and cannabis-based 
medicinal products, and will allow for an assessment to 
be made that balances harms and public health needs. 
The review will not cover the classification of cannabis as 
a class B drug, or any of the penalties for offences involv-
ing cannabis.
767. In the Netherlands, cannabis is sold openly in more 
than 500 so-called “coffee shops” operating in about a 
quarter of the 380 municipalities in the country. While 
the sale of cannabis under certain conditions in those 
outlets is tolerated, the supply of cannabis to the “coffee 
shops” is not permitted. This has created an illicit mar-
ket in cannabis production and wholesale distribution. In 
October 2017, the Government of the Netherlands 
declared its intention to permit an experiment on the 
legal supply of cannabis to “coffee shops” in up to 10 
municipalities. In March 2018, the Ministry of Justice and 
Security and the Ministry of Health, Welfare and Sport 
provided the country’s Parliament with details of the 
experiment, which will, among other things, require 
amendments to the drug control legislation, the designa-
tion of municipalities and cannabis growers and the 
establishment of a research consortium in order to facil-
itate a four-year period of cannabis production and sup-
ply of the substance to “coffee shops”. Following the 
completion of the experiment, the current regulations 
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governing the control of cannabis will be reinstated. The 
experiment, according to the authorities, is expected to 
allow for an evaluation of the impact of supplying 
 cannabis to “coffee shops” on public health, crime and 
public safety in the municipalities concerned.
768. The Board reiterates that the 1961 Convention, as 
amended, establishes in article 4 that the parties to the 
Convention are to take such legislative and administra-
tive measures as may be necessary to give effect to and 
carry out the provisions of the Convention within their 
own territories and to limit exclusively to medical and 
scientific purposes the production, manufacture, export, 
import, distribution of, trade in and use and possession 
of drugs.
4.  Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
769. Cannabis remains the most widely used drug in 
Europe. The drug accounts for the largest share (38 per 
cent) of the illicit drug retail market in the European 
Union, which in 2013 was estimated to be worth 24 bil-
lion euros. Herbal cannabis is both cultivated within 
Europe, mostly indoors, and trafficked from third coun-
tries. Cannabis resin is mostly trafficked from Morocco 
but is increasingly produced in Europe itself. 
770. In 2016, 763,000 seizures of cannabis products 
were reported in the European Union, including 420,000 
seizures of herbal cannabis, 317,000 seizures of cannabis 
resin and 22,000 seizures of cannabis plants. Spain, as a 
major point of entry for cannabis resin produced in 
Morocco, continued to account for most of the quantity 
of cannabis resin seized in the European Union in 2016. 
The countries in Europe that reported seizing more than 
1 ton of cannabis resin in 2017 were Spain (334.9 tons), 
France (57.4 tons), Italy (18.7 tons), Portugal (14.8 tons), 
Greece (6.3 tons), the United Kingdom (6.3 tons), Sweden 
(3.2 tons), Lithuania (2.1 tons), Norway (2.0 tons), Poland 
(1.2 tons) and the Russian Federation (1.1 tons). Seizure 
data for 2017 for some countries in Europe that have 
repeatedly reported cannabis resin seizures exceeding 
1  ton, notably Denmark and the Netherlands, were not 
available at the time of drafting the present report.
771. Seizures of cannabis plants may indicate its culti-
vation within a country. In 2017, seizures and eradication 
of cannabis plants illicitly cultivated outdoors and/or 
indoors were reported in most countries in the region, 
including a number of States members of the European 
Union, as well as Albania, Andorra, Bosnia and 
Herzegovina, Montenegro, the Russian Federation and 
Ukraine.
772. In Slovakia, both illicit outdoor and indoor canna-
bis cultivation for local use and trafficking abroad 
increased by 40 per cent during the reporting year. In 
Sweden, illicit cultivation has significantly decreased since 
its peak in 2014. That decrease is possibly a result of inter-
diction efforts taken by law enforcement authorities and 
of an increase in trafficking in cannabis products pur-
chased on the Internet into the country. 
773. Montenegro has emerged as an entry point and 
transit country for drugs being trafficked towards Western 
European markets. Despite having a small domestic mar-
ket, a slight increase in cannabis use was reported in 
Montenegro in 2017 owing to trafficking from neighbour-
ing Albania — a major cannabis producer in Eastern 
Europe — and also to small-scale local production. In 
2017, a new record of cannabis seizures was reached in 
the country, totalling 2.65 tons. The seizures were mainly 
of cannabis herb originating in Albania. 
774. In Belarus, the total amount of narcotic drugs and 
psychotropic substances seized by customs authorities in 
2017 increased by 60 times compared with 2016, accord-
ing to the Chair of the State Customs Committee. 
775. The potency of both herbal cannabis and cannabis 
resin has largely increased in countries of the European 
Union since 2006. While the content of THC in herbal 
cannabis stabilized at about 9–12 per cent in around 2013, 
THC content in cannabis resin continued to increase, to 
14–21 per cent in 2016. In 2016, the black-market price 
of both drugs was almost the same, in the range of 
8–12 euros and 9–13 euros per gram, respectively. 
776. Owing to the wide availability of heroin, primar-
ily sourced in Afghanistan, the illicit manufacture of 
 opioids in Europe has until recently been limited to 
home-made opium poppy products manufactured in 
some countries in Eastern Europe. The identification of 
several laboratories converting morphine to heroin in 
Czechia, the Netherlands and Spain in recent years sug-
gests that some heroin is now manufactured in Europe. 
The total amount of heroin seized in the European Union 
was 4.3 tons in 2016 and 4.5 tons in 2015. In 2017, 
 seizures of heroin larger than 100 kg were reported by 
the United Kingdom (845 kg), Bulgaria (698 kg), Italy 
(610 kg), Spain (524 kg), Greece (359 kg), Germany 
(298  kg) and Ukraine (110 kg). Bulgaria also reported 
seizures of sizeable amounts of morphine (221 kg). 
100  INCB REPORT 2018
According to authorities in Portugal, Mozambique might 
have become a new transit point for heroin being traf-
ficked into the country.
777. Other opioids available on the illicit European 
market include opium, medicinal morphine, methadone, 
buprenorphine, tramadol, fentanyl and fentanyl-related 
substances. Some opioids may have been diverted from 
legitimate pharmaceutical sources, while others may have 
been illegally manufactured. In 2017, seizures of diverted 
and/or illicitly manufactured substances of both types of 
origin were reported by Estonia, Finland, Norway, 
Portugal, Romania, Slovakia and Sweden, among others.
778. According to EMCDDA, the increase in cocaine 
manufacture in South America may have had an impact 
on the European Union market. While cocaine prices in 
countries of the European Union have remained stable, 
the purity of the drug is at its highest level in over a 
 decade; also of concern is the increased availability and 
use of “crack” cocaine. Wastewater analyses show increases 
in cocaine consumption in some locations in Europe over 
the period 2011–2017, notably in 2016 and 2017.
779. Cocaine is transported to Europe by various means, 
including passenger flights, air freight, postal consign-
ments, private aircraft, yachts and maritime containers. 
The total amount of cocaine reported seized within the 
European Union in 2016 was 70.9 tons. Given that 
Belgium (30 tons) surpassed Spain (15.6 tons) as the 
country with the largest amount of cocaine seized in the 
European Union in 2016, the importance of cocaine traf-
ficking routes to Europe through the Iberian Peninsula 
may have slightly declined in favour of ports in other 
European countries. In 2017, the countries reporting sei-
zures of cocaine hydrochloride of 1 ton or greater were 
Belgium (44.8 tons), Spain (41 tons), France (17.5 tons), 
Germany (8.2 tons), the United Kingdom (5.7 tons), Italy 
(4.1 tons) and Portugal (2.7 tons). However, seizure data 
for several European countries, including the Netherlands, 
were not available at the time of drafting the present 
report.
(b) Psychotropic substances
780. Amphetamine and methamphetamine are among 
the synthetic stimulant drugs illicitly manufactured in the 
European Union for the local illicit market, although some 
amphetamine in the region is also destined for markets in 
the Middle East, East and South-East Asia and Oceania. 
Most amphetamine manufacture is reported from Belgium, 
the Netherlands and Poland, and to a lesser extent 
Germany and the Baltic countries. In 2016, seizures of 
amphetamine reported by the European Union member 
States amounted to 5.7 tons. Overall, the quantity of 
amphetamine seized in the European Union has been 
 stable since 2010, fluctuating around 5 to 6 tons per year. 
Germany (1,669 kg), the United Kingdom (1,356  kg), 
Sweden (892 kg), Poland (582 kg), France (439 kg), 
Norway (427 kg), Bulgaria (400 kg), the Russian Federation 
(393 kg), Finland (203 kg) and Belgium (128  kg) were 
among the countries in Europe that reported seizures of 
amphetamine higher than 100 kg in 2017. 
781. Although the availability of methamphetamine has 
increased over the last decade in the European Union, it 
is still much lower than that of amphetamine. Most of 
the illicit manufacture of methamphetamine in the region 
takes place in Czechia, and to some extent at the border 
areas of its neighbouring countries. In 2016, of the 291 
illicit methamphetamine laboratories reported dismantled 
in the European Union, 261 were in Czechia. The pre-
dominant precursor chemical used in those laboratories 
was pseudoephedrine, extracted from medicinal products 
trafficked mainly from or through Poland. While the 
manufacture of methamphetamine was mostly confined 
to small-scale laboratories, large-scale manufacture of the 
drug destined for other countries in the region was also 
reported. In 2016, seizures of methamphetamine reported 
within the European Union amounted to 0.5 tons. In 
2017, seizures of methamphetamine larger than 50 kg 
were reported by the Russian Federation (1,131 kg), 
France (123 kg), Germany (114 kg), Czechia (93 kg), 
Norway (76 kg), Italy (57 kg), Finland (56 kg) and 
Slovakia (51 kg).
782. In Czechia, the illicit manufacture of methamphet-
amine remained stable, and 264 methamphetamine labo-
ratories were identified in 2017. Of those, 19 were 
considered medium-large-scale laboratories that could 
yield between 0.5 to 50 kg of drugs per typical manufac-
ture cycle. In 2017, authorities in Slovakia dismantled a 
total of 11 laboratories manufacturing methampheta-
mine: 8 were small kitchen laboratories, mostly produc-
ing the drug from pharmaceutical preparations containing 
pseudoephedrine, and the remaining 3 were medium-
scale laboratories capable of yielding up to 10 kg of the 
drug per manufacturing cycle. In 2017, five illicit meth-
amphetamine laboratories were dismantled in Poland, 
two in Germany and one in Spain. One clandestine lab-
oratory in which methamphetamine was being produced 
from 1-phenyl-2-propanone was also dismantled in 
Lithuania.
783. The apparent recent revival of the illicit market for 
“ecstasy” in the European Union has manifested itself in 
the increased number of drug production sites, increased 
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seizures of the drug and the increasing content of MDMA 
as the active ingredient in “ecstasy” tablets. In 2016, the 
member States of the European Union reported 24,000 
seizures of MDMA (295 kg of the substance), along with 
5.3 million tablets containing the substance. In addition, 
1.2 tons of MDMA, originating in Europe, were reported 
seized by Australia. In 2016, 11 illicit MDMA laborato-
ries were dismantled in the European Union (10 in the 
Netherlands and 1 in Belgium), which was more than 
double the number dismantled in 2015. In 2017, three 
illicit MDMA laboratories were identified in Sweden, one 
in Belgium and one in Poland.
784. In 2017, among the countries in Europe that 
reported seizures of synthetic drugs other than 
 amphetamine-type stimulants, Estonia, Lithuania, 
Luxembourg, Slovakia and the United Kingdom reported 
seizures of LSD; seizures of GHB were reported by 
Estonia, Luxembourg and Norway, among others. 
According to EMCDDA, the number of LSD seizures 
(about 1,800) almost doubled in the European Union 
 during the period 2010–2016, although the quantity of 
the drug seized fluctuated.
785. According to the Police Academy in the Netherlands, 
in its study entitled The Netherlands and Synthetic Drugs: 
An Inconvenient Truth, which was published in 2018, 
 revenue from the illicit synthetic drug market in the 
Netherlands amounted to at least 18.9 billion euros in 
2017. That estimated revenue excludes the revenue from 
the manufacture of amphetamines and MDMA by Dutch 
nationals abroad, and the revenue generated from the 
production of drugs other than synthetic ones.
(c) Precursors
786. For several years, countries in Europe have contin-
ued seizing both internationally controlled and non-
scheduled substances used for the illicit manufacture of 
synthetic drugs in the region, in particular amphetamine, 
methamphetamine and MDMA. Those substances 
included 3,4-MDP-2-P and 3,4-MDP-2 glycidic acid 
derivatives that can be used in the illicit manufacture of 
MDMA and ephedrines; 1-phenyl-2-propanone (P-2-P), 
including methyl glycidic acid derivatives of the sub-
stance; and APAAN and APAA, which can be used in the 
illicit manufacture of amphetamines. For example, in 
2017, a seizure of sizeable amount of APAAN (1.3 tons) 
was reported by Albania.
787. Since 2016, countries in the European Union have 
been increasingly targeted by traffickers seeking new 
sources of acetic anhydride. Attempts to divert the 
substance continued until about mid-2017, when the 
number of identified diversion attempts started declining, 
although did not disappear completely. In contrast to that 
decline in diversion attempts, the trafficking of previously 
diverted acetic anhydride continued throughout 2017 and 
2018, as evidenced by a number of seizures of the sub-
stance of suspected European origin both within and out-
side the region. It appears that the diversion of acetic 
anhydride and the subsequent trafficking in the substance 
from the region might have been facilitated by the differ-
ent approaches taken by the States members of the 
European Union with regard to the implementation of 
particular provisions of European Union precursor 
 control legislation. 
788. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in the region can be found 
in the report of the Board for 2018 on the implementa-
tion of article 12 of the 1988 Convention.
(d)  Substances not under  
international control
789. New psychoactive substances, in particular highly 
potent synthetic opioids and synthetic cannabinoids, have 
continued to cause public health problems in Europe. 
790. In 2017, 51 new psychoactive substances were 
detected for the first time on the European market: about 
one new substance every week. That number is lower 
compared with the previous five years, in particular 2014 
and 2015, when new identifications reached about 100 
annually. The reasons for that decrease in new detections 
are not clear, but they may include efforts to schedule 
new psychoactive substances at the international and 
national levels, and measures taken by the Government 
of China, in particular law enforcement operations 
 targeting laboratories producing new psychoactive 
 substances in that country.
791. Synthetic cannabinoids have continued to be the 
largest group of new psychoactive substances monitored 
by EMCDDA: in 2017, 10 new synthetic cannabinoids 
were reported to the agency. Synthetic cannabinoids were 
also the most frequently seized new psychoactive sub-
stances, accounting for 45 per cent (32,000 seizures) out 
of a total of 71,000 seizures of new psychoactive sub-
stances reported in Norway, Turkey and the European 
Union in 2016. Those synthetic cannabinoids were traf-
ficked to Europe from outside the region and then mixed 
with dried plant material and packaged in processing 
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facilities in the region. The five most commonly seized 
synthetic cannabinoids in 2016 were MDMB-CHMICA, 
5F-AKB-48, AB-CHMINACA, UR-144 and AMB-
FUBINACA, all but the last of which were listed in 
Schedule II of the 1971 Convention by the Commission 
on Narcotic Drugs in March 2017 or March 2018. 
792. The second-largest group of new psychoactive 
 substances monitored by EMCDDA was synthetic 
 cathinones. In 2017, 12 synthetic cathinones were detected 
for the first time, bringing the total number found on the 
European market to 130. With over 23,000 seizures, 
 synthetic cathinones accounted for 33 per cent of the total 
number of seizures of new psychoactive substances in 
2016; a minor decrease compared with the previous year. 
The five most commonly seized cathinones in 2016 were 
α-PVP, 4-CMC, 3-CMC, 4-methyl-N,N-dimethyl-
cathinone and 3-MMC; α-PVP was brought under 
 international control and placed in Schedule II of the 
1971 Convention in March 2016. 
793. In 2017, 13 new synthetic opioids, including 10 
fentanyl derivatives, were detected on the European illicit 
drug market. Although new fentanyl derivatives do not 
currently play a major role in that market, their high 
potency and availability on the market in diverse forms 
including nasal sprays or in mixtures with other drugs, 
such as heroin, cocaine or counterfeit medicines, pose a 
serious health risk not only for users but also for health 
and law enforcement personnel.
794. In 2016, the number of seizures of new synthetic 
opioids tripled compared with 2015, and accounted for 
2.3 per cent of all new psychoactive substances seized in 
that year. Fentanyl derivatives accounted for about three 
quarters of the approximately 1,600 seizures of new 
 synthetic opioids made in 2016.
795. Since 2015, 14 new benzodiazepines have been 
reported to the European Union Early Warning System. 
The increasing availability of both established and new 
benzodiazepines on the illicit drug market in some coun-
tries in Europe is of concern because of possible links 
between their use and opioid overdose deaths. 
796. By the end of 2017, EMCDDA was monitoring 23 
new benzodiazepines, of which 3 had been detected for 
the first time in Europe in that year. While the number 
of seizures of benzodiazepines decreased in 2016, when 
compared with 2015, the amount of the substances seized 
increased significantly. Other new psychoactive sub-
stances seized in 2016 included arylcyclohexylamines, 
phenethylamines, tryptamines, piperidines, pyrrolidines 
and arylalkylamines. 
797. Reports of increasing manufacture of new psycho-
active substances in Europe can be further corroborated 
by the identification of laboratories manufacturing or 
processing flunitrazolam, an internationally non- 
controlled benzodiazepine derivative, and cyclopropyl-
fentanyl, an internationally non-controlled opioid 
analgesic, in Sweden in 2017.
5. Abuse and treatment
798. More than 92 million people in the European 
Union, or over a quarter of the population aged 15 to 64, 
are estimated to have tried illicit drugs at least once in 
their lives. The prevalence of drug use in the European 
Union is higher among males (56.0 million) than females 
(36.3 million). Drug use in Europe encompasses a wide 
range of substances; polydrug use is common. Individual 
patterns of drug use range from experimental to more 
regular and harmful patterns of use. 
799. According to the EMCDDA report “Preventing 
overdose deaths in Europe”, published in 2017 as part of 
the Perspectives on Drugs series, at least 9,000 people in 
Norway, Turkey and the countries of the European Union 
died as a result of drug overdoses in 2016. Evidence shows 
that educational and training interventions for peers and 
family members, complemented by the implementation 
of take-home naloxone projects, can help decrease 
 overdose-related mortality rates. 
800. The prevalence of cannabis use in the European 
Union is about five times that of other substances: about 
87.6 million persons aged 15 to 64, or 26.3 per cent of 
that age group, have tried cannabis in their lives. It is esti-
mated that about 1 per cent of adults in Europe use can-
nabis daily or almost daily (20 days or more in the past 
month). Around three quarters of cannabis users are 
males aged 35 to 64. The most recent EMCDDA drug 
abuse survey indicates a stable or increasing trend in 
 last-year cannabis use among those aged 15 to 34.
801. Heroin remains the most commonly used illicit 
 opioid in Europe. Other opioids being abused in the region 
include methadone, buprenorphine, fentanyl, codeine, 
morphine, tramadol and oxycodone. Eighty per cent of 
first-time entrants into treatment in the European Union 
for opioids as the primary drug of abuse cited  heroin as 
the primary drug of abuse, followed by  methadone (8 per 
cent), buprenorphine (5 per cent),  fentanyl (0.3 per cent) 
and other opioids (about 7 per cent). In the European 
Union, 23 is the mean age of initiation of heroin use and 
34 is the mean age of heroin users  seeking treatment for 
drug dependence for the first time. 
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802. It is estimated that about 5.1 per cent of the pop-
ulation of European Union member States aged 15 to 64 
have tried cocaine in their lives. The highest last-year 
prevalence of cocaine use among young adults was 
reported by the United Kingdom (4.0 per cent), Denmark 
(3.9 per cent), the Netherlands (3.7 per cent), Spain 
(3.0  per cent) and Ireland (2.9 per cent). In 2017, some 
increase in cocaine use was reported by Albania, Croatia, 
Lithuania, Slovakia and Switzerland.
803. The available data suggest that, since around 2000, 
there has been a relatively stable situation in the use of 
amphetamines in countries in Europe. It is estimated that 
11.9 million of those aged 15 to 64 in the European 
Union, or 3.6 per cent of that age group, have tried 
amphetamines during their lives. In 2017, decreased use 
of amphetamine in Europe was reported by Bulgaria, Italy 
and the United Kingdom. In Norway, the use of amphet-
amine has increased.
804. Methamphetamine use, which in Europe has been 
generally low and historically concentrated in Czechia 
and Slovakia, is now also present in the areas of Germany 
that border with Czechia and in Cyprus, Spain and coun-
tries in Northern Europe, including Finland and Sweden. 
805. Approximately 35,000 drug users who entered spe-
cialized drug treatment in the European Union in 2016 
reported amphetamines as their primary drug; about 
15,000 of them were first-time clients. In Germany, 
Finland, Latvia and Poland, primary amphetamine users 
accounted for more than 15 per cent of all first-time treat-
ment entrants. Almost 90 per cent of the 9,200 drug users 
who entered specialized treatment in the European Union 
and who reported methamphetamine as their primary 
drug of abuse were from Czechia or Slovakia.
806. The mean age of initiation of use of amphetamines 
among drug users in the European Union is 20; 29 is the 
mean age of users of amphetamines entering treatment 
for drug dependence for the first time. Problems related 
to long-term, chronic and injecting amphetamine use are 
most evident in countries in Northern Europe; metham-
phetamine problems have been more noticeable in 
Czechia and Slovakia. 
807. Until recently, the prevalence of “ecstasy” use had 
been on the decline from the peak levels reached in many 
countries in the early to mid-2000s. It is estimated that 
4.1 per cent (13.5 million) of persons aged 15 to 64 in the 
European Union have tried “ecstasy” in their lives. 
Consumption of “ecstasy” is highest among those aged 15 
to 34; about 2.2 million (1.8 per cent) of that age group 
have used “ecstasy” in the last year. In that age group, the 
last-year prevalence of “ecstasy” use ranged from 0.2 per 
cent in Portugal and Romania to 7.4 per cent in the 
Netherlands. It is worth noting that use of “ecstasy” is only 
rarely cited as a reason for entering specialized drug 
treatment.
808. Although data on the availability of new psycho-
active substances in the European Union are gradually 
improving, estimating the demand for those substances 
remains a challenge for the region. Since 2011, 13 European 
countries have provided EMCDDA with national estimates 
of the use of new psychoactive substances; however, the 
use of different methods and survey questions limits the 
comparison of the outcomes of the surveys. 
809. The French Monitoring Centre for Drugs and Drug 
Addiction (OFDT), in a report from March 2018 con-
cerning users of and markets for psychoactive substances, 
indicated that the habitual use of new psychoactive 
 substances during the period 2016–2017 was confined to 
particular population groups, such as high-school stu-
dents aged 15 to 17 and adults who were using cannabis 
regularly. According to the report, the use of new psy-
choactive substances also includes inhalation of synthetic 
cannabinoids, advertised as “e-liquids”. The users of new 
psychoactive substances in France perceived that pur-
chasing such substances online was a guarantee of their 
quality; such a perception could motivate them to further 
use the substances.
810. Although use of new psychoactive substances in 
the European Union is low overall, their use by high-risk 
drug users is of particular concern. A number of coun-
tries reported the smoking of synthetic cannabinoids 
within marginalized communities, such as homeless peo-
ple and prisoners. For example, a survey conducted in 
prisons in the United Kingdom in 2016 found that 33 per 
cent of the 625 prison inmates surveyed reported use of 
synthetic cannabinoids (known as “Spice”) within the last 
month, whereas 14 per cent reported use of cannabis in 
the previous month. Use of new psychoactive substances 
does not, however, account for a sizeable proportion of 
drug treatment cases in Europe. 
811. According to the statistical bulletin of the Office 
for National Statistics of the United Kingdom, released in 
August 2018, 61 deaths in 2017 were reported as related 
to new psychoactive substance poisoning in England and 
Wales; a significant decrease from the 123 such deaths 
reported in 2016 following the Government’s approval of 
the Psychoactive Substances Act in 2016, which estab-
lished a blanket ban on the import, production and sup-
ply of most psychoactive substances not already covered 
by law. 
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812. The prevalence of LSD and hallucinogenic mushroom 
(containing psilocybin) use has been generally low and sta-
ble in Europe for many years. In 2017, Croatia, Greece, 
Norway, Lithuania and Portugal were among the countries 
that reported abuse of LSD or hallucinogenic mushrooms.
813. In the European Union, injecting drug use is 
mostly associated with opioids, although the injecting of 
stimulants such as amphetamines or cocaine has also 
been reported in a few countries. Since 2011, use of 
 heroin by injection was reported by 13 out of 16  countries 
from which such estimates of injecting drug use were 
available. Among the first-time entrants into treatment 
who reported heroin as their primary drug of abuse when 
entering specialized drug treatment in 2016, 27 per cent 
reported injecting as their main route of administration, 
down from 43 per cent in 2006. With regard to other 
drugs, abuse of buprenorphine by injecting was reported 
by, among others, Finland, synthetic cathinones by 
Hungary, cocaine by France, amphetamine by Latvia and 
methamphetamine by Czechia.
E. Oceania
1. Major developments
814. Oceania continues to be vulnerable to drug manu-
facturing and drug and precursor trafficking. Countries 
in Oceania reported seizures of considerable amounts of 
various drugs, including crystalline methamphetamine, 
the increase in manufacturing capacity and growing mar-
ket for which have become a significant concern in the 
region. National wastewater drug monitoring has shown 
that Australia has become a major consumer of metham-
phetamine, cocaine and “ecstasy”. Australia’s lucrative 
illicit market for drugs continues to attract transnational 
organized criminal groups. 
815. In recent years, seizures of large amounts of cocaine 
have been reported in a number of countries in the 
region. The general annual prevalence rate of cocaine 
abuse in Oceania is high, with Australia having a 2.5 per 
cent prevalence rate among the population aged 14 years 
and older in 2016. The weight of cocaine seized in 
Australia also exceeded the total estimated weight of 
cocaine that would be required to meet the estimated size 
of the national demand of the substance for abuse. The 
significant amount of cocaine seized in Tonga indicates 
that, in addition to being used as a transit point, cocaine 
abuse has spread to the country.
816. The lack of data related to drug trafficking and 
abuse in the region, other than for Australia and New 
Zealand, coupled with the fact that many countries have 
not yet become parties to the drug control treaties, is a 
matter of great concern to the Board. The Board has con-
ducted bilateral meetings with the Governments of Papua 
New Guinea and Solomon Islands to address those issues 
and has followed up with the Governments of all non-
States parties to one or more of the international drug 
control conventions in the region. In that connection, the 
Board was informed that the authorities of Papua New 
Guinea were to commence the national process of adher-
ing to the 1988 Convention in September 2018.
2. Regional cooperation
817. The Oceania Customs Organization84 held its twen-
tieth annual conference, on the theme “Strengthening 
regional connections to support a safe and prosperous 
Pacific”, in Melbourne, Australia, from 11 to 14 June 2018. 
During the meeting, customs administrations from the 
23 members signed a memorandum of understanding on 
customs cooperation to facilitate the exchange of infor-
mation between relevant border security agencies. 
Members endorsed the re-establishment of the Information 
Working Group and the progression of the Small Craft 
Mobile Application Project, developed by Australia, to 
phase 3 as of July 2018. The members also endorsed the 
signing the Declaration of Partnership between the Pacific 
Islands Chiefs of Police, the Pacific Immigration 
Development Community and the Oceania Customs 
Organization in March 2018. 
818. Under the UNODC global SMART programme, two 
national technical workshops were organized for the 
Governments of Solomon Islands and Vanuatu. The work-
shops brought together representatives of various national 
authorities and civil society organizations involved in 
countering the drug problem. They were composed of 
training and discussion sessions on enhancing illicit drug 
data collection in the countries. The workshops were held 
in Port Vila from 26 to 27 July 2018 and in Honiara on 1 
and 2 August 2018. Also under the global SMART pro-
gramme, UNODC provided support to the Government of 
Fiji, in particular by contributing to the third National 
Narcotic Committee meeting, held in Suva on 30 July 2018.
84 Customs administrations from the following countries and territo-
ries are members of the Oceania Customs Organization: American 
 Samoa, Australia, Cook Islands, Fiji, French Polynesia, Guam, Kiribati, 
Marshall Islands, Micronesia (Federated States of), Nauru, New 
 Caledonia, New Zealand, Niue, Northern Mariana Islands, Palau, Papua 
New Guinea, Samoa, Solomon Islands, Timor-Leste, Tonga, Tuvalu, 
 Vanuatu, and Wallis and Futuna Islands.
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819. In April 2018, the Marshall Islands, Micronesia 
(Federated States of) and Palau signed an agreement 
establishing the Micronesian Regional Transnational 
Crime Unit. Attorneys general from each of those coun-
tries were assigned to develop, create and establish a bind-
ing framework that could strengthen the Unit. It is 
anticipated that the Unit will strengthen mutual assistance 
in the national jurisdictions of each country by fostering 
stronger regional collaboration in areas including the pre-
vention, investigation and prosecution of drug trafficking 
and drug smuggling, cybercrime detection and preven-
tion, and information-sharing concerning national and 
regional criminal activity trends. 
820. The Nauru Police Force, in collaboration with the 
Australian Border Force and the Australian Federal 
Police, conducted training for police and border control 
officers and health-care staff on detecting illicit drugs 
from 4 to 6 July 2017. The training focused on the use 
of the narcotic identification kits to identify a variety of 
substances. It also covered detection and search princi-
ples such as examination procedures for bags and cargo, 
safety during examination of substances and post- 
detection procedures. Drug seizures have taken place 
recently in Nauru, but the country had a lack of  technical 
capacity to detect and test the drugs. 
821. The second standing meeting of Pacific Islands 
Forum Foreign Ministers was held in Suva on 11 August 
2017. The foreign ministers discussed a wide range of 
issues affecting the political and security environment of 
the Pacific, including the increased incidence of trans-
national organized crime. The increasing incidence of 
such crime in the region, including the rise in drug 
 trafficking, is a concern. 
3.  National legislation, policy  
and action
822. Several countries in Oceania are not yet parties to 
the international drug control conventions.85 This is a spe-
cific concern to INCB as it increases the vulnerability of 
those countries to drug and precursor trafficking and to 
being used as transit points for drug trafficking from 
other regions. The Board calls upon all States that are 
not yet parties to one or more of the international drug 
control conventions to accede to them without delay and 
85 Kiribati and Tuvalu have not adhered to any of the three inter-
national drug control conventions; the Cook Islands, Nauru, Niue, Samoa 
and Vanuatu are not parties to either the 1961 Convention or the 1971 
Convention; Solomon Islands is not a party to either the 1971 Convention 
or the 1988 Convention; and Palau and Papua New Guinea are not parties 
to the 1988 Convention.
reiterates its readiness and willingness to support them 
in that undertaking in any way possible. 
823. Australia introduced an instrument, the Narcotic 
Drugs Amendment (Cannabis) Regulations 2018, in 
February 2018. The purpose of the instrument is to 
amend the Narcotic Drugs Regulation 2016 to permit the 
export of medicinal cannabis products and allow medi-
cal cannabis products and raw cannabis and cannabis 
resin to be supplied directly to the holder of a manufac-
turing licence under the Therapeutic Goods Act 1989 for 
subsequent supply to patients in Australia or for export. 
824. The Misuse of Drugs (Medical Cannabis) 
Amendment Bill was introduced in the New Zealand 
Parliament in December 2017. The Bill would amend the 
Misuse of Drugs Act 1975 to improve access to medical 
cannabis for terminally ill people and those in chronic 
pain, with the intention of improving access to afforda-
ble cannabis products that meet quality standards. 
According to the amendment, the Bill would also include 
a regulation-making power to enable the setting of qual-
ity standards for medicinal cannabis products available 
on prescription and the de-scheduling of CBD as a con-
trolled substance. The Bill would provide an exception 
and a statutory defence for the possession and use of can-
nabis by people who have less than 12 months to live. 
The changes are expected to come into force in 2019. 
4.  Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
825. The amount of cannabis herb seized in 2016 (the 
latest year for which data are available) increased by 6 per 
cent in Oceania compared with 2015. Cannabis herb 
 seizures in Oceania accounted for 0.2 per cent of total 
global seizures. Most of the cannabis trafficked to the 
Pacific island States is cultivated within the region. 
However, in Australia, the main cannabis market in the 
region, illicit imports of cannabis were detected from dif-
ferent countries during the 12-month reporting period 
2015/16. 
826. In New Zealand, the quantity of cannabis seized 
was 538.8 kg in 2017, which was comparable to the 
524.2 kg seized in 2016. However, the number of  cannabis 
plants seized declined to 40,481 in 2017, from 78,358 in 
2016. The number of outdoor cannabis plants eradicated 
decreased significantly, to 19,559 plants in 2017 from 
104,725 plants in 2016. The number of indoor cannabis 
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plants eradicated increased slightly to 19,992 in 2017, 
from 18,903 in 2016. The quantity of cannabis herb seized 
in Australia increased substantially, to 19,200 kg in 2017, 
from 11,174 kg in 2016. 
827. The latest available data show that the quantity of 
cocaine seized in Oceania increased by more than 75 per 
cent between 2015 and 2016, reaching a record high level 
in the region, with Australia accounting for 98 per cent of 
all cocaine intercepted. The Australian Federal Police also 
reported making the largest cocaine seizures in the Pacific 
through different operations conducted in the country 
during the 12-month reporting period 2016/17. Another 
major cocaine seizure was of 1.28 tons of the drug, inter-
cepted through Operation Amorgos in January 2018 in 
collaboration with the New Zealand Police. Australia 
reported that the amount of cocaine seized  doubled in 
2017, to 4,140 kg, compared with 2,159 kg in 2016. 
828. In Tonga, 58 kg of cocaine were seized by police 
in the Ha’apai group of islands in June 2018, with the help 
of the country’s naval forces. Considering the size and 
population of Tonga (109,008 in 2018), it was a very large 
seizure to be made in one operation. The final destina-
tion of the cocaine was thought to be New Zealand or 
Australia. However, the seizure might also indicate the 
existence of local abuse of the drug.
829. In New Zealand, the amount of cocaine seized tri-
pled, to 108 kg in 2017, from 36 kg in 2016, as reported 
by the country’s police and customs authorities. That was 
supported by data on drug interceptions from the New 
Zealand Customs Service, which indicated a significant 
increase of cocaine seizures in 2017 compared with pre-
vious years. The number of seizures also increased, to 199 
in 2017, from 132 in 2016. The much smaller increase in 
the number of seizures compared with the amount seized 
between 2016 and 2017 indicates that drug traffickers are 
trying to smuggle a larger amount of cocaine at a time. 
The joint police and customs Operation Heracles saw a 
single seizure of 46 kg of cocaine in November 2017, the 
largest ever in New Zealand.
830. According to the Australian Federal Police, 
196.9  kg of heroin were intercepted in 2016/17, which 
was substantially lower than the amount seized in 2015/16 
(282.1 kg). About 30 kg of heroin destined for Australia 
had been intercepted in Fiji as part of Operation Okesi 
during the period 2016/17. East and South-East Asia 
remained the main source of heroin in Oceania, although 
there were indications of a decrease in heroin trafficking 
in the region. The amount of heroin seized in New 
Zealand increased significantly, from 49.27 g in 2016 to 
829 g in 2017.
(b) Psychotropic substances
831. The increasing amount of methamphetamine sei-
zures in Oceania might indicate the existence of a grow-
ing market in the region. Both the tablet and crystalline 
forms of methamphetamine are available in Oceania; 
however, crystalline methamphetamine is increasingly 
becoming a concern given the growing market for the 
substance and an increase in the amount of consumption, 
manufacturing capacity and seizures in the region.
832. Australian Federal Police reported seizing 3.5 tons 
of methamphetamine in the 12-month period 2016/17, 
which was lower than in the previous 12 months 
(3.9 tons). The seizures were a result of the different task 
forces and operations working in collaboration with the 
Australian Border Force. For example, through Taskforce 
Blaze, the Australian Federal Police and the National 
Narcotics Bureau of China jointly targeted a syndicate 
and seized 64 litres of liquid methamphetamine that had 
been trafficked from China. In December 2017, a record 
amount of methamphetamine, 1.2 tons, was seized in 
Australia through a multi-agency investigation involving 
the Australian Federal Police, the Australian Border 
Force, the Australian Criminal Intelligence Commission 
and other regional offices. 
833. The quantity of methamphetamine seized in New 
Zealand decreased by half, to 477.5 kg in 2017, from 
927.3 kg in 2016. However, the amount of the liquid form 
of methamphetamine seized in 2017 was 160.6 litres, sig-
nificantly higher than the 31 litres seized the previous 
year. The price of methamphetamine decreased to 500 
New Zealand dollars per gram in 2017, from 600 New 
Zealand dollars per gram in 2016, indicating a high avail-
ability of methamphetamine, despite a decrease in sei-
zures. Annual surveys in New Zealand have found that 
increasing methamphetamine supply and lower prices are 
consistent with the record amounts of methamphetamine 
seized in the past two years. Police in Tonga intercepted 
297 g of methamphetamine in April 2018: this and other 
recent seizures in Tonga indicate that the country is 
becoming a target of drug traffickers and indicates the 
potential spread of drug abuse among residents of the 
country. 
834. In Australia, seizures of amphetamine-type stimu-
lants by the Federal Police increased slightly, to 7.3 tons 
in 2016/17, compared with 7.2 tons in 2015/16. 
Methamphetamine accounted for the highest share 
(47  per cent) of the total amount of such substances 
seized in 2016/17. That growth was mainly a result of the 
significant increase in seizures of “ecstasy” in 2016/17 
(1.3  tons) compared with the previous year (0.2 tons).
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835. The amount of “ecstasy” seized in New Zealand 
increased from 11.4 kg in 2016 to 39.5 kg in 2017. By 
contrast, 1.18 kg of amphetamine were seized in 2017, 
which was a considerable decrease from 2016 (27.3 kg). 
Smaller amounts of “ecstasy” mimics such as α-PVP were 
seized in 2017 compared with previous years; however, a 
large amount of cathinone N-ethylpentylone was seized.
(c) Precursors
836. The quantity of precursors seized in Australia in 
2016/17 was 2.3 tons, a considerable increase from the 
0.3 tons seized during the previous 12 months. The 
Australian Border Force also reported seizing a sizable 
amount of ephedrine, including a single seizure, in 
October 2017, of 3.9 tons that had been intended for the 
manufacture of methamphetamine. This indicates that the 
strong demand for methamphetamine in the country 
continues.
837. Seizures of methamphetamine precursors (the 
majority being ephedrine) by customs and police author-
ities in New Zealand decreased to 723.8 kg in 2017, from 
1,237.9 kg in 2016. That was the lowest amount seized 
since 2012 (498 kg), when pseudoephedrine was the most 
prevalent imported precursor. In contrast, the amounts 
of finished methamphetamine seized remained high, sup-
porting intelligence that suppliers and users are choosing 
to import the end product.
(d)  Substances not under  
international control
838. According to the Australian Federal Police, a con-
siderable amount (1.32 tons) of sedatives, including GBL 
and GHB, were seized during the 12-month period 
2016/17. That was more than three times the amount 
seized in the previous year (364.2 kg). A significant amount 
(2.52 tons) of other stimulants, including cathinone ana-
logues, amphetamine analogues, khat, methylphenidate, 
phentermine, ethylphenidate and methiopropamine, was 
also seized during the reporting period. 
839. In New Zealand, N-ethylpentylone, a synthetic 
cathinone, was seized in large volumes both at the bor-
der and within the country in 2017. N-ethylpentylone is 
sold as a form of “ecstasy” and has a similar form and 
appearance to “ecstasy”, in both powder and crystalline 
form. In 2017, benzodiazepine seizures decreased to 
18,309 tablets, from 23,619 tablets in 2016. Benzodiazepine 
abuse is believed to be widespread, despite the decreas-
ing trend reported in New Zealand. Seizures of 
methylphenidate remained stable, with 2,817 tablets 
seized in 2017 and 2,700 tablets in 2016. 
5. Abuse and treatment
840. Cannabis continued to be the most widely abused 
drug globally in 2016, with 192.2 million past-year users 
among the population aged between 15 and 64. Oceania 
falls among the top three regions in terms of rates of can-
nabis use, with an 11 per cent prevalence rate, after West 
and Central Africa (13.2 per cent) and North America 
(12.9 per cent). 
841. The annual prevalence rate of cannabis use among 
the general population in New Zealand is 11.6 per cent, 
with an estimated 445,000 users. The annual prevalence 
rate among young people in the country is higher, at 
22.2 per cent. The number of drug-related deaths in New 
Zealand increased from 178 in 2013 to 254 in 2015, as a 
result of an increase in abuse of cannabis, which might 
include synthetic cannabis. However, amphetamine is the 
number one cause for deaths resulting from drug 
overdose. 
842. According to data collected in October and 
December 2017 and covering over half of the country’s 
population, methamphetamine continued to be the most 
abused drug of the substances measured as part of the 
National Wastewater Drug Monitoring Program (namely, 
amphetamine-type stimulants, cocaine and opioids) in all 
regions of Australia. Estimated average cocaine abuse had 
doubled in the capital city and increased threefold in 
regional sites since August 2016. Estimated consumption 
of other stimulants, including “ecstasy”, was lower, and 
overall consumption of heroin in Australia may have 
slightly decreased from August 2017 to December 2017. 
Similar to previous findings, mephedrone and methylone 
were detected at a number of sites, but in negligible 
amounts. However, the number of detections of mephe-
drone more than doubled between August 2017 and 
December 2017. 
843. In the Drug Use Monitoring in Australia: 2015 and 
2016 report on drug use among police detainees, published 
by the Australian Institute of Criminology, the use of 
drugs by 1,896 detainees in Australia in the 12-month 
period 2015/16 was analysed together with that of the 
1,551 detainees assessed for the same study in 2013/14. 
According to the report, the proportion of prison detain-
ees testing positive for methamphetamine increased 
significantly, from 34 per cent in 2013/14 to 48 per cent 
in 2015/16, making methamphetamine the most- 
frequently abused drug. The number of detainees testing 
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positive for cannabis was 831 (44 per cent) in 2015/16 
and 708 (46 per cent) in 2013/14. There were 116 detain-
ees (6 per cent) testing positive for heroin in 2015/16 and 
117 (8 per cent) in 2013/14; 20 detainees (1 per cent) 
tested positive for cocaine in 2015/16 and 31 (2 per cent) 
in 2013/14. Regarding “ecstasy”, the test showed an 
increase from 1.3 per cent in 2013/14 to 2.3 per cent in 
2015/16. In 2015/16, the proportion of self-reported drug 
abuse in the last 30 days for heroin, methamphetamine 
and cocaine was 73 per cent, 78 per cent and 65 per cent, 
respectively, of the total number of detainees who tested 
positive for those drugs. Those figures show that self-
reported use of those drugs was underreported by 
22–35 per cent of detainees. 
844. In its report entitled Alcohol and Other Drug 
Treatment Services in Australia 2016–17, the Australian 
Institute of Health and Welfare indicated that ampheta-
mines (i.e., methamphetamine and amphetamine), can-
nabis and heroin were the three principal illicit drugs of 
concern for patients seeking treatment for drug use in 
Australia in 2016/17, with 26 per cent, 22 per cent and 
5 per cent, respectively. The proportion of persons seek-
ing treatment for amphetamines increased from 23 per 
cent in 2015/16 to 26 per cent in 2016/17, meaning that 
amphetamines replaced cannabis as the second-most 
common drug of concern after alcohol. Counselling was 
the most common type of treatment that was provided, 
followed by assessment only and support and case man-
agement only. The rate of drug-induced deaths in Australia 
has been increasing since 2007 and reached 1,808 deaths 
in 2016, which was the highest on record since the late 
1990s. The deaths were mainly a result of the non- medical 
use of benzodiazepines and oxycodone; deaths resulting 
from the use of other controlled substances have also 
been increasing. 
845. In New Zealand, the proportion of persons 
detained by the police who had used methamphetamine 
in the previous year increased from 26 per cent in 2010 
to 38 per cent in 2016. That could be attributed to the 
increase in reported availability, coupled with the decrease 
in price. However, abuse of cannabis in the previous year 
by detainees declined from 76 per cent in 2011 to 68 per 
cent in 2016, as a result of cannabis being considered to 
be very difficult to find and of the effectiveness of police 
cannabis crop eradication operations. Likewise, the pro-
portion of those who had abused “ecstasy” in the previ-
ous year decreased from 28 per cent in 2011 to 14 per 
cent in 2016. The percentage of detainees who had tried 
opioids in their lifetime was 17 per cent in 2016, with no 
change from previous years. However, the percentage of 
detainees who had tried cocaine in their lifetime increased 
from 17 per cent in 2010 to 26 per cent in 2016, despite 
cocaine being reported as difficult to procure. The pro-
portion of detainees who had used synthetic cannabi-
noids in the previous 12 months declined from 47 per 
cent in 2013 to 20 per cent in 2016 and the proportion 
of detainees who had tried a drug for the first time 
declined from 32 per cent in 2013 to 17 per cent in 2016: 
19 per cent cited the new drug they had tried as meth-
amphetamine, 14 per cent cited “ecstasy”, 13 per cent cited 
synthetic cannabinoids and 9 per cent cited cocaine.
846. The 2016/17 annual health survey in New Zealand 
showed that 1.0 per cent of the population aged between 
16 to 64 abused amphetamine, which was slightly lower 
than the 2015/16 survey result (1.1 per cent). In general, 
the level of abuse had been stable over the previous six 
years. According to the survey, 11.6 per cent of the pop-
ulation aged 15 and above had used cannabis. The trend 
of cannabis use showed an increase from year to year 
since 2011/12 (8.0 per cent), with the exception of 
2014/15. 
847. Oceania is the region with the second-highest rate 
of use of amphetamines among those aged between 15 
and 64 in the past year. The abuse of “ecstasy” continued 
to be high in Oceania, and the estimated past-year prev-
alence rates for “ecstasy” abuse in the region are among 
the highest in the world. In a number of pilot testing 
areas in New Zealand, wastewater testing exhibited 
higher-than-anticipated levels of MDMA, showing that 
“ecstasy” use is still prevalent in the country.
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Chapter IV. 
Recommendations to Governments,  
the United Nations and other relevant 
international and national organizations
848. Following its review of the implementation of the 
international drug control conventions, the Board would 
like to present to Governments, the United Nations and 
relevant international and regional organizations its 
main conclusions and recommendations, as shown 
below.
Cannabis and cannabinoids for medical, 
scientific and “recreational” use
849. Cannabis is controlled under the 1961 Convention 
as it produces dependence and has adverse public health 
consequences. Under the 1961 Convention, the medical 
use of cannabinoids is possible if such use is medically 
supervised, safe and effective, and provided that the con-
trol measures envisaged in the Convention are in place. 
The Board notes that, while a number of medicinal prod-
ucts containing cannabinoids have been licensed in a 
number of countries for medical use in the treatment of 
specific conditions, cannabis and its derivatives are not a 
first-line treatment for medical conditions. Furthermore, 
the Board notes that the smoking of cannabis for medi-
cal purposes is not a medically accepted way to obtain 
standardized doses of cannabis or its derivatives.
850. Poorly regulated and poorly administered pro-
grammes for the medicinal use of cannabinoids can 
potentially have adverse effects on public health. Moreover, 
such programmes, and the associated perception of lower 
risk of the use of cannabis that they may convey, may 
also contribute to the legalization of non-medical 
cannabis use, which is contrary to the international drug 
control treaties.
Recommendation 1: The Board reiterates that: 
 (a)  Governments that wish to establish special-
access schemes to allow for the medical use of 
cannabinoids should do so only where there is 
evidence of efficacy and safety, should limit the 
use of such preparations to approved medicinal 
cannabinoids and should monitor their prescrip-
tion and use to minimize any risk of diversion 
and abuse; 
 (b)  Governments should ensure that such program-
mes do not result in the de facto legalization of 
cannabis for non-medical purposes; 
 (c)  Medical use of cannabinoids should be regulated 
and supervised in a manner that meets the 
requirements set out in the drug control treaties. 
The integrity of the pharmaceutical regulatory 
system must be maintained, in particular by 
ensuring that cannabinoids are used in medical 
practice only where there is evidence of their 
equal or superior effectiveness relative to other 
medicinal products, and evidence of their safety;
 (d)  Governments that allow the medicinal use of 
cannabinoids should monitor and evaluate the 
medicinal effectiveness as well as any unintended 
impact of those programmes. 
851. The universal adherence to the three international 
drug control treaties and the commitment to their imple-
mentation reaffirmed by Member States at the special ses-
sion of the General Assembly on the world drug problem 
held in 2016 are undermined by the developments in a 
few countries that have legalized or permitted the use of 
cannabis for non-medical purposes or that have tolerated 
its legalization at the subnational level. 
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852. The Board reiterates that the 1961 and the 1988 
Conventions limit the use of cannabis exclusively to medi-
cal and scientific purposes.
853. The above developments will reduce the perception 
of risk associated with the non-medical use of cannabis 
and will likely increase the adverse effects of cannabis on 
public health, such as higher rates of cannabis-related 
motor vehicle accidents and injuries, cannabis depend-
ence and abuse, physical and mental health conditions 
and poor medical and psychosocial outcomes among 
young people. 
Recommendation 2: Recalling the limitation of use of 
narcotic drugs and psychotropic substances to medical 
and scientific purposes as well as the health and welfare 
objectives of the treaties, the Board reiterates that the 
three international drug control treaties limit the use of 
cannabis exclusively to medical and scientific purposes. 
The Board calls upon the Governments of countries in 
which the use of cannabis or cannabis derivatives for 
non-medical, “recreational” purposes has been permit-
ted to take steps to bring the entirety of their territories 
back into compliance with the international drug  control 
conventions and their obligations thereunder. 
854. For detailed information on cannabis and cannab-
inoids for medical, scientific and “recreational” use, see 
chapter  I of the present report.
Fifty years of promoting the consistent 
application of the international drug 
control treaties 
855. 2018 marked the fiftieth anniversary of the estab-
lishment of INCB. Today, the three United Nations drug 
control conventions are among the most widely ratified 
inter national instruments in existence. As with other 
inter national treaties, the choice of policy, legislative and 
administrative measures to implement them is left to the 
discretion of Governments, within the limits set in the 
conventions.
Recommendation 3: INCB calls upon all States to respect 
their legal obligations under the conventions and recalls 
that treaties are binding and must be performed by par-
ties in good faith, that the provisions of internal law can-
not be used as justification for failure to meet the 
requirements of a treaty, unless so provided for in the 
concerned treaty, and that this is applicable to the gene-
ral objective of the international drug control conven-
tions limiting the use of narcotic drugs and psychotropic 
substances to medical and scientific purposes. 
Recommendation 4: INCB urges all Governments 
to  cooperate with the Board in fulfilling its mandate, 
which is to monitor the compliance of States with the 
international drug control conventions. The Board will 
continue to work with all States to facilitate the imple-
mentation of the international drug control treaties to 
ensure that their objectives, provisions and potential are 
fully realized for the benefit of the health and welfare 
of humankind. 
International drug control conventions 
and human rights
856. The fundamental goal of the international drug 
control conventions, to safeguard the health and welfare 
of humanity, includes the full enjoyment of human rights. 
State actions that violate human rights in the name of 
drug control policy are inconsistent with the international 
drug control conventions. Such actions include extrajudi-
cial responses to suspected drug-related criminality, 
which cannot be justified under the international drug 
control conventions. 
Recommendation 5: The Board reiterates its appeal to all 
States to address drug-related crime through formal 
criminal justice responses, in accordance with the 
Universal Declaration of Human Rights and the 
International Covenant on Civil and Political Rights, 
and in adherence to internationally recognized due 
 process standards. 
857. In addressing suspected drug-related crime, States 
should also be proportionate in their responses and in 
their treatment of suspected offenders. According to the 
principle of proportionality, offences of lesser relative 
gravity do not require States to subject those who have 
committed them to criminal sanction or punishment, 
including incarceration. 
Recommendation 6: States parties should consider apply-
ing the various alternatives to conviction, punishment 
and incarceration, including measures of treatment, 
education, aftercare, rehabilitation and social reintegra-
tion, provided for in the international drug control 
conventions. 
Recommendation 7: The Board reiterates recommenda-
tion 8 contained in its annual report for 2017, namely 
that the principle of proportionality must continue to 
be a guiding principle in drug-related matters. Although 
the determination of sanctions applicable to drug-
related crime remains the prerogative of States parties 
to the conventions, INCB reiterates its position on the 
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issue of capital punishment for drug-related offences 
and encourages States that retain capital punishment for 
drug-related offences to consider the abolition of the 
death penalty for that category of offence.
Prevention and treatment
858. An area in which the implementation of the inter-
national drug control conventions has not been fully real-
ized is the provision of prevention and treatment. These 
provisions do not mandate a specific approach, leaving 
States to determine which approaches are most suitable 
to their situation. The lack of adequate epidemiological 
data on drug use remains a barrier to the development 
of evidence-based drug policy to support the develop-
ment, formulation and provision of targeted and effective 
prevention and treatment interventions and to the effec-
tive utilization of resources. In many parts of the world, 
prevention initiatives are non-existent or insufficient and 
the provision of treatment services is inadequate, while 
insufficient mechanisms exist to combat stigma and  foster 
social reintegration. 
Recommendation 8: States should look at existing best 
practices and develop effective strategies for the preven-
tion of drug use, as well as mechanisms to address depend-
ence through evidence-based treatment, rehabilitation, 
aftercare and social reintegration. In that regard, 
Governments are encouraged to refer to chapter I of the 
Board’s annual report for 2017, entitled “Treatment, reha-
bilitation and social reintegration for drug use disorders: 
essential components of drug demand reduction”.
Availability
859. The lack of availability of controlled narcotic drugs 
and psychotropic substances for legitimate medical use 
continues to represent a pressing public health problem 
in many regions of the world today, a situation that has 
often been falsely attributed to the control requirements 
of the international drug control framework. In many 
States, access to and availability of controlled medicines 
have been hindered by the lack of capacity and training 
of national officials, weak and underresourced health-care 
systems, a lack of know-how on accurately evaluating the 
needs of the population, inadequate regulation and too 
few and insufficiently trained health-care professionals. 
Recommendation 9: Governments must foster access to 
and the availability of narcotic drugs and psychotropic 
substances for medical use through improved access to 
health services and effective systems of administrative 
controls that regulate the production, manufacture, 
import and export of such drugs and substances, keep-
ing in mind that States themselves must adequately eval-
uate their domestic requirements and report them to 
INCB. Such effective regulatory frameworks should 
allow the legitimate medical needs of the populations 
to be met.
Recommendation 10: Governments urgently need to 
address capacity and resource constraints in the health-
care field, especially in the field of pain management, 
including by increasing the availability and know-how 
of health-care professionals (including doctors, nurses, 
pharmacists and regulators). Medical practitioners 
should be adequately trained in the prescription of 
medi cines to those who genuinely need them and should 
be able to prescribe medicines without fear of sanction 
or prosecution. 
860. Further information and recommendations on the 
availability of controlled substances for medical purposes 
is contained in the supplement to the present report. 
Narcotic drugs 
861. The cultivation of opium poppy for the production 
of opium and opiate raw material is a matter of major 
international importance in relation to drug control and 
public health. While recognizing the challenge posed by 
existing disparities in access to opioid analgesics, for sev-
eral years the amount of opiate raw material available 
globally for the manufacture of narcotic drugs for medi-
cal purposes, including for pain management, has been 
more than sufficient to satisfy the current and anticipated 
levels of demand, as estimated by Governments, with 
both production and stocks continuing to increase. 
Recommendation 11: The Board recommends to all par-
ties that they prevent the accumulation of stocks of 
poppy straw in excess of the quantities required for the 
normal conduct of business, taking into account the 
prevailing market conditions.
Recommendation 12: The Board recalls that the 1961 
Convention sets out a number of mandatory control 
measures for the licit cultivation of opium poppy and 
the production of opiate raw materials to ensure that 
these are limited to licit medical and scientific purposes. 
Therefore, the Board urges countries that are consider-
ing or are intending to commence the licit cultivation 
of opium poppy for medical and scientific purposes to 
consider the importance of the principle of non- 
proliferation. This objective is emphasized in relevant 
112  INCB REPORT 2018
Economic and Social Council and Commission on 
Narcotic Drugs resolutions on the supply of and demand 
for opiates, in which the Council and Commission 
urged all Governments to cooperate in preventing the 
proliferation of sources of production of opiate raw 
materials and also urged all Governments of countries 
where opium poppy was not being cultivated for the licit 
production of opiate raw materials to refrain from 
engaging in the commercial cultivation of opium poppy, 
in the spirit of collective responsibility.
862. INCB would like to remind all States parties of the 
definition of cannabis and cannabis plant, as contained 
in the 1961 Convention, and would also like to remind 
all States parties that cannabis, cannabis resin and extracts 
and tinctures of cannabis are subject to international con-
trol by virtue of their inclusion in Schedule I of the 1961 
Convention. In addition, cannabis and cannabis resin are 
included in Schedule IV of the same Convention. Both 
the flowering and fruiting tops of the cannabis plants are 
controlled under the 1961 Convention, regardless of 
whether they are dried or not. 
863. According to article 28 of the 1961 Convention, 
States parties may permit the cultivation of cannabis for 
authorized medical and scientific purposes. Parties that 
permit such cultivation have an obligation to establish 
control measures in accordance with the Convention. 
Such measures include the establishment of an agency 
responsible for designating areas and issuing licences for 
cultivation, purchasing and taking physical possession of 
such crops as soon as possible and having the exclusive 
right of importing, exporting and wholesale trading and 
maintaining stocks other than those held by 
manufacturers.
864. In addition, the 1961 Convention limits the culti-
vation of cannabis for industrial purposes to fibre and 
seed. The cultivation of the cannabis plant for industrial 
purposes other than those explicitly indicated in article 
28, paragraph 2, should not be considered licit. 
Recommendation 13: The Board urges States parties to 
ensure that the cultivation of cannabis for industrial 
purposes in their territories is undertaken in line with 
the requirements outlined above and is not used for 
purposes other than those explicitly indicated in the 
1961 Convention.
Psychotropic substances
865. Diversion from licit domestic channels remains a 
major source of psychotropic substances used for illicit 
purposes; however, there are limited reports to the Board 
from Governments on their interdiction efforts. On the 
other hand, the number of countries submitting consump-
tion data on psychotropic substances continues to increase. 
Recommendation 14: The Board encourages all 
Governments to provide to the Board regular and timely 
reports on diversions or attempted diversions of psycho-
tropic substances from licit trade.
Recommendation 15: The Board welcomes the increas-
ing number of countries that submit data on consump-
tion of psychotropic substances and calls upon more 
Governments to do so, pursuant to Commission on 
Narcotic Drugs resolution 54/6, as these data are essen-
tial for the evaluation of the availability of psychotropic 
substances for medical and scientific purposes, and in 
order to ensure adequate availability for meeting 
 medical requirements.
Electronic tools and training
866. The Board notes the challenges faced by some 
Governments in the further implementation of I2ES and 
acknowledges the reported obstacles that have prevented 
wider participation in the system (see chapter II,  section F, 
of the present report). 
Recommendation 16: The Board encourages all 
Governments to utilize I2ES, which is provided free of 
charge. Specifically, the Board encourages existing users 
of I2ES to invite their trading partners to register with 
the system and to start using it as soon as possible. 
Precursors – 30 years of chemical 
control
867. 2018 marks the thirtieth anniversary of the adop-
tion of the 1988 Convention; significant results have been 
achieved during those 30 years. Nonetheless, non- 
scheduled chemicals, alternates, substitute chemicals and 
pre-precursors pose challenges to international drug con-
trol and cooperation. In particular, the prevention of their 
diversion, as stipulated in article 12 of the Convention, 
and investigation and prosecution of trafficking are not 
possible at the international level given that they are not 
under international control. The fact that scheduled pre-
cursors can be substituted by a large number of sub-
stances not under international control, including many 
that have no legitimate uses and are designed purely to 
circumvent controls, are strong incentives for scheduling 
those substances and establishing additional control 
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mechanisms. However, scheduling an ever-growing num-
ber of chemicals has practical implications, not least an 
ongoing “catch-up” game.
Recommendation 17: INCB considers that there is a need 
for a broader policy discussion about the options avail-
able to address the proliferation of non-scheduled chem-
icals and “designer” precursors at the international level. 
Such a policy discussion should complement and expand 
proven concepts in precursor control that have yielded 
results in the past and will continue to do so in most 
cases involving internationally controlled precursors.
Recommendation 18: The Board urges the international 
community to continue its efforts to prevent scheduled 
precursors from being used in the illicit manufacture of 
narcotic drugs and psychotropic substances by using the 
tools available, such as PEN Online, PICS and Projects 
Prism and Cohesion, building upon the achievements 
of the past 30 years of precursor control.
Recommendation 19: With regard to “designer” and 
non-scheduled precursors and new psychoactive sub-
stances, the Board calls upon Governments and regional 
and international organizations to build on existing pre-
cursor control mechanisms and initiatives to address 
new psychoactive substances, with a view to exploring 
and identifying legal and operational options for rap-
idly addressing the proliferation of such chemicals and 
substances and preventing them from reaching illicit 
markets and end users.
Recommendation 20: Efforts should focus on enabling 
authorities worldwide to disrupt the supply of non- 
scheduled chemicals to illicit drug manufacturers without 
creating an unnecessary regulatory burden. To that end, 
Member States could explore ways and means of  addressing 
series of chemical relatives and supporting the pro secution 
of relevant criminal cases. It should also be feasible to 
establish a separate category of precursor chemicals that 
do not have any currently recognized legitimate uses. 
INCB encourages Governments to consider all available 
options and to work with the Board within the framework 
of the international precursor control  system to more 
effectively respond to current challenges. 
Non-medical synthetic opioids and 
fentanyl-related substances
868. The illicit manufacture and abuse of and traffick-
ing in non-medical synthetic opioids present a growing 
challenge. Online vendors use the Internet, the darknet 
and social media sites to offer fentanyl analogues. 
Shipments are trafficked among the billions of letters and 
express parcels shipped around the world every year 
through international mail and express courier services. 
The Board recognized the problem and initiated activi-
ties under its new global Operational Partnerships to 
Interdict Opioids’ Illicit Distribution and Sales (OPIOIDS) 
Project. Those activities focus on partnerships between 
Governments, international organizations and the private 
sector as an effective means of preventing and interdict-
ing sales and the distribution of non-medical synthetic 
opioids.
Recommendation 21: Governments should work with 
INCB to expand partnerships with relevant industries 
to effectively identify and counter the manufacture, sale 
and distribution of and financial gain derived from the 
trafficking in non-medical synthetic opioids. Partnerships 
should expand on successful approaches and work to 
establish sector-relevant guidelines, training, codes of 
conduct and ongoing monitoring across a broader range 
of geographical regions and sectors.
Recommendation 22: Details from online sales, suspi-
cious shipments, drug or illicit laboratory seizures con-
cerning non-controlled substances represent valuable 
intelligence, when shared with agencies in a position to 
act. Governments should nominate focal points in rel-
evant national police, customs, postal, regulatory, 
health, forensic and toxicology authorities in a position 
to share information on the manufacture, sale or distri-
bution of non-medical synthetic opioids using IONICS. 
Improved submission of information 
to  the International Narcotics Control 
Board 
869. The regular submission of comprehensive and 
 reliable statistical data from Governments to the Board is 
vital for the proper overall functioning of the inter-
national drug control system and the analysis of global 
trends. Good-quality data also provide essential informa-
tion that is necessary to uncover diversions of controlled 
substances for illicit purposes. Deficiencies may reflect 
problems in the implementation of treaty provisions, for 
instance, gaps in national legislation, shortcomings in 
administrative regulations or a lack of training for staff 
of competent national authorities.
Recommendation 23: Governments should strengthen 
national mechanisms to monitor the licit cultivation, 
production and manufacture of and trade in controlled 
substances. This may be achieved, in part, by 
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improving and developing national data-collection sys-
tems, training staff of the competent national authori-
ties and ensuring that companies licensed to trade in 
internationally controlled substances fulfil the legal 
requirements associated with their licences.
Recommendation 24: The Board urges all Governments 
concerned to identify the causes of deficiencies in the 
regular submission of comprehensive and reliable sta-
tistical data relating to estimates for narcotic drugs and 
assessments of psychotropic substances and related 
information on international trade and consumption, 
and invites them to make full use of existing INCB tools, 
kits and guidelines, including I2ES, which are available 
on the INCB website free of charge and include train-
ing materials and the Guide on Estimating Requirements 
for Substances under International Control, which is avail-
able in the six official languages of the United Nations. 
Specific countries and regions 
870. As a result of significant increases in illicit opium 
production in Afghanistan, the illicit opiate economy in 
2017 substantially surpassed the level of the country’s 
total licit exports of goods and services. The Board 
remains very concerned by those developments and their 
impact on the health and welfare of people in Afghanistan 
and beyond its borders. 
Recommendation 25: On the basis of the provisions of 
article 14 bis of the 1961 Convention as amended, the 
Board calls the attention of the competent United 
Nations organs and specialized agencies to the drug 
control situation in Afghanistan and calls upon them to 
provide, individually and collectively, further technical 
and financial assistance, within their respective man-
dates, to address the drug control challenges in the 
country, in line with the provisions of the 1961 
Convention as amended. Such assistance may involve a 
multitude of measures, including, but not limited to, 
legislative and institutional capacity-building, provision 
of support for alternative livelihoods, direct financial 
assistance and the promotion of regional and interna-
tional cooperation. 
871. The Board has repeatedly drawn attention to the 
lack of systematic and regular data collection in several 
parts of the world, especially with regard to the preva-
lence of drug abuse, trends and patterns of abuse and 
available or necessary treatment, which hampers the for-
mulation of effective responses to challenges at the coun-
try level. In particular, countries in Oceania, South Asia, 
West Asia, Central America and the Caribbean, and 
Africa are not able to sufficiently assess the extent and 
nature of the drug abuse problems prevailing in their 
jurisdictions.
Recommendation 26: The Board calls upon Governments 
to address the need for more reliable data on drug abuse 
in order to devise policies, programmes and prevention 
and treatment services that are evidence-based and 
 tailored to the needs of their populations.
(Signed)
Viroj Sumyai, President
(Signed)
Bernard Leroy, Rapporteur
(Signed)
Andrés Finguerut, Secretary
Vienna, 16 November 2018
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 Annex I 
Regional and subregional groupings used  
in the report of the International Narcotics 
Control Board for 2018
The regional and subregional groupings used in the report of INCB for 2018, together with the States in each of those 
groupings, are listed below.
Africa
Algeria Guinea
Angola Guinea-Bissau
Benin Kenya
Botswana Lesotho
Burkina Faso Liberia
Burundi Libya
Cameroon Madagascar
Cabo Verde Malawi
Central African Republic Mali
Chad Mauritania
Comoros Mauritius
Congo Morocco
Côte d’Ivoire Mozambique
Democratic Republic of the Congo Namibia
Djibouti Niger
Egypt Nigeria
Equatorial Guinea Rwanda
Eritrea Sao Tome and Principe
Eswatini86 Senegal
Ethiopia Seychelles
Gabon Sierra Leone
Gambia Somalia
Ghana South Africa
86 Since 19 April 2018, “Eswatini” has replaced “Swaziland” as the short name used in the United Nations.
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South Sudan Uganda
Sudan United Republic of Tanzania
Togo Zambia
Tunisia Zimbabwe
Central America and the Caribbean
Antigua and Barbuda Guatemala
Bahamas Haiti
Barbados Honduras
Belize Jamaica
Costa Rica Nicaragua
Cuba Panama
Dominica Saint Kitts and Nevis
Dominican Republic Saint Lucia
El Salvador Saint Vincent and the Grenadines
Grenada Trinidad and Tobago
North America
Canada United States of America
Mexico
South America
Argentina Guyana
Bolivia (Plurinational State of) Paraguay
Brazil Peru
Chile Suriname
Colombia Uruguay
Ecuador Venezuela (Bolivarian Republic of)
East and South-East Asia
Brunei Darussalam Mongolia
Cambodia Myanmar
China Philippines
Democratic People’s Republic of Korea Republic of Korea
Indonesia Singapore
Japan Thailand
Lao People’s Democratic Republic Timor-Leste
Malaysia Viet Nam
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South Asia
Bangladesh Maldives
Bhutan Nepal
India Sri Lanka
West Asia
Afghanistan Oman
Armenia Pakistan
Azerbaijan Qatar
Bahrain Saudi Arabia
Georgia State of Palestine
Iran (Islamic Republic of) Syrian Arab Republic
Iraq Tajikistan
Israel Turkey
Jordan Turkmenistan
Kazakhstan United Arab Emirates
Kuwait Uzbekistan
Kyrgyzstan Yemen
Lebanon
Europe
Eastern Europe
Belarus Russian Federation
Republic of Moldova Ukraine
South-Eastern Europe
Albania Montenegro
Bosnia and Herzegovina Romania
Bulgaria Serbia
Croatia The former Yugoslav Republic of Macedonia
Western and Central Europe
Andorra France
Austria Germany
Belgium Greece
Cyprus Holy See
Czechia Hungary
Denmark Iceland
Estonia Ireland
Finland Italy
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Latvia Portugal
Liechtenstein San Marino
Lithuania Slovakia
Luxembourg Slovenia
Malta Spain
Monaco Sweden
Netherlands Switzerland
Norway United Kingdom of Great Britain and  
Northern IrelandPoland
Oceania
Australia Niue
Cook Islands Palau
Fiji Papua New Guinea
Kiribati Samoa
Marshall Islands Solomon Islands
Micronesia (Federated States of) Tonga
Nauru Tuvalu
New Zealand Vanuatu
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Annex II
Current membership of the International 
Narcotics Control Board
(BKA), Wiesbaden; Ludwig-Maximilian University, 
Munich Institute for Physical Biochemistry and Institute 
of Legal Medicine; Center of Human Genetics, Bremen 
University; Institute of Legal Medicine, Muenster 
University, Germany; United Nations Drug Laboratory, 
Vienna; Central Bureau of Investigation, New Delhi.
Member, special commission on preventing drug abuse, 
Office of the Prime Minister (since 2014). Founding edi-
tor, Turkish Journal of Legal Medicine (1982–1993). 
Member of the scientific board of the International 
Criminal Justice Review. Founding President, Turkish 
Society of Forensic Sciences; Honorary Member of the 
Mediterranean Academy of Forensic Sciences. Member of 
the International Society of Forensic Toxicology; the 
Indo-Pacific Association of Law, Medicine and Science; 
the International Association of Forensic Toxicologists; 
the American Academy of Forensic Sciences; the 
American Society of Crime Laboratory Directors; and the 
American Society of Criminology.
Member of INCB (2005–2010 and since 2017). Member 
(2006 and 2018) and Chair (2017) of the Committee on 
Finance and Administration. Member of the Standing 
Committee on Estimates (2007). Second Vice-President 
and Chair of the Standing Committee on Estimates 
(2006). Rapporteur (2007). First Vice-President of the 
Board (2008). President of the Board (2009).
Cornelis de Joncheere
Born in 1954. National of the Netherlands. Currently 
Chair of the Netherlands Antibiotics Development 
Platform, Vice-Chair of the Expert Advisory Group of the 
Sevil Atasoy
Born in 1949. National of Turkey. Professor of Biochemistry 
and Forensic Science, Vice-Rector and Director, Institute 
of Addiction and Forensic Science; Head, Department of 
Forensic Science; Director, Center for Violence and Crime 
Prevention, Uskudar University, Istanbul. Director, 
Institute of Forensic Science, Istanbul University (1988–
2010). Director, Department of Narcotics and Toxicology, 
Ministry of Justice of Turkey (1980–1993). Expert witness 
in civil and criminal courts (since 1980).
Bachelor of Science in Chemistry (1972), Master of 
Science in Biochemistry (1976), Doctor of Philosophy 
(PhD) in Biochemistry (1979), Istanbul University.
Lecturer in biochemistry, criminalistics and crime scene 
investigation (since 1982); supervisor of more than 50 
master’s and doctoral theses in the area of biochemistry 
and forensic science. Author of over 130 scientific papers, 
including papers on drug testing, drug chemistry, drug 
markets, drug-related and drug-induced crime, drug 
abuse prevention, clinical and forensic toxicology, crime 
scene investigation and DNA analysis.
Hubert H. Humphrey Fellow, United States of America 
Information Agency (1995–1996); Guest Scientist at the 
School of Public Health, Department of Forensic Science, 
University of California, Berkeley, and the Drug Abuse 
Research Center, University of California, Los Angeles; 
Department of Genetics, Stanford University; Department 
of Human Genetics, Emory University; California 
Criminalistics Institute; Federal Bureau of Investigation, 
Virginia; Crime Laboratories, Los Angeles Sheriff ’s 
Department, United States; Federal Criminal Police Office 
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Medicines Patent Pool in Geneva and a consultant to 
WHO on pharmaceutical policies.
Doctor of Pharmacy (PharmD) and Master of Science 
(MSc) in Pharmacy, University of Groningen and 
University of Amsterdam, the Netherlands (1975–1981); 
Master’s in Business Administration, University of San 
Diego, United States/San José, Costa Rica; Bachelor of 
Science (BSc). Pharmacy, cum Laude (Honorary student), 
University of Groningen, the Netherlands (1972–1975).
Previously held positions as Director, Department of 
Essential Medicines and Health Products at WHO in 
Geneva (2012–2016), which included work on access to 
controlled medicines, and the WHO Expert Committee 
on Drug Dependence; WHO Representative, Kyiv (2011–
2012); WHO Regional Adviser for Pharmaceuticals and 
Health Technologies, WHO Regional Office for Europe, 
Copenhagen (1996–2010); National Essential Drugs 
Programme Coordinator, Pan American Health 
Organization (PAHO)/WHO, Brazil (1994–1996); 
Pharmacist, Essential Drugs Projects Coordinator, PAHO/
WHO, Costa Rica (1988–1993); Pharmaceutical expert, 
PAHO/WHO, Panama (1986–1988); Pharmaceutical sup-
ply expert in Yemen, Ministry of Foreign Affairs, 
Directorate for International Cooperation, the Netherlands 
(1982–1985); hospital and community pharmacy in 
Amsterdam, the Netherlands (1981–1982).
President of the WHO Europe Staff Association (2006–
2010); Member of the WHO Guidelines Review 
Committee (2007–2011); Member of the Royal Dutch 
Pharmaceutical Society; author and co-author of numer-
ous publications in the fields of pharmaceutical and 
health sciences.
Member of INCB (since 2017). Rapporteur (2017). 
Member of the Standing Committee on Estimates (2017–
2018). Member of the Committee on Finance and 
Administration (2017–2018).
Wei Hao 
Born in 1957. National of China. Professor of Psychiatry 
and Deputy Director of the Mental Health Institute, 
Central South University, Changsha, China. Director of 
WHO Collaborating Centre for Psychosocial Factors, 
Substance Abuse and Health. Currently serving as Chair, 
Education Committee of the Asian-Pacific Society for 
Alcohol and Addiction Research, and as President, 
Chinese Association of Drug Abuse Prevention and 
Treatment and Chinese Association of Addiction 
Medicine.
Bachelor of Medicine, Anhui Medical University; Master’s 
and Doctoral degrees in Psychiatry, Hunan Medical 
University.
Previously held positions as Scientist, Substance Abuse 
Department, WHO, Geneva (1999–2000); Medical 
Officer, Department of Mental Health and Substance 
Abuse, WHO, Western Pacific Region (2004–2005), and 
President, Chinese Psychiatrist Association (2008–2011). 
Currently holding membership of the Expert Advisory 
Panel on Drug Dependence and Alcohol Problems, WHO 
(since 2006); and member of the Working Group on the 
Classification of Substance Abuse for the eleventh revi-
sion of the International Classification of Diseases (ICD-
11), WHO (since 2011).
Recipient of research support from various bodies at the 
national level (Ministry of Health, Ministry of Science 
and Technology, National Natural Science Foundation) 
and at the international level (WHO and the National 
Institute on Drug Abuse and the National Institute on 
Alcohol Abuse and Alcoholism of the United States). 
Coordinator of a series of WHO/China workshops on 
addictive behaviour. Member of the Expert Committee of 
the national project on mental health services in commu-
nities in China. Consultant for the development, imple-
mentation and evaluation of China’s mental health 
law,  and for the development of the anti-drug law and 
regulations in China.
Published over 400 academic articles and 60 books on 
alcohol and drug dependence. Selected recent publica-
tions in peer-reviewed journals include the following: 
“Longitudinal surveys of prevalence rates and use pat-
terns of illicit drugs at selected high-prevalence areas in 
China from 1993 to 2000”, Addiction (2004); “Drug pol-
icy in China: progress and challenges”, Lancet (2014); 
“Alcohol and the sustainable development goals”, Lancet 
(2016); “Transition of China’s drug policy: problems in 
practice” Addiction (2015); “Improving drug addiction 
treatment in China”, Addiction (2007); “Stigmatization of 
people with drug dependence in China: a community-
based study in Hunan province”, Drug Alcohol Dependence 
(2013); and “Drinking and drinking patterns and health 
status in the general population of five areas of China”, 
Alcohol & Alcoholism (2004).
Member of INCB (since 2015). Member of the Committee 
on Finance and Administration (2015–2016). Member of 
the Standing Committee on Estimates (since 2015). Vice-
Chair of the Standing Committee on Estimates (2016). 
Second Vice-President and Chair of the Standing 
Committee on Estimates (2018). First-Vice President of 
the Board (2017).
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David T. Johnson
Born in 1954. National of the United States. President, 
SwanJohnson LLC; retired diplomat. Bachelor’s degree in 
economics from Emory University; graduate of the 
National Defence College of Canada.
United States Foreign Service officer (1977–2011). 
Assistant Secretary for the Bureau of International 
Narcotics and Law Enforcement Affairs, United States 
Department of State (2007–2011). Deputy Chief of 
Mission (2005–2007) and Chargé d’affaires, a.i. (2003–
2005), United States Embassy, London. Afghan 
Coordinator for the United States (2002–2003). United 
States Ambassador to the Organization for Security and 
Cooperation in Europe (1998–2001). Deputy Press 
Secretary at the White House and Spokesman for the 
National Security Council (1995–1997). Deputy 
Spokesman at the State Department (1995) and Director 
of the State Department Press Office (1993–1995). United 
States Consul General, Vancouver (1990–1993). Assistant 
National Trust Examiner, Office of the Comptroller of the 
Currency, United States Treasury (1976–1977).
Member of INCB (since 2012). Member of the Committee 
on Finance and Administration (since 2012). Chair of the 
Committee on Finance and Administration (2014 and 2018).
Galina Korchagina
Born in 1953. National of the Russian Federation. 
Professor, Deputy Director of the National Centre for 
Research on Drug Addiction (since 2010).
Graduate of the Leningrad Paediatric Medical Institute, 
Russian Federation (1976); doctor of medicine (2001). 
Thesis based on clinical and epidemiological research 
dealing with new ways of looking at management of drug 
abuse in a time of change. 
Previously held positions as paediatrician at the Central 
District Hospital of Gatchina, Leningrad region, and  doctor 
at a boarding school (1976–1979). Head of the 
Organizational and Policy Division, Leningrad Regional 
Drug Clinic (1981–1989); Lecturer, Leningrad Regional 
Medical Academy (1981–1989); Head Doctor, City Drug 
Clinic, St. Petersburg (1989–1994); Assistant Lecturer 
(1991–1996) and Professor (2000–2001), Department of 
Social Technologies, State Institute for Services and 
Economics; Assistant Lecturer (1994–2000), Associate 
Professor (2001–2002) and Professor (2002–2008), 
Department for Research on Drug Addiction, St. Petersburg 
Medical Academy of Postgraduate Studies; Chief Professor 
and Head of the Department for Medical Research and 
Healthy Lifestyles, Herzen State Pedagogical University of 
Russia (2000–2008); Professor, Department for Conflict 
Studies, Faculty of Philosophy, St. Petersburg State 
University (2004–2008).
Member of many associations and societies, including the 
Association of Psychiatrists and Drug Addiction Specialists 
of the Russian Federation and St. Petersburg, the Kettil 
Bruun Society for Social and Epidemiological Research 
on Alcohol, the International Council on Alcohol and 
Addictions and the International Society of Addiction 
Medicine. Head of the sociology of science aspects of 
medical and biological research section of the Research 
Council on the Sociology of Science and the Organization 
of Scientific Research, St. Petersburg Scientific Centre of 
the Russian Academy of Sciences (2002–2008). 
Author of more than 100 publications, including more 
than 70 works published in the Russian Federation, chap-
ters in monographs and several practical guides. Award 
for excellence in health protection from the Ministry of 
Health of the Union of Soviet Socialist Republics (1987). 
Consultant, Global Business Coalition on HIV/AIDS, 
Tuberculosis and Malaria (since 2006).
Expert on the epidemiology of drug addiction, Pompidou 
Group of the Council of Europe (1994–2003); participa-
tion in the WHO cocaine project (1993–1994) as leading 
researcher; WHO Healthy Cities project (1992–1998) as 
leading coordinator in St. Petersburg; WHO alcohol 
action plan, realization on the basis of the city treatment 
centre, St. Petersburg (1992–1998). Co-trainer, WHO 
programmes “Helping people change” (since 1992) and 
“Skills for change” (since 1995); and temporary adviser, 
WHO (1992–2008). Participant in meetings of the 
Commission on Narcotic Drugs (2002–2008).
Member of INCB (2010–2015 and since 2017). Member 
(2018) and Vice-Chair of the Standing Committee on 
Estimates (2011–2012 and 2017). First Vice-President of 
the Board (2013).
Bernard Leroy 
Born in 1948. National of France. Honorary Deputy 
Prosecutor General and Director of the International 
Institute of Research against Counterfeit Medicines.
Degrees in Law from the University of Caen, Institute of 
European Studies of Saarbrucken, Germany, and 
University Paris X. Graduate of the French National 
School for the Judiciary (1979).
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Previously held positions of Deputy General Prosecutor, 
Versailles Court of Appeal (2010–2013). Senior Legal 
Adviser, UNODC (1990–2010). Adviser in charge of 
international, legislative and legal affairs in the French 
National Drug Coordination office (1988–1990). 
Investigating judge specializing in drug cases, Evry High 
Court (1979–1988). Head of the Legal Assistance 
Programme, UNODC, and Coordinator of the decentral-
ized team of legal experts, Bogotá, Tashkent and Bangkok 
(1990–2010). Leader of the legal assistance team assisting 
the Government of Afghanistan in the drafting process 
of the new drug control law, 2004. Co-author of the 
 preparatory study for the law introducing community 
 service sentencing as an alternative to imprisonment in 
France (1981). Co-founder of “Essonne Accueil”, a non-
governmental organization providing treatment services 
for drug addicts (1982). Member of the French delega-
tion for the final negotiations of the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988. Chair of the study group 
on cocaine trafficking in Europe, Council of Europe 
(1989). Author of the report resulting in the first European 
political coordinating committee to combat drugs (1989). 
Chair of the World Bank and UNODC joint team (the 
Stolen Asset Recovery (StAR) Initiative) which organized 
the freezing and subsequent recovery in Switzerland of 
the assets stolen by the former dictator Jean-Claude 
Duvalier in Haiti (2008).
Organizer of the lifelong learning programme on com-
bating drug trafficking and addiction for members of the 
French judiciary, French National School for the Judiciary 
(1984–1994). Lecturer for medical graduates in psychia-
try in the field of forensic expertise and responsibility, 
Faculty of Medicine, Paris-Sud University (1983–1990). 
Lecturer in the field of social work, University of Paris 
13 (1984–1988). Lecturer for second-year Master’s courses 
in Security and Public International Law, Jean Moulin 
Lyon 3 University (2005–2013).
Member of the Executive Board of the international 
 section of the National Association of Drug Court 
Professionals (2006). External member of the Management 
Board of the French Monitoring Centre for Drugs and 
Drug Addiction (2013). Member of the committee of the 
Reynaud report (2013). Honours: Chevalier of the Legion 
of Honour.
Selected publications include “Le travail au profit de la 
communauté, substitut aux courtes peines 
d’emprisonnement”, Revue de science criminelle et de droit 
comparé, No. 1 (Sirey, 1983); Drogues et drogués, École 
nationale de la magistrature, studies and research (1983); 
Étude comparative des législations et des pratiques 
judiciaires européennes face à la drogue (Commission of 
the European Communities, 1991); Ecstasy, Inserm 
Collective Expertise series (Editions Inserm, 1997); The 
International Drug Control System, in cooperation with 
Cherif Bassiouni and J.F. Thony, in International Criminal 
Law: Sources, Subjects and Contents (Martinus Nijhoff 
Publishers, 2007); Routledge Handbook of Transnational 
Criminal Law, Neil Boister and Robert Curie, eds. 
(Routledge, 2014).
Member of INCB (since 2015). Rapporteur (2015 and 
2018). Member of the Standing Committee on Estimates 
(2016).
Raúl Martín del Campo Sánchez
Born in 1975. National of Mexico. Director General of 
the National Commission against Addictions (May 2013–
December 2016).
Bachelor’s Degree in Psychology; Honourable Mention, 
Autonomous University of Aguascalientes, 1998. Master’s 
Degree in Health Psychology, Faculty of Psychology, 
National Autonomous University of Mexico, with resi-
dency in Addictions, 2002. Specialization in Drug 
Dependence and Related Crisis Situations, Drug 
Dependence Treatment Centre, Health Institute of the 
State of Mexico, 2010. 
Director of Coordination of National Programmes against 
Addictions, Mexican Observatory on Tobacco, Alcohol 
and Drugs, National Commission against Addictions 
(2012–2013); Director, Mexican Institute against 
Addictions (IMCA), State of Mexico (2007–2011); Head 
of the Indicator Monitoring Department, National 
Commission against Addictions (2003–2007); Head of the 
Psychology Unit (treatment of drug users), Drug Abuse 
Treatment Centre, Municipality of Aguascalientes (1999–
2000); residential therapist for drug users and psychiat-
ric patients, Addiction Treatment and Rehabilitation 
Centre (CAPRA) and Neuropsychiatric Centre of 
Aguascalientes (1999–2000); volunteer providing social 
services and support to the technical team, youth 
 integration centres, Aguascalientes (1997–2000). 
Author and co-author of, and contributor to, numerous 
publications on drug abuse prevention, treatment, surveys 
and related subjects, including: National Survey on Drug 
Use Among Students, 2014 (INPRFM, National Commission 
against Addictions, Ministry of Health of Mexico, 2015); 
“Is the medical use of cannabis supported by science?” 
(National Commission against Addictions, National 
Centre for the Prevention and Control of Addictions, 
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2014); “The treatment model used by the ‘Centros Nueva 
Vida’ addiction treatment centres and its relationship to 
primary health-care services” and “Addiction treatment 
based on models for the State of Mexico: cases in the study 
of risk factors and prevention through the Chimalli 
model”, Actualidades en adicciones 2012, vol. II (National 
Commission against Addictions, 2012); “Is alcohol an iso-
lated problem in children and adolescents?”, in Actualidades 
en adicciones 2012, vol. IV (National Commission against 
Addictions, 2012); “Alcohol in primary care mental health 
clinics”, in Alcohol use disorder (World Organization of 
National Colleges, Academies and Academic Associations 
of General Practitioners/Family Physicians, 2010); State of 
Mexico Survey on Alcohol, Tobacco and Drug Use among 
Students (INPRFM, Mexican Institute against Addictions 
(IMCA), 2009). 
Member of INCB (since 2016). Member of the Standing 
Committee on Estimates (since 2017).
Richard P. Mattick 
Born in 1955. National of Australia. Professor of Drug 
and Alcohol Studies at the National Drug and Alcohol 
Research Centre, Faculty of Medicine, University of New 
South Wales; Professor of Brain Sciences, University of 
New South Wales; Principal Research Fellow, Australian 
Government National Health and Medical Research 
Council (2013–2017), and Registered Clinical Psychologist.
Bachelor of Science (Psychology), Honours, Class 1, 
University of New South Wales, 1982; Master of 
Psychology (Clinical), University of New South Wales, 
1989; Doctor of Philosophy, University of New South 
Wales, 1988; and Certificate in Neuroanatomy, Anatomy, 
University of New South Wales, 1992.
Director of Research, Australian National Drug and 
Alcohol Research Centre (1995–2001), and Executive 
Director, Australian National Drug and Alcohol Research 
Centre, Faculty of Medicine, University of New South 
Wales (2001–2009). Member, Australian National Expert 
Advisory Committee on Illicit Drugs (2002–2004), 
Australian National Expert Advisory Group on Sustained 
Release Naltrexone (2002–2004), Monitoring Committee 
of the Medically Supervised Injecting Centre for the New 
South Wales Government Cabinet Office (2003–2004), 
Australian Ministerial Council on Drug Strategy Working 
Party on Performance and Image Enhancing Drugs 
(2003–2005), Australian Government Department of 
Health and Ageing Expert Advisory Committee on 
Cannabis and Health (2005–2006), New South Wales 
Expert Advisory Group on Drugs and Alcohol for the 
New South Wales Minister of Health (2004–2013), 
Australian National Council on Drugs advising the Prime 
Minister (2004–2010), WHO/UNODC Technical 
Guidelines Development Group on Pharmacotherapy of 
Opioid Dependence (2004–2008), Australian Research 
Alliance for Children and Youth (2005–2015).
Served on the editorial and executive boards of Drug and 
Alcohol Review (1994–2005), and as Deputy Editor (1995–
2000) and Executive Editor (2000–2005). Assistant Editor 
of the international peer-reviewed journal Addiction 
(1995–2005). Editor, Cochrane Review Group on Drugs 
and Alcohol (1998–2003). Authored over 300 books, 
chapters in edited volumes on substance abuse, addiction 
and treatment, and peer-reviewed academic journal arti-
cles on those subjects. Recent articles include 
“Buprenorphine maintenance versus placebo or metha-
done maintenance for opioid dependence”, “Young adult 
sequelae of adolescent cannabis use” and “The Pain and 
Opioids IN Treatment study: characteristics of a cohort 
using opioids to manage chronic non-cancer pain”. 
Recipient of academic and research support from the 
Australian Government Department of Health; the New 
South Wales Government Department of Health; the 
Australian National Drug Law Enforcement Research 
Fund; the Alcohol Education and Rehabilitation 
Foundation; UNODC; the National Institute on Drug 
Abuse of the United States; the Australian Research 
Council; and the Australian Government National Health 
and Medical Research Council.
Member of INCB (since 2015). Member of the Standing 
Committee on Estimates (2015–2016).
Luis Alberto Otárola Peñaranda
Born in 1967. National of Peru. Lawyer. Postgraduate 
degree in Public Policy and Public Management from the 
Pontifical Catholic University of Peru.
Executive Director of the National Commission for 
Development and Life without Drugs (2014–2016). 
President of the Inter-American Drug Abuse Control 
Commission of OAS (November 2015–September 2016). 
Minister of Defence (2012), Deputy Minister of the 
Interior (2011), Deputy Minister of Defence (2003), 
Officer of the Peruvian State before the Inter-American 
Court of Human Rights (2001), Professor of Constitutional 
Law and Human Rights.
Author or co-author of the following works: Compendio 
sobre Tráfico Ilícito de Drogas y Desarrollo Alternativo 
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(2015); La Constitución Explicada (2011); La Constitución 
de 1993: Estudio y Reforma a Quince Años de su Vigencia 
(2009); Modernización Democrática de las Fuerzas 
Armadas (2002); Parlamento y Ciudadanía (2001); La 
Constitución de 1993: Análisis Comparado (1999).
Order of Merit for Distinguished Services at the level of 
Grand Cross (decoration awarded by the Constitutional 
President of the Republic). Also received the Order of 
Ayacucho (highest distinction awarded by the Peruvian 
Army).
Presenter at the workshop entitled “Responding to the 
evolving drug challenge”, Deutsche Gesellschaft für 
Internationale Zusammenarbeit (GIZ), London (2015); 
presenter on alternative development at the Economic 
and Social Council, New York (2015); Head of the 
Peruvian delegation to the seventh meeting of the 
Peruvian Colombian Joint Committee on Drugs (2014); 
Head of the Peruvian delegation to the Twenty-fourth 
Meeting of Heads of National Drug Law Enforcement 
Agencies, Latin America and the Caribbean (2014); 
speaker at the second Latin American Seminar on 
Democracy and Corruption, Montevideo (2014); Head of 
the Peruvian delegation to the eighth meeting of the 
Peruvian-Brazilian Joint Committee on Drugs (2014); 
speaker at the Latin American Seminar on Youth and 
Democratic Governance, Cartagena de Indias, Colombia 
(2012); speaker at the Latin American Seminar on Youth, 
Violence and Culture of Peace, Antigua, Guatemala 
(2009).
Member of INCB (since 2017). Member of the Standing 
Committee on Estimates (since 2017).
Jagjit Pavadia 
Born in 1954. National of India. Graduate in English 
Honours (1974), Dhaka University, LLB from Delhi 
University (1988), Master’s Diploma in Public 
Administration, Indian Institute of Public Administration 
(1996). Completed dissertation “Forfeiture of Property 
under the Narcotics Drugs and Psychotropic Substances 
Act, 1985” towards completion of Master’s Diploma. 
Held several senior positions in the Indian Revenue 
Service for 35 years in the Government of India, includ-
ing Narcotics Commissioner of India, Central Bureau of 
Narcotics (2006–2012); Commissioner, Legal Affairs 
(2001–2005); Chief Vigilance Officer, Power Finance 
Corporation (1996–2001); Customs Training Adviser 
Maldives, deputed by the Commonwealth Secretariat 
(1994–1995); Deputy Director, Narcotics Control Bureau 
(1990–1994); and retired as Chief Commissioner, Customs, 
Central Excise and Service Tax, Nagpur, in 2014.
Recipient of Presidential Appreciation Certificate for 
Specially Distinguished Record of Service on the occa-
sion of Republic Day (2005), published in the Gazette of 
India Extraordinary.
Member of the Indian delegation to the Commission on 
Narcotic Drugs, Vienna (2007–2012); introduced resolu-
tions 51/15 (2008) and 53/12 (2010), adopted by the 
Commission on Narcotic Drugs, and organized a side 
event on the margins of the Commission’s 2011 session, 
presenting issues involved in the illegal movement of 
opium poppy seeds to producing, importing and export-
ing countries. As representative of the competent national 
authority, attended Project Prism and Project Cohesion 
task force meetings (2006–2012), and coordinated and 
organized the Project Prism and Project Cohesion meet-
ing in New Delhi (2008). Participated in the Thirtieth 
Meeting of Heads of National Drug Law Enforcement 
Agencies, Asia and the Pacific, held in Bangkok (2006), 
and organized the Thirty-fifth Meeting of Heads of 
National Drug Law Enforcement Agencies, Asia and the 
Pacific, held in Agra, India (2011). Member of the INCB 
advisory expert group on the scheduling of substances 
(2006), and member of the advisory group finalizing the 
INCB Guidelines for a Voluntary Code of Practice for the 
Chemical Industry (2008). Rapporteur of the forty-first 
session of the Subcommission on Illicit Drug Traffic and 
Related Matters in the Near and Middle East, held in 
Amman (2006); Chair of the forty-second session of the 
Subcommission, held in Accra, India (2007); organized 
the meeting of the Paris Pact Initiative Expert Working 
Group on Precursors, held in New Delhi (2011), and par-
ticipated in the International Drug Enforcement 
Conferences hosted by the United States Drug Enforcement 
Agency, held in Istanbul, Turkey (2008) and Cancún, 
Mexico (2011).
Member of INCB (since 2015). Second Vice-President 
and Chair of the Standing Committee on Estimates (2015 
and 2017). Vice-Chair of the Standing Committee on 
Estimates (2018). Member of the Committee on Finance 
and Administration (2016–2017). First Vice-President of 
the Board (2016).
Viroj Sumyai
Born in 1953. National of Thailand. Retired Assistant 
Secretary-General of the Food and Drug Administration, 
Ministry of Public Health of Thailand, and clinical phar-
macologist specializing in drug epidemiology. Professor, 
Mahidol University (since 2001).
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Bachelor of Science degree in chemistry (1976), Chiang 
Mai University. Bachelor’s degree in pharmacy (1979), 
Manila Central University. Master’s degree in clinical 
pharmacology (1983), Chulalongkorn University. 
Apprenticeship in narcotic drugs epidemiology at St. 
George’s University of London (1989). Doctor of 
Philosophy, Health Policy and Administration (2009), 
National Institute of Administration. Member of the 
Pharmaceutical Association of Thailand. Member of the 
Pharmacological and Therapeutic Society of Thailand. 
Member of the Thai Society of Toxicology. Author of nine 
books in the field of drug prevention and control, includ-
ing Drugging Drinks: Handbook for Predatory Drugs 
Prevention and Déjà vu: A Complete Handbook for 
Clandestine Chemistry, Pharmacology and Epidemiology of 
LSD. Columnist, Food and Drug Administration Journal. 
Recipient, Prime Minister’s Award for Drug Education 
and Prevention (2005). 
Member of INCB (since 2010). Member (2010–2016) and 
Chair (2012, 2014 and 2016) of the Standing Committee 
on Estimates. Chair of the Committee on Finance and 
Administration (2011 and 2013). Second Vice-President 
of the Board (2012, 2014 and 2016). President of the 
Board (since 2017).
Francisco E. Thoumi
Born in 1943. National of Colombia and the United 
States. Bachelor of Arts and Doctor of Philosophy in 
Economics. Senior Member of the Colombian Academy 
of Economic Sciences and Corresponding Member of the 
Royal Academy of Moral and Political Sciences (Spain).
Tinker Visiting Professor at the University of Texas, 
Professor at Rosario University and Universidad de Los 
Andes (Bogotá) and California State University, Chico. 
Worked for 15 years in the research departments of the 
World Bank and the Inter-American Development Bank. 
Founder and Director, Research and Monitoring Center 
on Drugs and Crime, Rosario University (August 2004–
December 2007); Research Coordinator, Global 
Programme against Money-Laundering, Proceeds of 
Crime and the Financing of Terrorism; Coordinator for 
the World Drug Report, UNODC (August 1999–September 
2000); Researcher, Comparative Study of Illegal Drugs in 
Six Countries, United Nations Research Institute for 
Social Development, Geneva (June 1991–December 
1992); Fellow, Woodrow Wilson International Center for 
Scholars (August 1996–July 1997); Research Coordinator, 
Research Programme on the Economic Impact of Illegal 
Drugs in the Andean Countries, United Nations 
Development Programme, Bogotá (November 1993–
January 1996).
Author of three books and co-author of one book on ille-
gal drugs in Colombia and the Andean region. Editor of 
three volumes and author of over 70 academic journal 
articles and book chapters on those subjects. Also 
authored one book, co-authored two books and published 
50 articles and book chapters on economic development, 
industrialization and international trade issues before 
focusing on drug issues.
Member of the Friedrich Ebert Foundation Observatory 
of Organized Crime in Latin America and the Caribbean 
(since 2008) and the World Economic Forum’s Global 
Agenda Council on Organized Crime (2012–2014). 
Member of INCB (since 2012). Rapporteur (2012). 
Member of the Committee on Finance and Administration 
(2014–2015 and 2018). Member of the Standing 
Committee on Estimates (2013, 2016 and since 2017).
Jallal Toufiq 
Born in 1963. National of Morocco. Head of the National 
Centre for Drug Abuse Prevention and Research; Director 
of the Moroccan National Observatory on Drugs and 
Addictions; Director of the Ar-razi University Psychiatric 
Hospital and Professor of Psychiatry at the Rabat Faculty 
of Medicine.
Medical Doctor, Rabat Faculty of Medicine (1989); 
Diploma of Specialization in Psychiatry (1994); and lec-
turer at the Rabat Faculty of Medicine (since 1995). 
Undertook specialized training in Paris at the Sainte-
Anne Psychiatric Hospital and Marmottan Centre (1990–
1991); and at Johns Hopkins University as a National 
Institute on Drug Abuse research fellow and Clinical 
Observer (1994–1995). Conducted research at the 
University of Pittsburgh (1995); and gained Clinical Drug 
Research certificates at the Vienna School of Clinical 
Research (2001 and 2002).
Currently holding positions in Morocco as Head of the 
Harm Reduction Programme, National Centre for Drug 
Abuse Prevention and Research; teaching and residency 
training coordinator, Ar-razi Hospital; Director of the 
National Diploma Programme on Treatment and 
Prevention of Drug Abuse, Rabat Faculty of Medicine; 
Director of the National Diploma Programme on Child 
Psychiatry, Rabat Faculty of Medicine and Member of the 
Ministry of Health Commission on Drug Abuse.
At the international level, Representative of the 
Mediterranean Network (MedNET) for Morocco 
(MedNET/Pompidou Group/Council of Europe); former 
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permanent correspondent of the Pompidou Group for 
Morocco (Council of Europe) on drug abuse prevention 
and research and former member of the Reference Group 
to the United Nations on HIV and Injecting Drug Use. 
Founding member and steering committee member, 
Middle East and North Africa Harm Reduction 
Association (MENAHRA); Director of Knowledge Hub 
Ar-razi for North Africa, MENAHRA; Member, Mentor 
International Scientific Advisory Network (drug abuse 
prevention in youth); former focal point/expert on pre-
vention, United Nations Office on Drug Control and 
Crime Prevention (local network for North Africa); 
founding member, MedNET (advisory group on AIDS 
and drug abuse policies) of the Council of Europe, and 
member of the Reference Group to the United Nations 
on HIV and Injecting Drug Use.
Held consultancy roles with the WHO Regional Office 
for the Eastern Mediterranean, UNODC and other inter-
national institutions, research fellowships and the National 
Institute on Drug Abuse of the United States. Published 
widely in the field of psychiatry, alcohol and drug abuse. 
Member of INCB (since 2015). Member of the Standing 
Committee on Estimates (2015). Member of the 
Committee on Finance and Administration (2016). First 
Vice-President of the Board (2018).
About the International Narcotics Control Board 
INCB is an independent and quasi-judicial control organ, 
established by treaty, for monitoring the implementation 
of the international drug control treaties. It had predeces-
sors under the former drug control treaties as far back as 
the time of the League of Nations.
Composition
INCB consists of 13 members who are elected by the 
Economic and Social Council and who serve in their per-
sonal capacity, not as government representatives. Three 
members with medical, pharmacological or pharmaceu-
tical experience are elected from a list of persons nomi-
nated by WHO and 10 members are elected from a list 
of persons nominated by Governments. Members of the 
Board are persons who, by their competence, impartial-
ity and disinterestedness, command general confidence. 
The Council, in consultation with INCB, makes all 
arrangements necessary to ensure the full technical inde-
pendence of the Board in carrying out its functions. INCB 
has a secretariat that assists it in the exercise of its treaty-
related functions. The INCB secretariat is an administra-
tive entity of UNODC, but it reports solely to the Board 
on matters of substance. INCB closely collaborates with 
UNODC in the framework of arrangements approved by 
the Council in its resolution 1991/48. INCB also cooper-
ates with other international bodies concerned with drug 
control, including not only the Council and its Commission 
on Narcotic Drugs, but also the relevant specialized agen-
cies of the United Nations, particularly WHO. It also 
cooperates with bodies outside the United Nations  system, 
especially INTERPOL and WCO.
Functions
The functions of INCB are laid down in the following 
treaties: Single Convention on Narcotic Drugs of 1961 as 
amended by the 1972 Protocol; Convention on 
Psychotropic Substances of 1971; and United Nations 
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988. Broadly speaking, INCB 
deals with the following:
 (a) As regards the licit manufacture of, trade in and 
use of drugs, INCB endeavours, in cooperation with 
Governments, to ensure that adequate supplies of drugs 
are available for medical and scientific uses and that the 
diversion of drugs from licit sources to illicit channels 
does not occur. INCB also monitors Governments’ con-
trol over chemicals used in the illicit manufacture of 
drugs and assists them in preventing the diversion of 
those chemicals into the illicit traffic;
 (b) As regards the illicit manufacture of, trafficking in 
and use of drugs, INCB identifies weaknesses in national 
and international control systems and contributes to cor-
recting such situations. INCB is also responsible for 
assessing chemicals used in the illicit manufacture of 
drugs, in order to determine whether they should be 
placed under international control.
In the discharge of its responsibilities, INCB:
 (a) Administers a system of estimates for narcotic 
drugs and a voluntary assessment system for psychotropic 
substances and monitors licit activities involving drugs 
through a statistical returns system, with a view to assist-
ing Governments in achieving, inter alia, a balance 
between supply and demand;
 (b) Monitors and promotes measures taken by 
Governments to prevent the diversion of substances fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances and assesses such substances 
to determine whether there is a need for changes in the 
scope of control of Tables I and II of the 1988 Convention;
 (c) Analyses information provided by Governments, 
United Nations bodies, specialized agencies or other com-
petent international organizations, with a view to ensur-
ing that the provisions of the international drug control 
treaties are adequately carried out by Governments, and 
recommends remedial measures;
 (d) Maintains a permanent dialogue with Governments 
to assist them in complying with their obligations under 
the international drug control treaties and, to that end, 
recommends, where appropriate, technical or financial 
assistance to be provided.
INCB is called upon to ask for explanations in the event 
of apparent violations of the treaties, to propose appro-
priate remedial measures to Governments that are not 
fully applying the provisions of the treaties or are encoun-
tering difficulties in applying them and, where necessary, 
to assist Governments in overcoming such difficulties. If, 
however, INCB notes that the measures necessary to rem-
edy a serious situation have not been taken, it may call 
the matter to the attention of the parties concerned, the 
Commission on Narcotic Drugs and the Economic and 
Social Council. As a last resort, the treaties empower 
INCB to recommend to parties that they stop importing 
drugs from a defaulting country, exporting drugs to it or 
both. In all cases, INCB acts in close cooperation with 
Governments.
INCB assists national administrations in meeting their 
obligations under the conventions. To that end, it pro-
poses and participates in regional training seminars and 
programmes for drug control administrators.
Reports
The international drug control treaties require INCB to 
prepare an annual report on its work. The annual report 
contains an analysis of the drug control situation world-
wide so that Governments are kept aware of existing and 
potential situations that may endanger the objectives of 
the international drug control treaties. INCB draws the 
attention of Governments to gaps and weaknesses in 
national control and in treaty compliance; it also makes 
suggestions and recommendations for improvements at 
both the national and international levels. The annual 
report is based on information provided by Governments 
to INCB, United Nations entities and other organizations. 
It also uses information provided through other inter-
national organizations, such as INTERPOL and WCO, as 
well as regional organizations.
The annual report of INCB is supplemented by detailed 
technical reports. They contain data on the licit move-
ment of narcotic drugs and psychotropic substances 
required for medical and scientific purposes, together 
with an analysis of those data by INCB. Those data are 
required for the proper functioning of the system of con-
trol over the licit movement of narcotic drugs and psy-
chotropic substances, including preventing their diversion 
to illicit channels. Moreover, under the provisions of arti-
cle 12 of the 1988 Convention, INCB reports annually to 
the Commission on Narcotic Drugs on the implementa-
tion of that article. That report, which gives an account 
of the results of the monitoring of precursors and of the 
chemicals frequently used in the illicit manufacture of 
narcotic drugs and psychotropic substances, is also 
 published as a supplement to the annual report.
Since 1992, the first chapter of the annual report has been 
devoted to a specific drug control issue on which INCB 
presents its conclusions and recommendations in order 
to contribute to policy-related discussions and decisions 
in national, regional and international drug control. The 
following topics were covered in past annual reports:
1992:  Legalization of the non-medical use of drugs
1993:  The importance of demand reduction
1994:  Evaluation of the effectiveness of the international 
drug control treaties
1995:  Giving more priority to combating 
money- laundering
1996:  Drug abuse and the criminal justice system
1997:  Preventing drug abuse in an environment of 
illicit drug promotion
1998:  International control of drugs: past, present and 
future
1999:  Freedom from pain and suffering
2000:  Overconsumption of internationally controlled 
drugs
2001:  Globalization and new technologies: challenges to 
drug law enforcement in the twenty-first century
2002:  Illicit drugs and economic development
2003:  Drugs, crime and violence: the microlevel impact
2004:  Integration of supply and demand reduction 
 strategies: moving beyond a balanced approach
2005:  Alternative development and legitimate 
livelihoods
2006:  Internationally controlled drugs and the unregu-
lated market
2007:  The principle of proportionality and drug-related 
offences
2008:  The international drug control conventions: 
history, achievements and challenges
2009: Primary prevention of drug abuse
2010: Drugs and corruption
2011:  Social cohesion, social disorganization and illegal 
drugs
2012: Shared responsibility in international drug control 
2013: Economic consequences of drug abuse
2014:  Implementation of a comprehensive, integrated 
and balanced approach to addressing the world 
drug problem
2015:  The health and welfare of mankind: challenges 
and opportunities for the international control of 
drugs
2016:  Women and drugs
2017:  Treatment, rehabilitation and social reintegration 
for drug use disorders: essential components of 
drug demand reduction
Chapter I of the report of the Board for 2018 is entitled 
“Cannabis and cannabinoids for medical, scientific and 
“recreational” use: risks and benefits”.
Chapter II presents an analysis of the operation of the 
international drug control system based primarily on 
information that Governments are required to submit 
directly to INCB in accordance with the international 
drug control treaties. Its focus is on the worldwide  control 
of all licit activities related to narcotic drugs and 
psychotropic substances, as well as chemicals used in the 
illicit manufacture of such drugs.
Chapter III presents some of the major developments in 
drug abuse and trafficking and measures by Governments 
to implement the international drug control treaties by 
addressing those problems.
Chapter IV presents the main recommendations addressed 
by INCB to Governments, UNODC, WHO and other 
 relevant international and regional organizations.

 United Nations system and drug control organs and their secretariat
General Assembly
Economic and Social 
Council
INCB Commission onNarcotic Drugs
UNODCa/INCB secretariatb
Key:
Direct connection (administrative or constitutional)
Reporting, cooperating and advising relationship 
a United Nations Office on Drugs and Crime.
b The INCB secretariat reports on substantive matters to INCB only.
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The International Narcotics Control Board (INCB) is the independent monitoring body for the 
implementation of United Nations international drug control conventions. It was established in 
1968 in accordance with the Single Convention on Narcotic Drugs, 1961. It had predecessors 
under the former drug control treaties as far back as the time of the League of Nations.
Based on its activities, INCB publishes an annual report that is submitted to the United Nations 
Economic and Social Council through the Commission on Narcotic Drugs. The report provides a 
comprehensive survey of the drug control situation in various parts of the world. As an impartial 
body, INCB tries to identify and predict dangerous trends and suggests necessary measures to 
be taken.
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